



US006955717B2

(12) **United States Patent**
Johnson et al.

(10) **Patent No.:** **US 6,955,717 B2**
(45) **Date of Patent:** **Oct. 18, 2005**

(54) **CRYSTALS AND STRUCTURE OF SYNAGIS FAB**

(75) Inventors: **Leslie S. Johnson**, Darnestown, MD (US); **Bradford Braden**, Baltimore, MD (US)

(73) Assignees: **Medimmune Inc.**, Gaithersburg, MD (US); **Bowie State University**, Bowie, MD (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 129 days.

(21) Appl. No.: **10/135,636**

(22) Filed: **Apr. 29, 2002**

(65) **Prior Publication Data**

US 2003/0097974 A1 May 29, 2003

Related U.S. Application Data

(60) Provisional application No. 60/288,005, filed on May 1, 2001.

(51) **Int. Cl.⁷** **C30B 29/58**

(52) **U.S. Cl.** **117/2**; 117/925; 117/926; 117/927; 424/133.1; 424/136.1; 435/70.21; 530/387.7; 530/388.1; 530/388.75; 530/388.85

(58) **Field of Search** 117/2, 925, 926, 117/927; 424/133.1, 136.1; 435/70.21; 530/387.7, 388.1, 388.75, 388.85

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,994,511 A 11/1999 Lowman et al.
6,113,898 A 9/2000 Anderson et al.
6,129,914 A 10/2000 Weiner et al.

FOREIGN PATENT DOCUMENTS

WO WO 96/40252 12/1996
WO WO 00/61618 10/2000
WO PCT/US 02/13583 4/2003

OTHER PUBLICATIONS

Hampton Research, "Crystal Screen Users Guide," (1991).
Johnson et al., "Development of a Humanized Monoclonal Antibody (MEDI-493) With Potent In Vitro and In Vivo Activity Against Respiratory Syncytial Virus," *The Journal of Infectious Diseases* (1997) 176:1215-24.

Meissner et al., "Immunoprophylaxis With Palivizumab, A Humanized Respiratory Syncytial Virus Monoclonal Antibody, For Prevention of Respiratory Syncytial Virus Infection In High Risk Infants: A Consensus Opinion," *Pediatr Infect Dis. J.* (1999) 18:223-31.

Primary Examiner—Robert Kunemund

(74) *Attorney, Agent, or Firm*—Jones Day

(57) **ABSTRACT**

The present invention provides machine readable media embedded with the three-dimensional atomic structure coordinates of Synagis Fab, and subsets thereof, and methods of using them.

17 Claims, 13 Drawing Sheets

Synagis Fab crystal
Orthorhombic form



Synagis Fab crystal
Orthorhombic form




FIG. 1




FIG. 2

Sequence ID No. 1

Synagis Heavy Chain Sequence (KABAT Numbering Scheme)

10 20 30 40
QVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMSVGVIRQPPGKALEWL

50 60 70 80 90
ADIWDDKKDYNPSLKSRLTISKDTSKNQVVLKVTNMDPADTATYYCARS

110 120 130 140
MITNWFYFDVWGAGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVK

150 160 170 180 190
DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQT

200 210 220 230 240
YICNVNHKPSNTKVKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKP

250 260 270 280 290
KDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN

300 310 320 330 340
STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQ

350 360 370 380 390
VYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPPV

400 410 420 430 440
LDS DGSFFLYSKLTVDKSRWQQGNV FSCSVMHEALHNHYTQKSLSLSPGK

Sequence ID No. 2

Synagis FAB Heavy Chain

10 20 30 40
QVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMSVGVIRQPPGKALEWL

50 60 70 80 90
ADIWDDKKDYNPSLKSRLTISKDTSKNQVVLKVTNMDPADTATYYCARS

110 120 130 140
MITNWFYFDVWGAGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVK

150 160 170 180 190
DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQT

200 210 220
YICNVNHKPSNTKVKRVEPKSCDKTH

FIG.3A-1

Sequence ID No. 3
Synagis FC

```
          230          240          250          260          270
TCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWY
          280          290          300          310          320
VDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPI
330          340          350          360          370          380
EKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQ
          390          400          410          420          430
PENNYKTTTPVLDSGDFLYSKLTVDKSRWQQGNV FSCSVMHEALHNHYTQKS
440
LSLSPGK
```

Sequence ID No. 4
Synagis CDR H1

```
26 27 28 29 30 31 32 33 34 35 35a 35b
G  F  S  L  S  T  S  G  M  S  V  G
```

FIG. 3A-2

Sequence ID No. 5
Synagis CDR H2

50 51 52 52a 52b 52c 53 54 55 56 57 58 59 60 61 62
D I W W D D K K D Y N P S L K S

Sequence ID No. 6
Synagis CDR H3

95 96 97 98 99 100 100A 100B 101 102
S M I T N W Y F D V

Sequence ID No. 7
Synagis Light Chain Sequence

10 20 30 40 50
DIQMTQSPSTLSASVGDRVTITCKCQLSVGMYHWYQQKPGKAPKLLIYDT

60 70 80 90 100
SKLASGVPSRFSGSGSGTEFTLTISLQPDDFATYYCFQGSGLYFDDYV

110 120 130 140 150
TKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVD

160 170 180 190 200
NALQSGNSQESVTEQDSKSTYSLSSTLTLSKADYEKHKVYACEVTHQGL

210
SSPVTKSFNRGEC

Sequence ID No. 8
CDR L1

24 25 26 28 29 30 31 32 33 34
K C Q L S V G Y M H

Sequence ID No. 9
CDR L2

50 51 52 53 54 55 56
D T S K L A S

Sequence ID No. 10
CDR L3

89 90 91 92 93 94 95 96 97
F Q G S G Y P F T

FIG.3B




FIG.4




FIG.5




FIG.6




FIG. 7A



FIG.7B




FIG. 8




FIG. 9




FIG.10

CRYSTALS AND STRUCTURE OF SYNAGIS FAB

1. CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit under 35 U.S.C. § 119 of copending provisional application No. 60/288,005, filed May 1, 2001, the content of which is hereby incorporated by reference in its entirety.

2. INTRODUCTION

The present invention concerns crystalline forms of polypeptides that correspond to Synagis (palivizumab) or a fragment thereof such as Synagis Fab, methods of obtaining such crystals and the high-resolution X-ray diffraction structures and atomic structure coordinates obtained therefrom. The crystals of the invention and the atomic structural information obtained therefrom are useful for solving the crystal and solution structures of related and unrelated proteins, and for screening for, identifying and/or designing compounds that bind and/or modulate a biological activity of respiratory syncytial virus.

3. BACKGROUND OF THE INVENTION

Respiratory Syncytial Virus ("RSV") is the most important respiratory pathogen in infancy and early childhood. Studies estimate that RSV causes up to 90% of bronchiolitis and approximately 90% of all pneumonia in infancy. These conditions result in over 90,000 hospitalizations and 4500 deaths annually in the United States alone (Hall, 1998, Textbook of Pediatric Infectious Diseases, 2084-2111). RSV infection in early childhood might be an important risk factor for subsequent development of recurrent wheezing and asthma (Eigen, 1999, J. Pediatr. 135:S1-S50; Stein et al., 1999, Lancet 354:541-545).

Current methods for treatment and prevention of RSV infection are limited. For instance, vaccination against RSV has not been successful to date. Vaccination of infants with an inactivated RSV actually increased the severity of RSV infection and pulmonary pathology when vaccinated infants were later challenged with RSV (Groothuis, 1994, Antiviral Res 23:1-10; Hall et al., 1995, Principles and Practice of Infectious Disease, 1501-1519; Wyde, 1998, Antiviral Res. 39:63-79).

Direct administration of antibodies against RSV has had some prophylactic effect. A human immunoglobulin against RSV ("RSVIG") was approved in 1996 for the prevention of serious lower respiratory tract disease caused by RSV in premature infants and infants with bronchopulmonary dysplasia (PREVENT study group, 1999, Pediatrics 99:93-99). Recently, Synagis (or palivizumab), a humanized monoclonal antibody against the surface fusion glycoprotein ("F protein") of RSV, was approved for similar indications (Meissner et al., 1999, Pediatrics 103:223-31; Johnson et al., 1997, J. Infect. Dis. 176:1215-1224; Impact-RSV Study Group, 1998, Pediatrics 102:531-537). In studies on test animals, Synagis was twice as potent as RSVIG in inhibiting the RSV-induced potentiation of inflammation when administered before or in the early phase of RSV infection (Piedimonte et al., 2000, Pediatric Research 47:351-356).

Although Synagis provides safe and effective prevention of RSV infection, improved therapeutics, such as small molecule therapeutics, are needed to treat and/or prevent RSV infection. Small molecule therapeutics are easier and less expensive to manufacture and also easier to administer

orally. In addition, a small molecule therapeutic such as an antigen that mimics the epitope recognized by Synagis could be administered to generate an immune response against RSV. A composition comprising an antigen that mimics RSV would provide a safer method of preventing RSV infection. An effective antigen mimic of RSV could be administered, to persons with a functioning immune system, as an immunoprophylactic to raise an immune response against the virus with minimal or no danger of infection caused by the immunoprophylactic itself.

The three-dimensional structure coordinates of crystalline Synagis would enable the design or selection of such an antigen mimic. Synagis is effective in preventing RSV infection in vivo, and a mimic of an antigen bound specifically by Synagis could raise an immune response that is as effective or even more effective than Synagis in preventing infection. The structure coordinates of the antigen binding region of crystalline Synagis and/or the structure coordinates of a co-crystal complex of Synagis and an antigen would elucidate the atomic requirements of binding between Synagis and the antigen. This atomic resolution information could then be used to design and/or select a mimic of the antigen to be used as an immunoprophylactic against RSV.

Furthermore, the atomic structure coordinates of crystalline Synagis would enable the design of an antibody with improved virus binding and/or neutralizing properties. The atomic structure coordinates of crystalline Synagis would identify those residues of Synagis that are involved in antigen-antibody binding. These residues could then be selectively altered to generate mutant Synagis molecules that could be screened for binding and/or virus neutralizing effects. These improved Synagis molecules would provide more and perhaps improved options for prevention of RSV infection.

Until the present invention, the ability to obtain the atomic structure coordinates of Synagis has not been realized.

4. SUMMARY OF THE INVENTION

In one aspect, the invention provides compositions comprising crystalline forms of polypeptides corresponding to Synagis (palivizumab), a humanized monoclonal antibody with specificity for the F protein of respiratory syncytial virus ("RSV"), or a fragment thereof such as an Fab fragment of Synagis ("Synagis Fab"). The amino acid sequences of the crystalline polypeptides may correspond to the sequence of wild-type Synagis Fab, or mutants thereof. The crystals of the invention include native crystals, in which the crystalline Synagis Fab is substantially pure; heavy-atom derivative crystals, in which the crystalline Synagis Fab is in association with one or more heavy-metal atoms; and co-crystals, in which the crystalline Synagis Fab is in association with one or more binding compounds, including but not limited to, antigens, epitopes, epitope analogs, inhibitors, etc. to form a crystalline co-complex. Preferably, such binding compounds bind the antigen binding site of Synagis Fab. The co-crystals may be native co-crystals, in which the co-complex is substantially pure, or they may be heavy-atom derivative co-crystals, in which the co-complex is in association with one or more heavy-metal atoms.

The Synagis Fab crystals (FIG. 1) of the invention are characterized by space group symmetry $P2_12_12_1$ and an orthorhombic unit cell (i.e., a unit cell wherein $a \neq b \neq c$; and $\alpha = \beta = \gamma = 90^\circ$) with dimensions of $a = 77.36 \pm 0.2 \text{ \AA}$, $b = 103.92 \pm 0.2 \text{ \AA}$ and $c = 68.87 \pm 0.2 \text{ \AA}$ and are preferably of diffraction quality. A typical diffraction pattern is illustrated in FIG. 2. In more preferred embodiments, the crystals of the

invention are of sufficient quality to permit the determination of the three-dimensional X-ray diffraction structure of the crystalline polypeptide to high resolution, preferably to a resolution of greater than about 3 Å, typically greater than about 2.5 Å, and more usually to a resolution of about 2 Å, 1.9 Å, 1.8 Å or even greater. The three-dimensional structural information may be used in a variety of methods to design and screen for compounds that bind Synagis Fab, as described in more detail below.

In another aspect, the invention provides methods of making the crystals of the invention. Generally, native crystals of the invention are grown by dissolving substantially pure Synagis Fab polypeptide in an aqueous buffer that includes a precipitant at a concentration just below that necessary to precipitate the polypeptide. Water is then removed by controlled evaporation to produce precipitating conditions, which are maintained until crystal growth ceases.

Co-crystals of the invention are prepared by soaking a native crystal prepared according to the above method in a liquor comprising the binding compound of the desired co-complex. Alternatively, the co-crystals may be prepared by co-crystallizing the polypeptide in the presence of the compound according to the method discussed above or by forming a co-complex comprising the polypeptide and the binding compound and crystallizing the co-complex.

Heavy-atom derivative crystals of the invention may be prepared by soaking native crystals or co-crystals prepared according to the above method in a liquor comprising a salt of a heavy atom or an organometallic compound. Alternatively, heavy-atom derivative crystals may be prepared by crystallizing a polypeptide comprising selenomethionine and/or selenocysteine residues according to the methods described previously for preparing native crystals.

In another aspect, the invention provides machine and/or computer-readable media embedded with the three-dimensional structural information obtained from the crystals of the invention, or portions or subsets thereof. Such three-dimensional structural information will typically include the atomic structure coordinates of the crystalline Synagis Fab polypeptides, either alone or in a co-complex with a binding compound, or the atomic structure coordinates of a portion thereof such as, for example, the atomic structure coordinates of residues comprising an antigen binding site, but may include other structural information, such as vector representations of the atomic structures coordinates, etc. The types of machine- or computer-readable media into which the structural information is embedded typically include magnetic tape, floppy discs, hard disc storage media, optical discs, CD-ROM, electrical storage media such as RAM or ROM, and hybrids of any of these storage media. Such media further include paper on which is recorded the structural information that can be read by a scanning device and converted into a three-dimensional structure with an OCR and also include stereo diagrams of three-dimensional structures from which coordinates can be derived. The machine readable media of the invention may further comprise additional information that is useful for representing the three-dimensional structure, including, but not limited to, thermal parameters, chain identifiers, and connectivity information.

The atomic structure coordinates and machine readable media of the invention have a variety of uses. For example, the coordinates are useful for solving the three-dimensional X-ray diffraction and/or solution structures of other proteins, including mutated Synagis Fab, co-complexes comprising

Synagis Fab, and unrelated proteins, to high resolution. Structural information may also be used in a variety of molecular modeling and computer-based screening applications to, for example, intelligently design mutants of the crystallized Synagis that have altered biological activity and to computationally design and identify compounds that bind the antibody or a portion or fragment of the antibody, such as the antigen binding site. Such compounds may be used as lead compounds in pharmaceutical efforts to identify compounds that mimic the epitope of the RSV F protein recognized by Synagis as a therapeutic approach toward the development of, e.g., an anti-idiotypic vaccine for the treatment of respiratory infections caused by RSV.

Accordingly, the invention further includes methods of designing or identifying compounds that bind Synagis Fab as an approach to developing new therapeutic agents. In one method, the three-dimensional structure of Synagis Fab can be used to design molecules which bind the antigen binding site of Synagis Fab. For instance, a binding molecule can be synthesized computationally from a series of chemical groups or fragments that bind Synagis Fab. Alternatively, the three-dimensional structure of can be used to screen a plurality of molecules to identify those that bind Synagis Fab at binding sites including, for example, the antigen binding site of Synagis Fab. The potential inhibitory or binding effect of molecules can be analyzed by actual synthesis and testing or by the use of modeling techniques. The compounds can be optimized by further modeling and/or testing.

4.1 Abbreviations

The amino acid notations used herein for the twenty genetically encoded L-amino acids are conventional and are as follows:

Amino Acid	One-Letter Symbol	Three-Letter Symbol
Alanine	A	Ala
Arginine	R	Arg
Asparagine	N	Asn
Aspartic acid	D	Asp
Cysteine	C	Cys
Glutamine	Q	Gln
Glutamic acid	E	Glu
Glycine	G	Gly
Histidine	H	His
Isoleucine	I	Ile
Leucine	L	Leu
Lysine	K	Lys
Methionine	M	Met
Phenylalanine	F	Phe
Proline	P	Pro
Serine	S	Ser
Threonine	T	Thr
Tryptophan	W	Trp
Tyrosine	Y	Tyr
Valine	V	Val

As used herein, unless specifically delineated otherwise, the three-letter amino acid abbreviations designate amino acids in either the D- or L-configuration. Specific enantiomers are preceded with a "D-" or "L-", depending upon the enantiomer. The capital one-letter abbreviations refer to amino acids in the L-configuration. Lower-case one-letter abbreviations designate amino acids in the D-configuration. For example, "R" and "L-Arg" designate L-arginine, and "r" and "D-Arg" designate D-arginine.

Unless noted otherwise, when polypeptide sequences are presented as a series of one-letter and/or three-letter

abbreviations, the sequences are presented in the N→C direction, in accordance with common practice.

4.2 Definitions

As used herein, the following terms shall have the following meanings:

“Genetically Encoded Amino Acid” refers to L-isomers of the twenty amino acids that are defined by genetic codons. The genetically encoded amino acids are the L-isomers of glycine, alanine, valine, leucine, isoleucine, serine, methionine, threonine, phenylalanine, tyrosine, tryptophan, cysteine, proline, histidine, aspartic acid, asparagine, glutamic acid, glutamine, arginine and lysine.

“Genetically Non-Encoded Amino Acid” refers to amino acids that are not defined by genetic codons. Genetically non-encoded amino acids include derivatives or analogs of the genetically-encoded amino acids that are capable of being enzymatically incorporated into nascent polypeptides using conventional expression systems, such as selenomethionine (SeMet) and selenocysteine (SeCys); isomers of the genetically-encoded amino acids that are not capable of being enzymatically incorporated into nascent polypeptides using conventional expression systems, such as D-isomers of the genetically-encoded amino acids; L- and D-isomers of naturally occurring or synthetic α -amino acids that are not defined by genetic codons, such as α -aminoisobutyric acid (Aib); and other amino acids that are not encoded by genetic codons such as β -amino acids, γ -amino acids, etc. In addition to the D-isomers of the genetically-encoded amino acids, common genetically non-encoded amino acids include, but are not limited to norleucine (Nle), penicillamine (Pen), N-methylvaline (MeVal), homocysteine (hCys), homoserine (hSer), 2,3-diaminobutyric acid (Dab) and ornithine (Orn). Additional exemplary genetically non-encoded amino acids are found, for example, in *Practical Handbook of Biochemistry and Molecular Biology*, 1989, Fasman, Ed., CRC Press, Inc., Boca Raton, Fla., pp. 3–76 and the various references cited therein.

“Hydrophilic Amino Acid” refers to an amino acid having a side chain exhibiting a hydrophobicity of less than zero according to the normalized consensus hydrophobicity scale of Eisenberg et al., 1984, J. Mol. Biol. 179:125–142. Genetically encoded hydrophilic amino acids include, but are not limited to, L-Thr (T), L-Ser (S), L-His (H), L-Glu (E), L-Asn (N), L-Gln (Q), L-Asp (D), L-Lys (K) and L-Arg (R). Genetically non-encoded hydrophilic amino acids include the D-isomers of the above-listed genetically-encoded amino acids, ornithine (Orn), 2,3-diaminobutyric acid (Dab) and homoserine (hSer).

“Acidic Amino Acid” refers to a hydrophilic amino acid having a side chain pK value of less than 7 under physiological conditions. Acidic amino acids typically have negatively charged side chains at physiological pH due to loss of a hydrogen ion. Genetically encoded acidic amino acids include, but are not limited to, L-Glu (E) and L-Asp (D). Genetically non-encoded acidic amino acids include, but are not limited to, D-Glu (e) and D-Asp (d).

“Basic Amino Acid” refers to a hydrophilic amino acid having a side chain pK value of greater than about 7 under physiological conditions. Basic amino acids typically have positively charged side chains at physiological pH due to association with hydronium ion. Genetically encoded basic amino acids include, but are not limited to, L-His (H), L-Arg (R) and L-Lys (K). Although L-His might have a pK value slightly less than 7.0 when included in a polypeptide, L-His residues are generally classified as basic amino acids.

Genetically non-encoded basic amino acids include, but are not limited to, the D-isomers of the above-listed genetically-encoded amino acids, ornithine (Orn) and 2,3-diaminobutyric acid (Dab).

“Polar Amino Acid” refers to a hydrophilic amino acid having a side chain that is uncharged at physiological pH, but which comprises at least one covalent bond in which the pair of electrons shared in common by two atoms is held more closely by one of the atoms and is thus capable of participating in a hydrogen bond. Genetically encoded polar amino acids include, but are not limited to, L-Asn (N), L-Gln (Q), L-Ser (S) and L-Thr (T). Genetically non-encoded polar amino acids include, but are not limited to, the D-isomers of the above-listed genetically-encoded amino acids and homoserine (hSer).

“Hydrophobic Amino Acid” refers to an amino acid having a side chain exhibiting a hydrophobicity of greater than zero according to the normalized consensus hydrophobicity scale of Eisenberg et al., 1984, J. Mol. Biol. 179:125–142. Genetically encoded hydrophobic amino acids include, but are not limited to, L-Pro (P), L-Ile (I), L-Phe (F), L-Val (V), L-Leu (L), L-Trp (W), L-Met (M), L-Ala (A), L-Gly (G) and L-Tyr (Y). Genetically non-encoded hydrophobic amino acids include, but are not limited to, the D-isomers of the above-listed genetically-encoded amino acids, norleucine (Nle) and N-methyl valine (MeVal).

“Aromatic Amino Acid” refers to a hydrophobic amino acid having a side chain comprising at least one aromatic or heteroaromatic ring. The aromatic or heteroaromatic ring may contain one or more substituents such as —OH, —SH, —CN, —F, —Cl, —Br, —I, —NO₂, —NO, —NH₂, —NHR, —NRR, —C(O)R, —C(O)OH, —C(O)OR, —C(O)NH₂, —C(O)NHR, —C(O)NRR and the like where each R is independently (C₁–C₆) alkyl, (C₂–C₆) alkenyl, or (C₂–C₆) alkynyl. Genetically encoded aromatic amino acids include, but are not limited to, L-Phe (F), L-Tyr (Y), L-Trp (W) and L-His (H). Genetically non-encoded aromatic amino acids include, but are not limited to, the D-isomers of the above-listed genetically-encoded amino acids.

“Apolar Amino Acid” refers to a hydrophobic amino acid having a side chain that is uncharged at physiological pH and which has bonds in which the pair of electrons shared in common by two atoms is generally held equally by each of the two atoms (i.e., the side chain is not polar). Genetically encoded apolar amino acids include, but are not limited to, L-Leu (L), L-Val (V), L-Ile (I), L-Met (M), L-Gly (G) and L-Ala (A). Genetically non-encoded apolar amino acids include, but are not limited to, the D-isomers of the above-listed genetically-encoded amino acids, norleucine (Nle) and N-methyl valine (MeVal).

“Aliphatic Amino Acid” refers to a hydrophobic amino acid having an aliphatic hydrocarbon side chain. Genetically encoded aliphatic amino acids include, but are not limited to, L-Ala (A), L-Val (V), L-Leu (L) and L-Ile (I). Genetically non-encoded aliphatic amino acids include, but are not limited to, the D-isomers of the above-listed genetically-encoded amino acids, norleucine (Nle) and N-methyl valine (MeVal).

“Helix-Breaking Amino Acid” refers to those amino acids that have a propensity to disrupt the structure of α -helices when contained at internal positions within the helix.

Amino acid residues exhibiting helix-breaking properties are well-known in the art (see, e.g., Chou & Fasman, 1978, Ann. Rev. Biochem. 47:251–276) and include, but are not limited to L-Pro (P), D-Pro (p), L-Gly (G) and potentially all

D-amino acids (when contained in an L-polypeptide; conversely, L-amino acids disrupt helical structure when contained in a D-polypeptide).

“Cysteine-like Amino Acid” refers to an amino acid having a side chain capable of participating in a disulfide linkage. Thus, cysteine-like amino acids generally have a side chain containing at least one thiol (—SH) group. Cysteine-like amino acids are unusual in that they can form disulfide bridges with other cysteine-like amino acids. The ability of L-Cys (C) -residues and other cysteine-like amino acids to exist in a polypeptide in either the reduced free —SH or oxidized disulfide-bridged form affects whether they contribute net hydrophobic or hydrophilic character to a polypeptide. Thus, while L-Cys (C) exhibits a hydrophobicity of 0.29 according to the consensus scale of Eisenberg (Eisenberg, 1984, supra), it is to be understood that for purposes of the present invention L-Cys (C) is categorized as a polar hydrophilic amino acid, notwithstanding the general classifications defined above. Other cysteine-like amino acids are similarly categorized as polar hydrophilic amino acids. Typical cysteine-like residues include, but are not limited to, penicillamine (Pen), homocysteine (hCys), etc.

As will be appreciated by those of skill in the art, the above-defined classes or categories are not mutually exclusive. Thus, amino acids having side chains exhibiting two or more physico-chemical properties can be included in multiple categories. For example, amino acid side chains having aromatic groups that have a side chain pKa that is ionizable above or below pH 7.0, such as His (H), may exhibit both aromatic hydrophobic properties and basic or acidic hydrophilic properties, and could therefore be included in both the aromatic and basic or acidic categories. Typically, amino acids will be categorized in the class or classes that most closely define their net physico-chemical properties. The appropriate categorization of any amino acid will be apparent to those of skill in the art.

The classifications of the genetically encoded and common non-encoded amino acids according to the categories defined above are summarized in Table 1, below. It is to be understood that Table 1 is for illustrative purposes only and does not purport to be an exhaustive list of the amino acid residues belonging to each class. Other amino acid residues not specifically mentioned herein can be readily categorized based on their observed physical and chemical properties in light of the definitions provided herein.

TABLE 1

Classification	CLASSIFICATIONS OF COMMONLY ENCOUNTERED AMINO ACIDS	
	Genetically Encoded	Genetically Non-Encoded
<u>Hydrophobic</u>		
Aromatic	F, Y, W	f, y, w
Apolar	L, V, I, M, G, A, P	l, v, i, m, a, p, Nle, MeVal
Aliphatic	A, V, L, I	a, v, l, i, Nle, MeVal
<u>Hydrophilic</u>		
Acidic	D, E	d, e
Basic	H, K, R	h, k, r, Orn, Dab
Polar	C, Q, N, S, T	c, q, n, s, t, hSer
Helix-Breaking	P, G	p

“Synagis” or “palivizumab” refers to the humanized monoclonal antibody that is sold under the tradename SYN-AGIS (MedImmune), or that is known by the name palivi-

zumab. Synagis comprises an immunoglobulin complex of a Synagis heavy chain and a Synagis light chain that specifically binds the F protein of respiratory syncytial virus (“RSV”), as defined herein.

“Synagis heavy chain” refers to a polypeptide having an amino acid sequence that corresponds identically to the amino acid sequence of SEQ ID NO:1 (FIG. 3A).

“Synagis light chain” refers to a polypeptide having an amino acid sequence that corresponds identically to the amino acid sequence of SEQ ID NO:7 (FIG. 3B).

“Smagis Fab” refers to the antigen binding fragment of Synagis which can be obtained by digesting Synagis with papain. Synagis Fab includes the antigen binding region of Synagis and comprises a complex of Synagis light chain (SEQ ID NO:7) and N-terminal fragment (residues 1 to 220) of Synagis heavy chain (SEQ ID NO:2) linked by a disulfide bridge between Cys 216 of SEQ ID NO:2 and Cys 214 of Synagis light chain (SEQ ID NO:7). Unless stated otherwise, “Synagis Fab” includes either wild-type Syangis Fab and mutant Synagis Fab as defined herein.

“Synagis Fc” refers to a fragment of Synagis which can be obtained by digesting Synagis with papain. Synagis Fc does not include the antigen binding region of Synagis and comprises a complex of two C-terminal fragments of Synagis heavy chain (SEQ ID NO:3) linked by at least two disulfide bridges, one between the Cys 222 residues of the two chains and the other between the Cys 225 residues of the two chains.

“Synagis Fv” refers to a complex comprising the N-terminal variable segment residues 1 to 105 of Synagis heavy chain (SEQ ID NO:1) and the N-terminal sequence residues 1 to 109 of Synagis light chain (SEQ. ID NO:7). Synagis Fv includes the complementarity determining regions (“CDRs”) of Synagis heavy chain, H1 (SEQ ID NO:4), H2 (SEQ ID NO:5) and H3 (SEQ ID NO:6), and the CDRs of Synagis light chain, L1 (SEQ ID NO:8), L2 (SEQ ID NO:9) and L3 (SEQ ID NO:10).

“Association” refers to a condition of proximity between a chemical entity or compound, or portions or fragments thereof, and a polypeptide such as Synagis Fab, or portions or fragments thereof. The association may be non-covalent, i.e., where the juxtaposition is energetically favored by, e.g., hydrogen-bonding, van der Waals, electrostatic or hydrophobic interactions, or it may be covalent.

“Co-Complex” refers to a complex between Synagis, Synagis Fab, Synagis Fv or another binding fragment of Synagis and another compound, for example, an antigen, an epitope, a hapten or an analog, a mimic or a fragment thereof or an inhibitor of Synagis.

“Antibody” or “Immunoglobulin” refers to a glycoprotein produced by B leukocyte cells in response to stimulation with an immunogen, or a synthetic or recombinant version or analog of such a glycoprotein. Antibodies comprise heavy chains and light chains linked together by disulfide bonds. IgG type antibodies typically comprise two antigen binding sites.

“Complementarity Determining Region” or “CDR” refers to the hypervariable regions of an antibody that form the three-dimensional cavity or surface where an antigen or an epitope binds to the antibody. Typically, heavy chains and light chains contribute three CDRs to the antigen binding region of an antibody.

“Antigen” refers to a substance that specifically binds with antibody CDRs.

“Epitope” refers to the smallest structural area on an antigen molecule that binds an antibody.

“Antigen binding site” or “antibody binding site” refers to the location on an antibody molecule where the antigen or epitope binds. The antigen binding site is located at the molecular surface defined by the N-terminal CDRs and/or in a cleft bordered by the N-terminal CDRs of the heavy and light chains of the Fab region of an antibody molecule.

“Crystallized Synagis” refers to Synagis which is in crystalline form.

“Crystallized Synagis Fab” refers to a Synagis Fab complex which is in the crystalline form.

“Wild-type” refers to a Synagis molecule, that comprises Synagis heavy chain corresponding identically to SEQ ID NO:1 and/or Synagis light chain corresponding identically to SEQ ID NO:7, or fragments thereof. Although Synagis is a humanized antibody not derived from a natural source, for convenience the phrase “wild-type” is used to refer to a molecule which corresponds identically to Synagis, or a fragment thereof, and the phrase “mutant” is used as defined below.

“Mutant” refers to a polypeptide or complex of polypeptides characterized by an amino acid sequence that differs from the wild-type Synagis heavy chain and/or light chain sequence by the substitution of at least one amino acid residue of the wild-type Synagis sequence with a different amino acid residue and/or by the addition and/or deletion of one or more amino acid residues to or from the wild-type Synagis sequence. The additions and/or deletions can be from an internal region of the wild-type Synagis sequence and/or at either or both of the N- or C-termini. A mutant may have, but need not have, Synagis activity. Preferably, a mutant displays biological activity that is substantially similar to that of Synagis.

“Conservative Mutant” refers to a mutant in which at least one amino acid residue from the wild-type Synagis heavy chain and/or light chain sequence is substituted with a different amino acid residue that has similar physical and chemical properties, i.e., an amino acid residue that is a member of the same class or category, as defined above. For example, a conservative mutant may be a polypeptide that differs in amino acid sequence from the wild-type Synagis sequence by the substitution of a specific aromatic Phe (F) residue with an aromatic Tyr (Y) or Trp (W) residue.

“Non-Conservative Mutant” refers to a mutant in which at least one amino acid residue from the wild-type Synagis heavy chain and/or light chain sequence is substituted with a different amino acid residue that has dissimilar physical and/or chemical properties, i.e., an amino acid residue that is a member of a different class or category, as defined above. For example, a non-conservative mutant may be a polypeptide that differs in amino acid sequence from the wild-type Synagis sequence by the substitution of an acidic Glu (E) residue with a basic Arg (R), Lys (K) or Orn residue.

“Deletion Mutant” refers to a mutant having an amino acid sequence that differs from the wild-type Synagis heavy chain and/or light chain sequence by the deletion of one or more amino acid residues from the wild-type sequence. The residues may be deleted from internal regions of the wild-type Synagis sequence and/or from one or both termini.

“Truncated Mutant” refers to a deletion mutant in which the deleted residues are from the N- and/or C-terminus of the wild-type Synagis sequence.

“Extended Mutant” refers to a mutant in which additional residues are added to the N- and/or C-terminus of the wild-type Synagis sequence.

“Methionine mutant” refers to (1) a mutant in which at least one methionine residue of the wild-type Synagis heavy

chain and/or light chain sequence is replaced with another residue, preferably with an aliphatic residue, most preferably with a Leu (L) or Ile (I) residue; or (2) a mutant in which a non-methionine residue, preferably an aliphatic residue, most preferably a Leu (L) or Ile (I) residue, of the wild-type Synagis sequence is replaced with a methionine residue.

“Selenomethionine mutant” refers to (1) a mutant which includes at least one selenomethionine (SeMet) residue, typically by substitution of one or more Met residues of the wild-type Synagis heavy chain and/or light chain sequence with a SeMet residue, or by addition of one or more SeMet residues at one or more termini, or (2) a methionine mutant in which at least one Met residue is substituted with a SeMet residue. Preferred SeMet mutants are those in which each Met residue is substituted with a SeMet residue.

“Cysteine mutant” refers to (1) a mutant in which at least one cysteine residue of the wild-type Synagis heavy chain and/or light chain sequence is replaced with another residue, preferably with a Ser (S) residue; or (2) a mutant in which a non-cysteine residue, preferably a Ser (S) residue, of the wild-type Synagis sequence is replaced with a cysteine residue.

“Selenocysteine mutant” refers to (1) a mutant which includes at least one selenocysteine (SeCys) residue, typically by substitution of one or more Cys residues of the wild-type Synagis heavy chain and/or light chain sequence with a SeCys residue, or by addition of one or more SeCys residues at one or more termini, or (2) a cysteine mutant in which at least one Cys residue is substituted with a SeCys residue. Preferred SeCys mutants are those in which each Cys residue or selected Cys residues of Synagis not typically involved in disulfide bonding under physiological conditions is substituted with a SeCys residue. One such Cys residue in the Synagis Fab fragment that may be substituted with selenocysteine is Cys 25 in the light chain (SEQ. ID NO: 7).

“Homologue” refers to a polypeptide having at least 70%, 80%, 90%, 95% or 99% amino acid sequence identity or having a BLAST score of 1×10^{-6} over at least 100 amino acids (Altschul et al., 1997, *Nucleic Acids Res.* 25:3389–402) with wild-type Synagis, Synagis heavy chain and/or Synagis light chain, or any functional domain of Synagis, Synagis heavy chain and/or Synagis light chain, as defined herein.

“Crystal” refers to a composition comprising a polypeptide and/or polypeptides in crystalline form. The term “crystal” includes native crystals, heavy-atom derivative crystals and co-crystals, as defined herein.

“Native Crystal” refers to a crystal wherein the polypeptide and/or polypeptides are substantially pure. As used herein, native crystals do not include crystals of polypeptides comprising amino acids that are modified with heavy atoms, such as crystals of selenomethionine mutants, selenocysteine mutants, etc.

“Heavy-atom Derivative Crystal” refers to a crystal wherein the polypeptide and/or polypeptides are in association with one or more heavy-metal atoms. As used herein, heavy-atom derivative crystals include native crystals into which a heavy metal atom is soaked, as well as crystals of selenomethionine mutants and selenocysteine mutants.

“Co-Crystal” refers to a composition comprising a co-complex, as defined above, in crystalline form. Co-crystals include native co-crystals and heavy-atom derivative co-crystals.

“Diffraction Quality Crystal” refers to a crystal that is well-ordered and of a sufficient size, i.e., at least 10 μm ,

preferably at least 50 μm , and most preferably at least 100 μm in its smallest dimension such that it produces measurable diffraction to at least 3 \AA resolution, preferably to at least 2 \AA resolution, and most preferably to at least 1.5 \AA resolution or lower. Diffraction quality crystals include native crystals, heavy-atom derivative crystals, and co-crystals.

“Unit Cell” refers to the smallest and simplest volume element (i.e., parallelepiped-shaped block) of a crystal that is completely representative of the unit or pattern of the crystal, such that the entire crystal can be generated by translation of the unit cell. The dimensions of the unit cell are defined by six numbers: dimensions a, b and c and angles α , β and γ (Blundel et al., 1976, Protein Crystallography, Academic Press.). A crystal is an efficiently packed array of many unit cells.

“Triclinic Unit Cell” refers to a unit cell in which $a \neq b \neq c$ and $\alpha \neq \beta \neq \gamma$.

“Monoclinic Unit Cell” refers to a unit cell in which $a \neq b \neq c$; $\alpha = \gamma = 90^\circ$; and $\beta \neq 90^\circ$, defined to be $\geq 90^\circ$.

“Orthorhombic Unit Cell” refers to a unit cell in which $a \neq b \neq c$; and $\alpha = \beta = \gamma = 90^\circ$.

“Tetragonal Unit Cell” refers to a unit cell in which $a = b \neq c$; and $\alpha = \beta = \gamma = 90^\circ$.

“Trigonal/Rhombohedral Unit Cell” refers to a unit cell in which $a = b = c$; and $\alpha = \beta = \gamma \neq 90^\circ$.

“Trigonal/Hexagonal Unit Cell” refers to a unit cell in which $a = b = c$; $\alpha = \beta = 90^\circ$; and $\gamma = 120^\circ$.

“Cubic Unit Cell” refers to a unit cell in which $a = b = c$; and $\alpha = \beta = \gamma = 90^\circ$.

“Crystal Lattice” refers to the array of points defined by the vertices of packed unit cells.

“Space Group” refers to the set of symmetry operations of a unit cell. In a space group designation (e.g., C2) the capital letter indicates the lattice type and the other symbols represent symmetry operations that can be carried out on the unit cell without changing its appearance.

“Asymmetric Unit” refers to the largest aggregate of molecules in the unit cell that possesses no symmetry elements that are part of the space group symmetry, but that can be juxtaposed on other identical entities by symmetry operations.

“Crystallographically-Related Dimer” refers to a dimer of two molecules wherein the symmetry axes or planes that relate the two molecules comprising the dimer coincide with the symmetry axes or planes of the crystal lattice.

“Non-Crystallographically-Related Dimer” refers to a dimer of two molecules wherein the symmetry axes or planes that relate the two molecules comprising the dimer do not coincide with the symmetry axes or planes of the crystal lattice.

“Isomorphous Replacement” refers to the method of using heavy-atom derivative crystals to obtain the phase information necessary to elucidate the three-dimensional structure of a crystallized polypeptide (Blundel et al., 1976, Protein Crystallography, Academic Press.).

“Multi-Wavelength Anomalous Dispersion or MAD” refers to a crystallographic technique in which X-ray diffraction data are collected at several different wavelengths from a single heavy-atom derivative crystal, wherein the heavy atom has absorption edges near the energy of incoming X-ray radiation. The resonance between X-rays and electron orbitals leads to differences in X-ray scattering from absorption of the X-rays (known as anomalous scattering)

and permits the locations of the heavy atoms to be identified, which in turn provides phase information for a crystal of a polypeptide. A detailed discussion of MAD analysis can be found in Hendrickson, 1985, Trans. Am. Crystallogr. Assoc., 21:11; Hendrickson et al, 1990, EMBO J. 9:1665; and Hendrickson, 1991, Science 4:91.

“Single Wavelength Anomalous Dispersion or SAD” refers to a crystallographic technique in which X-ray diffraction data are collected at a single wavelength from a single native or heavy-atom derivative crystal, and phase information is extracted using anomalous scattering information from atoms such as sulfur or chlorine in the native crystal or from the heavy atoms in the heavy-atom derivative crystal. The wavelength of X-rays used to collect data for this phasing technique need not be close to the absorption edge of the anomalous scatterer. A detailed discussion of SAD analysis can be found in Brodersen et al., 2000, Acta Cryst., D56:431–441.

“Single Isomorphous Replacement With Anomalous Scattering or SIRAS” refers to a crystallographic technique that combines isomorphous replacement and anomalous scattering techniques to provide phase information for a crystal of a polypeptide. X-ray diffraction data are collected at a single wavelength, usually from a single heavy-atom derivative crystal. Phase information obtained only from the location of the heavy atoms in a single heavy-atom derivative crystal leads to an ambiguity in the phase angle, which is resolved using anomalous scattering from the heavy atoms. Phase information is therefore extracted from both the location of the heavy atoms and from anomalous scattering of the heavy atoms. A detailed discussion of SIRAS analysis can be found in North, 1965, Acta Cryst. 18:212–216; Matthews, 1966, Acta Cryst. 20:82–86.

“Molecular Replacement” refers to the method of calculating initial phases for a new crystal of a polypeptide whose structure coordinates are unknown by orienting and positioning a polypeptide whose structure coordinates are known within the unit cell of the new crystal so as to best account for the observed diffraction pattern of the new crystal. Phases are then calculated from the oriented and positioned polypeptide and combined with observed amplitudes to provide an approximate Fourier synthesis of the structure of the polypeptides comprising the new crystal. This, in turn, is subject to any of several methods of refinement to provide a final, accurate set of structure coordinates for the new crystal (Lattman, 1985, Methods in Enzymology 115:55–77; Rossmann, 1972, “The Molecular Replacement Method,” Int. Sci. Rev. Ser. No. 13, Gordon & Breach, New York; Brünger et al, 1991, Acta Crystallogr A. 47:195–204).

“Having Substantially the Same Three-dimensional Structure” refers to a polypeptide that is characterized by a set of atomic structure coordinates that have a root mean square deviation (r.m.s.d.) of less than or equal to about 2 \AA when superimposed onto the atomic structure coordinates of Table 2, or a subset thereof such as individual CDRs, individual secondary structure elements or grouped secondary structure elements such as β -sheets, when at least about 50% to 100% of the $C\alpha$ atoms of the coordinates are included in the superposition.

“ $C\alpha$.” As used herein, “ $C\alpha$ ” refers to the alpha carbon of an amino acid residue.

5. BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 provides a photograph of an orthorhombic crystal of Synagis Fab;

FIG. 2 provides a diffraction pattern (1° oscillation) of Synagis Fab prepared as described in the Examples;

FIG. 3A provides the amino acid sequences of Synagis heavy chain (SEQ ID NO:1), Synagis heavy chain Fab fragment (SEQ ID NO:2), Synagis heavy chain Fc fragment (SEQ ID NO:3), Synagis heavy chain variable region H1 (SEQ ID NO:4), heavy chain variable region H2 (SEQ ID NO:5) and Synagis heavy chain variable region H3 (SEQ ID NO:6).

FIG. 3B provides the amino acid sequences of Synagis light chain (SEQ ID NO:7), Synagis light chain variable region L1 (SEQ ID NO:8), Synagis light chain variable region L2 (SEQ ID NO:9) and Synagis light chain variable region L3 (SEQ ID NO:10).

FIG. 4 provides a ribbon diagram of the three-dimensional X-ray diffraction structure of Synagis Fab;

FIG. 5 provides a photograph of a tetragonal crystal form of Synagis Fab;

FIG. 6 provides a schematic representation of a generalized IgG type antibody showing the relative positions of the light chain VL and CL domains and the heavy chain VH, CH1, CH2 and CH3 domains;

FIG. 7A provides a ribbon diagram of the three-dimensional structure of Synagis VH and VL domains;

FIG. 7B provides a ribbon diagram of the three-dimensional structure of Synagis Fab CL and CH1 domains;

FIG. 8 provides a stereo view of a superposition of Synagis light chain CDRs L1, L2 & L3 with representative canonical structures;

FIG. 9 provides a stereo view of a superposition of Synagis heavy chain CDRs H1 & H2 with representative canonical structures; and

FIG. 10 provides a Ramachandran plot of the model Synagis Fab crystal structure.

5.1. BRIEF DESCRIPTION OF THE TABLES

Table 1 Classifications of Commonly Encountered Amino Acids;

Table 2 Coordinates of Synagis Fab;

Table 3 Description and Comparison of Synagis Light Chain CDR Canonical Structure;

Table 4 Description and Comparison of Synagis Heavy Chain CDR Canonical Structure;

Table 5 Data Collection Summary;

Table 6 Refinement Parameters.

6. DETAILED DESCRIPTION OF THE INVENTION

6.1 Crystalline Synagis Fab

The crystals of the invention may be obtained include native crystals and heavy-atom derivative crystals. Native crystals generally comprise substantially pure polypeptides corresponding to Synagis Fab in crystalline form.

It is to be understood that the crystalline Synagis Fab of the invention that can be obtained is not limited to wild-type Synagis Fab. Indeed, the crystals may comprise mutants of wild-type Synagis Fab. Mutants of wild-type Synagis Fab are obtained by replacing at least one amino acid residue in the sequence of the wild-type Synagis Fab with a different amino acid residue, or by adding or deleting one or more amino acid residues within the wild-type sequence and/or at the N- and/or C-terminus of the wild-type Synagis Fab. Such mutants should crystallize under crystallization conditions that are substantially similar to those used to crystallize the wild-type Synagis Fab.

The types of mutants contemplated by this invention include conservative mutants, non-conservative mutants, deletion mutants, truncated mutants, extended mutants, methionine mutants, selenomethionine mutants, cysteine mutants and selenocysteine mutants. A mutant or a fragment may have, but need not have, Synagis activity. Preferably, a mutant or a fragment displays biological activity that is substantially similar to that of the wild-type Synagis. Methionine, selenomethionine, cysteine, and selenocysteine mutants are particularly useful for producing heavy-atom derivative crystals, as described in detail, below.

It will be recognized by one of skill in the art that the types of mutants contemplated herein are not mutually exclusive; that is, for example, a polypeptide having a conservative mutation in one amino acid may in addition have a truncation of residues at the N-terminus, and several Leu or Ile→Met mutations.

Sequence alignments of polypeptides in a protein family or of homologous polypeptide domains can be used to identify potential amino acid residues in the polypeptide sequence that are candidates for mutation. Identifying mutations that do not significantly interfere with the three-dimensional structure of Synagis and/or that do not deleteriously affect, and that may even enhance, the activity of Synagis will depend, in part, on the region where the mutation occurs. In the CDR regions of the molecule, such as those shown in FIG. 4, non-conservative substitutions as well as conservative substitutions may be tolerated without significantly disrupting the three-dimensional structure and/or biological activity of the molecule. In framework regions, or regions containing significant secondary structure, such as those regions shown in FIG. 4, conservative amino acid substitutions are preferred.

Conservative amino acid substitutions are well-known in the art, and include substitutions made on the basis of a similarity in polarity, charge, solubility, size, hydrophobicity and/or the hydrophilicity of the amino acid residues involved. Typical conservative substitutions are those in which the amino acid is substituted with a different amino acid that is a member of the same class or category, as those classes are defined herein. Thus, typical conservative substitutions include aromatic to aromatic, apolar to apolar, aliphatic to aliphatic, acidic to acidic, basic to basic, polar to polar, etc. Other conservative amino acid substitutions are well known in the art. It will be recognized by those of skill in the art that generally, a total of about 20% or fewer, typically about 10% or fewer, most usually about 5% or fewer, of the amino acids in the wild-type polypeptide sequence can be conservatively substituted with other amino acids without deleteriously affecting the biological activity and/or three-dimensional structure of the molecule, provided that such substitutions do not involve residues that are critical for structure or activity, as discussed above. There has been no complete examination of the effect of conservative mutations of the closely conserved amino acids in immunoglobulin framework regions.

In some embodiments, it may be desirable to make mutations in the active site of a protein or in the antigen binding site of an antibody, e.g., to reduce or completely eliminate antibody activity. While in most instances the amino acids of Synagis will be substituted with genetically-encoded amino acids, in certain circumstances mutants may include genetically non-encoded amino acids. For example, non-encoded derivatives of certain encoded amino acids, such as SeMet and/or SeCys, may be incorporated into the polypeptide chain using biological expression systems (such as SeMet and SeCys mutants are described in more detail, infra).

Alternatively, in instances where the mutant will be prepared in whole or in part by chemical synthesis, virtually any non-encoded amino acids may be used, ranging from D-isomers of the genetically encoded amino acids to non-encoded naturally-occurring natural and synthetic amino acids.

Conservative amino acid substitutions for many of the commonly known non-genetically encoded amino acids are well known in the art. Conservative substitutions for other non-encoded amino acids can be determined based on their physical properties as compared to the properties of the genetically encoded amino acids.

In some instances, it may be particularly advantageous or convenient to substitute, delete from and/or add amino acid residues to Synagis in order to provide convenient cloning sites in cDNA encoding the polypeptide, to aid in purification of the polypeptide, etc. Such substitutions, deletions and/or additions that do not substantially alter the three dimensional structure of the native Synagis will be apparent to those having skills in the art. These substitutions, deletions and/or additions include, but are not limited to, His tags, intein-containing self-cleaving tags, maltose binding protein fusions, glutathione S-transferase protein fusions, antibody fusions, green fluorescent protein fusions, signal peptide fusions, biotin accepting peptide fusions, and the like.

Mutations may also be introduced into a polypeptide sequence where there are residues, e.g., cysteine residues, that interfere with crystallization. Such cysteine residues can be substituted with an appropriate amino acid that does not readily form covalent bonds with other amino acid residues under crystallization conditions; e.g., by substituting the cysteine with Ala, Ser or Gly. Any cysteine residue that does not form disulfide bonds either between a heavy chain and a light chain or between two heavy chains of Synagis is a good candidate for replacement. Preferably, Cys residues that are known to participate in disulfide bridges are not substituted or are conservatively substituted with other cysteine-like amino acids so that the residue can participate in a disulfide bridge. In addition, other cysteine residues located in a non-helical or non- β -stranded segment, based on secondary structure assignments, are good candidates for replacement. One such Cys residue in the Synagis Fab crystal structure is at light chain position 25 (SEQ. ID NO: 7).

It should be noted that the mutants contemplated herein need not exhibit Synagis activity. Indeed, amino acid substitutions, additions or deletions that interfere with the activity of Synagis are specifically contemplated by the invention. Such crystalline polypeptides, or the atomic structure coordinates obtained therefrom, can be used to provide phase information to aid the determination of the three-dimensional X-ray structures of other related or non-related crystalline polypeptides.

The heavy-atom derivative crystals from which the atomic structure coordinates of the invention can be obtained generally comprise a crystalline Synagis Fab complex in association with one or more heavy metal atoms. The complex may correspond to a wild-type or a mutant Synagis Fab, which may optionally be in co-complex with one or more molecules, as previously described. The complex may also correspond to another Synagis fragment or to a mutated form thereof. There are two types of heavy-atom derivatives of polypeptides: heavy-atom derivatives resulting from exposure of the protein to a heavy metal in solution, wherein crystals are grown in medium comprising the heavy metal,

or in crystalline form, wherein the heavy metal diffuses into the crystal, and heavy-atom derivatives wherein the polypeptide comprises heavy-atom containing amino acids, e.g., selenomethionine and/or selenocysteine mutants.

In practice, heavy-atom derivatives of the first type can be formed by soaking a native crystal in a solution comprising heavy metal atom salts, or organometallic compounds, e.g., lead chloride, gold thiomalate, ethylmercurithiosalicylic acid-sodium salt (thimerosal), uranyl acetate, platinum tetrachloride, osmium tetroxide, zinc sulfate, and cobalt hexamine, which can diffuse through the crystal and bind to the crystalline polypeptide.

Heavy-atom derivatives of this type can also be formed by adding to a crystallization solution comprising the polypeptide to be crystallized an amount of a heavy metal atom salt, which may associate with the protein and be incorporated into the crystal. The location(s) of the bound heavy metal atom(s) can be determined by X-ray diffraction analysis of the crystal. This information, in turn, is used to generate the phase information needed to construct the three-dimensional structure of the protein.

Heavy-atom derivative crystals may also be prepared from polypeptides that include one or more SeMet and/or SeCys residues (SeMet and/or SeCys mutants). Such selenocysteine or selenomethionine mutants may be made from wild-type or mutant Synagis Fab by expression of Synagis Fab-encoding cDNAs in auxotrophic *E. coli* strains. Hendrickson et al., 1990, EMBO J. 9(5):1665-1672. The selenocysteine or selenomethionine mutants may also be made from intact Synagis, other fragments of Synagis, or mutated forms thereof. In this method, a cDNA encoding a wild-type or mutant Synagis polypeptide may be expressed in a host organism on a growth medium depleted of either natural cysteine or methionine (or both) but enriched in selenocysteine or selenomethionine (or both). Alternatively, selenocysteine or selenomethionine mutants may be made using nonauxotrophic *E. coli* strains, e.g., by inhibiting methionine biosynthesis in these strains with high concentrations of Ile, Lys, Thr, Phe, Leu or Val and then providing selenomethionine in the medium (Doublé, 1997, Methods in Enzymology 276:523-530). Furthermore, selenocysteine can be selectively incorporated into polypeptides by exploiting the prokaryotic and eukaryotic mechanisms for selenocysteine incorporation into certain classes of proteins in vivo, as described in U.S. Pat. No. 5,700,660 to Leonard et al. (filed Jun. 7, 1995). One of skill in the art will recognize that selenocysteine is preferably not incorporated in place of cysteine residues that form disulfide bridges, as these may be important for maintaining the three-dimensional structure of the protein and are preferably not to be eliminated. One of skill in the art will further recognize that, in order to obtain accurate phase information, approximately one selenium atom should be incorporated for every 140 amino acid residues of the polypeptide chain. The number of selenium atoms incorporated into the polypeptide chain can be conveniently controlled by designing a Met or Cys mutant having an appropriate number of Met and/or Cys residues, as described more fully below.

In some instances, a polypeptide to be crystallized may not contain cysteine or methionine residues. Therefore, if selenomethionine and/or selenocysteine mutants are to be used to obtain heavy-atom derivative crystals, methionine and/or cysteine residues must be introduced into the polypeptide chain. Likewise, Cys residues may be introduced into the polypeptide chain if the use of a cysteine-binding heavy metal, such as mercury, is contemplated for production of a heavy-atom derivative crystal.

Such mutations are preferably introduced into the polypeptide sequence at sites that will not disturb the overall protein fold. For example, a residue that is conserved among many members of the protein family or that is thought to be involved in maintaining its activity or structural integrity, as determined by, e.g., sequence alignments, should not be mutated to a Met or Cys. In addition, conservative mutations, such as Ser to Cys, or Leu or Ile to Met, are preferably introduced. One additional consideration is that, in order for a heavy-atom derivative crystal to provide phase information for structure determination, the location of the heavy atom(s) in the crystal unit cell must be determinable and provide phase information. Therefore, a mutation is preferably not introduced into a portion of the protein that is likely to be mobile, e.g., at, or within about 1–5 residues of, the N- and C-termini.

Conversely, if there are too many methionine and/or cysteine residues in a polypeptide sequence, over-incorporation of the selenium-containing side chains can lead to the inability of the polypeptide to fold and/or crystallize, as well as to complications in solving the crystal structure. In this case, methionine and/or cysteine mutants are prepared by substituting one or more of these Met and/or Cys residues with another residue. The considerations for these substitutions are the same as those discussed above for mutations that introduce methionine and/or cysteine residues into the polypeptide. Specifically, the Met and/or Cys residues are preferably conservatively substituted with Leu/Ile and Ser, respectively.

As DNA encoding cysteine and methionine mutants can be used in the methods described above for obtaining SeCys and SeMet heavy-atom derivative crystals, the preferred Cys or Met mutant will have one Cys or Met residue for every 140 amino acids.

6.2 Production of Polypeptides

The native and mutated Synagis polypeptides described herein may be chemically synthesized in whole or part using techniques that are well-known in the art (see, e.g., Creighton, 1983, *Proteins: Structures and Molecular Principles*, W. H. Freeman & Co., NY.). Alternatively, methods that are well known to those skilled in the art can be used to construct expression vectors containing a native or mutated Synagis polypeptide coding sequence and appropriate transcriptional/translational control signals. These methods include in vitro recombinant DNA techniques, synthetic techniques and in vivo recombination/genetic recombination. See, for example, the techniques described in Maniatis et al., 1989, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory, NY and Ausubel et al., 1989, *Current Protocols in Molecular Biology*, Greene Publishing Associates and Wiley Interscience, NY.

A variety of host-expression vector systems may be utilized to express Synagis coding sequences. These include but are not limited to microorganisms such as bacteria transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing the Synagis coding sequences; yeast transformed with recombinant yeast expression vectors containing the Synagis coding sequences; insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus) containing the Synagis coding sequences; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing the Synagis coding sequences; or

animal cell systems. The expression elements of these systems vary in their strength and specificities.

Specifically designed vectors allow the shuttling of DNA between hosts such as bacteria-yeast or bacteria-animal cells. An appropriately constructed expression vector may contain: an origin of replication for autonomous replication in host cells, selectable markers, a limited number of useful restriction enzyme sites, a potential for high copy number, and active promoters. A promoter is defined as a DNA sequence that directs RNA polymerase to bind to DNA and initiate RNA synthesis. A strong promoter is one that causes mRNAs to be initiated at high frequency.

Depending on the host/vector system utilized, any of a number of suitable transcription and translation elements, including constitutive and inducible promoters, may be used in the expression vector. For example, when cloning in bacterial systems, inducible promoters such as the T7 promoter, pL of bacteriophage λ , plac, ptrp, ptac (ptrp-lac hybrid promoter) and the like may be used; when cloning in insect cell systems, promoters such as the baculovirus polyhedrin promoter may be used; when cloning in plant cell systems, promoters derived from the genome of plant cells (e.g., heat shock promoters; the promoter for the small subunit of RUBISCO; the promoter for the chlorophyll a/b binding protein) or from plant viruses (e.g., the 35S RNA promoter of CaMV; the coat protein promoter of TMV) may be used; when cloning in mammalian cell systems, promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g., the adenovirus late promoter; the vaccinia virus 7.5K promoter) may be used; when generating cell lines that contain multiple copies of the tyrosine kinase domain DNA, SV40-, BPV- and EBV-based vectors may be used with an appropriate selectable marker.

The expression vector may be introduced into host cells via any one of a number of techniques including but not limited to transformation, transfection, infection, protoplast fusion, and electroporation. The expression vector-containing cells are clonally propagated and individually analyzed to determine whether they produce Synagis. Identification of Synagis expressing host cell clones may be done by several means, including but not limited to immunological reactivity with anti-Synagis antibodies, and the presence of host cell-associated Synagis activity.

Expression of Synagis cDNA may also be performed using in vitro produced synthetic mRNA. Synthetic mRNA can be efficiently translated in various cell-free systems, including but not limited to wheat germ extracts and reticulocyte extracts, as well as efficiently translated in cell based systems, including but not limited to microinjection into frog oocytes.

To determine the Synagis cDNA sequence(s) that yields optimal levels of Synagis activity and/or Synagis protein, modified Synagis cDNA molecules are constructed. Host cells are transformed with the cDNA molecules and the levels of Synagis RNA and/or protein are measured.

Levels of Synagis protein in host cells are quantitated by a variety of methods such as immunoaffinity and/or ligand affinity techniques, Synagis-specific affinity beads or Synagis-specific antibodies are used to isolate ^{35}S -methionine labeled or unlabeled Synagis protein. Labeled or unlabeled Synagis protein is analyzed by SDS-PAGE. Unlabeled Synagis is detected by Western blotting, ELISA or RIA employing Synagis-specific antibodies.

Following expression of a Synagis polypeptide in a recombinant host cell, the Synagis polypeptide may be

recovered to provide Synagis Fab in active form. Several Synagis purification procedures are available and suitable for use. Recombinant Synagis may be purified from cell lysates or from conditioned culture media, by various combinations of, or individual application of, fractionation, or chromatography steps that are known in the art.

In addition, a recombinant Synagis polypeptide can be separated from other cellular proteins by use of an immunoaffinity column made with monoclonal or polyclonal antibodies specific for full length nascent Synagis or polypeptide fragments thereof.

Alternatively, a Synagis polypeptide may be recovered from a host cell in an unfolded, inactive form, e.g., from inclusion bodies of bacteria. Proteins recovered in this form may be solubilized using a denaturant, e.g., guanidinium hydrochloride, and then refolded into an active form using methods known to those skilled in the art, such as dialysis (Rudolph & Lee, *FASEB J.*, 10:49–56).

6.3 Crystallization of Polypeptides and Characterization of Crystal

The native crystalline Synagis Fab from which the atomic structure coordinates of the invention are obtained can be obtained by conventional means and are well-known in the art of protein crystallography, including batch, liquid bridge, dialysis, and vapor diffusion methods (see, e.g., McPherson, 1982, *Preparation and Analysis of Protein Crystals*, John Wiley, New York; McPherson, 1990, *Eur. J. Biochem.* 189:1–23.; Weber, 1991, *Adv. Protein Chem.* 41:1–36.).

Generally, native crystals are grown by dissolving substantially pure Synagis Fab in an aqueous buffer containing a precipitant at a concentration just below that necessary to precipitate the protein. Examples of precipitants include, but are not limited to, polyethylene glycol, ammonium sulfate, 2-methyl-2,4-pentanediol, sodium citrate, sodium chloride, glycerol, isopropanol, lithium sulfate, sodium acetate, sodium formate, potassium sodium tartrate, ethanol, hexanediol, ethylene glycol, dioxane, t-butanol and combinations thereof. Water is removed by controlled evaporation to produce precipitating conditions, which are maintained until crystal growth ceases.

In a preferred embodiment, native crystals are grown by vapor diffusion in hanging drops (McPherson, 1982, *Preparation and Analysis of Protein Crystals*, John Wiley, New York; McPherson, 1990, *Eur. J. Biochem.* 189:1–23.). In this method, the polypeptide/precipitant solution is allowed to equilibrate in a closed container with a larger aqueous reservoir having a precipitant concentration optimal for producing crystals. Generally, less than about 25 μL of substantially pure polypeptide solution is mixed with an equal volume of reservoir solution, giving a precipitant concentration about half that required for crystallization. This solution is suspended as a droplet underneath a coverslip, which is sealed onto the top of the reservoir. The sealed container is allowed to stand, usually for about 2–6 weeks, until crystals grow.

For native crystals from which the atomic structure coordinates of the invention are obtained, it has been found that hanging drops or sitting drops containing about 2 μL of Synagis Fab (15 mg/mL in 1 mM Tris, pH 7.6) and 2 μL reservoir solution (15% w/v PEG 4000, 10% 2-propanol, 0.2 M ammonium sulfate and 100 mM Tris, pH 8.5) suspended over 500 μL reservoir solution for about 10 to 14 days at 22° C. provide diffraction quality crystals.

Of course, those having skill in the art will recognize that the above-described crystallization conditions can be varied.

Such variations may be used alone or in combination, and include polypeptide solutions containing Synagis Fab concentrations between 3 mg/mL and 10 mg/mL, Tris concentrations between 50 mM and 100 mM, 2-propanol concentrations between 7% and 20%, pH ranges between 6.4 and 11, PEG concentrations of 7% to 10%, PEG molecular weights of 3350 to 8000; and equilibrated with reservoir solutions containing PEG 4000 concentrations between 14% and 20% (w/v), polyethylene glycol molecular weights between 3350 and 8000, 2-propanol concentrations between 7% and 20% (v/v). Other buffer solutions may be used such as sodium cacodylate, HEPES, CAPS, CAPSO, bicine and glycine buffer, so long as the desired pH range is maintained.

Synagis Fab has also been crystallized using ammonium sulfate as the precipitant. These crystals (FIG. 5) are grown from a solution of 15 mg/ml Synagis Fab with equal volume of 1.8 to 2.1 M ammonium sulfate, pH 9.0, equilibrated against 1.8 to 2.1 M ammonium sulfate. The crystals are tetragonal, space group R32 with $a=b=92.63 \text{ \AA}$, $c=179.02 \text{ \AA}$, $\alpha=\beta=\gamma=90^\circ$. These Synagis Fab crystals diffract to 3.5 \AA or better.

Heavy-atom derivative crystals can be obtained by soaking native crystals in mother liquor containing salts of heavy metal atoms. It has been found that soaking a native crystal in a solution identical to the crystallization solution and additionally containing 1 mM to about 100 mM of a molecule containing the desired heavy atom (Hg, Ur, Pt, Sm, Cd, W, Os, Ir, Pb, ect.) for about 1 hour to several months. One to two day soakings of the crystal in the heavy atom containing solution should be sufficient to provide derivative crystals suitable for use as isomorphous replacements in determining the X-ray crystal structure of the Synagis Fab polypeptide.

Heavy-atom derivative crystals can also be obtained from SeMet and/or SeCys mutants, as described above for native crystals.

Mutant proteins may crystallize under slightly different crystallization conditions than wild-type protein, or under very different crystallization conditions, depending on the nature of the mutation, and its location in the protein. For example, a non-conservative mutation may result in alteration of the hydrophilicity of the mutant, which may in turn make the mutant protein either more soluble or less soluble than the wild-type protein. Typically, if a protein becomes more hydrophilic as a result of a mutation, it will be more soluble than the wild-type protein in an aqueous solution and a higher precipitant concentration will be needed to cause it to crystallize. Conversely, if a protein becomes less hydrophilic as a result of a mutation, it will be less soluble in an aqueous solution and a lower precipitant concentration will be needed to cause it to crystallize. If the mutation happens to be in a region of the protein involved in crystal lattice contacts, crystallization conditions may be affected in more unpredictable ways.

Co-crystals can be obtained by soaking a native crystal in mother liquor containing compound that binds Synagis Fab such as an antigen or an analog thereof, or by co-crystallizing Synagis Fab in the presence of one or more binding compounds.

6.4 Characterization of Crystals

The dimensions of a unit cell of a crystal are defined by six numbers, the lengths of three unique edges, a , b , and c , and three unique angles, α , β , and γ . The type of unit cell that comprises a crystal is dependent on the values of these variables, as discussed above in Section 3.2.

When a crystal is placed in an X-ray beam, the incident X-rays interact with the electron cloud of the molecules that make up the crystal, resulting in X-ray scatter. The combination of X-ray scatter with the lattice of the crystal gives rise to nonuniformity of the scatter; areas of high intensity are called diffracted X-rays. The angle at which diffracted beams emerge from the crystal can be computed by treating diffraction as if it were reflection from sets of equivalent, parallel planes of atoms in a crystal (Bragg's Law). The most obvious sets of planes in a crystal lattice are those that are parallel to the faces of the unit cell. These and other sets of planes can be drawn through the lattice points. Each set of planes is identified by three indices, hkl. The h index gives the number of parts into which the a edge of the unit cell is cut, the k index gives the number of parts into which the b edge of the unit cell is cut, and the l index gives the number of parts into which the c edge of the unit cell is cut by the set of hkl planes. Thus, for example, the 235 planes cut the a edge of each unit cell into halves, the b edge of each unit cell into thirds, and the c edge of each unit cell into fifths. Planes that are parallel to the bc face of the unit cell are the 100 planes; planes that are parallel to the ac face of the unit cell are the 010 planes; and planes that are parallel to the ab face of the unit cell are the 001 planes.

When a detector is placed in the path of the diffracted X-rays, in effect cutting into the sphere of diffraction, a series of spots, or reflections, are recorded to produce a "still" diffraction pattern. Each reflection is the result of X-rays reflecting off one set of parallel planes, and is characterized by an intensity, which is related to the distribution of molecules in the unit cell, and hkl indices, which correspond to the parallel planes from which the beam producing that spot was reflected. If the crystal is rotated about an axis perpendicular to the X-ray beam, a large number of reflections is recorded on the detector, resulting in a diffraction pattern as shown in FIG. 2.

The unit cell dimensions and space group of a crystal can be determined from its diffraction pattern. First, the spacing of reflections is inversely proportional to the lengths of the edges of the unit cell. Therefore, if a diffraction pattern is recorded when the X-ray beam is perpendicular to a face of the unit cell, two of the unit cell dimensions may be deduced from the spacing of the reflections in the x and y directions of the detector, the crystal-to-detector distance, and the wavelength of the X-rays. Those of skill in the art will appreciate that, in order to obtain all three unit cell dimensions, the crystal must be rotated such that the X-ray beam is perpendicular to another face of the unit cell. Second, the angles of a unit cell can be determined by the angles between lines of spots on the diffraction pattern. Third, the absence of certain reflections and the repetitive nature of the diffraction pattern, which may be evident by visual inspection, indicate the internal symmetry, or space group, of the crystal. Therefore, a crystal may be characterized by its unit cell and space group, as well as by its diffraction pattern. Because the lengths of the unit cell axes in a protein crystal are large and the concomitant reciprocal cell lengths are very short, the unit cell dimensions and space group of a protein crystal can be determined from one reciprocal space photograph if the crystal is rotated through approximately one degree. A digital representative of such a photograph is shown in FIG. 2 for the orthorhombic Synagis Fab crystal.

Once the dimensions of the unit cell are determined, the likely number of polypeptides in the asymmetric unit can be deduced from the size of the polypeptide, the density of the average protein, and the typical solvent content of a protein

crystal, which is usually in the range of 30–70% of the unit cell volume (Matthews, 1968. *J. Mol. Biol.* 33:491–497).

The Synagis Fab crystals of the present invention are generally characterized by a diffraction pattern, as shown in FIG. 2. The crystals are further characterized by unit cell dimensions and space group symmetry information obtained from the diffraction patterns, as described above. The crystals, which may be native crystals, heavy-atom derivative crystals or co-crystals, have an orthorhombic unit cell (i.e., unit cells wherein $a \neq b \neq c$; and $\alpha = \beta = \gamma = 90^\circ$) and space group symmetry $P2_12_12_1$.

In one form of crystalline Synagis Fab, the unit cell has dimensions of $a = 77.36 \pm 0.2 \text{ \AA}$, $b = 103.92 \pm 0.2 \text{ \AA}$, $c = 68.87 \pm 0.2 \text{ \AA}$. There is one Synagis Fab complex in the asymmetric unit.

6.5 Collection of Data and Determination of Structure Solutions

The diffraction pattern is related to the three-dimensional shape of the molecule by a Fourier transform. The process of determining the solution is in essence a re-focusing of the diffracted X-rays to produce a three-dimensional image of the molecule in the crystal. Since re-focusing of X-rays cannot be done with a lens at this time, it is done via mathematical operations.

The sphere of diffraction has symmetry that depends on the internal symmetry of the crystal, which means that certain orientations of the crystal will produce the same set of reflections. Thus, a crystal with high symmetry has a more repetitive diffraction pattern, and there are fewer unique reflections that need to be recorded in order to have a complete representation of the diffraction. The goal of data collection, a dataset, is a set of consistently measured, indexed intensities for as many reflections as possible. A complete dataset is collected if at least 80%, preferably at least 90%, most preferably at least 95% of unique reflections are recorded. In one embodiment, a complete dataset is collected using one crystal. In another embodiment, a complete dataset is collected using more than one crystal of the same type.

Sources of X-rays include, but are not limited to, a rotating anode X-ray generator such as a Rigaku RU-200 or a beamline at a synchrotron light source, such as the Advanced Photon Source at Argonne National Laboratory. Suitable detectors for recording diffraction patterns include, but are not limited to, X-ray sensitive film, multiwire area detectors, image plates coated with phosphorus, and CCD cameras. Typically, the detector and the X-ray beam remain stationary, so that, in order to record diffraction from different parts of the crystal's sphere of diffraction, the crystal itself is moved via an automated system of moveable circles called a goniostat.

One of the biggest problems in data collection, particularly from macromolecular crystals having a high solvent content, is the rapid degradation of the crystal in the X-ray beam. In order to slow the degradation, data is often collected from a crystal at liquid nitrogen temperatures. In order for a crystal to survive the initial exposure to liquid nitrogen, the formation of ice within the crystal must be prevented by the use of a cryoprotectant. Suitable cryoprotectants include, but are not limited to, low molecular weight polyethylene glycols, ethylene glycol, sucrose, glycerol, xylitol, and combinations thereof. Crystals may be soaked in a solution comprising the one or more cryoprotectants prior to exposure to liquid nitrogen, or the one or more cryoprotectants may be added to the crystallization solution. Data collection

at liquid nitrogen temperatures may allow the collection of an entire dataset from one crystal.

Once a dataset is collected, the information is used to determine the three-dimensional structure of the molecule in the crystal. However, this cannot be done from a single measurement of reflection intensities because certain information, known as phase information, is lost between the three-dimensional shape of the molecule and its Fourier transform, the diffraction pattern. This phase information must be acquired by methods described below in order to perform a Fourier transform on the diffraction pattern to obtain the three-dimensional structure of the molecule in the crystal. It is the determination of phase information that in effect refocuses X-rays to produce the image of the molecule.

One method of obtaining phase information is by isomorphous replacement, in which heavy-atom derivative crystals are used. In this method, the positions of heavy atoms bound to the molecules in the heavy-atom derivative crystal are determined, and this information is then used to obtain the phase information necessary to elucidate the three-dimensional structure of a native crystal. (Blundel et al., 1976, *Protein Crystallography*, Academic Press).

Another method of obtaining phase information is by molecular replacement, which is a method of calculating initial phases for a new crystal of a polypeptide whose structure coordinates are unknown by orienting and positioning a polypeptide whose structure coordinates are known, and believed to be similar to the polypeptide of unknown structure, within the unit cell of the new crystal so as to best account for the observed diffraction pattern of the new crystal. Phases are then calculated from the oriented and positioned polypeptide and combined with observed amplitudes to provide an approximate Fourier synthesis of the structure of the molecules comprising the new crystal. (Lattman, 1985, *Methods in Enzymology* 115:55-77; Rossmann, 1972, "The Molecular Replacement Method," *Int. Sci. Rev. Ser. No. 13*, Gordon & Breach, New York; Brünger et al., 1991, *Acta Crystallogr. A.* 47:195-204).

A third method of phase determination is multi-wavelength anomalous diffraction or MAD. In this method, X-ray diffraction data are collected at several different wavelengths from a single crystal containing at least one heavy atom with absorption edges near the energy of incoming X-ray radiation. The resonance between X-rays and electron orbitals leads to differences in X-ray scattering that permits the locations of the heavy atoms to be identified, which in turn provides phase information for a crystal of a polypeptide. A detailed discussion of MAD analysis can be found in Hendrickson, 1985, *Trans. Am. Crystallogr. Assoc.*, 21:11; Hendrickson et al., 1990, *EMBO J.* 9:1665; and Hendrickson, 1991, *Science* 4:91.

A fourth method of determining phase information is single wavelength anomalous dispersion or SAD. In this technique, X-ray diffraction data are collected at a single wavelength from a single native or heavy-atom derivative crystal, and phase information is extracted using anomalous scattering information from atoms such as sulfur or chlorine in the native crystal or from the heavy atoms in the heavy-atom derivative crystal. The wavelength of X-rays used to collect data for this phasing technique need not be close to the absorption edge of the anomalous scatterer. A detailed discussion of SAD analysis can be found in Brodersen et al., 2000, *Acta Cryst.*, D56:431-441.

A fifth method of determining phase information is single isomorphous replacement with anomalous scattering or

SIRAS. This technique combines isomorphous replacement and anomalous scattering techniques to provide phase information for a crystal of a polypeptide. X-ray diffraction data are collected at a single wavelength, usually from a single heavy-atom derivative crystal. Phase information obtained only from the location of the heavy atoms in a single heavy-atom derivative crystal leads to an ambiguity in the phase angle, which is resolved using anomalous scattering from the heavy atoms. Phase information is therefore extracted from both the location of the heavy atoms and from anomalous scattering of the heavy atoms. A detailed discussion of SIRAS analysis can be found in North, 1965, *Acta Cryst.* 18:212-216; Matthews, 1966, *Acta Cryst.* 20:82-86.

Once phase information is obtained, it is combined with the diffraction data to produce an electron density map, an image of the electron clouds that surround the atoms of the molecule(s) in the unit cell. The higher the resolution of the data, the more distinguishable are the features of the electron density map, e.g., amino acid side chains and the positions of carbonyl oxygen atoms in the peptide backbones, because atoms that are closer together are resolvable. A model of the macromolecule is then built into the electron density map with the aid of a computer, using as a guide all available information, such as the polypeptide sequence and the established rules of molecular structure and stereochemistry. Interpreting the electron density map is a process of finding the chemically realistic conformation that fits the map precisely.

After a model is generated, a structure is refined. Refinement is the process of minimizing the function

$$R - \text{factor} = \frac{\sum_{(h,k,l)} ||F_{obs}(h, k, l)| - |F_{calc}(h, k, l)||}{\sum_{(h,k,l)} |F_{obs}(h, k, l)|}$$

which is an average of the differences between observed structure factors (square-root of intensity) and calculated structure factors which are a function of the position, temperature factor and occupancy of each non-hydrogen atom in the model. This usually involves alternate cycles of real space refinement, i.e., calculation of electron density maps and model building, and reciprocal space refinement, i.e., computational attempts to improve the agreement between the original intensity data and intensity data generated from each successive model. Refinement ends when the R-factor converges on a minimum wherein the model fits the electron density map and is stereochemically and conformationally reasonable. During refinement, ordered solvent molecules are added to the structure.

6.6.1 Structures of Synagis Fab

The present invention provides, for the first time, the high-resolution three-dimensional structures and atomic structure coordinates of crystalline Synagis Fab as determined by X-ray crystallography. The specific methods used to obtain the structure coordinates are provided in the examples, infra. The atomic structure coordinates of crystalline Synagis Fab, obtained from the P₂₁2₁2₁ form of the crystal to 1.8 Å resolution, are listed in Table 2.

Those having skill in the art will recognize that atomic structure coordinates as determined by X-ray crystallography are not without error. Thus, it is to be understood that any set of structure coordinates obtained for crystals of Synagis Fab, whether native crystals, heavy-atom derivative crystals or co-crystals, that have a root mean square devia-

tion (“r.m.s.d.”) of less than or equal to about 2 Å when superimposed, using backbone atoms (N, C α , C and O), on the structure coordinates listed in Table 2 are considered to be identical with the structure coordinates listed in the Table when at least about 50% to 100% of the backbone atoms of Synagis Fab are included in the superposition.

All IgG-type antibodies have a common structure of two identical light chains of about 25 kilodaltons and two identical heavy chains of about 50 kilodaltons. Each light chain is attached to a heavy chain by disulfide bridges and the two heavy chains are likewise attached by disulfide bridges (FIG. 6). Both the light and heavy chains contain a series of repeating, homologous units, each about 110 amino acids residues in length and a characteristic molecular weight of 12 kDa. Each of these homologous units or domains fold independently into a common structural motif call an immunoglobulin fold (FIG. 7A; FIG. 7B). The amino acid sequences of the amino terminal domains of the heavy and light chains are called variable regions (V_H and V_L) due to sequence diversity between antibodies at the variable domain CDRs. The remaining domains, C_L of the light chain and C_{H1}, C_{H2} and C_{H3} of the heavy chain differ less among antibodies and are thus classified as constant regions.

In IgG-type antibodies light chains fall into one of two so-called isotypes, κ and λ . Each member of a light-chain isotype shares amino acid sequence identity of the carboxy terminus with all other members of that isotype. As for IgG light chains, IgG heavy chain polypeptides contain a series of segments, each approximately 110 amino acid residues in length. The segments are likewise homologous to each other and all fold into characteristic 12 kilodalton domains. As in the light chains, the amino terminal variable domain (V_H) displays the greatest sequence variation among heavy chains, and the most variable residues are concentrated into three stretches of amino acids called CDR1, CDR2 and CDR3.

The association between light and heavy chains involves both covalent and non-covalent interactions. Covalent interactions are in the form of disulfide bonds between the carboxy terminus of the light chain and the C_{H1} domain of the heavy chain. Non-covalent interactions arise primarily from hydrophobic interactions between V_L and V_H domains and between the C_L and C_{H1} domains.

Immunoglobulin V and C domains consists of sequence discontinuous antiparallel β -strands forming two β -pleated sheets linked by an intrachain disulfide bond. In the V domains, nine such β -strands form the β -sheets (FIG. 7A) while in the C domains seven strands form the β -sheets (FIG. 7B). The β strands of the V domains, comprising the ‘framework’ regions support the hypervariable loops or complementary determining regions that form the antigen binding site. As the β -strands are tightly packed in the formation of the β -sheets through hydrogen bonding to main-chain atoms and by side chain interactions, non-conservative mutants of the framework amino acids may be deleterious to the proper formation of these so-called “immunoglobulin folds” (Poljak et al., 1973, Proc. Natl. Acad. Sci. USA 70:3305–3310). Additionally, the quaternary structure of immunoglobulins requires the association of the domains of the heavy and light immunoglobulin chains. As such, amino acids involved in the associations of the β -strands forming the β -pleated sheets and of the β -pleated sheets of individual domains in the formation of immunoglobulin quaternary structure are assumed to be strongly conserved, or replaceable by closely conserved amino acids. The solvent exposed amino acids on the exterior of the V_L-V_H complex and C_L-C_{H1} complex, are assumed to be subject to less restriction in the substitution of amino acids.

The antigen binding fragment Fab, composed of the four domains V_H, V_L, C_{H1} and C_L, has been the subject of numerous X-ray crystallographic structure determinations (reviewed in Padlan, 1994, Mol. Immunol. 31:169–217). Each immunoglobulin domain is paired with a second (i.e. V_H-V_L, C_{H1}-C_L) with the components of each of these pairs related by a pseudo two-fold rotation axis (FIG. 4). Moreover, each antibody domain is joined to a subsequent domain (i.e. V_H-C_{H1}, V_L-C_L) by a short segment of polypeptide sometimes referred to as the “switch”. This sequence of extended polypeptide permits intersegmental flexibility of the Fab and, as such, allows for differing relative orientations of the V_H, V_L (i.e. the Fv fragment) and the C_{H1} and C_L domains. The relative disposition of the variable and constant domains (the so-called elbow angle) of an Fab is defined as the angle between the pseudo two-fold rotation axes of the Fv and C_{H1}-C_L domains. Thus, an elbow angle of 180° specifies that the pseudo two-fold axes of the Fv and C_{H1}-C_L domains are colinear and angles greater or less than 180° specify an Fab which is asymmetric.

The structure of the Fv fragment consists of the two immunoglobulin variable domains (V_H and V_L) which, as stated previously, are related by a pseudo two-fold rotation axis. Six hypervariable segments, or complementarity-determining-regions (CDRs), three each from the V_H (H1, H2 and H3; FIG. 4) and V_L (L1, L2 and L3; FIG. 4) domains, are formed from loops which connect beta strands in the immunoglobulin variable domains. The conformation of the CDR loops are generally determined by the length of the loop, the distance between the invariant (framework) residues which anchor the loop and the primary sequence of amino acids. By comparing the sequences and lengths of CDR loops of known structure, Chothia et al., 1989, Nature 342:877–833 discovered that each CDR loop, with the exception of the third hypervariable loop of the heavy chain (CDR H3), generally conformed to one of a few structural possibilities (i.e. canonical models). Thus, while there may be an extremely large repertoire of primary sequences of hypervariable loops, there appears to be some limit to the number of tertiary structures into which the backbone polypeptide chain at each loop can fold. This limits the overall structural design but still provides for structural diversity at the level of the amino acid side chain. As yet, no canonical models have been suggested for CDR H3. Since the specificity of antigen binding is determined almost exclusively by the topology of the CDRs, the structure of the CDRs and the interaction of the CDR with antigen has been the primary focus in the study of antibody structure.

The hypervariable loops, or CDRs, L1, L2, L3, H1 and H2 from immunoglobulins have been noted to usually have one of a small number of main chain conformations or canonical structures. The conformation of a particular canonical structure is determined by the length of the loop and residues present at key sites that interact with the loop. The conformation of CDR H3, however, does not appear to be limited based on the length of the loop as are the other CDRs.

The canonical classification of the CDRs for the Synagis Fab crystal structure were assigned by comparing loop lengths, sequences and root-mean-square deviations to example canonical loops. Tables 3 and 4 detail the canonical conformations for the free Synagis Fab crystal structure and selected representative CDRs for each canonical loop. The average main chain atom deviations for each of the defined canonical structures are significantly less than 1.0 Å and unambiguously assign the 5 CDRs to canonical classes. It is interesting to note that CDR L1 is a member of the type 1 canonical structure which is absent in the human V_L reper-

toire. Superpositioning of the Synagis CDRs with representative canonical loops as shown in FIGS. 8 & 9.

6.7 Structure Coordinates

The atomic structure coordinates can be used in molecular modeling and design, as described more fully below. The present invention encompasses the structure coordinates and other information, e.g., amino acid sequence, connectivity tables, vector-based representations, temperature factors, etc., used to generate the three-dimensional structure of the polypeptide for use in the software programs described below and other software programs.

The invention encompasses machine readable media embedded with the three-dimensional structure of the model described herein, or with portions thereof. As used herein, "machine readable medium" refers to any medium that can be read and accessed directly by a computer or scanner. Such media include, but are not limited to: magnetic storage media, such as floppy discs, hard disc storage medium and magnetic tape; optical storage media such as optical discs or CD-ROM; electrical storage media such as RAM or ROM; and hybrids of these categories such as magnetic/optical storage media. Such media further include paper on which is recorded a representation of the atomic structure coordinates, e.g., Cartesian coordinates, that can be read by a scanning device and converted into a three-dimensional structure with an OCR.

A variety of data storage structures are available to a skilled artisan for creating a computer readable medium having recorded thereon the atomic structure coordinates of the invention or portions thereof and/or X-ray diffraction data. The choice of the data storage structure will generally be based on the means chosen to access the stored information. In addition, a variety of data processor programs and formats can be used to store the sequence and X-ray data information on a computer readable medium. Such formats include, but are not limited to, Protein Data Bank ("PDB") format (Research Collaboratory for Structural Bioinformatics; http://www.rcsb.org/pdb/docs/format/pdbguide2.2/guide2.2_frame.html); Cambridge Crystallographic Data Centre format (http://www.ccdc.cam.ac.uk/support/csd_doc/volume3/z323.html); Structure-data ("SD") file format (MDL Information Systems, Inc.; Dalby et al., 1992, J. Chem. Inf. Comp. Sci. 32:244-255), and line-notation, e.g., as used in SMILES (Weininger, 1988, J. Chem. Inf. Comp. Sci. 28:31-36). Methods of converting between various formats read by different computer software will be readily apparent to those of skill in the art, e.g., BABEL (v. 1.06, Walters & Stahl, ©1992, 1993, 1994; <http://www.brunel.ac.uk/departments/chem/babel.htm>.) All format representations of the polypeptide coordinates described herein, or portions thereof, are contemplated by the present invention. By providing computer readable medium having stored thereon the atomic coordinates of the invention, one of skill in the art can routinely access the atomic coordinates of the invention, or portions thereof, and related information for use in modeling and design programs, described in detail below.

While Cartesian coordinates are important and convenient representations of the three-dimensional structure of a polypeptide, those of skill in the art will readily recognize that other representations of the structure are also useful. Therefore, the three-dimensional structure of a polypeptide, as discussed herein, includes not only the Cartesian coordinate representation, but also all alternative representations of the three-dimensional distribution of atoms. For example,

atomic coordinates may be represented as a Z-matrix, wherein a first atom of the protein is chosen, a second atom is placed at a defined distance from the first atom, a third atom is placed at a defined distance from the second atom so that it makes a defined angle with the first atom. Each subsequent atom is placed at a defined distance from a previously placed atom with a specified angle with respect to the third atom, and at a specified torsion angle with respect to a fourth atom. Atomic coordinates may also be represented as a Patterson function, wherein all interatomic vectors are drawn and are then placed with their tails at the origin. This representation is particularly useful for locating heavy atoms in a unit cell. In addition, atomic coordinates may be represented as a series of vectors having magnitude and direction and drawn from a chosen origin to each atom in the polypeptide structure. Furthermore, the positions of atoms in a three-dimensional structure may be represented as fractions of the unit cell (fractional coordinates), or in spherical polar coordinates.

Additional information, such as thermal parameters, which measure the motion of each atom in the structure, chain identifiers, which identify the particular chain of a multi-chain protein in which an atom is located, and connectivity information, which indicates to which atoms a particular atom is bonded, is also useful for representing a three-dimensional molecular structure.

6.8 Uses of the Atomic Structure Coordinates

Structure information, typically in the form of the atomic structure coordinates, can be used in a variety of computational or computer-based methods to, for example, design, screen for and/or identify compounds that bind crystallized Synagis Fab or a portion or fragment thereof, or to intelligently design mutants that have altered biological properties.

In one embodiment, the crystals and structure coordinates obtained therefrom are useful for identifying and/or designing compounds that bind Synagis Fab as an approach towards developing new therapeutic agents. For example, a high resolution X-ray structure will often show the locations of ordered solvent molecules around the protein, and in particular at or near putative binding sites on the protein. This information can then be used to design molecules that bind these sites, the compounds synthesized and tested for binding in biological assays. Travis, 1993, Science 262:1374.

In another embodiment, the structure is probed with a plurality of molecules to determine their ability to bind to the Synagis Fab at various sites. Such compounds can be used as targets or leads in medicinal chemistry efforts to identify, for example, inhibitors of potential therapeutic importance.

In still another embodiment, compounds that can isomerize to short-lived reaction intermediates in the chemical reaction of a Synagis Fab-binding compound with Synagis Fab can be developed. Thus, the time-dependent analysis of structural changes in Synagis Fab during its interaction with other molecules is enabled. The reaction intermediates of Synagis Fab can also be deduced from the reaction product in co-complex with Synagis Fab. Such information is useful to design improved analogues of known Synagis Fab inhibitors or to design novel classes of inhibitors based on the reaction intermediates of Synagis Fab and Synagis Fab-inhibitor co-complexes. This provides a novel route for designing Synagis Fab inhibitors with both high specificity and stability.

In yet another embodiment, the structure can be used to computationally screen small molecule data bases for

chemical entities or compounds that can bind in whole, or in part, to Synagis Fab. In this screening, the quality of fit of such entities or compounds to the binding site may be judged either by shape complementarity or by estimated interaction energy. Meng et al., 1992, *J. Comp. Chem.* 13:505–524.

The design of compounds that bind to or inhibit Synagis Fab according to this invention generally involves consideration of two factors. First, the compound must be capable of physically and structurally associating with Synagis Fab. This association can be covalent or non-covalent. For example, covalent interactions may be important for designing irreversible or suicide inhibitors of a protein. Non-covalent molecular interactions important in the association of Synagis Fab with its substrate include hydrogen bonding, ionic interactions and van der Waals and hydrophobic interactions. Second, the compound must be able to assume a conformation that allows it to associate with Synagis Fab. Although certain portions of the compound will not directly participate in this association with Synagis Fab, those portions may still influence the overall conformation of the molecule. This, in turn, may have a significant impact on potency. Such conformational requirements include the overall three-dimensional structure and orientation of the chemical group or compound in relation to all or a portion of the binding site, or the spacing between functional groups of a compound comprising several chemical groups that directly interact with Synagis Fab.

The potential inhibitory or binding effect of a chemical compound on Synagis Fab may be analyzed prior to its actual synthesis and testing by the use of computer modeling techniques. If the theoretical structure of the given compound suggests insufficient interaction and association between it and Synagis Fab, synthesis and testing of the compound is unnecessary. However, if computer modeling indicates a strong interaction, the molecule may then be synthesized and tested for its ability to bind to Synagis Fab and inhibit its activity. In this manner, synthesis of ineffective compounds may be avoided.

An inhibitory or other binding compound of Synagis Fab may be computationally evaluated and designed by means of a series of steps in which chemical groups or fragments are screened and selected for their ability to associate with the individual binding pockets or other areas of Synagis Fab. One skilled in the art may use one of several methods to screen chemical groups or fragments for their ability to associate with Synagis Fab. This process may begin by visual inspection of, for example, the active site on the computer screen based on the Synagis Fab coordinates. Selected fragments or chemical groups may then be positioned in a variety of orientations, or docked, within an individual binding pocket of Synagis Fab as defined supra. Docking may be accomplished using software such as QUANTA and SYBYL, followed by energy minimization and molecular dynamics with standard molecular mechanics forcefields, such as CHARMM and AMBER.

Specialized computer programs may also assist in the process of selecting fragments or chemical groups. These include:

1. GRID (Goodford, 1985, *J. Med. Chem.* 28:849–857). GRID is available from Oxford University, Oxford, UK;
2. MCSS (Miranker & Karplus, 1991, *Proteins: Structure, Function and Genetics* 11:29–34). MCSS is available from Molecular Simulations, Burlington, Mass.;
3. AUTODOCK (Goodsell & Olsen, 1990, *Proteins: Structure, Function, and Genetics* 8:195–202). AUTODOCK is available from Scripps Research Institute, La Jolla, Calif.; and

4. DOCK (Kuntz et al., 1982, *J. Mol. Biol.* 161:269–288). DOCK is available from University of California, San Francisco, Calif.

Once suitable chemical groups or fragments have been selected, they can be assembled into a single compound or inhibitor. Assembly may proceed by visual inspection of the relationship of the fragments to each other in the three-dimensional image displayed on a computer screen in relation to the structure coordinates of Synagis Fab. This would be followed by manual model building using software such as QUANTA or SYBYL.

Useful programs to aid one of skill in the art in connecting the individual chemical groups or fragments include:

1. CAVEAT (Bartlett et al., 1989, 'CAVEAT: A Program to Facilitate the Structure-Derived Design of Biologically Active Molecules'. In *Molecular Recognition in Chemical and Biological Problems*, Special Pub., Royal Chem. Soc. 78:182–196). CAVEAT is available from the University of California, Berkeley, Calif.;

2. 3D Database systems such as MACCS-3D (MDL Information Systems, San Leandro, Calif.). This area is reviewed in Martin, 1992, *J. Med. Chem.* 35:2145–2154); and

3. HOOK (available from Molecular Simulations, Burlington, Mass.).

Instead of proceeding to build a Synagis Fab inhibitor in a step-wise fashion one fragment or chemical group at a time, as described above, Synagis Fab binding compounds may be designed as a whole or 'de novo' using either an empty active site or optionally including some portion(s) of a known inhibitor(s). These methods include:

1. LUDI (Bohm, 1992, *J. Comp. Aid. Molec. Design* 6:61–78). LUDI is available from Molecular Simulations, Inc., San Diego, Calif.;

2. LEGEND (Nishibata & Itai, 1991, *Tetrahedron* 47:8985). LEGEND is available from Molecular Simulations, Burlington, Mass.; and

3. LeapFrog (available from Tripos, Inc., St. Louis, Mo.).

Other molecular modeling techniques may also be employed in accordance with this invention. See, e.g., Cohen et al, 1990, *J. Med. Chem.* 33:883–894. See also, Navia & Murcko, 1992, *Current Opinions in Structural Biology* 2:202–210.

Once a compound has been designed or selected by the above methods, the efficiency with which that compound may bind to Synagis Fab may be tested and optimized by computational evaluation. For example, a compound that has been designed or selected to function as a Synagis Fab-inhibitor must also preferably occupy a volume not overlapping the volume occupied by the active site residues when the native substrate is bound. An effective Synagis Fab inhibitor must preferably demonstrate a relatively small difference in energy between its bound and free states (i.e., it must have a small deformation energy of binding). Thus, the most efficient Synagis Fab inhibitors should preferably be designed with a deformation energy of binding of not greater than about 10 kcal/mol, preferably, not greater than 7 kcal/mol. Synagis Fab inhibitors may interact with the protein in more than one conformation that is similar in overall binding energy. In those cases, the deformation energy of binding is taken to be the difference between the energy of the free compound and the average energy of the conformations observed when the inhibitor binds to the enzyme.

A compound selected or designed for binding to Synagis Fab may be further computationally optimized so that in its

bound state it would preferably lack repulsive electrostatic interaction with the target protein. Such non-complementary electrostatic interactions include repulsive charge-charge, dipole-dipole and charge-dipole interactions. Specifically, the sum of all electrostatic interactions between the inhibitor and the protein when the inhibitor is bound to it preferably make a neutral or favorable contribution to the enthalpy of binding.

Specific computer software is available in the art to evaluate compound deformation energy and electrostatic interaction. Examples of programs designed for such uses include: Gaussian 92, revision C (Frisch, Gaussian, Inc., Pittsburgh, Pa. ©1992); AMBER, version 4.0 (Kollman, University of California at San Francisco, ©1994); QUANTA/CHARMM (Molecular Simulations, Inc., Burlington, Mass., ©1994); and Insight II/Discover (Biosym Technologies Inc., San Diego, Calif., ©1994). These programs may be implemented, for instance, using a computer workstation, as are well-known in the art. Other hardware systems and software packages will be known to those skilled in the art.

Once a Synagis Fab-binding compound has been optimally selected or designed, as described above, substitutions may then be made in some of its atoms or chemical groups in order to improve or modify its binding properties. Generally, initial substitutions are conservative, i.e., the replacement group will have approximately the same size, shape, hydrophobicity and charge as the original group. One of skill in the art will understand that substitutions known in the art to alter conformation should be avoided. Such altered chemical compounds may then be analyzed for efficiency of binding to Synagis Fab by the same computer methods described in detail above.

Because Synagis Fab may crystallize in more than one crystal form, the structure coordinates of Synagis Fab, or portions thereof, are particularly useful to solve the structure of those other crystal forms of Synagis or other Synagis fragments. They may also be used to solve the structure of Synagis mutants, Synagis co-complexes, fragments thereof, or of the crystalline form of any other protein that shares significant amino acid sequence homology with a structural domain of Synagis Fab.

One method that may be employed for this purpose is molecular replacement. In this method, the unknown crystal structure, whether it is another crystal form of Synagis Fab, a Synagis Fab mutant, or a Synagis Fab co-complex, or the crystal of some other protein with significant amino acid sequence homology to any functional domain of Synagis Fab, may be determined using phase information from the Synagis Fab structure coordinates. The phase information may also be used to determine the crystal structure of full-length Synagis, fragments of Synagis other than Synagis Fab, and mutants or co-complexes thereof, and other proteins with significant homology to Synagis or fragments thereof. This method will provide an accurate three-dimensional structure for the unknown protein in the new crystal more quickly and efficiently than attempting to determine such information ab initio. In addition, in accordance with this invention, Synagis Fab mutants may be crystallized in co-complex with known Synagis Fab inhibitors. The crystal structures of a series of such complexes may then be solved by molecular replacement and compared with that of wild-type Synagis Fab. Potential sites for modification within the various binding sites of the protein may thus be identified. This information provides an additional tool for determining the most efficient binding interactions, for example, increased hydrophobic interactions, between Synagis Fab and a chemical group or compound.

If an unknown crystal form has the same space group as and similar cell dimensions to the known Synagis Fab crystal form, then the phases derived from the known crystal form can be directly applied to the unknown crystal form, and in turn, an electron density map for the unknown crystal form can be calculated. Difference electron density maps can then be used to examine the differences between the unknown crystal form and the known crystal form. A difference electron density map is a subtraction of one electron density map, e.g., that derived from the known crystal form, from another electron density map, e.g., that derived from the unknown crystal form. Therefore, all similar features of the two electron density maps are eliminated in the subtraction and only the differences between the two structures remain. For example, if the unknown crystal form is of a Synagis Fab co-complex, then a difference electron density map between this map and the map derived from the native, uncomplexed crystal will ideally show only the electron density of the ligand. Similarly, if amino acid side chains have different conformations in the two crystal forms, then those differences will be highlighted by peaks (positive electron density) and valleys (negative electron density) in the difference electron density map, making the differences between the two crystal forms easy to detect. However, if the space groups and/or cell dimensions of the two crystal forms are different, then this approach will not work and molecular replacement must be used in order to derive phases for the unknown crystal form.

All of the complexes referred to above may be studied using well-known X-ray diffraction techniques and may be refined versus 50 Å to 1.5 Å or greater resolution X-ray data to an R value of about 0.20 or less using computer software, such as X-PLOR (Yale University, (c) 1992, distributed by Molecular Simulations, Inc.). See, e.g., Blundel et al., 1976, Protein Crystallography, Academic Press.; Methods in Enzymology, vol. 114 & 115, Wyckoff et al., eds., Academic Press, 1985. This information may thus be used to optimize known classes of Synagis Fab inhibitors, and more importantly, to design and synthesize novel classes of Synagis Fab inhibitors.

The structure coordinates of Synagis Fab mutants will also facilitate the identification of related proteins or enzymes analogous to Synagis Fab in function, structure or both, thereby further leading to novel therapeutic modes for treating or preventing Synagis Fab mediated diseases.

Subsets of the atomic structure coordinates can be used in any of the above methods. Particularly useful subsets of the coordinates include, but are not limited to, coordinates of single domains, coordinates of residues lining an antigen binding site, coordinates of residues of a CDR, coordinates of residues that participate in important protein-protein contacts at an interface, and Ca coordinates. For example, the coordinates of a fragment of an antibody that contains the antigen binding site may be used to design inhibitors that bind to that site, even though the antibody is fully described by a larger set of atomic coordinates. Therefore, a set of atomic coordinates that define the entire polypeptide chain, although useful for many applications, do not necessarily need to be used for the methods described herein.

7. EXAMPLE

Preparation of Crystals of Synagis Fab

The subsections below describe the production of a polypeptide containing the Synagis Fab, and the preparation and characterization of diffraction quality crystals, heavy-atom derivative crystals.

7.1 Production and Purification of Synagis Fab

Synagis IgG was prepared as described in U.S. Pat. No. 5,824,307, which is hereby incorporated by reference in its entirety.

The Synagis Fab fragment was produced by papain digestion of Synagis IgG. In brief, 20 mg of IgG was digested in a solution of PBS buffer, 1 mM EDTA, 1 mM b-mercaptoethanol and 0.2 mg papain. Digestion was carried out for 45 minutes at 37° C. The resultant digested antibody was concentrated to 250 ul in 50 mM Tris buffer, pH 8.5. This solution was applied to a Q-2 anion exchange column (BioRad) with a flow rate of 1 ml/min. The Fab fragment eluted in the void volume. The Fab preparation was further purified by size exclusion chromatography using a Pharmacia S-200 SEC column and PBS buffer flowing at a rate of 0.5 ml/min. Pure Fab eluted as a sharp peak at the appropriate molecular weight. Finally, the Fab preparation was concentrated and buffer-exchanged with Centricon P-20 centrifugal concentrators (Spectrum).

The final concentration of Synagis Fab measured at 280 nm was 15 mg/mL in approximately 1 mM Tris, pH 7.6.

7.1.1 Preparation of Synagis Fab Native Crystals

Crystals were grown at room temperature by the hanging drop vapor diffusion method using Linbro multi-well plates. Drops containing 2 μ L of the protein solution and 2 μ L of precipitant buffer were equilibrated against 500 μ L precipitant buffer. The precipitant buffer was 15% PEG 4000, 10% 2-propanol, 0.2 M ammonium sulfate, 0.1 M Tris, pH 8.5. Crystals shaped as long rectangular prisms appeared after 4 days and grew to a maximum size of 0.8 \times 0.1 \times 0.1 mm in 10 to 14 days.

7.2 Analysis and Characterization of Synagis Fab

Crystals

7.2.1 Diffraction Data Collection

X-ray diffraction data were collected using graphite-monochromated Cu K α x-rays from a Siemens rotating anode source. Intensities were measured in 1° oscillation steps using a MAR 345 imaging plate and processed with the Denzo/Scalepack suite of programs. A single crystal was used to collect the diffraction data. The crystal was cryoprotected in a solution of the crystallization buffer with the addition of glycerol. The crystal was mounted in a nylon loop and flash frozen to 100 K. Data indicate that the crystals are orthorhombic, space group P2 1 2 $_1$ 2 $_1$ and cell parameters a=77.361, b=103.925, c=68.866. Data extend to 1.8 Å, the limit available by detector geometry at the crystal to detector distance of 12 cm. Statistics for the data collection and data reduction are listed in Table 5.

7.2.2 Structure Determination

Estimation of solvent content suggest one Fab molecule per asymmetric unit in the crystal. A preliminary model for the Synagis Fab structure was determined by molecular replacement techniques. The procedure was carried out using the program XPLOR (Brunger) running on a Silicon Graphics Indigo2 workstation. The procedure followed that used for the molecular replacement solution of Fab 26-10 (Brunger). For the test model, the anti-tumor Fab (CTM01, IgG1 κ , Protein Data Bank code 1AD9) was chosen. Best rotation and translation solutions were found with the model modified by a -20° change in the elbow angle. A single solution emerged from the application of rotation function, PC-refinement and translation function. Using the molecular replacement solution an initial crystallographic R-value, based on rigid body refinement of the four 1AD9 model domains (V $_L$, C $_L$, V $_H$ and C $_{H1}$), was calculated to be 0.42.

Using the model from the molecular replacement approach and the rigid body refinement, a single cycle of

simulated annealing refinement (SA) followed by a cycle of grouped B-factor refinement resulted in a crystallographic residual of 0.29. Inspection of initial 2Fo-Fc and Fo-Fc electron density maps clearly indicated the differences in amino acid sequence between and model and Synagis Fab. Refinement was continued with alternate cycles of manual model building using the visualization program TURBO and simulated annealing refinement using XPLOR, and by the 5th cycle of refinement, the complete Synagis Fab sequence was fit to electron density. Refinement continued for an additional 15 cycles with improvements to stereochemistry of the polypeptide and the addition of solvent water molecules. Refinement was terminated when no peaks in an Fo-Fc difference Fourier were greater than 2.5 σ . Electron density for the light chain is well resolved from residues 4 through the C-terminus residue 213. The entire heavy chain has been modeled from the N-terminus residue 1 through C-terminus residue 220. No breaks in the electron density for the modeled polypeptides are found.

TABLE 5

Data Collection Summary

	Native
X-ray source	Cu Rotating Anode
Resolution limit (Å)	1.86Å
R $_{sym}$ ^b (%)	6.0
Total observations	425,773
Unique reflections	39,800
Completeness (%)	92
Signal % > 2 σ	83

$$^bR_{sym} = 100 \times \frac{\sum_h \sum_i |I_i(h) - \langle I(h) \rangle|}{\sum_h \sum_i I_i(h)}$$

7.2.3 Structure Analyses

A Ramachandran (Φ , Ψ) plot of the final model shows only one residue in a region usually considered to be disallowed (light chain Thr 51, CDR L2, FIG. 10). This residue, at residue i+1 of a γ turn, has been noted to occur with this conformation in class 3 γ turns (Milner-White & Poet, 1987). Moreover, the conformation of this residue is in agreement with the classification of CDR L2 as a class 1 canonical loop. The errors in atomic coordinates estimated by the method of Luzzatti (1952) are 0.21 Å.

The following table summarizes the X-ray crystallography refinement parameters of the structure of crystalline Synagis Fab of the invention.

TABLE 6

Refinement Parameters
Synagis Fab: 429 residues, 357 water molecules (3664 atoms)

	R-		R.m.s.d.			
	d-spacings (Å)	Reflections (N)	value ^a (%)	bonds (Å)	angles (°)	B-values ^b (Å 2)
Synagis Fab:	1.86	33,300	19.4 (21.4) ^c	0.01	1.84	25.6

^aR-value = $100 \times \frac{\sum_h ||F_{obs}(h)| - |F_{calc}(h)||}{\sum_h |F_{obs}(h)|}$ for reflections with $F_{obs} > 2\sigma$.

^bFor bonded protein atoms.

^cValue in parentheses is the free R-value (Brunger, 1992, "Free R value: a novel statistical quantity for assessing the accuracy of crystal structures," Nature 355:472-475.) determined from 5% of the data.

Table 2, following this page, provides the atomic structure coordinates of Synagis Fab. The amino acid residue numbers coincide with those used in FIGS. 3A and 3B.

The following abbreviations are used in Table 2:

"Atom Type" refers to the element whose coordinates are provided. The first letter in the column defines the element.

“A.A.” refers to amino acid.

“X, Y and Z” provide the Cartesian coordinates of the element.

“B” is a thermal factor that measures movement of the atom around its atomic center.

“OCC” refers to occupancy, and represents the percentage of time the atom type occupies the particular coordinate. OCC values range from 0 to 1, with 1 being 100%.

Structures coordinates for Synagis Fab according to Table 2 may be modified by mathematical manipulation. Such manipulations include, but are not limited to, crystallographic permutations of the raw structure coordinates, fractionalization of the raw structure coordinates, integer additions or subtractions to sets of the raw structure coordinates, inversion of the raw structure coordinates and any combination of the above.

The present invention is not to be limited in scope by the exemplified embodiments, which are intended as illustrations of single aspects of the invention. Indeed, various modifications of the invention in addition to those described herein will become apparent to those having skill in the art from the foregoing description and accompanying drawings. Such modifications are intended to fall within the scope of the appended claims.

TABLE 3

Synagis VL CDR canonical structure L1-canonical structure type 1-10 residues Torsion Angles						
Synagis				J539 (PDB code 2FBJ)		
Residue	Amino Acid	Φ	Ψ	Amino Acid	Φ	Ψ
24	Lys	-114	123	Ser	-123	143
25	Cys	-107	151	Ala	-107	147
26	Gln	-73	-26	Ser	-71	-16
28	Leu	-105	147	Ser	-157	169
29	Ser	-61	145	Ser	-59	133
30	Val	-123	140	Val	-113	151
31	Gly	-71	-61	Ser	-75	-37
32	Tyr	-142	164	Ser	-157	160
33	Met	-128	148	Leu	-141	140
34	His	-117	149	His	-136	156

r.m.s. difference Ca positions = 0.297A; r.m.s. difference main-chain atoms = 0.685A

L2-canonical structure type 1 Torsion Angles

Synagis				HyHel-5 (PDB code 1BQL)		
Residue	Amino Acid	Φ	Ψ	Amino Acid	Φ	Ψ
50	Asp	48	43	Asp	41	57
51	Thr	67	-46	Thr	54	-64
52	Ser	-133	5	Ser	-107	-6
53	Lys	-85	119	Lys	-85	124
54	Leu	-68	126	Leu	-72	139
55	Ala	-71	166	Ala	-78	161
56	Ser	-69	135	Ser	-53	100

r.m.s. difference Ca positions = 0.098A; r.m.s. difference main-chain atoms = 0.261A

L3-canonical structure type 1 Torsion Angles

Synagis				TE33 (PDB code 1TET)		
Residue	Amino Acid	Φ	Ψ	Amino Acid	Φ	Ψ
89	Phe	-132	129	Phe	-142	141
90	Gln	-107	106	Gln	-117	135
91	Gly	-120	10	Gly	-129	32
92	Ser	-80	-21	Ser	-97	-35

TABLE 3-continued

93	Gly	-152	167	His	-124	125
94	Tyr	-87	142	Phe	-81	124
95	Pro	-88	150	Pro	-81	140
96	Phe	-67	131	Phe	-61	128
97	Thr	-147	153	Thr	-124	151

r.m.s. difference Ca positions = 0.240A; r.m.s. difference main-chain atoms = 0.622A

TABLE 4

Synagis V _H CDR canonical structure residues and torsion angles						
H1-canonical structure type 1						
Synagis				50.1 (PDB code 2GGI)		
Residue	Amino Acid	Φ	Ψ	Amino Acid	Φ	Ψ
26	Gly	92	0	Gly	114	-14
27	Phe	-169	168	Phe	-165	132
27A	Ser	-124	135	Ser	-80	145
27B	Leu	-73	1	Leu	-77	6
28	Ser	-93	-18	Ser	-90	-13
29	Thr	-65	132	Thr	-65	127
30	Ser	-43	134	Tyr	-60	124
31	Gly	85	-10	Gly	94	6
32	Met	-76	143	Met	-82	154
33	Ser	-150	151	Gly	179	159
34	Val	-129	124	Val	-132	135
35	Gly	-116	165	Ser	-100	154

r.m.s. difference Ca positions = 0.218A; r.m.s. difference main-chain atoms = 0.390A

H2-canonical structure type 1

Synagis				HC19 (PDB code 1GIG)		
Residue	Amino Acid	Φ	Ψ	Amino Acid	Φ	Ψ
50	Asp	-152	167	Val	-143	149
51	Ile	-138	134	Ile	-126	117
52	Trp	-90	165	Trp	-79	165
53	Trp	-55	-29	Ala	-50	-42
54	Asp	-91	12	Gly	-75	-5
55	Asp	77	8	Gly	98	-5
56	Lys	-70	132	Asn	-69	144
57	Lys	-112	140	Thr	-125	155
58	Asp	-130	143	Asn	-138	143
59	Tyr	-135	149	Tyr	-123	154
60	Asn	-67	125	Asn	-66	125
61	Pro	-55	125	Ser	-56	-35
62	Ser	-58	-31	Ala	-58	-40
63	Leu	-111	-12	Leu	-90	-32
64	Lys	-34	-47	Met	-3	-59
65	Ser	-53	-34	Ser	-66	-44

r.m.s. difference Ca positions = 0.106A; r.m.s. difference main-chain atoms = 0.243A

TABLE 2

		Atom A.A. Type		X	Y	Z	Occ	B	
ATOM	CB	MET	L	4	69.801	42.361	-3.359	1.00	52.70
ATOM	CG	MET	L	4	70.492	41.405	-4.309	1.00	51.32
ATOM	SD	MET	L	4	72.128	42.056	-4.674	1.00	57.06
ATOM	CE	MET	L	4	72.891	41.926	-3.102	1.00	53.48
ATOM	C	MET	L	4	67.468	42.053	-4.233	1.00	49.95
ATOM	O	MET	L	4	66.690	41.125	-4.478	1.00	51.62
ATOM	N	MET	L	4	68.326	40.617	-2.404	1.00	53.46
ATOM	CA	MET	L	4	68.367	41.989	-2.995	1.00	51.42
ATOM	N	THR	L	5	67.583	43.119	-5.019	1.00	44.36
ATOM	CA	THR	L	5	66.756	43.254	-6.205	1.00	40.62
ATOM	CB	THR	L	5	66.015	44.603	-6.189	1.00	40.31
ATOM	OG1	THR	L	5	65.256	44.692	-4.977	1.00	42.05
ATOM	CG2	THR	L	5	65.074	44.729	-7.390	1.00	38.21
ATOM	C	THR	L	5	67.506	43.078	-7.527	1.00	37.94
ATOM	O	THR	L	5	68.429	43.831	-7.841	1.00	35.88
ATOM	N	GLN	L	6	67.085	42.085	-8.305	1.00	33.98
ATOM	CA	GLN	L	6	67.696	41.816	-9.598	1.00	31.54
ATOM	CB	GLN	L	6	68.193	40.367	-9.660	1.00	29.52
ATOM	CG	GLN	L	6	69.005	40.022	-10.899	1.00	23.42
ATOM	CD	GLN	L	6	69.621	38.625	-10.838	1.00	23.94
ATOM	OE1	GLN	L	6	70.059	38.085	-11.855	1.00	25.77
ATOM	NE2	GLN	L	6	69.684	38.048	-9.643	1.00	17.08
ATOM	C	GLN	L	6	66.673	42.086	-10.701	1.00	29.67
ATOM	O	GLN	L	6	65.479	41.868	-10.530	1.00	29.35
ATOM	N	SER	L	7	67.141	42.560	-11.838	1.00	29.10
ATOM	CA	SER	L	7	66.244	42.855	-12.927	1.00	29.63
ATOM	CB	SER	L	7	65.667	44.273	-12.772	1.00	33.97
ATOM	OG	SER	L	7	66.678	45.280	-12.827	1.00	38.37
ATOM	C	SER	L	7	67.021	42.748	-14.217	1.00	28.45
ATOM	O	SER	L	7	68.242	42.910	-14.216	1.00	27.60
ATOM	N	PRO	L	8	66.348	42.341	-15.308	1.00	28.70
ATOM	CD	PRO	L	8	66.881	42.417	-16.681	1.00	28.01
ATOM	CA	PRO	L	8	64.922	41.991	-15.316	1.00	28.37
ATOM	CB	PRO	L	8	64.554	42.151	-16.783	1.00	29.19
ATOM	CG	PRO	L	8	65.817	41.747	-17.482	1.00	29.51
ATOM	C	PRO	L	8	64.743	40.547	-14.832	1.00	29.08
ATOM	O	PRO	L	8	65.667	39.752	-14.932	1.00	30.35
ATOM	N	SER	L	9	63.575	40.212	-14.294	1.00	28.83
ATOM	CA	SER	L	9	63.333	38.857	-13.797	1.00	30.10
ATOM	CB	SER	L	9	61.986	38.773	-13.061	1.00	31.53
ATOM	OG	SER	L	9	60.912	38.862	-13.978	1.00	37.73
ATOM	C	SER	L	9	63.356	37.849	-14.945	1.00	29.29
ATOM	O	SER	L	9	63.765	36.689	-14.781	1.00	27.22
ATOM	N	THR	L	10	62.883	38.296	-16.098	1.00	28.81
ATOM	CA	THR	L	10	62.839	37.468	-17.292	1.00	31.44
ATOM	CB	THR	L	10	61.426	36.830	-17.508	1.00	30.75
ATOM	OG1	THR	L	10	60.415	37.843	-17.438	1.00	34.36
ATOM	CG2	THR	L	10	61.128	35.787	-16.441	1.00	30.35
ATOM	C	THR	L	10	63.225	38.341	-18.487	1.00	31.24
ATOM	O	THR	L	10	63.135	39.568	-18.433	1.00	31.34
ATOM	N	LEU	L	11	63.737	37.712	-19.528	1.00	32.55
ATOM	CA	LEU	L	11	64.132	38.432	-20.717	1.00	33.50
ATOM	CB	LEU	L	11	65.473	39.126	-20.500	1.00	35.64
ATOM	CG	LEU	L	11	65.986	39.917	-21.709	1.00	39.37
ATOM	CD1	LEU	L	11	65.040	41.089	-22.003	1.00	39.67
ATOM	CD2	LEU	L	11	67.387	40.421	-21.437	1.00	39.27
ATOM	C	LEU	L	11	64.261	37.471	-21.881	1.00	33.70
ATOM	O	LEU	L	11	64.755	36.361	-21.723	1.00	32.16
ATOM	N	SER	L	12	63.751	37.881	-23.031	1.00	33.08
ATOM	CA	SER	L	12	63.857	37.090	-24.245	1.00	34.60
ATOM	CB	SER	L	12	62.479	36.805	-24.827	1.00	34.91
ATOM	OG	SER	L	12	61.601	36.360	-23.810	1.00	42.30
ATOM	C	SER	L	12	64.610	38.050	-25.140	1.00	33.62
ATOM	O	SER	L	12	64.251	39.232	-25.224	1.00	35.15
ATOM	N	ALA	L	13	65.691	37.583	-25.742	1.00	30.90
ATOM	CA	ALA	L	13	66.482	38.439	-26.599	1.00	30.58
ATOM	CE	ALA	L	13	67.607	39.084	-25.801	1.00	30.23
ATOM	C	ALA	L	13	67.039	37.583	-27.707	1.00	31.78
ATOM	O	ALA	L	13	67.214	36.380	-27.544	1.00	31.55
ATOM	N	SER	L	14	67.289	38.204	-28.851	1.00	33.80
ATOM	CA	SER	L	14	67.816	37.494	-30.011	1.00	33.44
ATOM	CB	SER	L	14	67.526	38.294	-31.277	1.00	33.43
ATOM	OG	SER	L	14	66.232	38.878	-31.214	1.00	37.66
ATOM	C	SER	L	14	69.308	37.280	-29.897	1.00	31.30
ATOM	O	SER	L	14	69.984	37.924	-29.101	1.00	33.92
ATOM	N	VAL	L	15	69.820	36.367	-30.698	1.00	31.26

TABLE 2-continued

		Atom A.A.			X	Y	Z	Occ	B
		Type							
ATOM	CA	VAL	L	15	71.239	36.100	-30.720	1.00	29.90
ATOM	CB	VAL	L	15	71.525	34.913	-31.632	1.00	26.09
ATOM	CG1	VAL	L	15	72.997	34.762	-31.859	1.00	27.20
ATOM	CG2	VAL	L	15	70.977	33.662	-31.014	1.00	25.79
ATOM	C	VAL	L	15	71.940	37.371	-31.239	1.00	33.94
ATOM	O	VAL	L	15	71.432	38.085	-32.122	1.00	33.32
ATOM	N	GLY	L	16	73.086	37.682	-30.644	1.00	36.81
ATOM	CA	GLY	L	16	73.840	38.853	-31.045	1.00	35.94
ATOM	C	GLY	L	16	73.498	40.058	-30.212	1.00	35.51
ATOM	O	GLY	L	16	74.262	41.014	-30.194	1.00	39.24
ATOM	N	ASP	L	17	72.366	40.016	-29.520	1.00	34.04
ATOM	CA	ASP	L	17	71.946	41.121	-28.672	1.00	34.26
ATOM	CE	ASP	L	17	70.547	40.856	-28.113	1.00	34.85
ATOM	CG	ASP	L	17	69.447	41.156	-29.110	1.00	37.86
ATOM	OD1	ASP	L	17	68.303	41.380	-28.658	1.00	37.46
ATOM	OD2	ASP	L	17	69.717	41.172	-30.332	1.00	38.37
ATOM	C	ASP	L	17	72.896	41.368	-27.500	1.00	34.67
ATOM	O	ASP	L	17	73.665	40.484	-27.112	1.00	33.04
ATOM	N	ARG	L	18	72.857	42.581	-26.956	1.00	33.25
ATOM	CA	ARG	L	18	73.666	42.913	-25.803	1.00	32.51
ATOM	CE	ARG	L	18	74.286	44.304	-25.932	1.00	37.82
ATOM	CG	ARG	L	18	75.007	44.766	-24.667	1.00	42.38
ATOM	CD	ARG	L	18	75.722	46.081	-24.870	1.00	45.92
ATOM	NE	ARG	L	18	77.152	45.955	-24.600	1.00	52.00
ATOM	CZ	ARG	L	18	78.042	45.463	-25.459	1.00	55.43
ATOM	NH1	ARG	L	18	77.660	45.038	-26.661	1.00	56.79
ATOM	NH2	ARG	L	18	79.324	45.401	-25.119	1.00	57.64
ATOM	C	ARG	L	18	72.662	42.882	-24.671	1.00	32.18
ATOM	O	ARG	L	18	71.569	43.443	-24.793	1.00	32.94
ATOM	N	VAL	L	19	73.018	42.215	-23.579	1.00	30.42
ATOM	CA	VAL	L	19	72.118	42.081	-22.449	1.00	29.59
ATOM	CB	VAL	L	19	71.638	40.584	-22.304	1.00	30.77
ATOM	CG1	VAL	L	19	70.816	40.395	-21.036	1.00	28.91
ATOM	CG2	VAL	L	19	70.803	40.173	-23.538	1.00	29.02
ATOM	C	VAL	L	19	72.795	42.561	-21.173	1.00	28.10
ATOM	O	VAL	L	19	73.964	42.275	-20.941	1.00	27.17
ATOM	N	THR	L	20	72.035	43.285	-20.359	1.00	28.30
ATOM	CA	THR	L	20	72.508	43.827	-19.100	1.00	31.45
ATOM	CE	THR	L	20	72.585	45.362	-19.149	1.00	33.55
ATOM	OG1	THR	L	20	73.469	45.771	-20.204	1.00	33.44
ATOM	CG2	THR	L	20	73.075	45.916	-17.801	1.00	32.77
ATOM	C	THR	L	20	71.540	43.456	-17.982	1.00	33.30
ATOM	O	THR	L	20	70.343	43.747	-18.061	1.00	32.85
ATOM	N	ILE	L	21	72.082	42.840	-16.935	1.00	34.18
ATOM	CA	ILE	L	21	71.324	42.415	-15.763	1.00	31.59
ATOM	CB	ILE	L	21	71.602	40.918	-15.467	1.00	31.26
ATOM	CG2	ILE	L	21	70.863	40.470	-14.234	1.00	31.18
ATOM	CG1	ILE	L	21	71.200	40.073	-16.680	1.00	32.87
ATOM	CD1	ILE	L	21	71.639	38.629	-16.607	1.00	32.99
ATOM	C	ILE	L	21	71.802	43.294	-14.602	1.00	30.37
ATOM	O	ILE	L	21	73.000	43.557	-14.468	1.00	26.47
ATOM	N	THR	L	22	70.872	43.721	-13.756	1.00	29.86
ATOM	CA	THR	L	22	71.206	44.592	-12.643	1.00	31.35
ATOM	CB	THR	L	22	70.612	46.032	-12.903	1.00	30.91
ATOM	OG1	THR	L	22	71.159	46.574	-14.117	1.00	29.08
ATOM	CG2	THR	L	22	70.925	46.988	-11.743	1.00	31.26
ATOM	C	THR	L	22	70.765	44.090	-11.253	1.00	31.33
ATOM	O	THR	L	22	69.677	43.530	-11.093	1.00	31.64
ATOM	N	CYS	L	23	71.648	44.245	-10.268	1.00	32.19
ATOM	CA	CYS	L	23	71.351	43.899	-8.877	1.00	32.45
ATOM	C	CYS	L	23	71.574	45.153	-8.040	1.00	33.34
ATOM	O	CYS	L	23	72.639	45.759	-8.090	1.00	30.85
ATOM	CB	CYS	L	23	72.213	42.738	-8.358	1.00	31.61
ATOM	SG	CYS	L	23	71.545	41.112	-8.839	1.00	32.93
ATOM	N	LYS	L	24	70.513	45.586	-7.370	1.00	37.25
ATOM	CA	LYS	L	24	70.523	46.764	-6.518	1.00	42.39
ATOM	CB	LYS	L	24	69.405	47.728	-6.922	1.00	45.13
ATOM	CG	LYS	L	24	69.514	48.293	-8.333	1.00	50.30
ATOM	CD	LYS	L	24	68.276	49.122	-8.680	1.00	52.53
ATOM	CE	LYS	L	24	68.393	49.784	-10.042	1.00	54.46
ATOM	NZ	LYS	L	24	67.154	50.539	-10.379	1.00	56.06
ATOM	C	LYS	L	24	70.282	46.314	-5.087	1.00	44.53
ATOM	O	LYS	L	24	69.300	45.614	-4.792	1.00	45.31
ATOM	N	CYS	L	25	71.204	46.662	-4.205	1.00	47.46
ATOM	CA	CYS	L	25	71.064	46.302	-2.813	1.00	50.46
ATOM	CB	CYS	L	25	72.361	45.719	-2.262	1.00	51.49

TABLE 2-continued

		Atom A.A. Type		X	Y	Z	Occ	B
ATOM	SG	CYS L	25	72.217	45.136	-0.553	1.00	55.90
ATOM	C	CYS L	25	70.726	47.576	-2.084	1.00	52.05
ATOM	O	CYS L	25	71.080	48.673	-2.527	1.00	51.90
ATOM	N	GLN L	26	70.002	47.434	-0.985	1.00	55.05
ATOM	CA	GLN L	26	69.611	48.584	-0.177	1.00	58.36
ATOM	CB	GLN L	26	68.491	48.207	0.811	1.00	60.14
ATOM	CG	GLN L	26	68.266	46.704	1.019	1.00	63.23
ATOM	CD	GLN L	26	67.641	46.023	-0.200	1.00	66.56
ATOM	OE1	GLN L	26	68.181	45.039	-0.729	1.00	67.74
ATOM	NE2	GLN L	26	66.508	46.551	-0.656	1.00	67.30
ATOM	C	GLN L	26	70.841	49.078	0.579	1.00	58.79
ATOM	O	GLN L	26	70.977	50.263	0.891	1.00	59.68
ATOM	N	LEU L	28	71.759	48.152	0.820	1.00	57.89
ATOM	CA	LEU L	28	72.977	48.441	1.547	1.00	55.81
ATOM	CB	LEU L	28	73.202	47.342	2.594	1.00	56.86
ATOM	CG	LEU L	28	71.922	46.791	3.252	1.00	57.59
ATOM	CD1	LEU L	28	72.278	45.712	4.269	1.00	57.76
ATOM	CD2	LEU L	28	71.117	47.912	3.921	1.00	58.04
ATOM	C	LEU L	28	74.139	48.487	0.568	1.00	53.54
ATOM	O	LEU L	28	74.132	47.788	-0.447	1.00	51.34
ATOM	N	SER L	29	75.117	49.338	0.858	1.00	52.55
ATOM	CA	SER L	29	76.292	49.456	0.007	1.00	50.75
ATOM	CB	SER L	29	77.226	50.551	0.521	1.00	51.65
ATOM	OG	SER L	29	77.860	51.233	-0.547	1.00	52.04
ATOM	C	SER L	29	76.979	48.093	0.021	1.00	48.93
ATOM	O	SER L	29	76.977	47.387	1.035	1.00	50.11
ATOM	N	VAL L	30	77.566	47.733	-1.106	1.00	45.38
ATOM	CA	VAL L	30	78.194	46.441	-1.256	1.00	43.49
ATOM	CB	VAL L	30	77.446	45.616	-2.348	1.00	45.26
ATOM	CG1	VAL L	30	78.148	44.296	-2.627	1.00	45.55
ATOM	CG2	VAL L	30	76.008	45.374	-1.926	1.00	45.67
ATOM	C	VAL L	30	79.633	46.609	-1.662	1.00	40.20
ATOM	O	VAL L	30	79.954	47.472	-2.474	1.00	40.25
ATOM	N	GLY L	31	80.496	45.770	-1.104	1.00	37.47
ATOM	CA	GLY L	31	81.902	45.830	-1.442	1.00	36.78
ATOM	C	GLY L	31	82.132	45.328	-2.857	1.00	36.26
ATOM	O	GLY L	31	82.562	46.082	-3.725	1.00	36.41
ATOM	N	TYR L	32	81.794	44.064	-3.096	1.00	35.02
ATOM	CA	TYR L	32	81.967	43.427	-4.401	1.00	33.17
ATOM	CB	TYR L	32	83.290	42.658	-4.431	1.00	31.32
ATOM	CG	TYR L	32	83.436	41.688	-3.276	1.00	33.00
ATOM	CD1	TYR L	32	82.777	40.454	-3.279	1.00	33.06
ATOM	CE1	TYR L	32	82.852	39.586	-2.191	1.00	32.01
ATOM	CD2	TYR L	32	84.183	42.025	-2.154	1.00	33.11
ATOM	CE2	TYR L	32	84.267	41.161	-1.057	1.00	33.14
ATOM	CZ	TYR L	32	83.595	39.945	-1.085	1.00	32.91
ATOM	OH	TYR L	32	83.651	39.107	0.002	1.00	30.28
ATOM	C	TYR L	32	80.780	42.483	-4.692	1.00	33.63
ATOM	O	TYR L	32	80.035	42.099	-3.771	1.00	33.48
ATOM	N	MET L	33	80.632	42.082	-5.954	1.00	31.62
ATOM	CA	MET L	33	79.532	41.209	-6.373	1.00	27.51
ATOM	CB	MET L	33	78.556	42.016	-7.245	1.00	27.25
ATOM	CG	MET L	33	77.203	41.373	-7.521	1.00	26.66
ATOM	SD	MET L	33	76.102	41.202	-6.088	1.00	31.44
ATOM	CE	MET L	33	75.676	42.936	-5.687	1.00	28.65
ATOM	C	MET L	33	80.048	39.999	-7.150	1.00	24.55
ATOM	O	MET L	33	81.115	40.062	-7.767	1.00	22.26
ATOM	N	HIS L	34	79.342	38.875	-7.029	1.00	22.23
ATOM	CA	HIS L	34	79.684	37.641	-7.754	1.00	21.25
ATOM	CB	HIS L	34	79.853	36.452	-6.789	1.00	19.84
ATOM	CG	HIS L	34	81.229	36.312	-6.199	1.00	19.58
ATOM	CD2	HIS L	34	82.214	35.415	-6.443	1.00	16.56
ATOM	ND1	HIS L	34	81.702	37.133	-5.195	1.00	17.59
ATOM	CE1	HIS L	34	82.917	36.747	-4.847	1.00	17.33
ATOM	NE2	HIS L	34	83.251	35.709	-5.591	1.00	16.19
ATOM	C	HIS L	34	78.489	37.349	-8.662	1.00	21.03
ATOM	O	HIS L	34	77.356	37.702	-8.323	1.00	22.35
ATOM	N	TRP L	35	78.726	36.736	-9.816	1.00	22.50
ATOM	CA	TRP L	35	77.634	36.390	-10.738	1.00	20.38
ATOM	CB	TRP L	35	77.665	37.258	-12.003	1.00	20.95
ATOM	CG	TRP L	35	77.300	38.704	-11.763	1.00	20.91
ATOM	CD2	TRP L	35	75.977	39.281	-11.759	1.00	19.43
ATOM	CE2	TRP L	35	76.123	40.660	-11.473	1.00	19.35
ATOM	CE3	TRP L	35	74.689	38.768	-11.966	1.00	19.03
ATOM	CD	TRP L	35	78.165	39.730	-11.495	1.00	18.32
ATOM	NE1	TRP L	35	77.465	40.904	-11.323	1.00	17.92

TABLE 2-continued

		Atom A.A.			X	Y	Z	Occ	B
		Type							
ATOM	CZ2	TRP	L	35	75.026	41.534	-11.382	1.00	18.46
ATOM	CZ3	TRP	L	35	73.593	39.644	-11.877	1.00	18.57
ATOM	CH2	TRP	L	35	73.777	41.010	-11.584	1.00	20.31
ATOM	C	TRP	L	35	77.747	34.922	-11.115	1.00	19.11
ATOM	O	TRP	L	35	78.856	34.411	-11.342	1.00	17.52
ATOM	N	TYR	L	36	76.607	34.243	-11.151	1.00	17.89
ATOM	CA	TYR	L	36	76.554	32.824	-11.496	1.00	18.67
ATOM	CE	TYR	L	36	76.157	31.973	-10.277	1.00	16.85
ATOM	CG	TYR	L	36	77.103	32.151	-9.112	1.00	18.90
ATOM	CD1	TYR	L	36	78.206	31.301	-8.943	1.00	17.35
ATOM	CE1	TYR	L	36	79.138	31.515	-7.925	1.00	15.46
ATOM	CD2	TYR	L	36	76.948	33.215	-8.225	1.00	16.62
ATOM	CE2	TYR	L	36	77.870	33.435	-7.210	1.00	18.33
ATOM	CZ	TYR	L	36	78.959	32.586	-7.072	1.00	16.23
ATOM	OH	TYR	L	36	79.879	32.834	-6.101	1.00	16.90
ATOM	C	TYR	L	36	75.586	32.547	-12.640	1.00	18.87
ATOM	O	TYR	L	36	74.598	33.266	-12.833	1.00	16.77
ATOM	N	GLN	L	37	75.912	31.511	-13.406	1.00	20.01
ATOM	CA	GLN	L	37	75.099	31.069	-14.524	1.00	20.83
ATOM	CE	GLN	L	37	75.938	31.002	-15.791	1.00	19.79
ATOM	CG	GLN	L	37	75.133	30.614	-17.009	1.00	21.34
ATOM	CD	GLN	L	37	76.012	30.207	-18.156	1.00	21.69
ATOM	OE1	GLN	L	37	76.829	29.295	-18.022	1.00	20.70
ATOM	NE2	GLN	L	37	75.862	30.880	-19.293	1.00	22.45
ATOM	C	GLN	L	37	74.565	29.677	-14.217	1.00	17.81
ATOM	O	GLN	L	37	75.338	28.763	-13.982	1.00	16.05
ATOM	N	GLN	L	38	73.251	29.508	-14.231	1.00	19.04
ATOM	CA	GLN	L	38	72.697	28.199	-13.952	1.00	19.08
ATOM	CB	GLN	L	38	71.947	28.200	-12.625	1.00	18.05
ATOM	CG	GLN	L	38	71.425	26.836	-12.231	1.00	16.18
ATOM	CD	GLN	L	38	70.504	26.879	-11.020	1.00	19.78
ATOM	OE1	GLN	L	38	70.437	25.910	-10.242	1.00	20.20
ATOM	NE2	GLN	L	38	69.780	27.986	-10.854	1.00	13.17
ATOM	C	GLN	L	38	71.799	27.644	-15.043	1.00	21.27
ATOM	O	GLN	L	38	70.754	28.206	-15.345	1.00	19.19
ATOM	N	LYS	L	39	72.238	26.545	-15.648	1.00	26.27
ATOM	CA	LYS	L	39	71.463	25.856	-16.671	1.00	30.24
ATOM	CB	LYS	L	39	72.360	24.926	-17.482	1.00	31.09
ATOM	CG	LYS	L	39	73.184	25.657	-18.549	1.00	31.78
ATOM	CD	LYS	L	39	72.269	26.309	-19.569	1.00	36.19
ATOM	CE	LYS	L	39	73.016	26.722	-20.839	1.00	38.15
ATOM	NZ	LYS	L	39	72.095	27.028	-22.005	1.00	33.68
ATOM	C	LYS	L	39	70.411	25.081	-15.886	1.00	34.01
ATOM	O	LYS	L	39	70.687	24.575	-14.793	1.00	31.70
ATOM	N	PRO	L	40	69.185	24.995	-16.422	1.00	38.94
ATOM	CD	PRO	L	40	68.854	25.278	-17.829	1.00	41.35
ATOM	CA	PRO	L	40	68.073	24.296	-15.770	1.00	39.98
ATOM	CB	PRO	L	40	67.076	24.070	-16.919	1.00	42.33
ATOM	CG	PRO	L	40	67.934	24.119	-18.165	1.00	43.50
ATOM	C	PRO	L	40	68.406	23.007	-15.020	1.00	40.98
ATOM	O	PRO	L	40	69.001	22.066	-15.576	1.00	39.72
ATOM	N	GLY	L	41	68.063	23.017	-13.730	1.00	41.78
ATOM	CA	GLY	L	41	68.267	21.872	-12.861	1.00	41.84
ATOM	C	GLY	L	41	69.698	21.410	-12.703	1.00	42.49
ATOM	O	GLY	L	41	69.927	20.346	-12.125	1.00	45.08
ATOM	N	LYS	L	42	70.648	22.195	-13.215	1.00	39.68
ATOM	CA	LYS	L	42	72.073	21.891	-13.136	1.00	33.25
ATOM	CB	LYS	L	42	72.723	22.072	-14.513	1.00	37.87
ATOM	CG	LYS	L	42	74.156	21.538	-14.609	1.00	45.96
ATOM	CD	LYS	L	42	75.019	22.270	-15.667	1.00	47.70
ATOM	CE	LYS	L	42	75.041	21.551	-17.009	1.00	51.25
ATOM	NZ	LYS	L	42	75.556	20.145	-16.892	1.00	53.52
ATOM	C	LYS	L	42	72.667	22.867	-12.115	1.00	27.28
ATOM	O	LYS	L	42	72.048	23.868	-11.785	1.00	22.25
ATOM	N	ALA	L	43	73.842	22.555	-11.584	1.00	25.53
ATOM	CA	ALA	L	43	74.485	23.416	-10.591	1.00	23.99
ATOM	CB	ALA	L	43	75.633	22.685	-9.919	1.00	24.09
ATOM	C	ALA	L	43	74.976	24.738	-11.178	1.00	21.59
ATOM	O	ALA	L	43	75.360	24.796	-12.353	1.00	20.16
ATOM	N	PRO	L	44	74.928	25.829	-10.377	1.00	18.22
ATOM	CD	PRO	L	44	74.263	25.938	-9.068	1.00	14.64
ATOM	CA	PRO	L	44	75.379	27.152	-10.834	1.00	18.30
ATOM	CB	PRO	L	44	75.067	28.053	-9.637	1.00	16.73
ATOM	CG	PRO	L	44	73.859	27.389	-9.035	1.00	15.24
ATOM	C	PRO	L	44	76.872	27.159	-11.169	1.00	19.43
ATOM	O	PRO	L	44	77.649	26.404	-10.573	1.00	18.33

TABLE 2-continued

		Atom A.A.			X	Y	Z	Occ	B
		Type							
ATOM	N	LYS	L	45	77.238	27.955	-12.174	1.00	18.18
ATOM	CA	LYS	L	45	78.621	28.103	-12.620	1.00	18.06
ATOM	CB	LYS	L	45	78.747	27.822	-14.125	1.00	20.32
ATOM	CG	LYS	L	45	80.192	27.912	-14.647	1.00	25.63
ATOM	CD	LYS	L	45	80.284	27.852	-16.169	1.00	28.87
ATOM	CE	LYS	L	45	79.679	29.096	-16.801	1.00	36.26
ATOM	NZ	LYS	L	45	79.705	29.101	-18.297	1.00	37.77
ATOM	C	LYS	L	45	79.091	29.525	-12.346	1.00	15.28
ATOM	O	LYS	L	45	78.433	30.493	-12.719	1.00	13.64
ATOM	N	LEU	L	46	80.222	29.646	-11.676	1.00	16.78
ATOM	CA	LEU	L	46	80.781	30.950	-11.375	1.00	18.03
ATOM	CB	LEU	L	46	81.979	30.795	-10.430	1.00	17.46
ATOM	CG	LEU	L	46	82.748	32.077	-10.079	1.00	18.46
ATOM	CD1	LEU	L	46	81.862	33.118	-9.387	1.00	15.94
ATOM	CD2	LEU	L	46	83.924	31.719	-9.199	1.00	21.70
ATOM	C	LEU	L	46	81.208	31.666	-12.662	1.00	17.99
ATOM	O	LEU	L	46	81.974	31.122	-13.446	1.00	16.91
ATOM	N	LEU	L	47	80.703	32.877	-12.880	1.00	19.12
ATOM	CA	LEU	L	47	81.066	33.661	-14.068	1.00	21.92
ATOM	CB	LEU	L	47	79.830	34.286	-14.736	1.00	23.03
ATOM	CG	LEU	L	47	78.726	33.442	-15.371	1.00	24.65
ATOM	CD1	LEU	L	47	77.572	34.351	-15.770	1.00	23.61
ATOM	CD2	LEU	L	47	79.261	32.674	-16.578	1.00	22.42
ATOM	C	LEU	L	47	82.008	34.816	-13.729	1.00	23.45
ATOM	O	LEU	L	47	83.011	35.034	-14.404	1.00	24.27
ATOM	N	ILE	L	48	81.644	35.572	-12.697	1.00	24.75
ATOM	CA	ILE	L	48	82.388	36.748	-12.287	1.00	24.56
ATOM	CB	ILE	L	48	81.603	38.041	-12.743	1.00	26.86
ATOM	CG2	ILE	L	48	82.215	39.316	-12.148	1.00	23.10
ATOM	CG1	ILE	L	48	81.460	38.105	-14.276	1.00	27.21
ATOM	CD1	ILE	L	48	82.758	38.266	-15.051	1.00	29.72
ATOM	C	ILE	L	48	82.540	36.814	-10.763	1.00	27.68
ATOM	O	ILE	L	48	81.572	36.581	-10.016	1.00	28.36
ATOM	N	TYR	L	49	83.749	37.130	-10.304	1.00	27.66
ATOM	CA	TYR	L	49	84.010	37.313	-8.879	1.00	26.50
ATOM	CB	TYR	L	49	84.961	36.242	-8.338	1.00	25.78
ATOM	CG	TYR	L	49	86.345	36.242	-8.942	1.00	27.79
ATOM	CD1	TYR	L	49	87.318	37.147	-8.510	1.00	27.87
ATOM	CE1	TYR	L	49	88.610	37.122	-9.023	1.00	26.39
ATOM	CD2	TYR	L	49	86.702	35.308	-9.913	1.00	28.91
ATOM	CE2	TYR	L	49	87.995	35.275	-10.437	1.00	29.68
ATOM	CZ	TYR	L	49	88.939	36.189	-9.982	1.00	28.14
ATOM	OH	TYR	L	49	90.205	36.178	-10.499	1.00	27.11
ATOM	C	TYR	L	49	84.608	38.715	-8.710	1.00	28.04
ATOM	O	TYR	L	49	84.987	39.351	-9.701	1.00	26.90
ATOM	N	ASP	L	50	84.668	39.203	-7.471	1.00	27.93
ATOM	CA	ASP	L	50	85.228	40.526	-7.166	1.00	30.07
ATOM	CB	ASP	L	50	86.764	40.450	-7.231	1.00	32.48
ATOM	OG	ASP	L	50	87.455	41.699	-6.684	1.00	34.53
ATOM	OD1	ASP	L	50	86.809	42.526	-5.994	1.00	33.00
ATOM	OD2	ASP	L	50	88.669	41.836	-6.955	1.00	34.56
ATOM	C	ASP	L	50	84.670	41.625	-8.093	1.00	29.48
ATOM	O	ASP	L	50	85.408	42.469	-8.621	1.00	28.02
ATOM	N	THR	L	51	83.360	41.563	-8.312	1.00	28.37
ATOM	CA	THR	L	51	82.637	42.514	-9.150	1.00	29.26
ATOM	CB	THR	L	51	82.819	43.979	-8.642	1.00	29.35
ATOM	OG1	THR	L	51	82.378	44.070	-7.281	1.00	29.46
ATOM	CG2	THR	L	51	82.007	44.957	-9.474	1.00	26.57
ATOM	C	THR	L	51	82.901	42.458	-10.657	1.00	29.27
ATOM	O	THR	L	51	81.950	42.407	-11.448	1.00	28.35
ATOM	N	SER	L	52	84.167	42.388	-11.057	1.00	29.47
ATOM	CA	SER	L	52	84.492	42.413	-12.475	1.00	29.99
ATOM	CB	SER	L	52	84.959	43.829	-12.841	1.00	32.61
ATOM	OG	SER	L	52	85.836	44.382	-11.852	1.00	34.91
ATOM	C	SER	L	52	85.492	41.397	-12.999	1.00	30.37
ATOM	O	SER	L	52	85.854	41.431	-14.172	1.00	30.49
ATOM	N	LYS	L	53	85.923	40.472	-12.159	1.00	30.92
ATOM	CA	LYS	L	53	86.898	39.488	-12.603	1.00	33.14
ATOM	CB	LYS	L	53	87.752	39.014	-11.427	1.00	35.84
ATOM	CG	LYS	L	53	88.815	40.005	-10.988	1.00	37.91
ATOM	CD	LYS	L	53	89.913	40.093	-12.024	1.00	41.62
ATOM	CE	LYS	L	53	90.774	41.308	-11.779	1.00	45.49
ATOM	NZ	LYS	L	53	89.949	42.558	-11.856	1.00	50.35
ATOM	C	LYS	L	53	86.273	38.290	-13.281	2.00	33.94
ATOM	O	LYS	L	53	85.488	37.568	-12.666	1.00	35.02
ATOM	N	LEU	L	54	86.624	38.076	-14.544	1.00	33.95

TABLE 2-continued

		Atom A.A.			X	Y	Z	Occ	B
		Type							
ATOM	CA	LEU	L	54	86.112	36.934	-15.287	1.00	35.46
ATOM	CB	LEU	L	54	86.500	37.029	-16.770	1.00	36.70
ATOM	CG	LEU	L	54	85.401	37.137	-17.837	1.00	37.08
ATOM	CD1	LEU	L	54	85.948	36.771	-19.210	1.00	33.57
ATOM	CD2	LEU	L	54	84.264	36.216	-17.493	1.00	36.74
ATOM	C	LEU	L	54	86.715	35.664	-14.687	1.00	35.69
ATOM	O	LEU	L	54	87.932	35.555	-14.545	1.00	35.01
ATOM	N	ALA	L	55	85.860	34.714	-14.324	1.00	36.81
ATOM	CA	ALA	L	55	86.317	33.451	-13.753	1.00	37.12
ATOM	CB	ALA	L	55	85.154	32.709	-13.126	1.00	34.93
ATOM	C	ALA	L	55	86.968	32.609	-14.849	1.00	38.49
ATOM	O	ALA	L	55	86.818	32.903	-16.034	1.00	39.16
ATOM	N	SER	L	56	87.687	31.561	-14.468	1.00	40.87
ATOM	CA	SER	L	56	88.356	30.728	-15.461	1.00	43.84
ATOM	CB	SER	L	56	89.365	29.779	-14.795	1.00	46.40
ATOM	OG	SER	L	56	88.718	28.774	-14.024	1.00	50.55
ATOM	C	SER	L	56	87.352	29.937	-16.282	1.00	44.04
ATOM	O	SER	L	56	86.409	29.359	-15.735	1.00	44.83
ATOM	N	GLY	L	57	87.567	29.903	-17.594	1.00	44.28
ATOM	CA	GLY	L	57	86.666	29.176	-18.475	1.00	43.67
ATOM	C	GLY	L	57	85.361	29.904	-18.758	1.00	42.62
ATOM	O	GLY	L	57	84.320	29.277	-18.963	1.00	43.63
ATOM	N	VAL	L	58	85.405	31.229	-18.758	1.00	39.62
ATOM	CA	VAL	L	58	84.210	32.012	-19.014	1.00	38.57
ATOM	CB	VAL	L	58	83.758	32.788	-17.742	1.00	35.08
ATOM	CG1	VAL	L	58	82.474	33.549	-18.020	1.00	34.33
ATOM	CG2	VAL	L	58	83.553	31.826	-16.585	1.00	28.89
ATOM	C	VAL	L	58	84.481	32.972	-20.174	1.00	40.23
ATOM	O	VAL	L	58	85.455	33.716	-20.158	1.00	40.10
ATOM	N	PRO	L	59	83.656	32.910	-21.230	1.00	42.12
ATOM	CD	PRO	L	59	82.539	31.958	-21.393	1.00	42.64
ATOM	CA	PRO	L	59	83.791	33.767	-22.414	1.00	41.98
ATOM	CB	PRO	L	59	82.505	33.470	-23.186	1.00	42.48
ATOM	CG	PRO	L	59	82.260	32.023	-22.872	1.00	41.91
ATOM	C	PRO	L	59	83.896	35.255	-22.083	1.00	42.11
ATOM	O	PRO	L	59	83.106	35.782	-21.290	1.00	40.98
ATOM	N	SER	L	60	84.818	35.942	-22.760	1.00	42.19
ATOM	CA	SER	L	60	85.031	37.376	-22.566	1.00	42.32
ATOM	CB	SER	L	60	86.131	37.869	-23.493	1.00	44.75
ATOM	CG	SER	L	60	85.777	37.637	-24.846	1.00	48.53
ATOM	C	SER	L	60	83.756	38.145	-22.867	1.00	41.50
ATOM	O	SER	L	60	83.689	39.363	-22.684	1.00	41.56
ATOM	N	ARG	L	61	82.772	37.411	-23.385	1.00	41.32
ATOM	CA	ARG	L	61	81.446	37.907	-23.745	1.00	40.02
ATOM	CB	ARG	L	61	80.649	36.727	-24.312	1.00	41.65
ATOM	CG	ARG	L	61	79.520	37.058	-25.262	1.00	44.33
ATOM	CD	ARG	L	61	78.721	35.782	-25.563	1.00	45.07
ATOM	NE	ARG	L	61	79.586	34.654	-25.902	1.00	42.81
ATOM	CZ	ARG	L	61	79.368	33.400	-25.523	1.00	41.29
ATOM	NH1	ARG	L	61	78.314	33.096	-24.790	1.00	39.59
ATOM	NH2	ARG	L	61	80.205	32.442	-25.887	1.00	42.30
ATOM	C	ARG	L	61	80.738	38.458	-22.499	1.00	38.03
ATOM	O	ARG	L	61	79.912	39.367	-22.583	1.00	37.15
ATOM	N	PHE	L	62	81.052	37.876	-21.347	1.00	36.07
ATOM	CA	PHE	L	62	80.451	38.293	-20.092	1.00	34.13
ATOM	CB	PHE	L	62	80.242	37.079	-19.191	1.00	32.20
ATOM	CG	PHE	L	62	79.316	36.040	-19.753	1.00	30.05
ATOM	CD1	PHE	L	62	79.813	34.969	-20.475	1.00	28.20
ATOM	CD2	PHE	L	62	77.950	36.097	-19.498	1.00	29.72
ATOM	CE1	PHE	L	62	78.963	33.970	-20.928	1.00	28.11
ATOM	CE2	PHE	L	62	77.092	35.099	-19.950	1.00	27.00
ATOM	CZ	PHE	L	62	77.597	34.038	-20.662	1.00	24.59
ATOM	C	PHE	L	62	81.363	39.263	-19.354	1.00	32.87
ATOM	O	PHE	L	62	82.579	39.113	-19.382	1.00	32.64
ATOM	N	SER	L	63	80.782	40.235	-18.670	1.00	32.15
ATOM	CA	SER	L	63	81.572	41.176	-17.890	1.00	32.65
ATOM	CB	SER	L	63	82.113	42.318	-18.757	1.00	32.01
ATOM	OG	SER	L	63	81.080	43.183	-19.173	1.00	32.88
ATOM	C	SER	L	63	80.718	41.731	-16.759	1.00	33.28
ATOM	O	SER	L	63	79.486	41.746	-16.850	1.00	34.08
ATOM	N	GLY	L	64	81.377	42.150	-15.682	1.00	33.66
ATOM	CA	GLY	L	64	80.678	42.695	-14.541	1.00	30.72
ATOM	C	GLY	L	64	81.233	44.058	-14.191	1.00	31.74
ATOM	O	GLY	L	64	82.415	44.338	-14.403	1.00	29.96
ATOM	N	SER	L	65	80.368	44.908	-13.653	1.00	31.35
ATOM	CA	SER	L	65	80.743	46.249	-13.250	1.00	32.13

TABLE 2-continued

		Atom A.A.			X	Y	Z	Occ	B
		Type							
ATOM	CB	SER	L	65	80.579	47.198	-14.427	1.00	33.39
ATOM	OG	SER	L	65	81.199	48.432	-14.145	1.00	38.02
ATOM	C	SER	L	65	79.836	46.687	-12.107	1.00	32.01
ATOM	O	SER	L	65	78.958	45.936	-11.670	1.00	32.14
ATOM	N	GLY	L	66	80.069	47.883	-11.587	1.00	32.03
ATOM	CA	GLY	L	66	79.229	48.367	-10.514	1.00	31.82
ATOM	C	GLY	L	66	79.988	48.757	-9.268	1.00	32.34
ATOM	O	GLY	L	66	81.187	48.499	-9.149	1.00	33.45
ATOM	N	SER	L	67	79.275	49.387	-8.342	1.00	33.28
ATOM	CA	SER	L	67	79.829	49.819	-7.070	1.00	33.09
ATOM	CB	SER	L	67	80.853	50.946	-7.281	1.00	34.89
ATOM	OG	SER	L	67	80.222	52.176	-7.613	1.00	36.97
ATOM	C	SER	L	67	78.673	50.308	-6.203	1.00	33.38
ATOM	O	SER	L	67	77.529	50.430	-6.665	1.00	32.21
ATOM	N	GLY	L	68	78.967	50.573	-4.939	1.00	34.02
ATOM	CA	GLY	L	68	77.946	51.067	-4.043	1.00	35.08
ATOM	C	GLY	L	68	76.785	50.114	-3.895	1.00	36.51
ATOM	O	GLY	L	68	76.953	49.014	-3.381	1.00	37.01
ATOM	N	THR	L	69	75.614	50.526	-4.362	1.00	38.06
ATOM	CA	THR	L	69	74.413	49.706	-4.257	1.00	39.69
ATOM	CB	THR	L	69	73.238	50.539	-3.709	1.00	41.73
ATOM	OG1	THR	L	69	73.143	51.764	-4.451	1.00	44.69
ATOM	CG2	THR	L	69	73.435	50.853	-2.226	1.00	43.12
ATOM	C	THR	L	69	73.959	49.053	-5.568	1.00	39.10
ATOM	O	THR	L	69	73.035	48.239	-5.559	1.00	40.25
ATOM	N	GLU	L	70	74.596	49.393	-6.686	1.00	36.36
ATOM	CA	GLU	L	70	74.190	48.823	-7.963	1.00	33.95
ATOM	CB	GLU	L	70	73.480	49.869	-8.803	1.00	35.14
ATOM	C	GLU	L	70	75.331	48.192	-8.749	1.00	32.26
ATOM	O	GLU	L	70	76.366	48.816	-8.994	1.00	31.16
ATOM	N	PHE	L	71	75.129	46.939	-9.141	1.00	30.51
ATOM	CA	PHE	L	71	76.125	46.192	-9.885	1.00	29.00
ATOM	CB	PHE	L	71	76.713	45.102	-8.983	1.00	25.95
ATOM	CG	PHE	L	71	77.425	45.644	-7.766	1.00	26.50
ATOM	CD1	PHE	L	71	78.818	45.695	-7.718	1.00	23.83
ATOM	CD2	PHE	L	71	76.704	46.140	-6.681	1.00	23.86
ATOM	CE1	PHE	L	71	79.472	46.231	-6.615	1.00	23.12
ATOM	CE2	PHE	L	71	77.360	46.682	-5.574	1.00	25.02
ATOM	CZ	PHE	L	71	78.743	46.726	-5.543	1.00	19.89
ATOM	C	PHE	L	71	75.440	45.591	-11.103	1.00	31.37
ATOM	O	PHE	L	71	74.215	45.385	-11.089	1.00	32.37
ATOM	N	THR	L	72	76.213	45.319	-12.154	1.00	31.74
ATOM	CA	THR	L	72	75.660	44.756	-13.381	1.00	31.21
ATOM	CB	THR	L	72	75.437	45.846	-14.458	1.00	33.86
ATOM	OG1	THR	L	72	76.680	46.488	-14.753	1.00	34.13
ATOM	CG2	THR	L	72	74.408	46.887	-13.991	1.00	33.49
ATOM	C	THR	L	72	76.460	43.632	-14.038	1.00	31.02
ATOM	O	THR	L	72	77.683	43.518	-13.867	1.00	27.20
ATOM	N	LEU	L	73	75.730	42.792	-14.768	1.00	29.35
ATOM	CA	LEU	L	73	76.297	41.685	-15.521	1.00	30.38
ATOM	CB	LEU	L	73	75.674	40.341	-15.120	1.00	28.33
ATOM	CG	LEU	L	73	76.122	39.098	-15.913	1.00	28.85
ATOM	CG1	LEU	L	73	77.598	38.759	-15.662	1.00	26.27
ATOM	CD2	LEU	L	73	75.221	37.917	-15.559	1.00	26.75
ATOM	C	LEU	L	73	75.939	41.994	-16.971	1.00	30.49
ATOM	O	LEU	L	73	74.778	42.295	-17.282	1.00	29.18
ATOM	N	THR	L	74	76.922	41.896	-17.855	1.00	30.05
ATOM	CA	THR	L	74	76.682	42.181	-19.253	1.00	31.19
ATOM	CB	THR	L	74	77.270	43.566	-19.662	1.00	31.37
ATOM	OG1	THR	L	74	76.667	44.597	-18.868	1.00	28.24
ATOM	CG2	THR	L	74	77.014	43.849	-21.158	1.00	30.50
ATOM	C	THR	L	74	77.222	41.106	-20.172	1.00	29.92
ATOM	O	THR	L	74	78.336	40.621	-20.002	1.00	28.40
ATOM	N	ILE	L	75	76.373	40.714	-21.114	1.00	33.76
ATOM	CA	ILE	L	75	76.679	39.712	-22.140	1.00	38.02
ATOM	CB	ILE	L	75	75.587	38.579	-22.177	1.00	38.72
ATOM	CG2	ILE	L	75	76.058	37.421	-23.055	1.00	37.88
ATOM	CG1	ILE	L	75	75.312	38.071	-20.744	1.00	39.78
ATOM	CD1	ILE	L	75	74.105	37.164	-20.583	1.00	37.31
ATOM	C	ILE	L	75	76.635	40.580	-23.406	1.00	38.55
ATOM	O	ILE	L	75	75.579	41.106	-23.771	1.00	38.37
ATOM	N	SER	L	76	77.802	40.787	-24.008	1.00	40.06
ATOM	CA	SER	L	76	77.944	41.651	-25.170	1.00	42.95
ATOM	CB	SER	L	76	79.420	41.847	-25.484	1.00	42.51
ATOM	OG	SER	L	76	80.107	40.607	-25.441	1.00	47.98
ATOM	C	SER	L	76	77.173	41.258	-26.418	1.00	44.99

TABLE 2-continued

		Atom A.A.			X	Y	Z	Occ	B
		Type							
ATOM	O	SER	L	76	76.675	42.128	-27.141	1.00	47.12
ATOM	N	SER	L	77	77.078	39.961	-26.677	1.00	43.59
ATOM	CA	SER	L	77	76.346	39.475	-27.834	1.00	44.13
ATOM	CB	SER	L	77	77.226	39.498	-29.075	1.00	45.12
ATOM	OG	SER	L	77	78.508	38.981	-28.772	1.00	51.53
ATOM	C	SER	L	77	75.870	38.069	-27.523	1.00	43.98
ATOM	O	SER	L	77	76.590	37.086	-27.689	1.00	42.87
ATOM	N	LEU	L	78	74.664	38.012	-26.991	1.00	43.76
ATOM	CA	LEU	L	78	74.010	36.786	-26.591	1.00	44.13
ATOM	CB	LEU	L	78	72.550	37.110	-26.295	1.00	45.19
ATOM	CG	LEU	L	78	71.735	36.161	-25.433	1.00	45.72
ATOM	CD1	LEU	L	78	72.357	36.067	-24.054	1.00	44.08
ATOM	CD2	LEU	L	78	70.315	36.697	-25.359	1.00	46.47
ATOM	C	LEU	L	78	74.076	35.704	-27.654	1.00	43.75
ATOM	O	LEU	L	78	74.230	35.988	-28.834	1.00	45.19
ATOM	N	GLN	L	79	74.002	34.455	-27.226	1.00	43.45
ATOM	CA	GLN	L	79	73.989	33.350	-28.162	1.00	44.42
ATOM	CB	GLN	L	79	75.384	32.990	-28.648	1.00	46.01
ATOM	CG	GLN	L	79	76.334	32.491	-27.653	1.00	53.13
ATOM	CD	GLN	L	79	77.643	32.175	-28.330	1.00	60.30
ATOM	OE1	GLN	L	79	78.434	33.077	-28.630	1.00	63.72
ATOM	NE2	GLN	L	79	77.860	30.898	-28.635	1.00	62.41
ATOM	C	GLN	L	79	73.229	32.184	-27.551	1.00	42.80
ATOM	O	GLN	L	79	73.019	32.155	-26.343	1.00	42.45
ATOM	N	PRO	L	80	72.754	31.238	-28.382	1.00	42.66
ATOM	CD	PRO	L	80	73.022	31.156	-29.831	1.00	41.71
ATOM	CA	PRO	L	80	71.989	30.064	-27.942	1.00	40.32
ATOM	CB	PRO	L	80	72.141	29.113	-29.123	1.00	42.49
ATOM	CG	PRO	L	80	72.095	30.051	-30.277	1.00	42.33
ATOM	C	PRO	L	80	72.347	29.406	-26.604	1.00	37.21
ATOM	O	PRO	L	80	71.466	29.170	-25.774	1.00	34.11
ATOM	N	ASP	L	81	73.631	29.153	-26.369	1.00	36.25
ATOM	CA	ASP	L	81	74.053	28.513	-25.121	1.00	35.32
ATOM	CB	ASP	L	81	75.428	27.880	-25.283	1.00	37.14
ATOM	CG	ASP	L	81	75.785	26.986	-24.115	1.00	41.90
ATOM	OD1	ASP	L	81	76.936	27.061	-23.634	1.00	48.22
ATOM	OD2	ASP	L	81	74.908	26.221	-23.661	1.00	41.44
ATOM	C	ASP	L	81	74.031	29.405	-23.879	1.00	30.85
ATOM	O	ASP	L	81	74.419	28.986	-22.791	1.00	28.33
ATOM	N	ASP	L	82	73.571	30.636	-24.046	1.00	30.80
ATOM	CA	ASP	L	82	73.497	31.587	-22.943	1.00	29.65
ATOM	CB	ASP	L	82	73.750	33.011	-23.438	1.00	29.14
ATOM	CG	ASP	L	82	75.183	33.230	-23.872	1.00	29.25
ATOM	OD1	ASP	L	82	75.430	34.180	-24.636	1.00	31.44
ATOM	OD2	ASP	L	82	76.067	32.463	-23.438	1.00	29.20
ATOM	C	ASP	L	82	72.151	31.494	-22.260	1.00	27.63
ATOM	O	ASP	L	82	71.843	32.270	-21.359	1.00	27.38
ATOM	N	PHE	L	83	71.324	30.570	-22.730	1.00	24.99
ATOM	CA	PHE	L	83	70.025	30.371	-22.116	1.00	23.55
ATOM	CB	PHE	L	83	69.218	29.325	-22.901	1.00	20.70
ATOM	CG	PHE	L	83	68.164	28.651	-22.088	1.00	19.09
ATOM	CG1	PHE	L	83	67.068	29.359	-21.634	1.00	16.96
ATOM	CD2	PHE	L	83	68.306	27.313	-21.720	1.00	20.10
ATOM	CE1	PHE	L	83	66.133	28.753	-20.823	1.00	18.32
ATOM	CE2	PHE	L	83	67.368	26.694	-20.905	1.00	19.05
ATOM	CZ	PHE	L	83	66.282	27.412	-20.455	1.00	19.06
ATOM	C	PHE	L	83	70.368	29.850	-20.727	1.00	20.93
ATOM	O	PHE	L	83	71.155	28.921	-20.618	1.00	22.26
ATOM	N	ALA	L	84	69.843	30.485	-19.684	1.00	19.63
ATOM	CA	ALA	L	84	70.095	30.070	-18.304	1.00	19.18
ATOM	CB	ALA	L	84	71.600	29.995	-18.039	1.00	17.02
ATOM	C	ALA	L	84	69.483	31.081	-17.357	1.00	18.18
ATOM	O	ALA	L	84	68.926	32.085	-17.786	1.00	20.57
ATOM	N	THR	L	85	69.513	30.778	-16.070	1.00	18.27
ATOM	CA	THR	L	85	69.046	31.733	-15.078	1.00	18.66
ATOM	CB	THR	L	85	68.138	31.090	-14.007	1.00	16.55
ATOM	OG1	THR	L	85	66.921	30.664	-14.625	1.00	19.88
ATOM	CG2	THR	L	85	67.776	32.102	-12.943	1.00	12.55
ATOM	C	THR	L	85	70.328	32.298	-14.449	1.00	18.52
ATOM	O	THR	L	85	71.240	31.533	-14.081	1.00	16.60
ATOM	N	TYR	L	86	70.440	33.625	-14.453	1.00	17.64
ATOM	CA	TYR	L	86	71.598	34.311	-13.895	1.00	19.24
ATOM	CB	TYR	L	86	72.066	35.426	-14.817	1.00	18.33
ATOM	CG	TYR	L	86	72.555	34.865	-16.118	1.00	18.76
ATOM	CD1	TYR	L	86	71.673	34.633	-17.172	1.00	21.98
ATOM	CE1	TYR	L	86	72.111	34.050	-18.360	1.00	21.65

TABLE 2-continued

		Atom A.A.		X	Y	Z	Occ	B	
		Type							
ATOM	CD2	TYR	L	86	73.890	34.502	-16.283	1.00	15.25
ATOM	CE2	TYR	L	86	74.335	33.923	-17.456	1.00	18.24
ATOM	CZ	TYR	L	86	73.441	33.700	-18.492	1.00	18.78
ATOM	OH	TYR	L	86	73.879	33.135	-19.663	1.00	21.03
ATOM	C	TYR	L	86	71.303	34.847	-12.519	1.00	19.80
ATOM	O	TYR	L	86	70.173	35.270	-12.237	1.00	19.56
ATOM	N	TYR	L	87	72.309	34.760	-11.645	1.00	19.65
ATOM	CA	TYR	L	87	72.180	35.201	-10.259	1.00	19.63
ATOM	CB	TYR	L	87	72.042	33.995	-9.324	1.00	17.97
ATOM	CG	TYR	L	87	70.802	33.165	-9.522	1.00	15.59
ATOM	CD1	TYR	L	87	70.854	31.964	-10.233	1.00	14.99
ATOM	CE1	TYR	L	87	69.746	31.158	-10.356	1.00	14.07
ATOM	CD2	TYR	L	87	69.596	33.538	-8.945	1.00	15.68
ATOM	CE2	TYR	L	87	68.466	32.731	-9.058	1.00	16.41
ATOM	CZ	TYR	L	87	68.548	31.542	-9.767	1.00	15.92
ATOM	OH	TYR	L	87	67.444	30.735	-9.911	1.00	16.14
ATOM	C	TYR	L	87	73.376	35.984	-9.773	1.00	19.98
ATOM	O	TYR	L	87	74.518	35.626	-10.061	1.00	21.18
ATOM	N	CYS	L	88	73.117	37.049	-9.030	1.00	19.62
ATOM	CA	CYS	L	88	742.96	37.811	-8.445	1.00	20.76
ATOM	C	CYS	L	88	74.219	37.345	-6.995	1.00	22.45
ATOM	O	CYS	L	88	732.87	36.914	-6.448	1.00	22.65
ATOM	CB	CYS	L	88	73.915	39.305	-8.494	1.00	20.25
ATOM	SG	CYS	L	88	72.419	39.779	-7.595	1.00	23.98
ATOM	N	PHE	L	89	75.399	37.375	-6.392	1.00	21.08
ATOM	CA	PHE	L	89	75.556	36.982	-5.011	1.00	20.36
ATOM	CB	PHE	L	89	76.258	35.622	-4.910	1.00	19.78
ATOM	CG	PHE	L	89	76.577	35.202	-3.488	1.00	21.53
ATOM	CD1	PHE	L	89	77.898	35.078	-3.060	1.00	21.75
ATOM	CD2	PHE	L	89	75.553	34.945	-2.573	1.00	21.04
ATOM	CE1	PHE	L	89	782.89	34.709	-1.747	1.00	22.24
ATOM	CE2	PHE	L	89	75.838	34.577	-1.264	1.00	22.75
ATOM	CZ	PHE	L	89	77.160	34.459	-0.849	1.00	22.39
ATOM	C	PHE	L	89	76.387	38.044	-4.295	1.00	21.40
ATOM	O	PHE	L	89	77.455	38.454	-4.784	1.00	19.17
ATOM	N	GLN	L	90	75.878	38.497	-3.155	1.00	22.20
ATOM	CA	GLN	L	90	76.567	39.480	-2.337	1.00	25.57
ATOM	CB	GLN	L	90	75.629	40.659	-1.999	1.00	27.68
ATOM	CG	GLN	L	90	75.673	41.205	-0.555	1.00	34.37
ATOM	CD	GLN	L	90	76.975	41.908	-0.185	1.00	36.51
ATOM	OE1	GLN	L	90	78.050	41.538	-0.647	1.00	37.64
ATOM	NE2	GLN	L	90	76.879	42.923	0.666	1.00	42.09
ATOM	C	GLN	L	90	77.091	38.771	-1.084	1.00	24.62
ATOM	O	GLN	L	90	76.316	38.362	-0.220	1.00	24.09
ATOM	N	GLY	L	91	78.405	38.560	-1.045	1.00	24.26
ATOM	CA	GLY	L	91	79.036	37.915	0.088	1.00	25.85
ATOM	C	GLY	L	91	80.073	38.818	0.743	1.00	27.80
ATOM	O	GLY	L	91	80.845	38.369	1.590	1.00	28.54
ATOM	N	SER	L	92	802.01	40.089	0.354	1.00	28.11
ATOM	CA	SER	L	92	81.052	41.037	0.922	1.00	29.42
ATOM	CB	SER	L	92	81.342	42.170	-0.067	1.00	27.86
ATOM	OG	SER	L	92	80.172	42.809	-0.525	1.00	28.57
ATOM	C	SER	L	92	80.628	41.603	2.279	1.00	29.98
ATOM	O	SER	L	92	81.464	42.051	3.053	1.00	29.20
ATOM	N	GLY	L	93	79.334	41.554	2.571	1.00	31.33
ATOM	CA	GLY	L	93	78.825	42.063	3.833	1.00	32.06
ATOM	C	GLY	L	93	77.548	41.346	4.230	1.00	32.98
ATOM	O	GLY	L	93	76.951	40.646	3.412	1.00	31.29
ATOM	N	TYR	L	94	77.116	41.524	5.474	1.00	34.98
ATOM	CA	TYR	L	94	75.907	40.862	5.956	1.00	39.24
ATOM	CB	TYR	L	94	76.044	40.534	7.438	1.00	41.36
ATOM	CG	TYR	L	94	77.141	39.539	7.743	1.00	45.93
ATOM	CD1	TYR	L	94	78.125	39.829	8.691	1.00	47.27
ATOM	CE1	TYR	L	94	79.121	38.916	8.996	1.00	48.93
ATOM	CD2	TYR	L	94	772.87	38.299	7.102	1.00	45.87
ATOM	CR2	TYR	L	94	78.183	37.377	7.400	1.00	47.29
ATOM	CZ	TYR	L	94	79.147	37.692	8.348	1.00	48.81
ATOM	OH	TYR	L	94	80.149	36.795	8.645	1.00	51.35
ATOM	C	TYR	L	94	74.390	41.606	5.696	1.00	39.68
ATOM	O	TYR	L	94	74.534	42.837	5.735	1.00	40.70
ATOM	N	PRO	L	95	73.516	40.859	5.375	1.00	39.57
ATOM	CG	PRO	L	95	72.146	41.409	5.309	1.00	40.15
ATOM	CA	PRO	L	95	73.503	39.395	5.249	1.00	36.54
ATOM	CB	PRO	L	95	72.055	39.050	5.573	1.00	36.84
ATOM	CG	PRO	L	95	71.308	40.192	4.948	1.00	38.59
ATOM	C	PRO	L	95	73.877	38.944	3.835	1.00	33.17

TABLE 2-continued

		Atom A.A.			X	Y	Z	Occ	B
		Type							
ATOM	O	PRO	L	95	73.645	39.662	2.863	1.00	32.32
ATOM	N	PHE	L	96	74.469	37.762	3.726	1.00	32.39
ATOM	CA	PHE	L	96	74.850	37.231	2.421	1.00	33.60
ATOM	CB	PHE	L	96	75.661	35.947	2.576	1.00	30.98
ATOM	CG	PHE	L	96	76.991	36.139	3.242	1.00	33.91
ATOM	CD1	PHE	L	96	77.518	37.416	3.432	1.00	33.81
ATOM	CD2	PHE	L	96	77.733	35.033	3.662	1.00	36.87
ATOM	CE1	PHE	L	96	78.759	37.595	4.027	1.00	36.46
ATOM	CE2	PHE	L	96	78.987	35.196	4.266	1.00	38.28
ATOM	CZ	PHE	L	96	79.500	36.481	4.447	1.00	37.60
ATOM	C	PHE	L	96	73.558	36.938	1.685	1.00	29.65
ATOM	O	PHE	L	96	72.661	36.310	2.241	1.00	29.87
ATOM	N	THR	L	97	73.447	37.377	0.442	1.00	27.80
ATOM	CA	THR	L	97	72.217	37.154	-0.294	1.00	27.85
ATOM	CB	THR	L	97	71.252	38.356	-0.119	1.00	31.07
ATOM	OG1	THR	L	97	71.957	39.581	-0.373	1.00	34.91
ATOM	CG2	THR	L	97	70.670	38.394	1.283	1.00	34.02
ATOM	C	THR	L	97	72.421	36.964	-1.780	1.00	25.56
ATOM	O	THR	L	97	73.385	37.468	-2.354	1.00	25.97
ATOM	N	PHE	L	98	71.493	36.243	-2.395	1.00	23.93
ATOM	CA	PHE	L	98	71.494	36.003	-3.837	1.00	22.96
ATOM	CB	PHE	L	98	71.203	34.545	-4.157	1.00	20.08
ATOM	CG	PHE	L	98	72.257	33.586	-4.165	1.00	17.47
ATOM	CD1	PHE	L	98	72.517	32.782	-3.068	1.00	18.73
ATOM	CD2	PHE	L	98	73.109	33.517	-5.252	1.00	15.42
ATOM	CE1	PHE	L	98	73.616	31.930	-3.053	1.00	18.52
ATOM	CE2	PHE	L	98	74.207	32.664	-5.239	1.00	17.15
ATOM	CZ	PHE	L	98	74.159	31.874	-4.138	1.00	16.08
ATOM	C	PHE	L	98	70.424	36.910	-4.436	1.00	23.92
ATOM	O	PHE	L	98	69.522	37.385	-3.734	1.00	26.57
ATOM	N	GLY	L	99	70.537	37.190	-5.723	1.00	24.88
ATOM	CA	GLY	L	99	69.512	37.977	-6.370	1.00	24.29
ATOM	C	GLY	L	99	68.379	37.008	-6.685	1.00	24.25
ATOM	O	GLY	L	99	68.569	35.778	-6.622	1.00	22.05
ATOM	N	GLY	L	100	67.213	37.553	-7.032	1.00	22.89
ATOM	CA	GLY	L	100	66.059	36.732	-7.357	1.00	19.67
ATOM	C	GLY	L	100	66.275	35.998	-8.683	1.00	20.73
ATOM	O	GLY	L	100	65.395	35.082	-8.959	1.00	18.00
ATOM	N	GLY	L	101	67.116	36.420	-9.521	1.00	19.87
ATOM	CA	GLY	L	101	67.306	35.765	-10.797	1.00	19.54
ATOM	C	GLY	L	101	66.184	36.508	-12.017	1.00	20.81
ATOM	O	GLY	L	101	65.922	37.391	-11.930	1.00	20.98
ATOM	N	THR	L	102	67.389	36.176	-13.151	1.00	21.18
ATOM	CA	THR	L	102	67.038	36.707	-14.459	1.00	22.07
ATOM	CD	THR	L	102	68.080	37.735	-14.978	1.00	22.40
ATOM	OG1	THR	L	102	68.114	38.880	-14.116	1.00	23.14
ATOM	CG2	THR	L	102	67.721	38.190	-16.378	1.00	22.44
ATOM	C	THR	L	102	67.085	35.483	-15.379	1.00	22.40
ATOM	O	THR	L	102	68.170	34.937	-15.636	1.00	20.43
ATOM	N	LYS	L	103	65.913	34.990	-15.782	1.00	22.47
ATOM	CA	LYS	L	103	65.851	33.843	-16.684	1.00	23.31
ATOM	CB	LYS	L	103	64.583	33.021	-16.478	1.00	21.12
ATOM	CG	LYS	L	103	64.550	31.824	-17.392	1.00	22.43
ATOM	CD	LYS	L	103	63.660	30.711	-16.876	1.00	24.88
ATOM	CE	LYS	L	103	63.733	29.481	-17.797	1.00	23.83
ATOM	NZ	LYS	L	103	63.023	28.313	-17.241	1.00	21.06
ATOM	G	LYS	L	103	65.908	34.396	-18.093	1.00	25.31
ATOM	O	LYS	L	103	65.044	35.172	-18.512	1.00	26.75
ATOM	N	LEU	L	104	66.930	33.987	-18.824	1.00	25.69
ATOM	CA	LEU	L	104	67.161	34.469	-20.168	1.00	27.01
ATOM	CD	LEU	L	104	68.650	34.808	-20.298	1.00	27.67
ATOM	CG	LEU	L	104	69.152	35.661	-21.448	1.00	27.93
ATOM	CD1	LEU	L	104	68.423	36.985	-21.446	1.00	29.85
ATOM	CD2	LEU	L	104	70.630	35.881	-21.265	1.00	29.69
ATOM	C	LEU	L	104	66.754	33.473	-21.244	1.00	28.40
ATOM	O	LEU	L	104	67.285	32.364	-21.301	1.00	30.35
ATOM	N	GLU	L	105	65.813	33.874	-22.092	1.00	28.05
ATOM	CA	GLU	L	105	65.343	33.039	-23.191	1.00	29.59
ATOM	CB	GLU	L	105	63.823	33.113	-23.325	1.00	32.46
ATOM	CG	GLU	L	105	63.264	32.079	-24.291	1.00	39.22
ATOM	CD	GLU	L	105	62.213	32.632	-25.237	1.00	41.09
ATOM	OE1	GLU	L	105	62.584	33.444	-26.101	1.00	43.86
ATOM	OE2	GLU	L	105	61.028	32.240	-25.138	1.00	39.88
ATOM	C	GLU	L	105	65.965	33.593	-24.456	1.00	28.60
ATOM	O	GLU	L	105	66.142	34.797	-24.581	1.00	28.67
ATOM	N	ILE	L	106	66.272	32.716	-25.399	1.00	29.12

TABLE 2-continued

		Atom A.A.			X	Y	Z	Occ	B
		Type							
ATOM	CA	ILE	L	106	66.870	33.111	-26.670	1.00	30.41
ATOM	CB	ILE	L	106	68.039	32.149	-27.066	1.00	30.16
ATOM	CG2	ILE	L	106	68.710	32.616	-28.340	1.00	32.05
ATOM	CG1	ILE	L	106	69.056	32.011	-25.928	1.00	29.52
ATOM	CD1	ILE	L	106	69.615	33.317	-25.418	1.00	30.24
ATOM	C	ILE	L	106	65.792	33.091	-27.773	1.00	31.27
ATOM	O	ILE	L	106	65.043	32.116	-27.916	1.00	32.16
ATOM	N	LYS	L	107	65.676	34.187	-28.514	1.00	30.72
ATOM	CA	LYS	L	107	64.69B	34.265	-29.585	1.00	32.13
ATOM	CB	LYS	L	107	64.400	35.716	-29.968	1.00	32.27
ATOM	CG	LYS	L	107	63.701	36.569	-28.945	1.00	34.00
ATOM	CD	LYS	L	107	63.503	37.967	-29.540	1.00	34.55
ATOM	CE	LYS	L	107	62.918	38.935	-28.536	1.00	37.68
ATOM	NZ	LYS	L	107	61.661	38.391	-27.962	1.00	40.96
ATOM	C	LYS	L	107	65.270	33.593	-30.817	1.00	31.68
ATOM	O	LYS	L	107	66.462	33.684	-31.074	1.00	32.74
ATOM	N	ARG	L	108	64.413	32.937	-31.586	1.00	31.51
ATOM	CA	ARG	L	108	64.821	32.295	-32.824	1.00	29.52
ATOM	CB	ARG	L	108	65.265	30.861	-32.591	1.00	29.77
ATOM	CG	ARG	L	108	64.243	29.994	-31.905	1.00	30.89
ATOM	CD	ARG	L	108	64.344	28.565	-32.408	1.00	30.81
ATOM	NE	ARG	L	108	64.038	28.496	-33.829	1.00	30.96
ATOM	CZ	ARG	L	108	64.564	27.618	-34.674	1.00	31.44
ATOM	NH1	ARG	L	108	65.440	26.716	-34.250	1.00	27.52
ATOM	NH2	ARG	L	108	64.205	27.646	-35.952	1.00	29.16
ATOM	C	ARG	L	108	63.636	32.342	-33.771	1.00	28.69
ATOM	O	ARG	L	108	62.572	32.852	-33.421	1.00	28.53
ATOM	N	THR	L	109	63.832	31.858	-34.985	1.00	29.11
ATOM	CA	THR	L	109	62.168	31.858	-35.976	1.00	30.78
ATOM	CB	THR	L	109	63.315	31.518	-37.370	1.00	32.45
ATOM	OG1	THR	L	109	64.064	30.299	-37.309	1.00	35.48
ATOM	CG2	THR	L	109	64.223	32.635	-37.874	1.00	30.66
ATOM	C	THR	L	109	61.693	30.850	-35.595	1.00	31.46
ATOM	O	THR	L	109	61.937	29.954	-34.795	1.00	31.24
ATOM	N	VAL	L	110	60.496	31.009	-36.146	1.00	31.64
ATOM	CA	VAL	L	110	59.417	30.086	-35.836	1.00	31.60
ATOM	CB	VAL	L	110	58.057	30.560	-36.394	1.00	32.31
ATOM	CG1	VAL	L	110	56.964	29.541	-36.066	1.00	31.80
ATOM	CG2	VAL	L	110	57.692	31.919	-35.807	1.00	31.73
ATOM	C	VAL	L	110	59.760	28.722	-36.400	1.00	30.86
ATOM	O	VAL	L	110	60.394	28.614	-37.451	1.00	30.96
ATOM	N	ALA	L	111	59.434	27.693	-35.634	1.00	29.60
ATOM	CA	ALA	L	111	59.680	26.318	-36.032	1.00	28.26
ATOM	CB	ALA	L	111	60.901	25.755	-35.316	1.00	26.88
ATOM	C	ALA	L	111	58.431	25.567	-35.618	1.00	27.23
ATOM	O	ALA	L	111	57.993	25.646	-34.466	1.00	25.20
ATOM	N	ALA	L	112	57.807	24.910	-36.581	1.00	26.83
ATOM	CA	ALA	L	112	56.602	24.153	-36.308	1.00	26.48
ATOM	CB	ALA	L	112	55.840	23.880	-37.610	1.00	27.20
ATOM	C	ALA	L	112	56.943	22.843	-35.606	1.00	23.94
ATOM	O	ALA	L	112	57.988	22.244	-35.855	1.00	23.22
ATOM	N	PRO	L	113	56.075	22.409	-34.691	1.00	22.26
ATOM	CD	PRO	L	113	54.924	23.154	-34.147	1.00	20.36
ATOM	CA	PRO	L	113	56.286	21.161	-33.957	1.00	23.79
ATOM	CB	PRO	L	113	55.244	21.249	-32.838	1.00	22.36
ATOM	CG	PRO	L	113	54.149	22.066	-33.453	1.00	23.79
ATOM	C	PRO	L	113	56.013	19.922	-34.794	1.00	23.47
ATOM	O	PRO	L	113	55.136	19.931	-35.655	1.00	25.95
ATOM	N	SER	L	114	56.769	18.863	-34.535	1.00	21.45
ATOM	CA	SER	L	114	56.557	17.580	-35.194	1.00	21.91
ATOM	CB	SER	L	114	57.871	16.823	-35.335	1.00	24.05
ATOM	OG	SER	L	114	58.789	17.547	-36.137	1.00	28.55
ATOM	C	SER	L	114	55.670	16.904	-34.157	1.00	20.29
ATOM	O	SER	L	114	56.077	16.777	-32.997	1.00	21.52
ATOM	N	VAL	L	115	54.463	16.509	-34.552	1.00	17.56
ATOM	CA	VAL	L	115	53.500	15.914	-33.621	1.00	17.02
ATOM	CB	VAL	L	115	52.110	16.578	-33.810	1.00	16.79
ATOM	CG1	VAL	L	115	51.120	16.067	-32.800	1.00	14.41
ATOM	CG2	VAL	L	115	52.244	18.092	-33.709	1.00	16.01
ATOM	C	VAL	L	115	53.379	14.394	-33.693	1.00	17.60
ATOM	O	VAL	L	115	53.355	13.818	-34.786	1.00	20.11
ATOM	N	PHE	L	116	53.347	13.746	-32.528	1.00	15.99
ATOM	CA	PHE	L	116	53.226	12.289	-32.439	1.00	17.49
ATOM	CB	PHE	L	116	54.562	11.646	-32.059	1.00	15.67
ATOM	CG	PHE	L	116	55.701	12.057	-32.926	1.00	16.56
ATOM	CD1	PHE	L	116	56.376	13.258	-32.687	1.00	15.63

TABLE 2-continued

		Atom A.A.		X	Y	Z	Occ	B	
		Type							
ATOM	CD2	PHE	L	116	56.115	11.246	-33.984	1.00	17.82
ATOM	CE1	PHE	L	116	57.452	13.652	-33.489	1.00	18.32
ATOM	CE2	PHE	L	116	57.186	11.627	-34.792	1.00	18.08
ATOM	CZ	PHE	L	116	57.860	12.839	-34.542	1.00	17.81
ATOM	C	PHE	L	116	52.219	11.915	-31.355	1.00	19.64
ATOM	O	PHE	L	116	52.139	12.586	-30.321	1.00	20.26
ATOM	N	ILE	L	117	51.447	10.858	-31.585	1.00	18.75
ATOM	CA	ILE	L	117	50.490	10.392	-30.585	1.00	19.77
ATOM	CB	ILE	L	117	49.029	10.490	-31.075	1.00	20.51
ATOM	CG2	ILE	L	117	48.815	9.610	-32.295	1.00	18.97
ATOM	CG1	ILE	L	117	48.071	10.086	-29.946	1.00	18.35
ATOM	CG1	ILE	L	117	45.635	10.459	-30.206	1.00	17.73
ATOM	C	ILE	L	117	50.833	8.941	-30.213	1.00	20.69
ATOM	O	ILE	L	117	51.222	8.143	-31.076	1.00	20.52
ATOM	N	PHE	L	118	50.741	8.611	-28.929	1.00	19.61
ATOM	CA	PHE	L	118	51.047	7.262	-28.477	1.00	17.90
ATOM	CB	PHE	L	118	52.268	7.252	-27.557	1.00	16.09
ATOM	CG	PHE	L	118	53.491	7.832	-28.175	1.00	18.71
ATOM	CD1	PHE	L	118	53.868	9.141	-27.902	1.00	18.19
ATOM	CD2	PHE	L	118	54.283	7.069	-29.034	1.00	17.56
ATOM	CE1	PHE	L	118	55.014	9.686	-28.471	1.00	19.36
ATOM	CE2	PHE	L	118	55.436	7.613	-29.608	1.00	20.45
ATOM	CZ	PHE	L	118	55.799	8.917	-29.328	1.00	18.79
ATOM	C	PHE	L	118	49.883	6.662	-27.714	1.00	18.98
ATOM	O	PHE	L	118	49.391	7.261	-26.759	1.00	18.51
ATOM	N	PRO	L	119	49.363	5.519	-28.193	1.00	19.68
ATOM	CD	PRO	L	119	49.626	4.897	-29.503	1.00	19.95
ATOM	CA	PRO	L	119	48.254	4.839	-27.527	1.00	19.86
ATOM	CB	PRO	L	119	47.843	3.789	-28.562	1.00	16.77
ATOM	CG	PRO	L	119	49.099	3.521	-29.297	1.00	19.18
ATOM	C	PRO	L	119	48.778	4.176	-26.243	1.00	18.58
ATOM	O	PRO	L	119	49.997	4.040	-26.050	1.00	15.88
ATOM	N	PRO	L	120	47.872	3.839	-25.312	1.00	20.20
ATOM	CD	PRO	L	120	46.416	4.079	-25.288	1.00	19.97
ATOM	CA	PRO	L	120	48.314	3.193	-24.073	1.00	20.19
ATOM	CB	PRO	L	120	47.030	3.132	-23.245	1.00	19.86
ATOM	CG	PRO	L	120	45.958	3.059	-24.282	1.00	19.24
ATOM	C	PRO	L	120	48.826	1.788	-24.393	1.00	23.23
ATOM	O	PRO	L	120	48.385	1.155	-25.371	1.00	23.12
ATOM	N	SER	L	121	49.770	1.309	-23.593	1.00	23.42
ATOM	CA	SER	L	121	50.327	-0.018	-23.803	1.00	21.02
ATOM	CB	SER	L	121	51.678	-0.139	-23.087	1.00	21.17
ATOM	OG	SER	L	121	51.545	0.081	-21.687	1.00	21.28
ATOM	C	SER	L	121	49.346	-1.019	-23.229	1.00	20.91
ATOM	O	SER	L	121	48.540	-0.664	-22.356	1.00	17.96
ATOM	N	ASP	L	122	49.380	-2.251	-23.734	1.00	20.98
ATOM	CA	ASP	L	122	48.493	-3.292	-23.213	1.00	23.86
ATOM	CB	ASP	L	122	48.631	-4.578	-24.018	1.00	24.89
ATOM	CG	ASP	L	122	48.131	-4.424	-25.433	1.00	27.96
ATOM	OD1	ASP	L	122	47.303	-3.524	-25.681	1.00	27.84
ATOM	OD2	ASP	L	122	48.576	-5.193	-26.305	1.00	32.19
ATOM	C	ASP	L	122	48.845	-3.544	-21.757	1.00	23.60
ATOM	O	ASP	L	122	47.977	-3.813	-20.932	1.00	21.88
ATOM	N	GLU	L	123	50.130	-3.411	-21.454	1.00	23.93
ATOM	CA	GLU	L	123	50.642	-3.585	-20.109	1.00	27.91
ATOM	CD	GLU	L	123	52.163	-3.426	-20.122	1.00	32.19
ATOM	CG	GLU	L	123	52.830	-3.698	-18.791	1.00	40.41
ATOM	CD	GLU	L	123	54.258	-3.194	-18.748	1.00	47.82
ATOM	OE1	GLU	L	123	55.115	-3.894	-18.169	1.00	53.21
ATOM	OE2	GLU	L	123	54.527	-2.092	-19.280	1.00	51.56
ATOM	C	GLU	L	123	50.001	-2.588	-19.117	1.00	27.85
ATOM	O	GLU	L	123	49.575	-2.977	-18.019	1.00	27.68
ATOM	N	GLN	L	124	49.938	-1.308	-19.480	1.00	24.64
ATOM	CA	GLN	L	124	49.332	-0.337	-18.578	1.00	23.22
ATOM	CB	GLN	L	124	49.514	1.088	-19.072	1.00	20.28
ATOM	CG	GLN	L	124	49.008	2.087	-18.064	1.00	14.77
ATOM	CD	GLN	L	124	48.953	3.485	-18.578	1.00	14.59
ATOM	OE1	GLN	L	124	48.958	3.730	-19.780	1.00	17.10
ATOM	NE2	GLN	L	124	48.861	4.424	-17.665	1.00	15.03
ATOM	C	GLN	L	124	47.842	-0.597	-18.400	1.00	25.72
ATOM	O	GLN	L	124	47.315	-0.529	-17.285	1.00	26.05
ATOM	N	LEU	L	125	47.155	-0.864	-19.504	1.00	27.91
ATOM	CA	LEU	L	125	45.723	-1.132	-19.467	1.00	30.96
ATOM	CB	LEU	L	125	45.219	-1.558	-20.847	1.00	28.53
ATOM	CG	LEU	L	125	45.112	-0.447	-21.887	1.00	27.48
ATOM	CE1	LEU	L	125	44.392	-0.998	-23.088	1.00	28.97

TABLE 2-continued

		Atom A.A.			X	Y	Z	Occ	B
		Type							
ATOM	CD2	LEU	L	125	44.352	0.738	-21.318	1.00	27.09
ATOM	C	LEU	L	125	45.416	-2.208	-18.439	1.00	33.69
ATOM	O	LEU	L	125	44.440	-2.107	-17.698	1.00	34.97
ATOM	N	LYS	L	126	46.286	-3.207	-18.357	1.00	36.13
ATOM	CA	LYS	L	126	46.107	-4.282	-17.401	1.00	39.52
ATOM	CB	LYS	L	126	47.296	-5.246	-17.441	1.00	45.42
ATOM	CG	LYS	L	126	46.968	-6.615	-16.849	1.00	52.87
ATOM	CD	LYS	L	126	48.168	-7.301	-16.193	1.00	55.14
ATOM	CE	LYS	L	126	47.770	-8.667	-15.616	1.00	56.30
ATOM	NZ	LYS	L	126	46.588	-8.603	-14.695	1.00	56.59
ATOM	C	LYS	L	126	45.958	-3.715	-15.989	1.00	39.37
ATOM	O	LYS	L	126	45.105	-4.170	-15.232	1.00	40.56
ATOM	N	SER	L	127	46.745	-2.686	-15.667	1.00	38.46
ATOM	CA	SER	L	127	46.730	-2.052	-14.343	1.00	36.08
ATOM	CB	SER	L	127	47.994	-1.191	-14.125	1.00	36.59
ATOM	OG	SER	L	127	47.895	0.119	-14.693	1.00	38.49
ATOM	C	SER	L	127	45.478	-1.227	-14.072	1.00	33.85
ATOM	O	SER	L	127	45.333	-0.633	-13.000	1.00	36.40
ATOM	N	GLY	L	128	44.583	-1.166	-15.048	1.00	31.83
ATOM	CA	GLY	L	128	43.354	-0.414	-14.865	1.00	28.09
ATOM	C	GLY	L	128	43.336	1.015	-15.374	1.00	28.23
ATOM	O	GLY	L	128	42.290	1.666	-15.312	1.00	27.58
ATOM	N	THR	L	129	44.454	1.513	-15.894	1.00	26.97
ATOM	CA	THR	L	129	44.486	2.883	-16.390	1.00	26.43
ATOM	CB	THR	L	129	45.222	3.804	-15.424	1.00	28.39
ATOM	OG1	THR	L	129	44.466	3.862	-14.194	1.00	32.69
ATOM	OG2	THR	L	129	45.325	5.214	-15.997	1.00	29.42
ATOM	C	THR	L	129	45.071	3.015	-17.774	1.00	23.68
ATOM	O	THR	L	129	45.875	2.192	-18.194	1.00	25.37
ATOM	N	ALA	L	130	44.625	4.044	-18.487	1.00	20.97
ATOM	CA	ALA	L	130	45.069	4.323	-19.639	1.00	19.62
ATOM	CB	ALA	L	130	43.909	4.148	-20.807	1.00	18.49
ATOM	C	ALA	L	130	45.637	5.739	-19.961	1.00	19.53
ATOM	O	ALA	L	130	44.955	6.718	-19.646	1.00	19.42
ATOM	N	SER	L	131	46.909	5.832	-20.347	1.00	16.98
ATOM	CA	SER	L	131	47.656	7.114	-20.553	1.00	16.02
ATOM	CB	SER	L	131	48.899	7.186	-19.834	1.00	14.60
ATOM	OG	SER	L	131	48.729	7.094	-18.434	1.00	16.28
ATOM	C	SER	L	131	47.760	7.262	-22.048	1.00	15.07
ATOM	O	SER	L	131	48.211	6.333	-22.708	1.00	15.64
ATOM	N	VAL	L	132	47.325	8.389	-22.593	1.00	15.03
ATOM	CA	VAL	L	132	47.475	8.667	-24.010	1.00	16.30
ATOM	CB	VAL	L	132	46.116	9.021	-24.691	1.00	15.74
ATOM	CG1	VAL	L	132	46.291	9.031	-26.210	1.00	14.83
ATOM	CG2	VAL	L	132	45.014	8.034	-24.255	1.00	12.79
ATOM	C	VAL	L	132	48.420	9.861	-24.039	1.00	16.78
ATOM	O	VAL	L	132	48.193	10.852	-23.349	1.00	15.30
ATOM	N	VAL	L	133	49.601	9.736	-24.796	1.00	14.90
ATOM	CA	VAL	L	133	50.497	10.786	-24.853	1.00	16.13
ATOM	CB	VAL	L	133	51.901	10.246	-24.396	1.00	15.26
ATOM	CG1	VAL	L	133	52.953	11.362	-24.412	1.00	14.56
ATOM	CG2	VAL	L	133	51.794	9.620	-23.018	1.00	13.03
ATOM	C	VAL	L	133	50.622	11.409	-26.226	1.00	14.37
ATOM	O	VAL	L	133	50.629	10.721	-27.251	1.00	13.58
ATOM	N	CYS	L	134	50.734	12.727	-26.222	1.00	16.21
ATOM	CA	CYS	L	134	50.906	13.508	-27.433	1.00	16.73
ATOM	C	CYS	L	134	52.188	14.309	-27.250	1.00	17.07
ATOM	O	CYS	L	134	52.391	14.974	-26.229	1.00	16.97
ATOM	CB	CYS	L	134	49.727	14.456	-27.645	1.00	18.80
ATOM	SG	CYS	L	134	49.723	15.237	-29.291	1.00	24.75
ATOM	N	LEU	L	135	53.075	14.186	-28.216	1.00	16.87
ATOM	CA	LEU	L	135	54.339	14.872	-28.187	1.00	17.83
ATOM	CB	LEU	L	135	55.458	13.849	-28.433	1.00	14.08
ATOM	CG	LEU	L	135	56.857	14.414	-28.734	1.00	16.16
ATOM	CD1	LEU	L	135	57.424	15.070	-27.488	1.00	13.93
ATOM	CD2	LEU	L	135	57.794	13.329	-29.223	1.00	14.15
ATOM	C	LEU	L	135	54.364	15.922	-29.294	1.00	19.16
ATOM	O	LEU	L	135	53.898	15.648	-30.401	1.00	18.16
ATOM	N	LEU	L	136	54.826	17.136	-28.974	1.00	19.85
ATOM	CA	LEU	L	136	55.005	18.200	-29.973	1.00	18.72
ATOM	CB	LEU	L	136	54.371	19.523	-29.578	1.00	16.93
ATOM	CG	LEU	L	136	53.008	19.601	-28.922	1.00	22.19
ATOM	CD1	LEU	L	136	52.444	20.977	-29.261	1.00	20.90
ATOM	CD2	LEU	L	136	52.077	18.504	-29.370	1.00	16.66
ATOM	C	LEU	L	136	56.494	18.330	-29.821	1.00	18.78
ATOM	O	LEU	L	136	56.968	18.683	-28.745	1.00	19.77

TABLE 2-continued

		Atom A.A.			X	Y	Z	Occ	B
		Type							
ATOM	N	ASN	L	137	57.231	18.044	-30.878	1.00	17.88
ATOM	CA	ASN	L	137	58.677	18.051	-30.811	1.00	17.03
ATOM	CB	ASN	L	137	59.198	16.728	-31.408	1.00	18.02
ATOM	CG	ASN	L	137	60.452	16.198	-30.714	1.00	19.89
ATOM	OD1	ASN	L	137	60.761	16.559	-29.569	1.00	21.01
ATOM	ND2	ASN	L	137	61.160	15.309	-31.396	1.00	17.37
ATOM	C	ASN	L	137	59.382	19.211	-31.487	1.00	17.90
ATOM	O	ASN	L	137	59.030	19.624	-32.601	1.00	19.36
ATOM	N	ASN	L	138	60.371	19.745	-30.786	1.00	18.41
ATOM	CA	ASN	L	138	61.225	20.806	-31.298	1.00	19.22
ATOM	CB	ASN	L	138	62.269	20.191	-32.234	1.00	19.52
ATOM	CG	ASN	L	138	63.097	19.099	-31.563	1.00	19.73
ATOM	OD1	ASN	L	138	63.268	19.078	-30.340	1.00	19.78
ATOM	ND2	ASN	L	138	63.612	18.186	-32.364	1.00	23.67
ATOM	C	ASN	L	138	60.576	21.998	-31.987	1.00	20.58
ATOM	O	ASN	L	138	60.845	22.240	-33.153	1.00	22.46
ATOM	N	PHE	L	139	59.841	22.811	-31.232	1.00	21.42
ATOM	CA	PHE	L	139	59.142	23.976	-31.777	1.00	21.68
ATOM	CB	PHE	L	139	57.630	23.775	-31.654	1.00	18.86
ATOM	CG	PHE	L	139	57.128	23.694	-30.227	1.00	17.94
ATOM	CD1	PHE	L	139	56.634	24.822	-29.582	1.00	17.65
ATOM	CD2	PHE	L	139	57.081	22.478	-29.556	1.00	17.82
ATOM	CE1	PHE	L	139	56.091	24.744	-28.299	1.00	15.73
ATOM	CE2	PHE	L	139	56.540	22.399	-28.272	1.00	18.39
ATOM	CZ	PHE	L	139	56.042	23.541	-27.646	1.00	15.75
ATOM	C	PHE	L	139	59.902	25.314	-31.137	1.00	20.62
ATOM	O	PHE	L	139	60.190	25.369	-30.129	1.00	20.00
ATOM	N	TYR	L	140	59.018	26.390	-31.738	1.00	21.80
ATOM	CA	TYR	L	140	59.239	27.746	-31.232	1.00	25.88
ATOM	CB	TYR	L	140	60.712	28.166	-31.365	1.00	28.61
ATOM	CG	TYR	L	140	61.014	29.491	-30.677	1.00	32.85
ATOM	CG1	TYR	L	140	60.690	30.704	-31.285	1.00	32.88
ATOM	CE1	TYR	L	140	60.943	31.915	-30.648	1.00	33.51
ATOM	CD2	TYR	L	140	61.607	29.532	-29.408	1.00	31.57
ATOM	CE2	TYR	L	140	61.866	30.740	-28.772	1.00	29.63
ATOM	CE	TYR	L	140	61.530	31.922	-29.394	1.00	31.58
ATOM	OH	TYR	L	140	61.766	33.127	-28.777	1.00	32.96
ATOM	C	TYR	L	140	58.344	28.729	-31.992	1.00	25.00
ATOM	O	TYR	L	140	58.228	28.649	-33.216	1.00	26.01
ATOM	N	PRO	L	141	57.716	29.682	-31.290	1.00	25.66
ATOM	CD	PRO	L	141	56.823	30.618	-31.995	1.00	26.17
ATOM	CA	PRO	L	141	57.729	29.979	-29.855	1.00	26.74
ATOM	CB	PRO	L	141	56.894	31.257	-29.772	1.00	26.54
ATOM	CG	PRO	L	141	55.924	31.091	-30.885	1.00	25.01
ATOM	C	PRO	L	141	57.149	28.887	-28.972	1.00	27.91
ATOM	O	PRO	L	141	56.590	27.910	-29.468	1.00	27.79
ATOM	N	ARG	L	142	57.267	29.086	-27.661	1.00	28.05
ATOM	CA	ARG	L	142	56.781	28.140	-26.660	1.00	29.58
ATOM	CB	ARG	L	142	57.336	28.500	-25.282	1.00	32.03
ATOM	CG	ARG	L	142	57.042	27.480	-24.205	1.00	36.16
ATOM	CD	ARG	L	142	57.579	27.937	-22.862	1.00	43.89
ATOM	NE	ARG	L	142	56.887	27.256	-21.769	1.00	52.50
ATOM	CZ	ARG	L	142	55.698	27.622	-21.285	1.00	56.42
ATOM	NH1	ARG	L	142	55.061	28.684	-21.787	1.00	57.72
ATOM	NH2	ARG	L	142	55.115	26.889	-20.337	1.00	56.76
ATOM	C	ARG	L	142	55.264	27.995	-26.579	1.00	29.52
ATOM	O	ARG	L	142	54.771	26.935	-26.189	1.00	31.05
ATOM	N	GLU	L	143	54.523	29.044	-26.925	1.00	27.77
ATOM	CA	GLU	L	143	53.064	28.994	-26.878	1.00	29.28
ATOM	CB	GLU	L	143	52.461	30.381	-27.143	1.00	33.40
ATOM	CG	GLU	L	143	51.192	30.739	-26.316	1.00	43.31
ATOM	CD	GLU	L	143	49.989	29.789	-26.518	1.00	49.45
ATOM	OE1	GLU	L	143	49.242	29.944	-27.521	1.00	51.48
ATOM	OE2	GLU	L	143	49.767	28.909	-25.643	1.00	51.44
ATOM	CG	GLU	L	143	52.529	27.985	-27.900	1.00	28.06
ATOM	O	GLU	L	143	52.854	28.036	-29.094	1.00	27.27
ATOM	N	ALA	L	144	51.722	27.054	-27.419	1.00	26.94
ATOM	CA	ALA	L	144	51.138	26.036	-28.272	1.00	28.67
ATOM	CB	ALA	L	144	52.129	24.898	-28.509	1.00	25.66
ATOM	C	ALA	L	144	49.514	25.527	-27.546	1.00	29.63
ATOM	O	ALA	L	144	49.903	25.442	-26.311	1.00	30.81
ATOM	N	LYS	L	145	48.860	25.259	-28.307	1.00	30.65
ATOM	CA	LYS	L	145	47.623	24.756	-27.734	1.00	30.11
ATOM	CB	LYS	L	145	46.446	25.673	-28.075	1.00	33.51
ATOM	CG	LYS	L	145	45.168	25.314	-27.333	1.00	38.19
ATOM	CD	LYS	L	145	44.013	25.039	-28.287	1.00	44.45

TABLE 2-continued

		Atom A.A.			X	Y	Z	Occ	B
		Type							
ATOM	CE	LYS	L	145	43.662	26.272	-29.116	1.00	45.04
ATOM	NZ	LYS	L	145	42.426	26.059	-29.917	1.00	45.43
ATOM	C	LYS	L	145	47.362	23.357	-28.251	1.00	28.14
ATOM	O	LYS	L	145	47.377	23.103	-29.461	1.00	26.62
ATOM	N	VAL	L	146	47.171	22.437	-27.325	1.00	28.70
ATOM	CA	VAL	L	146	46.907	21.065	-27.690	1.00	30.08
ATOM	CB	VAL	L	146	48.104	20.097	-27.325	1.00	30.21
ATOM	CG1	VAL	L	146	49.130	20.784	-26.451	1.00	30.48
ATOM	CG2	VAL	L	146	47.606	18.807	-26.701	1.00	29.81
ATOM	C	VAL	L	146	45.593	20.657	-27.057	1.00	29.32
ATOM	O	VAL	L	146	45.391	20.831	-25.860	1.00	29.58
ATOM	N	GLN	L	147	44.661	20.233	-27.902	1.00	30.06
ATOM	CA	GLN	L	147	43.346	19.802	-27.455	1.00	30.42
ATOM	CB	GLN	L	147	42.236	20.636	-28.113	1.00	35.67
ATOM	CG	GLN	L	147	42.091	22.049	-27.550	1.00	40.36
ATOM	CD	GLN	L	147	40.817	22.745	-28.005	1.00	43.14
ATOM	CE1	GLN	L	147	39.992	23.141	-27.186	1.00	43.76
ATOM	NE2	GLN	L	147	40.856	22.903	-29.314	1.00	43.31
ATOM	C	GLN	L	147	43.117	18.330	-27.745	1.00	28.02
ATOM	O	GLN	L	147	43.417	17.837	-28.838	1.00	25.81
ATOM	N	TRP	L	148	42.622	17.624	-26.742	1.00	25.59
ATOM	CA	TRP	L	148	42.333	16.213	-26.882	1.00	25.12
ATOM	CB	TRP	L	148	42.574	15.493	-25.573	1.00	23.52
ATOM	CG	TRP	L	148	44.015	15.322	-25.266	1.00	22.59
ATOM	CD2	TRP	L	148	44.870	14.282	-25.753	1.00	21.52
ATOM	CE2	TRP	L	148	46.114	14.439	-25.122	1.00	17.40
ATOM	CE3	TRP	L	148	44.898	13.226	-26.660	1.00	21.73
ATOM	CD1	TRP	L	148	44.760	16.063	-24.401	1.00	19.92
ATOM	NE1	TRP	L	148	46.020	15.532	-24.304	1.00	18.98
ATOM	CZ2	TRP	L	148	47.185	13.579	-25.359	1.00	19.15
ATOM	CZ3	TRP	L	148	45.767	12.372	-26.900	1.00	19.55
ATOM	CH2	TRP	L	148	46.993	12.555	-26.249	1.00	17.26
ATOM	C	TRP	L	148	40.897	16.050	-27.267	1.00	27.24
ATOM	O	TRP	L	148	40.021	16.706	-26.704	1.00	29.09
ATOM	N	LYS	L	149	40.842	15.170	-28.218	1.00	27.78
ATOM	CA	LYS	L	149	39.286	14.927	-28.655	1.00	28.56
ATOM	CB	LYS	L	149	39.065	15.540	-30.043	1.00	33.33
ATOM	CG	LYS	L	149	39.014	17.083	-30.049	1.00	40.99
ATOM	CD	LYS	L	149	39.056	17.665	-31.460	1.00	45.80
ATOM	CE	LYS	L	149	40.413	17.409	-32.118	1.00	50.94
ATOM	NZ	LYS	L	149	40.478	17.798	-33.568	1.00	52.55
ATOM	C	LYS	L	149	39.064	13.431	-28.673	1.00	27.65
ATOM	O	LYS	L	149	39.836	12.686	-29.274	1.00	26.68
ATOM	N	VAL	L	150	38.064	12.979	-27.932	1.00	28.55
ATOM	CA	VAL	L	150	37.736	11.555	-27.890	1.00	30.17
ATOM	CB	VAL	L	150	37.694	11.019	-26.437	1.00	29.56
ATOM	CG1	VAL	L	150	37.346	9.542	-26.446	1.00	31.46
ATOM	CG2	VAL	L	150	39.049	11.233	-25.747	1.00	28.62
ATOM	C	VAL	L	150	36.376	11.403	-28.584	1.00	32.05
ATOM	O	VAL	L	150	35.356	11.919	-28.106	1.00	31.85
ATOM	N	ASP	L	151	36.380	10.737	-29.736	1.00	33.92
ATOM	CA	ASP	L	151	35.177	10.553	-30.555	1.00	34.55
ATOM	CB	ASP	L	151	34.146	9.661	-29.863	1.00	34.11
ATOM	CG	ASP	L	151	34.488	8.190	-29.982	1.00	35.60
ATOM	OD1	ASP	L	151	35.120	7.820	-30.992	1.00	34.60
ATOM	OD2	ASP	L	151	34.129	7.405	-29.076	1.00	38.15
ATOM	C	ASP	L	151	34.601	11.916	-30.912	1.00	34.81
ATOM	O	ASP	L	151	33.396	12.141	-30.887	1.00	35.02
ATOM	N	ASN	L	152	35.513	12.837	-31.189	1.00	34.49
ATOM	CA	ASN	L	152	35.190	14.191	-31.574	1.00	35.32
ATOM	CB	ASN	L	152	34.202	14.168	-32.734	1.00	39.44
ATOM	CG	ASN	L	152	34.735	13.365	-33.910	1.00	44.85
ATOM	OD1	ASN	L	152	34.762	12.136	-33.877	1.00	46.35
ATOM	ND2	ASN	L	152	35.233	14.059	-34.922	1.00	48.06
ATOM	C	ASN	L	152	34.729	15.076	-30.435	1.00	33.57
ATOM	O	ASN	L	152	34.545	16.275	-30.619	1.00	36.79
ATOM	N	ALA	L	153	34.614	14.506	-29.243	1.00	31.08
ATOM	CA	ALA	L	153	34.207	15.266	-28.073	1.00	28.26
ATOM	CB	ALA	L	153	33.481	14.371	-27.116	1.00	28.75
ATOM	C	ALA	L	153	35.439	15.875	-27.403	1.00	28.92
ATOM	O	ALA	L	153	36.384	15.155	-27.053	1.00	26.45
ATOM	N	LEU	L	154	35.422	17.195	-27.221	1.00	29.49
ATOM	CA	LEU	L	154	36.532	17.924	-26.606	1.00	30.90
ATOM	CB	LEU	L	154	36.386	19.416	-26.835	1.00	33.24
ATOM	CG	LEU	L	154	37.433	20.289	-26.146	1.00	36.75
ATOM	CD1	LEU	L	154	38.831	19.982	-26.665	1.00	38.15

TABLE 2-continued

		Atom A.A.			X	Y	Z	Occ	B
		Type							
ATOM	CD2	LEU	L	154	37.086	21.748	-26.380	1.00	39.59
ATOM	C	LEU	L	154	36.645	17.642	-25.117	1.00	31.55
ATOM	O	LEU	L	154	35.690	17.838	-24.362	1.00	31.00
ATOM	N	GLN	L	155	37.840	17.209	-24.713	1.00	31.11
ATOM	CA	GLN	L	155	38.151	16.846	-23.336	1.00	28.18
ATOM	CB	GLN	L	155	39.328	15.878	-23.317	1.00	25.72
ATOM	CG	GLN	L	155	39.079	14.638	-24.112	1.00	23.68
ATOM	CD	GLN	L	155	37.881	13.888	-23.604	1.00	25.63
ATOM	OE1	GLN	L	155	37.975	13.140	-22.639	1.00	26.96
ATOM	NE2	GLN	L	155	36.737	14.094	-24.237	1.00	25.22
ATOM	C	GLN	L	155	38.485	18.050	-22.492	1.00	29.16
ATOM	O	GLN	L	155	39.007	19.047	-22.995	1.00	28.96
ATOM	N	SER	L	156	38.231	17.931	-21.196	1.00	29.53
ATOM	CA	SER	L	156	38.498	19.015	-20.273	1.00	30.80
ATOM	CB	SER	L	156	37.260	19.914	-20.143	1.00	34.66
ATOM	OG	SER	L	156	36.	60	20.429-21.409	1.00	43.01
ATOM	C	SER	L	156	38.838	18.467	-18.907	1.00	29.08
ATOM	O	SER	L	156	38.103	17.641	-18.368	1.00	29.54
ATOM	N	GLY	L	157	39.972	18.901	-18.368	1.00	28.54
ATOM	CA	GLY	L	157	40.372	18.490	-17.038	1.00	26.39
ATOM	C	GLY	L	157	40.936	17.101	-16.850	1.00	26.37
ATOM	O	GLY	L	157	41.120	16.671	-15.715	1.00	29.38
ATOM	N	ASN	L	158	41.216	16.385	-17.928	1.00	23.45
ATOM	CA	ASN	L	158	41.770	15.049	-17.777	1.00	21.09
ATOM	CB	ASN	L	158	40.764	13.989	-18.244	1.00	19.33
ATOM	CG	ASN	L	158	40.216	14.252	-19.630	1.00	17.19
ATOM	OG1	ASN	L	158	40.588	15.213	-20.302	1.00	18.35
ATOM	ND2	ASN	L	158	39.331	13.387	-20.066	1.00	18.99
ATOM	C	ASN	L	158	43.136	14.867	-18.440	1.00	19.26
ATOM	O	ASN	L	158	43.534	13.753	-18.767	1.00	21.16
ATOM	N	SER	L	159	43.874	15.959	-18.600	1.00	18.71
ATOM	CA	SER	L	159	45.187	15.890	-19.218	1.00	20.76
ATOM	CB	SER	L	159	45.077	16.188	-20.714	1.00	18.72
ATOM	OG	SER	L	159	44.532	17.477	-20.945	1.00	20.62
ATOM	C	SER	L	159	46.131	16.882	-18.553	1.00	23.10
ATOM	O	SER	L	159	45.685	17.868	-17.957	1.00	24.15
ATOM	N	GLN	L	160	47.427	16.585	-18.592	1.00	21.31
ATOM	CA	GLN	L	160	48.442	17.471	-18.021	1.00	21.04
ATOM	CB	GLN	L	160	49.069	16.879	-16.736	1.00	23.45
ATOM	OG	GLN	L	160	48.154	16.872	-15.510	1.00	27.10
ATOM	CD	GLN	L	160	48.835	16.394	-14.231	1.00	28.51
ATOM	GE1	GLN	L	160	49.047	15.187	-14.036	1.00	24.70
ATOM	NE2	GLN	L	160	49.135	17.334	-13.329	1.00	25.84
ATOM	C	GLN	L	160	49.532	17.659	-19.066	1.00	20.99
ATOM	O	GLN	L	160	49.863	16.734	-19.816	1.00	21.59
ATOM	N	GLU	L	161	50.098	18.853	-19.124	1.00	20.61
ATOM	CA	GLU	L	161	51.172	19.106	-20.072	1.00	20.46
ATOM	CB	GLU	L	161	50.901	20.359	-20.890	1.00	20.91
ATOM	CG	GLU	L	161	49.611	20.349	-21.674	1.00	24.55
ATOM	CD	GLU	L	161	49.542	21.528	-22.619	1.00	26.26
ATOM	OE1	GLU	L	161	50.300	22.486	-22.485	1.00	29.28
ATOM	OE2	GLU	L	161	48.648	21.497	-23.507	1.00	28.66
ATOM	C	GLU	L	161	52.476	19.303	-19.328	1.00	19.83
ATOM	O	GLU	L	161	52.493	19.602	-18.134	1.00	20.07
ATOM	N	SER	L	162	53.569	19.107	-20.036	1.00	17.23
ATOM	CA	SER	L	162	54.865	19.323	-19.455	1.00	17.53
ATOM	CB	SER	L	162	55.447	18.035	-18.889	1.00	14.42
ATOM	OG	SER	L	162	56.762	18.252	-18.431	1.00	18.03
ATOM	C	SER	L	162	55.709	19.870	-20.579	1.00	16.58
ATOM	O	SER	L	162	55.655	19.376	-21.705	1.00	17.04
ATOM	N	VAL	L	163	56.386	20.975	-20.311	1.00	19.21
ATOM	CA	VAL	L	163	57.226	21.568	-21.323	1.00	18.37
ATOM	CB	VAL	L	163	56.819	23.039	-21.669	1.00	18.75
ATOM	CG1	VAL	L	163	56.923	23.931	-20.442	2.00	20.07
ATOM	CG2	VAL	L	163	57.696	23.590	-22.802	1.00	13.07
ATOM	C	VAL	L	163	58.686	21.463	-20.921	1.00	19.06
ATOM	O	VAL	L	163	59.071	21.541	-19.744	1.00	16.78
ATOM	N	THR	L	164	59.484	21.211	-21.936	1.00	18.83
ATOM	CA	THR	L	164	60.915	21.063	-21.827	1.00	19.31
ATOM	CE	THR	L	164	61.331	20.278	-23.114	1.00	19.43
ATOM	OG1	THR	L	164	61.683	18.919	-22.809	1.00	22.69
ATOM	CG2	THR	L	164	62.355	20.966	-23.872	1.00	16.60
ATOM	C	THR	L	164	61.579	22.474	-21.698	1.00	19.84
ATOM	O	THR	L	164	60.976	23.506	-22.053	1.00	17.28
ATOM	N	GLU	L	165	62.756	22.535	-21.083	1.00	19.36

TABLE 2-continued

		Atom A.A.			X	Y	Z	Occ	B
		Type							
ATOM	CA	GLU	L	165	63.471	23.800	-20.983	1.00	19.55
ATOM	CB	GLU	L	165	64.575	23.736	-19.925	1.00	23.79
ATOM	CG	GLU	L	165	64.076	23.813	-18.473	1.00	31.50
ATOM	CD	GLU	L	165	63.482	25.178	-18.114	1.00	38.33
ATOM	OE1	GLU	L	165	64.068	26.216	-18.506	1.00	42.53
ATOM	OE2	GLU	L	165	62.426	25.220	-17.441	1.00	42.33
ATOM	C	GLU	L	165	64.063	24.052	-22.364	1.00	17.91
ATOM	O	GLU	L	165	64.328	23.115	-23.111	1.00	16.78
ATOM	N	GLN	L	166	64.261	25.311	-22.715	1.00	19.48
ATOM	CA	GLN	L	166	64.794	25.653	-24.030	1.00	22.17
ATOM	CB	GLN	L	166	65.000	27.162	-24.135	1.00	23.76
ATOM	CG	GLN	L	166	65.302	27.660	-25.525	1.00	22.40
ATOM	CD	GLN	L	166	65.300	29.163	-25.585	1.00	24.53
ATOM	OE1	GLN	L	166	65.665	29.834	-24.615	1.00	23.40
ATOM	NE2	GLN	L	166	64.862	29.710	-26.710	1.00	22.79
ATOM	C	GLN	L	166	66.082	24.923	-24.354	1.00	22.88
ATOM	O	GLN	L	166	66.968	24.829	-23.514	1.00	23.51
ATOM	N	ASP	L	167	66.277	24.395	-25.570	1.00	24.27
ATOM	CA	ASP	L	167	67.363	23.665	-25.995	1.00	24.79
ATOM	CB	ASP	L	167	67.086	22.929	-27.307	1.00	25.67
ATOM	CG	ASP	L	167	68.201	21.975	-27.691	1.00	26.79
ATOM	OD1	ASP	L	167	68.072	20.765	-27.439	1.00	29.58
ATOM	OD2	ASP	L	167	69.206	22.429	-28.260	1.00	28.02
ATOM	C	ASP	L	167	68.528	24.647	-26.147	1.00	25.55
ATOM	O	ASP	L	167	68.392	25.708	-26.753	1.00	23.48
ATOM	N	SER	L	168	69.675	24.277	-25.597	1.00	27.95
ATOM	CA	SER	L	168	70.860	25.120	-25.625	1.00	29.28
ATOM	CB	SER	L	168	71.831	24.670	-24.531	1.00	28.03
ATOM	OG	SER	L	168	71.341	24.844	-23.243	1.00	28.54
ATOM	C	SER	L	168	71.554	25.200	-26.987	1.00	31.24
ATOM	O	SER	L	168	72.477	25.993	-27.164	1.00	33.45
ATOM	N	LYS	L	169	71.122	24.369	-27.935	1.00	32.30
ATOM	CA	LYS	L	169	71.692	24.370	-29.287	1.00	32.24
ATOM	CB	LYS	L	169	71.975	22.947	-29.796	1.00	33.42
ATOM	CG	LYS	L	169	73.305	22.207	-29.102	1.00	41.01
ATOM	CD	LYS	L	169	72.677	21.620	-27.743	1.00	50.52
ATOM	CE	LYS	L	169	71.807	20.369	-27.899	1.00	53.08
ATOM	NZ	LYS	L	169	70.996	20.036	-26.688	1.00	53.75
ATOM	C	LYS	L	169	70.744	25.064	-30.261	1.00	31.01
ATOM	O	LYS	L	169	71.098	26.081	-30.867	1.00	30.68
ATOM	N	ASP	L	170	69.534	24.522	-30.407	1.00	28.81
ATOM	CA	ASP	L	170	68.577	25.097	-31.337	1.00	25.15
ATOM	CB	ASP	L	170	67.953	24.024	-32.229	1.00	26.91
ATOM	CG	ASP	L	170	67.157	22.996	-31.460	1.00	28.83
ATOM	OD1	ASP	L	170	66.590	23.320	-30.406	1.00	30.B3
ATOM	OD2	ASP	L	170	67.082	21.846	-31.927	1.00	33.97
ATOM	C	ASP	L	170	67.515	26.027	-30.786	1.00	25.54
ATOM	O	ASP	L	170	66.600	26.397	-31.512	1.00	25.89
ATOM	N	SER	L	171	67.607	26.368	-29.504	1.00	24.11
ATOM	CA	SER	L	171	66.662	27.300	-28.878	1.00	25.64
ATOM	CB	SER	L	171	66.966	28.712	-29.391	1.00	25.56
ATOM	OG	SER	L	171	68.371	28.936	-29.352	1.00	28.30
ATOM	C	SER	L	171	65.175	26.947	-29.074	1.00	23.90
ATOM	O	SER	L	171	64.279	27.800	-29.011	1.00	25.67
ATOM	N	THR	L	172	64.929	25.653	-29.168	1.00	23.05
ATOM	CA	THR	L	172	63.609	25.103	-29.394	1.00	22.83
ATOM	CB	THR	L	172	63.769	24.085	-30.562	1.00	24.46
ATOM	OG1	THR	L	172	62.989	24.482	-31.695	1.00	28.40
ATOM	CG2	THR	L	172	63.498	22.695	-30.140	1.00	18.05
ATOM	C	THR	L	172	63.030	24.465	-28.099	1.00	23.36
ATOM	O	THR	L	172	63.743	24.308	-27.094	1.00	20.90
ATOM	N	TYR	L	173	61.735	24.141	-28.123	1.00	23.45
ATOM	CA	TYR	L	173	61.033	23.508	-26.999	1.00	21.92
ATOM	CB	TYR	L	173	59.935	24.431	-26.453	1.00	22.23
ATOM	CG	TYR	L	173	60.430	25.740	-25.917	1.00	24.83
ATOM	CD1	TYR	L	173	61.023	25.808	-24.664	1.00	25.38
ATOM	CE1	TYR	L	173	61.483	26.991	-24.161	1.00	24.43
ATOM	CD2	TYR	L	173	60.311	26.912	-26.659	1.00	25.09
ATOM	CE2	TYR	L	173	60.774	28.115	-26.160	1.00	26.35
ATOM	CZ	TYR	L	173	61.559	28.143	-24.903	1.00	25.86
ATOM	OH	TYR	L	173	61.799	29.324	-24.366	1.00	26.61
ATOM	C	TYR	L	173	60.325	22.231	-27.463	1.00	20.70
ATOM	O	TYR	L	173	60.063	22.049	-28.648	1.00	18.08
ATOM	N	SER	L	174	60.025	21.354	-26.515	1.00	18.47
ATOM	CA	SER	L	174	59.275	20.134	-26.785	1.00	17.88
ATOM	CB	SER	L	174	60.178	18.904	-26.831	1.00	15.91

TABLE 2-continued

		Atom A.A.			X	Y	Z	Occ	B
		Type							
ATOM	OG	SER	L	174	60.833	18.848	-28.095	1.00	17.19
ATOM	C	SER	L	174	58.212	20.047	-25.692	1.00	17.46
ATOM	O	SER	L	174	58.445	20.462	-24.555	1.00	16.26
ATOM	N	LEU	L	175	57.035	19.548	-26.036	1.00	17.03
ATOM	CA	LEU	L	175	55.952	19.487	-25.076	1.00	17.80
ATOM	CB	LEU	L	175	54.352	20.613	-25.378	1.00	16.17
ATOM	CG	LEU	L	175	53.705	20.835	-24.513	1.00	19.25
ATOM	CD1	LEU	L	175	53.316	22.301	-24.587	1.00	19.61
ATOM	CD2	LEU	L	175	52.537	19.964	-24.943	1.00	18.86
ATOM	C	LEU	L	175	55.233	18.154	-25.138	1.00	18.23
ATOM	O	LEU	L	175	55.153	17.549	-26.207	1.00	18.92
ATOM	N	SER	L	176	54.150	17.691	-23.985	1.00	17.34
ATOM	CA	SER	L	176	53.983	16.460	-23.912	1.00	16.51
ATOM	CB	SER	L	176	54.722	15.383	-23.107	1.00	16.81
ATOM	OG	SER	L	176	54.108	15.643	-21.710	1.00	18.80
ATOM	C	SER	L	176	52.648	16.785	-23.236	1.00	18.21
ATOM	O	SER	L	176	52.599	17.593	-22.291	1.00	17.16
ATOM	N	SER	L	177	51.563	16.269	-23.804	1.00	16.60
ATOM	CA	SER	L	177	50.242	16.426	-23.221	1.00	15.84
ATOM	CB	SER	L	177	49.266	17.107	-24.170	1.00	17.29
ATOM	OG	SER	L	177	47.980	17.148	-23.580	1.00	18.53
ATOM	C	SER	L	177	49.830	14.986	-22.963	1.00	16.07
ATOM	O	SER	L	177	49.953	14.120	-23.843	1.00	15.65
ATOM	N	THR	L	178	49.399	14.706	-21.740	1.00	15.55
ATOM	CA	THR	L	178	49.039	13.355	-21.395	1.00	14.30
ATOM	CB	THR	L	178	50.000	12.811	-20.331	1.00	15.61
ATOM	OG1	THR	L	178	51.350	12.944	-20.813	1.00	15.71
ATOM	CG2	THR	L	178	49.686	11.333	-20.008	1.00	15.89
ATOM	C	THR	L	178	47.626	13.286	-20.905	1.00	16.11
ATOM	O	THR	L	178	47.253	14.017	-19.981	1.00	14.99
ATOM	N	LEU	L	179	46.843	12.431	-21.562	1.00	16.21
ATOM	CA	LEU	L	179	45.428	12.195	-21.247	1.00	17.85
ATOM	CB	LEU	L	179	44.639	12.046	-22.551	1.00	16.22
ATOM	CG	LEU	L	179	43.152	11.701	-22.489	1.00	16.81
ATOM	CD1	LEU	L	179	42.374	12.854	-21.907	1.00	15.95
ATOM	CD2	LEU	L	179	42.664	11.397	-23.890	1.00	17.04
ATOM	C	LEU	L	179	45.305	10.909	-20.424	1.00	19.34
ATOM	O	LEU	L	179	45.805	9.862	-20.843	1.00	19.74
ATOM	N	THR	L	180	44.686	10.984	-19.245	1.00	19.39
ATOM	CA	THR	L	180	44.528	9.800	-18.402	1.00	20.40
ATOM	CB	THR	L	180	45.074	10.010	-16.980	1.00	21.84
ATOM	OG1	THR	L	180	46.378	10.611	-17.036	1.00	22.46
ATOM	CG2	THR	L	180	45.181	8.668	-16.261	1.00	20.50
ATOM	C	THR	L	180	43.061	9.406	-18.294	1.00	23.01
ATOM	O	THR	L	180	42.192	10.237	-17.975	1.00	21.76
ATOM	N	LEU	L	181	42.797	8.132	-18.553	1.00	23.18
ATOM	CA	LEU	L	181	41.456	7.579	-18.503	1.00	24.23
ATOM	CB	LEU	L	181	40.928	7.330	-19.917	1.00	25.07
ATOM	CG	LEU	L	181	40.619	8.578	-20.729	1.00	26.14
ATOM	CD1	LEU	L	181	40.168	8.204	-22.132	1.00	28.53
ATOM	CD2	LEU	L	181	39.545	9.361	-19.998	1.00	30.01
ATOM	C	LEU	L	181	41.504	6.256	-17.784	1.00	24.92
ATOM	O	LEU	L	181	42.558	5.637	-17.691	1.00	25.25
ATOM	N	SER	L	182	40.364	5.848	-17.237	1.00	27.27
ATOM	CA	SER	L	182	40.250	4.567	-16.563	1.00	25.98
ATOM	CB	SER	L	182	38.940	4.502	-15.780	1.00	28.54
ATOM	OG	SER	L	182	37.810	4.674	-16.630	1.00	27.58
ATOM	C	SER	L	182	40.176	3.594	-17.715	1.00	26.31
ATOM	O	SER	L	182	39.793	3.991	-18.826	1.00	25.06
ATOM	N	LYS	L	183	40.556	2.341	-17.477	1.00	25.27
ATOM	CA	LYS	L	183	40.489	1.336	-18.526	1.00	29.03
ATOM	CB	LYS	L	183	40.914	-0.032	-17.992	1.00	30.64
ATOM	CG	LYS	L	183	40.694	-1.155	-18.969	1.00	32.86
ATOM	CD	LYS	L	183	41.393	-2.411	-18.519	1.00	38.66
ATOM	CE	LYS	L	183	41.157	-3.533	-19.526	1.00	43.79
ATOM	NZ	LYS	L	183	42.049	-4.722	-19.316	1.00	50.95
ATOM	C	LYS	L	183	39.049	1.276	-19.027	1.00	31.27
ATOM	O	LYS	L	183	38.800	1.120	-20.227	1.00	32.73
ATOM	N	ALA	L	184	38.110	1.419	-18.093	1.00	32.33
ATOM	CA	ALA	L	184	36.683	1.402	-18.389	1.00	32.00
ATOM	CB	ALA	L	184	35.885	1.598	-17.112	1.00	32.27
ATOM	C	ALA	L	184	36.316	2.476	-19.395	1.00	31.78
ATOM	O	ALA	L	184	35.759	2.179	-20.453	1.00	34.22
ATOM	N	ASP	L	185	36.660	3.719	-19.086	1.00	31.26
ATOM	CA	ASP	L	185	36.335	4.827	-19.976	1.00	33.90
ATOM	CB	ASP	L	185	36.558	6.151	-19.268	1.00	38.89

TABLE 2-continued

		Atom A.A.			X	Y	Z	Occ	B
		Type							
ATOM	CG	ASP	L	185	35.528	6.392	-18.184	1.00	45.46
ATOM	OD1	ASP	L	185	34.316	6.444	-18.507	1.00	48.98
ATOM	OD2	ASP	L	185	35.919	6.493	-17.006	1.00	50.41
ATOM	C	ASP	L	185	37.042	4.801	-21.315	1.00	32.24
ATOM	O	ASP	L	185	36.468	5.185	-22.333	1.00	31.83
ATOM	N	TYR	L	186	38.283	4.327	-21.311	1.00	31.61
ATOM	CA	TYR	L	186	39.078	4.226	-22.520	1.00	28.14
ATOM	CB	TYR	L	186	40.493	3.754	-22.174	1.00	24.69
ATOM	CG	TYR	L	186	41.352	3.542	-23.390	1.00	21.62
ATOM	CD1	TYR	L	186	41.837	4.623	-24.114	1.00	22.76
ATOM	CE1	TYR	L	186	42.592	4.437	-25.250	1.00	20.71
ATOM	CD2	TYR	L	186	41.652	2.260	-23.841	1.00	20.70
ATOM	CE2	TYR	L	186	42.411	2.064	-24.981	1.00	20.68
ATOM	CZ	TYR	L	186	42.874	3.164	-25.673	1.00	20.70
ATOM	OH	TYR	L	186	43.646	2.996	-26.787	1.00	26.48
ATOM	C	TYR	L	186	38.420	3.256	-23.500	1.00	30.06
ATOM	O	TYR	L	186	38.380	3.506	-24.708	1.00	27.70
ATOM	N	GLU	L	187	37.885	2.157	-22.973	1.00	33.21
ATOM	CA	GLU	L	187	37.236	1.147	-23.803	1.00	35.81
ATOM	CB	GLU	L	187	37.307	-0.211	-23.122	1.00	37.97
ATOM	CG	GLU	L	187	38.738	-0.704	-23.053	1.00	43.63
ATOM	CD	GLU	L	187	38.909	-1.895	-22.158	1.00	47.42
ATOM	OE1	GLU	L	187	39.179	-2.736	-22.466	1.00	49.65
ATOM	OE2	GLU	L	187	38.185	-1.984	-21.143	1.00	50.40
ATOM	C	GLU	L	187	35.816	1.495	-24.207	1.00	35.32
ATOM	O	GLU	L	187	35.171	0.766	-24.948	1.00	35.82
ATOM	N	LYS	L	188	35.361	2.650	-23.747	1.00	36.88
ATOM	CA	LYS	L	188	34.034	3.159	-24.049	1.00	36.72
ATOM	CB	LYS	L	188	33.581	4.028	-22.867	1.00	40.35
ATOM	CG	LYS	L	188	32.390	4.606	-22.957	1.00	48.51
ATOM	CD	LYS	L	188	31.859	5.399	-21.684	1.00	55.80
ATOM	CE	LYS	L	188	30.375	5.811	-21.620	1.00	58.80
ATOM	NZ	LYS	L	188	29.969	6.745	-22.711	1.00	61.10
ATOM	C	LYS	L	188	34.121	4.004	-25.333	1.00	35.19
ATOM	O	LYS	L	188	33.099	4.440	-25.875	1.00	33.77
ATOM	N	HIS	L	189	35.338	4.222	-25.832	1.00	31.64
ATOM	CA	HIS	L	189	35.517	5.062	-27.014	1.00	30.51
ATOM	CB	HIS	L	189	35.936	6.465	-26.585	1.00	31.61
ATOM	CG	HIS	L	189	35.092	7.012	-25.479	1.00	33.55
ATOM	CD2	HIS	L	189	35.356	7.192	-24.162	1.00	34.11
ATOM	ND1	HIS	L	189	33.766	7.340	-25.652	1.00	33.12
ATOM	CE1	HIS	L	189	33.246	7.690	-24.489	1.00	34.25
ATOM	NE2	HIS	L	189	34.190	7.608	-23.570	1.00	35.58
ATOM	C	HIS	L	189	36.447	4.525	-28.081	1.00	29.17
ATOM	O	HIS	L	189	37.263	3.650	-27.821	1.00	26.39
ATOM	N	LYS	L	190	36.310	5.087	-29.283	1.00	30.68
ATOM	CA	LYS	L	190	37.075	4.672	-30.455	1.00	32.94
ATOM	CB	LYS	L	190	36.120	4.481	-31.650	1.00	36.49
ATOM	CG	LYS	L	190	36.776	4.064	-32.983	1.00	39.14
ATOM	CD	LYS	L	190	37.615	2.800	-32.838	1.00	41.61
ATOM	CE	LYS	L	190	36.773	1.619	-32.404	1.00	43.23
ATOM	NZ	LYS	L	190	37.611	0.436	-32.111	1.00	44.23
ATOM	C	LYS	L	190	38.240	5.571	-30.867	1.00	31.98
ATOM	O	LYS	L	190	39.395	5.159	-30.759	1.00	32.68
ATOM	N	VAL	L	191	37.956	6.776	-31.363	1.00	29.70
ATOM	CA	VAL	L	191	39.040	7.635	-31.805	1.00	27.93
ATOM	CB	VAL	L	191	38.770	8.312	-33.177	1.00	27.89
ATOM	CG1	VAL	L	191	37.581	7.663	-33.876	1.00	30.46
ATOM	CG2	VAL	L	191	38.601	9.791	-33.042	1.00	30.08
ATOM	C	VAL	L	191	39.569	8.620	-30.783	1.00	25.97
ATOM	O	VAL	L	191	38.816	9.303	-30.081	1.00	25.01
ATOM	N	TYR	L	192	40.891	8.605	-30.668	1.00	25.08
ATOM	CA	TYR	L	192	41.644	9.461	-29.756	1.00	21.91
ATOM	CB	TYR	L	192	42.505	8.596	-28.825	1.00	19.53
ATOM	CG	TYR	L	192	41.653	7.806	-27.853	1.00	20.50
ATOM	CD1	TYR	L	192	41.307	8.349	-26.619	1.00	21.28
ATOM	CE1	TYR	L	192	40.415	7.714	-25.773	1.00	20.30
ATOM	CD2	TYR	L	192	41.082	6.575	-28.211	1.00	22.35
ATOM	CE2	TYR	L	192	40.176	5.930	-27.359	1.00	21.21
ATOM	CZ	TYR	L	192	39.853	6.517	-26.144	1.00	23.15
ATOM	OH	TYR	L	192	38.963	5.935	-25.280	1.00	26.13
ATOM	C	TYR	L	192	42.478	10.352	-30.665	1.00	19.39
ATOM	O	TYR	L	192	43.240	9.869	-31.490	1.00	16.16
ATOM	N	ALA	L	193	42.243	11.652	-30.574	1.00	17.37
ATOM	CA	ALA	L	193	42.925	12.609	-31.416	1.00	1.38
ATOM	CB	ALA	L	193	41.951	13.200	-32.422	1.00	14.68

TABLE 2-continued

		Atom A.A.			X	Y	Z	Occ	B
		Type							
ATOM	C	ALA	L	193	43.546	13.714	-30.591	1.00	19.81
ATOM	O	ALA	L	193	42.991	14.144	-29.568	1.00	19.87
ATOM	N	CYS	L	194	44.721	14.143	-31.029	1.00	19.00
ATOM	CA	CYS	L	194	45.446	15.212	-30.390	1.00	20.02
ATOM	C	CYS	L	194	45.533	16.306	-31.451	1.00	22.09
ATOM	O	CYS	L	194	46.104	16.099	-32.526	1.00	23.10
ATOM	CB	CYS	L	194	46.836	14.736	-29.982	1.00	20.62
ATOM	SG	CYS	L	194	47.887	16.076	-29.359	1.00	27.82
ATOM	N	GLU	L	195	44.897	17.438	-31.198	1.00	21.48
ATOM	CA	GLU	L	195	44.922	18.522	-32.155	1.00	26.37
ATOM	CB	GLU	L	195	43.508	19.070	-32.380	1.00	30.62
ATOM	CG	GLU	L	195	43.452	20.166	-33.425	1.00	39.13
ATOM	CD	GLU	L	195	42.043	20.556	-33.786	1.00	46.06
ATOM	OE1	GLU	L	195	41.281	20.924	-32.866	1.00	49.26
ATOM	OE2	GLU	L	195	41.697	20.467	-34.992	1.00	50.81
ATOM	C	GLU	L	195	45.870	19.607	-31.669	1.00	25.13
ATOM	O	GLU	L	195	45.711	20.140	-30.571	1.00	24.45
ATOM	N	VAL	L	196	46.825	19.965	-32.519	1.00	24.78
ATOM	CA	VAL	L	196	47.839	20.960	-32.187	1.00	26.26
ATOM	CB	VAL	L	196	49.255	20.369	-32.373	1.00	23.55
ATOM	CG1	VAL	L	196	50.325	21.443	-32.160	1.00	23.61
ATOM	CG2	VAL	L	196	49.454	19.172	-31.429	1.00	20.96
ATOM	C	VAL	L	196	47.749	22.271	-32.965	1.00	28.29
ATOM	O	VAL	L	196	47.776	22.287	-34.200	1.00	28.62
ATOM	N	THR	L	197	47.664	23.369	-32.225	1.00	28.72
ATOM	CA	THR	L	197	47.612	24.694	-32.820	1.00	31.05
ATOM	CB	THR	L	197	46.441	25.524	-32.232	1.00	30.50
ATOM	OG1	THR	L	197	45.202	24.869	-32.519	1.00	31.44
ATOM	CG2	THR	L	197	46.399	26.909	-32.834	1.00	30.89
ATOM	C	THR	L	197	48.952	25.356	-32.472	1.00	32.18
ATOM	O	THR	L	197	49.396	25.309	-31.313	1.00	31.68
ATOM	N	HIS	L	198	49.612	25.938	-33.468	1.00	32.23
ATOM	CA	HIS	L	198	50.884	26.602	-33.225	1.00	32.28
ATOM	CB	HIS	L	198	52.018	25.577	-33.141	1.00	31.15
ATOM	CG	HIS	L	198	53.331	26.168	-32.727	1.00	30.40
ATOM	CD2	HIS	L	198	53.626	26.466	-31.500	1.00	29.70
ATOM	ND1	HIS	L	198	54.299	26.545	-33.635	1.00	27.78
ATOM	CE1	HIS	L	198	55.332	27.052	-32.984	1.00	29.10
ATOM	NE2	HIS	L	198	55.071	27.014	-31.688	1.00	28.06
ATOM	C	HIS	L	198	51.186	27.622	-34.313	1.00	33.18
ATOM	O	HIS	L	198	50.840	27.421	-35.471	1.00	33.74
ATOM	N	GLN	L	199	51.877	28.691	-33.933	1.00	35.27
ATOM	CA	GLN	L	199	52.247	29.767	-34.846	1.00	36.38
ATOM	CB	GLN	L	199	53.225	30.727	-34.156	1.00	37.34
ATOM	CG	GLN	L	199	53.508	31.989	-34.964	1.00	43.51
ATOM	CD	GLN	L	199	54.222	33.074	-34.174	1.00	45.57
ATOM	OE1	GLN	L	199	54.997	33.848	-34.733	1.00	47.22
ATOM	NE2	GLN	L	199	53.943	33.153	-32.879	1.00	46.45
ATOM	C	GLN	L	199	52.833	29.255	-36.162	1.00	35.85
ATOM	O	GLN	L	199	52.477	29.725	-37.233	1.00	36.61
ATOM	N	GLY	L	200	53.706	28.263	-36.083	1.00	35.48
ATOM	CA	GLY	L	200	54.310	27.734	-37.291	1.00	35.01
ATOM	C	GLY	L	200	53.403	26.833	-38.102	1.00	35.20
ATOM	O	GLY	L	200	53.837	26.247	-39.087	1.00	35.29
ATOM	N	LEU	L	201	52.152	26.699	-37.682	1.00	35.81
ATOM	CA	LEU	L	201	51.198	25.857	-38.393	1.00	36.05
ATOM	CB	LEU	L	201	50.543	24.862	-37.433	1.00	33.90
ATOM	CG	LEU	L	201	51.478	23.925	-36.668	1.00	33.97
ATOM	CD1	LEU	L	201	50.674	23.147	-35.641	1.00	32.30
ATOM	CD2	LEU	L	201	52.204	22.978	-37.632	1.00	31.98
ATOM	C	LEU	L	201	50.133	26.743	-39.033	1.00	36.97
ATOM	O	LEU	L	201	49.499	27.558	-38.346	1.00	36.27
ATOM	N	SER	L	202	49.968	26.609	-40.349	1.00	38.32
ATOM	CA	SER	L	202	48.973	27.388	-41.085	1.00	40.35
ATOM	CB	SER	L	202	49.179	27.229	-42.588	1.00	39.68
ATOM	OG	SER	L	202	49.055	25.874	-42.981	1.00	43.15
ATOM	C	SER	L	202	47.580	26.907	-40.688	1.00	41.57
ATOM	O	SER	L	202	46.599	27.656	-40.750	1.00	43.86
ATOM	N	SER	L	203	47.512	25.653	-40.261	1.00	40.52
ATOM	CA	SER	L	203	46.269	25.049	-39.824	1.00	40.76
ATOM	CB	SER	L	203	45.526	24.478	-41.028	1.00	42.78
ATOM	OG	SER	L	203	46.420	23.731	-41.838	1.00	50.38
ATOM	C	SER	L	203	46.623	23.942	-38.834	1.00	39.15
ATOM	O	SER	L	203	47.654	23.273	-38.992	1.00	38.36
ATOM	N	PRO	L	204	45.801	23.774	-37.778	1.00	37.58
ATOM	CD	PRO	L	204	44.653	24.641	-37.453	1.00	36.52

TABLE 2-continued

		Atom A.A.			X	Y	Z	Occ	B
		Type							
ATOM	CA	PRO	L	204	45.983	22.764	-36.731	1.00	36.27
ATOM	CB	PRO	L	204	44.648	22.806	-35.989	1.00	36.27
ATOM	CG	PRO	L	204	44.336	24.256	-36.011	1.00	37.26
ATOM	C	PRO	L	204	46.274	21.379	-37.270	1.00	34.75
ATOM	O	PRO	L	204	45.661	20.931	-38.238	1.00	33.73
ATOM	N	VAL	L	205	47.260	20.733	-36.663	1.00	34.45
ATOM	CA	VAL	L	205	47.652	19.390	-37.047	1.00	31.64
ATOM	CB	VAL	L	205	49.170	19.203	-36.935	1.00	29.36
ATOM	CG1	VAL	L	205	49.545	17.778	-37.215	1.00	28.96
ATOM	CG2	VAL	L	205	49.855	20.097	-37.919	1.00	31.43
ATOM	C	VAL	L	205	46.952	18.438	-36.099	1.00	31.45
ATOM	O	VAL	L	205	46.809	18.732	-34.919	1.00	31.91
ATOM	N	THR	L	206	46.480	17.315	-36.618	1.00	30.31
ATOM	CA	THR	L	206	45.812	16.348	-35.776	1.00	27.81
ATOM	CB	THR	L	206	44.286	16.304	-36.030	1.00	28.22
ATOM	OG1	THR	L	206	43.699	17.541	-35.612	1.00	30.85
ATOM	CG2	THR	L	206	43.639	15.180	-35.227	1.00	25.07
ATOM	C	THR	L	206	46.403	14.969	-35.954	1.00	26.65
ATOM	O	THR	L	206	46.585	14.49B	-37.075	1.00	26.93
ATOM	N	LYS	L	207	46.801	14.375	-34.834	1.00	26.50
ATOM	CA	LYS	L	207	47.340	13.013	-34.803	1.00	24.40
ATOM	CB	LYS	L	207	48.719	12.976	-34.138	1.00	22.17
ATOM	CG	LYS	L	207	49.800	13.584	-35.000	1.00	22.70
ATOM	CD	LYS	L	207	49.682	13.080	-36.420	1.00	25.39
ATOM	CE	LYS	L	207	50.876	13.490	-37.283	1.00	27.96
ATOM	NZ	LYS	L	207	50.979	14.962	-37.448	1.00	32.56
ATOM	C	LYS	L	207	46.332	12.152	-34.041	1.00	21.89
ATOM	O	LYS	L	207	45.836	12.552	-32.990	1.00	29.91
ATOM	N	SER	L	208	46.002	10.986	-34.573	1.00	20.67
ATOM	CA	SER	L	208	45.023	10.160	-33.895	1.00	22.53
ATOM	CB	SER	L	208	43.607	10.641	-34.229	1.00	23.05
ATOM	OG	SER	L	208	43.309	10.503	-35.605	1.00	22.35
ATOM	C	SER	L	208	45.152	8.692	-34.236	1.00	21.41
ATOM	O	SER	L	208	45.917	8.323	-35.128	1.00	23.53
ATOM	N	PHE	L	209	44.414	7.867	-33.503	1.00	20.17
ATOM	CA	PHE	L	209	44.384	6.428	-33.709	1.00	19.98
ATOM	CB	PHE	L	209	45.499	5.733	-32.917	1.00	27.21
ATOM	CG	PHE	L	209	45.340	5.830	-31.421	1.00	17.15
ATOM	CG1	PHE	L	209	45.980	6.838	-30.705	1.00	15.87
ATOM	CD2	PHE	L	209	44.544	4.926	-30.735	1.00	14.47
ATOM	CE1	PHE	L	209	45.826	6.945	-29.335	1.00	13.72
ATOM	CE2	PHE	L	209	44.379	5.024	-29.363	1.00	15.39
ATOM	CZ	PHE	L	209	45.024	6.039	-28.659	1.00	15.16
ATOM	C	PHE	L	209	43.027	5.919	-33.241	1.00	20.93
ATOM	O	PHE	L	209	42.326	6.582	-32.474	1.00	20.26
ATOM	N	ASN	L	210	42.643	4.745	-33.709	1.00	23.29
ATOM	CA	ASN	L	210	41.384	4.167	-33.285	1.00	25.15
ATOM	CB	ASN	L	210	40.588	3.627	-34.469	1.00	27.36
ATOM	CG	ASN	L	210	40.138	4.709	-35.406	1.00	28.83
ATOM	OG1	ASN	L	210	39.666	5.761	-34.986	1.00	30.55
ATOM	ND2	ASN	L	210	40.284	4.459	-36.691	1.00	32.86
ATOM	C	ASN	L	210	41.735	3.020	-32.361	1.00	25.95
ATOM	O	ASN	L	210	42.595	2.177	-32.691	1.00	23.37
ATOM	N	ARG	L	211	41.107	3.016	-31.190	1.00	24.99
ATOM	CA	ARG	L	211	41.310	1.973	-30.200	1.00	26.72
ATOM	CB	ARG	L	211	40.272	2.126	-29.096	1.00	29.08
ATOM	CG	ARG	L	211	40.439	1.203	-27.920	1.00	32.37
ATOM	CD	ARG	L	211	39.260	1.337	-26.982	1.00	38.35
ATOM	NE	ARG	L	211	38.303	0.250	-27.164	1.00	44.72
ATOM	CZ	ARG	L	211	37.227	0.300	-27.942	1.00	47.51
ATOM	NE1	ARG	L	211	36.934	1.387	-28.635	1.00	50.78
ATOM	NH2	ARG	L	211	36.460	-0.770	-28.060	1.00	52.10
ATOM	C	ARG	L	211	41.086	0.649	-30.920	1.00	27.05
ATOM	O	ARG	L	211	40.070	0.488	-31.598	1.00	25.38
ATOM	N	GLY	L	212	42.075	-0.240	-30.863	1.00	25.25
ATOM	CA	GLY	L	212	41.935	-1.528	-31.512	1.00	27.36
ATOM	C	GLY	L	212	42.467	-1.669	-32.931	1.00	28.73
ATOM	O	GLY	L	212	42.374	-2.753	-33.500	1.00	30.55
ATOM	N	GLU	L	213	43.013	-0.603	-33.519	1.00	28.63
ATOM	CA	GLU	L	213	43.559	-0.706	-34.878	1.00	28.38
ATOM	CB	GLU	L	213	43.809	0.676	-35.485	1.00	27.47
ATOM	CG	GLU	L	213	44.767	1.547	-34.702	1.00	30.90
ATOM	CD	GLU	L	213	45.140	2.811	-35.442	1.00	32.32
ATOM	OE1	GLU	L	213	44.256	3.660	-35.697	1.00	28.43
ATOM	OE2	GLU	L	213	46.337	2.951	-35.777	1.00	38.75
ATOM	C	GLU	L	213	44.848	-1.545	-34.912	1.00	27.34

TABLE 2-continued

		Atom A.A.			X	Y	Z	Occ	B
		Type							
ATOM	O	GLU	L	213	45.340	-1.905	-35.984	1.00	27.73
ATOM	N	CYS	L	214	45.386	-1.824	-33.730	1.00	23.79
ATOM	CA	CYS	L	214	46.588	-2.617	-33.568	1.00	24.14
ATOM	CB	CYS	L	214	47.832	-1.793	-33.929	1.00	21.09
ATOM	SG	CYS	L	214	49.402	-2.696	-33.720	1.00	21.16
ATOM	C	CYS	L	214	46.655	-3.098	-32.113	1.00	25.60
ATOM	O	CYS	L	214	46.497	-4.317	-31.886	1.00	26.55
ATOM	OXT	CYS	L	214	46.812	-2.250	-31.208	1.00	25.04
ATOM	CB	GLN	H	1	89.041	17.551	-11.026	1.00	38.73
ATOM	CG	GLN	H	1	89.504	16.894	-12.327	1.00	43.69
ATOM	CD	GLN	H	1	90.587	17.700	-13.054	1.00	47.34
ATOM	OE1	GLN	H	1	91.700	17.172	-13.322	1.00	49.92
ATOM	NE2	GLN	H	1	90.284	18.983	-13.367	1.00	44.36
ATOM	C	GLN	H	1	89.366	17.829	-8.582	1.00	32.86
ATOM	O	GLN	H	1	89.282	16.917	-7.752	1.00	32.27
ATOM	N	GLN	H	1	90.700	16.216	-9.797	1.00	36.03
ATOM	CA	GLN	H	1	90.081	17.570	-9.909	1.00	35.50
ATOM	N	VAL	H	2	88.863	19.049	-8.385	1.00	31.14
ATOM	CA	VAL	H	2	88.124	19.398	-7.168	1.00	27.15
ATOM	CB	VAL	H	2	88.139	20.922	-6.901	1.00	28.34
ATOM	CG1	VAL	H	2	87.231	21.267	-5.723	1.00	25.54
ATOM	CG2	VAL	H	2	89.545	21.385	-6.600	1.00	31.24
ATOM	C	VAL	H	2	86.677	18.955	-7.400	1.00	24.53
ATOM	O	VAL	H	2	86.089	19.295	-8.435	1.00	23.94
ATOM	N	THR	H	3	86.120	18.198	-6.452	1.00	20.44
ATOM	CA	THR	H	3	84.749	17.696	-6.557	1.00	21.79
ATOM	CB	THR	H	3	84.695	16.180	-7.087	1.00	21.21
ATOM	OG1	THR	H	3	85.135	15.276	-6.066	1.00	24.96
ATOM	CG2	THR	H	3	85.595	15.968	-8.301	1.00	19.19
ATOM	C	THR	H	3	84.047	17.771	-5.198	1.00	19.89
ATOM	O	THR	H	3	84.687	17.698	-4.146	1.00	20.44
ATOM	N	LEU	H	4	82.737	17.982	-5.222	1.00	21.46
ATOM	CA	LEU	H	4	81.932	18.026	-3.996	1.00	21.29
ATOM	CB	LEU	H	4	81.412	19.433	-3.711	1.00	20.12
ATOM	CG	LEU	H	4	82.224	20.719	-3.514	1.00	23.52
ATOM	CD1	LEU	H	4	82.836	20.766	-2.153	1.00	21.59
ATOM	CD2	LEU	H	4	83.219	20.968	-4.618	1.00	22.05
ATOM	C	LEU	H	4	80.726	17.137	-4.299	1.00	20.12
ATOM	O	LEU	H	4	80.291	17.071	-5.447	1.00	20.31
ATOM	N	ARG	H	5	80.207	16.432	-3.299	1.00	19.84
ATOM	CA	ARG	H	5	79.032	15.574	-3.504	1.00	19.68
ATOM	CB	ARG	H	5	79.	57	14.128	-3.746	1.00
									25.17
ATOM	CG	ARG	H	5	78.424	13.305	-4.463	1.00	29.51
ATOM	CD	ARG	H	5	78.626	11.812	-4.206	1.00	38.74
ATOM	NE	ARG	H	5	78.217	11.422	-2.851	1.00	46.80
ATOM	CZ	ARG	H	5	79.055	11.063	-1.879	1.00	49.80
ATOM	NH1	ARG	H	5	80.369	11.032	-2.093	1.00	51.08
ATOM	NH2	ARG	H	5	78.574	10.751	-0.682	1.00	51.13
ATOM	C	ARG	H	5	78.100	15.618	-2.301	1.00	15.95
ATOM	O	ARG	H	5	78.504	15.298	-1.190	1.00	15.47
ATOM	N	GLU	H	6	76.842	15.968	-2.533	1.00	16.47
ATOM	CA	GLU	H	6	75.860	16.042	-1.450	1.00	15.47
ATOM	CB	GLU	H	6	74.865	17.196	-1.654	1.00	15.61
ATOM	CG	GLU	H	6	75.459	18.549	-1.986	1.00	13.15
ATOM	CD	GLU	H	6	75.769	18.732	-3.474	1.00	14.34
ATOM	OE1	GLU	H	6	75.679	17.763	-4.264	1.00	14.15
ATOM	OE2	GLU	H	6	76.100	19.869	-3.860	1.00	16.39
ATOM	C	GLU	H	6	75.077	14.735	-1.382	1.00	14.85
ATOM	O	GLU	H	6	74.811	14.095	-2.405	1.00	13.49
ATOM	N	SER	H	7	74.730	14.335	-0.169	1.00	16.74
ATOM	CA	SER	H	7	73.953	13.131	0.045	1.00	16.80
ATOM	CB	SER	H	7	74.876	11.897	0.097	1.00	18.29
ATOM	OG	SER	H	7	75.885	12.018	1.085	1.00	20.20
ATOM	C	SER	H	7	73.087	13.260	1.302	1.00	14.45
ATOM	O	SER	H	7	73.379	14.039	2.220	1.00	12.60
ATOM	N	GLY	H	8	71.972	12.556	1.292	1.00	13.11
ATOM	CA	GLY	H	8	71.061	12.581	2.411	1.00	13.45
ATOM	C	GLY	H	8	69.796	11.883	1.963	1.00	15.80
ATOM	O	GLY	H	8	69.751	11.362	0.840	1.00	16.91
ATOM	N	PRO	H	9	68.786	11.766	2.827	1.00	15.87
ATOM	CD	PRO	H	9	68.706	12.263	4.210	1.00	16.52
ATOM	CA	PRO	H	9	67. 36	11.105	2.419	1.00	16.14
ATOM	CB	PRO	H	9	66.747	11.050	3.718	1.00	15.96
ATOM	CG	PRO	H	9	67.217	12.297	4.431	1.00	19.96
ATOM	C	PRO	H	9	66.820	11.970	1.378	1.00	16.98

TABLE 2-continued

		Atom A.A.			X	Y	Z	Occ	B
		Type							
ATOM	O	PRO	H	9	66.961	13.204	1.366	1.00	15.45
ATOM	N	ALA	H	10	66.069	11.337	0.491	1.00	16.97
ATOM	CA	ALA	H	10	65.359	12.091	-0.536	1.00	17.03
ATOM	CB	ALA	H	10	65.148	11.232	-1.762	1.00	17.55
ATOM	C	ALA	H	10	64.016	12.627	-0.042	1.00	16.22
ATOM	O	ALA	H	10	63.475	13.574	-0.607	1.00	14.92
ATOM	N	LEU	H	11	63.517	12.059	1.049	1.00	16.76
ATOM	CA	LEU	H	11	62.231	12.444	1.590	1.00	17.28
ATOM	CB	LEU	H	11	61.224	11.333	1.282	1.00	20.63
ATOM	CG	LEU	H	11	59.722	11.535	1.042	1.00	23.90
ATOM	CD1	LEU	H	11	59.037	10.144	1.116	1.00	17.36
ATOM	CD2	LEU	H	11	59.111	12.498	2.054	1.00	26.18
ATOM	C	LEU	H	11	62.409	12.524	3.083	1.00	18.81
ATOM	O	LEU	H	11	63.081	11.682	3.670	1.00	20.70
ATOM	N	VAL	H	12	61.817	13.535	3.697	1.00	18.51
ATOM	CA	VAL	H	12	61.890	13.700	5.137	1.00	19.38
ATOM	CB	VAL	H	12	63.009	14.740	5.513	1.00	21.22
ATOM	CG1	VAL	H	12	62.819	16.018	4.757	1.00	22.31
ATOM	CG2	VAL	H	12	63.045	15.008	6.991	1.00	22.98
ATOM	C	VAL	H	12	60.472	14.120	5.559	1.00	17.45
ATOM	O	VAL	H	12	59.737	14.698	4.769	1.00	19.16
ATOM	N	LYS	H	13	60.044	13.757	6.753	1.00	16.45
ATOM	CA	LYS	H	13	58.705	14.125	7.193	1.00	19.16
ATOM	CB	LYS	H	13	58.119	13.002	8.045	1.00	19.92
ATOM	CG	LYS	H	13	57.944	11.718	7.279	1.00	21.38
ATOM	CD	LYS	H	13	57.493	10.592	8.168	1.00	23.63
ATOM	CE	LYS	H	13	57.213	9.342	7.350	1.00	26.68
ATOM	NZ	LYS	H	13	55.952	9.380	6.548	1.00	29.75
ATOM	C	LYS	H	13	58.678	15.447	7.959	1.00	21.82
ATOM	O	LYS	H	13	59.659	15.813	8.630	1.00	23.05
ATOM	N	PRO	H	14	57.564	16.202	7.852	1.00	20.98
ATOM	CD	PRO	H	14	56.341	15.940	7.068	1.00	20.16
ATOM	CA	PRO	H	14	57.468	17.480	8.564	1.00	20.48
ATOM	CB	PRO	H	14	55.980	17.813	8.457	1.00	20.21
ATOM	CG	PRO	H	14	55.622	17.275	7.117	1.00	19.19
ATOM	C	PRO	H	14	57.908	17.318	10.020	1.00	19.76
ATOM	O	PRO	H	14	57.703	16.263	10.616	1.00	19.05
ATOM	N	THR	H	15	58.572	18.345	10.543	1.00	22.03
ATOM	CA	THR	H	15	59.089	18.410	11.917	1.00	22.23
ATOM	CB	THR	H	15	58.010	18.048	13.007	1.00	22.84
ATOM	OG1	THR	H	15	57.795	16.628	13.049	1.00	21.55
ATOM	CG2	THR	H	15	56.672	18.786	12.719	1.00	23.91
ATOM	C	THR	H	15	60.356	17.613	12.182	1.00	22.65
ATOM	O	THR	H	15	61.010	17.825	13.208	1.00	21.92
ATOM	N	GLN	H	16	60.695	16.687	11.284	1.00	22.77
ATOM	CA	GLN	H	16	61.911	15.889	11.442	1.00	20.54
ATOM	CB	GLN	H	16	61.865	14.639	10.571	1.00	22.36
ATOM	CG	GLN	H	16	60.807	13.651	11.000	1.00	25.78
ATOM	CD	GLN	H	16	60.906	12.346	10.260	1.00	26.82
ATOM	OE1	GLN	H	16	61.223	12.305	9.063	1.00	26.33
ATOM	NE2	GLN	H	16	60.636	11.262	10.962	1.00	27.32
ATOM	C	GLN	H	16	63.178	16.681	11.141	1.00	18.94
ATOM	O	GLN	H	16	63.131	17.828	10.702	1.00	16.50
ATOM	N	THR	H	17	64.318	16.077	11.435	1.00	19.96
ATOM	CA	THR	H	17	65.582	16.737	11.197	1.00	20.38
ATOM	CB	THR	H	17	66.533	16.591	12.400	1.00	22.26
ATOM	OG1	THR	H	17	65.940	17.211	13.549	1.00	24.95
ATOM	CG2	THR	H	17	67.886	17.266	12.106	1.00	24.40
ATOM	C	THR	H	17	66.244	16.162	9.969	1.00	19.47
ATOM	O	THR	H	17	66.210	14.940	9.746	1.00	21.06
ATOM	N	LEU	H	18	66.776	17.056	9.141	1.00	17.08
ATOM	CA	LEU	H	18	67.481	16.660	7.934	1.00	18.72
ATOM	CB	LEU	H	18	67.118	17.590	6.771	1.00	16.71
ATOM	CG	LEU	H	18	67.911	17.343	5.481	1.00	17.37
ATOM	CD1	LEU	H	18	67.516	16.008	4.874	1.00	17.23
ATOM	CD2	LEU	H	18	67.684	18.478	4.489	1.00	16.91
ATOM	C	LEU	H	18	68.993	16.734	8.176	1.00	17.32
ATOM	O	LEU	H	18	69.488	17.704	8.724	1.00	16.61
ATOM	N	THR	H	19	69.707	15.683	7.803	1.00	18.33
ATOM	CA	THR	H	19	71.157	15.663	7.923	1.00	17.82
ATOM	CB	THR	H	19	71.628	14.541	8.862	1.00	18.17
ATOM	OG1	THR	H	19	71.181	14.838	10.188	1.00	19.18
ATOM	CG2	THR	H	19	73.162	14.394	8.833	1.00	16.07
ATOM	C	THR	H	19	71.728	15.472	6.511	1.00	17.19
ATOM	O	THR	H	19	71.464	14.460	5.846	1.00	17.03
ATOM	N	LEU	H	20	72.412	16.503	6.023	1.00	15.96

TABLE 2-continued

		Atom A.A.			X	Y	Z	Occ	B
		Type							
ATOM	CA	LEU	H	20	73.021	16.477	4.705	1.00	16.02
ATOM	CB	LEU	H	20	72.693	17.760	3.935	1.00	12.09
ATOM	CG	LEU	H	20	71.242	17.974	3.533	1.00	14.01
ATOM	CG1	LEU	H	20	71.021	19.422	3.324	1.00	15.03
ATOM	CG2	LEU	H	20	70.877	17.173	2.312	1.00	14.28
ATOM	C	LEU	H	20	74.531	16.353	4.858	1.00	16.97
ATOM	O	LEU	H	20	75.122	16.960	5.754	1.00	17.31
ATOM	N	THR	H	21	75.151	15.586	3.972	1.00	15.60
ATOM	CA	THR	H	21	76.587	15.414	4.024	1.00	16.81
ATOM	CB	THR	H	21	76.941	13.958	4.332	1.00	15.79
ATOM	OG1	THR	H	21	76.304	13.571	5.561	1.00	14.35
ATOM	OG2	THR	H	21	78.458	13.798	4.472	1.00	14.58
ATOM	C	THR	H	21	77.219	15.863	2.714	1.00	15.76
ATOM	O	THR	H	21	76.689	15.595	1.646	1.00	15.65
ATOM	N	CYS	H	22	78.292	16.635	2.806	1.00	15.22
ATOM	CA	CYS	H	22	79.007	17.100	1.624	1.00	16.61
ATOM	C	CYS	H	22	80.386	16.462	1.661	1.00	17.70
ATOM	O	CYS	H	22	81.212	16.808	2.509	1.00	17.86
ATOM	CB	CYS	H	22	79.164	18.622	1.624	1.00	16.86
ATOM	SG	CYS	H	22	80.150	19.286	0.243	1.00	14.84
ATOM	N	THR	H	23	80.609	15.512	0.760	1.00	18.33
ATOM	CA	THR	H	23	81.879	14.812	0.670	1.00	19.26
ATOM	CB	THR	H	23	81.662	13.312	0.509	1.00	19.33
ATOM	OG1	THR	H	23	80.879	12.853	1.613	1.00	22.21
ATOM	CG2	THR	H	23	82.974	12.586	0.528	1.00	22.05
ATOM	C	THR	H	23	82.640	15.389	-0.495	1.00	18.33
ATOM	O	THR	H	23	82.122	15.497	-1.610	1.00	17.83
ATOM	N	PHE	H	24	83.875	15.782	-0.236	1.00	19.13
ATOM	CA	PHE	H	24	84.656	16.408	-1.288	1.00	22.34
ATOM	CB	PHE	H	24	84.806	17.918	-0.994	1.00	21.75
ATOM	CG	PHE	H	24	85.421	18.218	0.347	1.00	20.43
ATOM	CD1	PHE	H	24	86.808	18.263	0.496	1.00	22.58
ATOM	CD2	PHE	H	24	84.623	18.387	1.467	1.00	19.58
ATOM	CE1	PHE	H	24	87.383	18.462	1.743	1.00	21.78
ATOM	CE2	PHE	H	24	85.182	18.585	2.713	1.00	18.19
ATOM	CZ	PHE	H	24	86.564	18.621	2.859	1.00	21.55
ATOM	C	PHE	H	24	86.020	15.778	-1.498	1.00	23.38
ATOM	O	PHE	H	24	86.434	14.911	-0.743	1.00	24.19
ATOM	N	SER	H	25	86.685	16.209	-2.559	1.00	25.12
ATOM	CA	SER	H	25	88.021	15.754	-2.885	1.00	27.58
ATOM	CB	SER	H	25	88.004	14.355	-3.510	1.00	25.80
ATOM	OG	SER	H	25	87.469	14.384	-4.822	1.00	28.75
ATOM	C	SER	H	25	88.628	16.788	-3.837	1.00	28.21
ATOM	O	SER	H	25	87.931	17.666	-4.365	1.00	26.90
ATOM	NH	GLY	H	26	89.936	16.692	-4.035	1.00	30.76
ATOM	CA	GLY	H	26	90.625	17.627	-4.900	1.00	27.87
ATOM	C	GLY	H	26	91.146	18.782	-4.070	1.00	29.61
ATOM	O	GLY	H	26	91.781	19.678	-4.611	1.00	30.97
ATOM	N	PHE	H	27	90.888	18.761	-2.761	1.00	26.72
ATOM	CA	PHE	H	27	91.332	19.830	-1.884	1.00	27.11
ATOM	CB	PHE	H	27	90.600	21.166	-2.190	1.00	27.71
ATOM	CG	PHE	H	27	89.159	21.233	-1.700	1.00	26.87
ATOM	CD1	PHE	H	27	88.858	21.733	-0.431	1.00	24.48
ATOM	CD2	PHE	H	27	88.110	20.820	-2.513	1.00	27.17
ATOM	CE1	PHE	H	27	87.537	21.817	0.020	1.00	25.75
ATOM	CE2	PHE	H	27	86.787	20.905	-2.067	1.00	25.89
ATOM	CZ	PHE	H	27	86.506	21.402	-0.801	1.00	24.60
ATOM	C	PHE	H	27	91.133	19.435	-0.438	1.00	26.87
ATOM	O	PHE	H	27	90.467	18.439	-0.150	1.00	27.66
ATOM	N	SER	H	28	91.714	20.223	0.464	1.00	26.42
ATOM	CA	SER	H	28	91.612	19.970	1.890	1.00	24.77
ATOM	CB	SER	H	28	92.976	19.626	2.481	1.00	21.30
ATOM	OG	SER	H	28	92.934	19.678	3.901	1.00	22.82
ATOM	C	SER	H	28	91.053	21.162	2.625	1.00	25.66
ATOM	O	SER	H	28	91.508	22.292	2.433	1.00	27.14
ATOM	N	LEU	H	29	90.131	20.888	3.540	1.00	26.30
ATOM	CA	LEU	H	29	89.508	21.926	4.334	1.00	26.90
ATOM	CB	LEU	H	29	88.237	21.399	5.013	1.00	27.65
ATOM	CG	LEU	H	29	86.958	22.199	4.723	1.00	27.49
ATOM	CD1	LEU	H	29	85.790	21.609	5.467	1.00	25.56
ATOM	CD2	LEU	H	29	87.123	23.664	5.097	1.00	26.24
ATOM	C	LEU	H	29	90.478	22.442	5.378	1.00	28.20
ATOM	O	LEU	H	29	90.104	23.243	6.225	1.00	30.84
ATOM	N	SER	H	30	91.699	21.917	5.381	1.00	29.52
ATOM	CA	SER	H	30	92.696	22.371	6.336	1.00	30.23
ATOM	CB	SER	H	30	93.591	21.223	6.779	1.00	32.80

TABLE 2-continued

		Atom A.A.			X	Y	Z	Occ	B
		Type							
ATOM	OG	SER	H	30	92.878	20.324	7.605	1.00	40.53
ATOM	C	SER	H	30	93.533	23.473	5.719	1.00	28.60
ATOM	O	SER	H	30	94.197	24.228	6.426	1.00	30.68
ATOM	N	THR	H	31	93.507	23.553	4.399	1.00	25.79
ATOM	CA	THR	H	31	94.251	24.574	3.689	1.00	25.17
ATOM	CB	THR	H	31	94.168	24.342	2.185	1.00	22.82
ATOM	OG1	THR	H	31	94.642	23.026	1.884	1.00	21.22
ATOM	CG2	THR	H	31	94.992	25.387	1.430	1.00	25.49
ATOM	C	THR	H	31	93.706	25.975	4.008	1.00	26.42
ATOM	O	THR	H	31	92.515	26.265	3.804	1.00	25.36
ATOM	N	SER	H	32	94.586	26.835	4.510	1.00	25.43
ATOM	CA	SER	H	32	94.243	28.204	4.846	1.00	22.79
ATOM	CB	SER	H	32	95.532	29.001	5.032	1.00	25.70
ATOM	OG	SER	H	32	95.273	30.390	5.103	1.00	28.76
ATOM	C	SER	H	32	93.391	28.837	3.744	1.00	21.57
ATOM	O	SER	H	32	93.675	28.691	2.548	1.00	17.71
ATOM	N	GLY	H	33	92.324	29.510	4.160	1.00	20.10
ATOM	CA	GLY	H	33	91.419	30.167	3.225	1.00	18.48
ATOM	C	GLY	H	33	90.306	29.308	2.637	1.00	18.96
ATOM	O	GLY	H	33	89.391	29.840	1.992	1.00	17.36
ATOM	N	MET	H	34	90.367	27.993	2.846	1.00	18.43
ATOM	CA	MET	H	34	89.353	27.091	2.301	1.00	21.06
ATOM	CB	MET	H	34	89.896	25.660	2.232	1.00	23.04
ATOM	CG	MET	H	34	89.583	24.932	0.932	1.00	24.08
ATOM	SD	MET	H	34	90.321	25.677	-0.522	1.00	29.23
ATOM	CE	MET	H	34	91.809	24.779	-0.645	1.00	28.50
ATOM	C	MET	H	34	88.032	27.140	3.088	1.00	20.35
ATOM	O	MET	H	34	88.023	27.277	4.321	1.00	20.61
ATOM	N	SER	H	35	86.921	27.022	2.367	1.00	18.89
ATOM	CA	SER	H	35	85.595	27.082	2.970	1.00	17.02
ATOM	CB	SER	H	35	85.119	28.554	2.963	1.00	16.91
ATOM	OG	SER	H	35	83.744	28.731	3.303	1.00	15.81
ATOM	C	SER	H	35	84.630	26.226	2.148	1.00	16.42
ATOM	O	SER	H	35	84.839	26.014	0.954	1.00	13.99
ATOM	N	VAL	H	35A	83.609	25.695	2.813	1.00	17.17
ATOM	CA	VAL	H	35A	82.561	24.928	2.145	1.00	18.21
ATOM	CB	VAL	H	35A	82.627	23.410	2.457	1.00	10.71
ATOM	CG1	VAL	H	35A	81.375	22.712	1.965	1.00	19.97
ATOM	CG2	VAL	H	35A	83.834	22.791	1.780	1.00	19.38
ATOM	C	VAL	H	35A	81.230	25.524	2.621	1.00	17.91
ATOM	O	VAL	H	35A	81.013	25.716	3.821	1.00	17.18
ATOM	N	GLY	H	35B	80.400	25.934	1.668	1.00	19.58
ATOM	CA	GLY	H	35B	79.101	26.501	1.997	1.00	17.30
ATOM	C	GLY	H	35B	77.953	25.659	1.464	1.00	13.26
ATOM	O	GLY	H	35B	78.140	24.770	0.641	1.00	7.81
ATOM	N	TRP	H	36	76.760	25.939	1.961	1.00	16.00
ATOM	CA	TRP	H	36	75.554	25.254	1.546	1.00	14.93
ATOM	CB	TRP	H	36	74.910	24.504	2.711	1.00	12.98
ATOM	CG	TRP	H	36	75.636	23.264	3.120	1.00	14.47
ATOM	CD2	TRP	H	36	75.431	21.931	2.608	1.00	14.01
ATOM	CE2	TRP	H	36	76.264	21.066	3.353	1.00	12.94
ATOM	CE3	TRP	H	36	74.619	21.388	1.598	1.00	11.52
ATOM	CD1	TRP	H	36	76.574	23.150	4.115	1.00	14.35
ATOM	NE1	TRP	H	36	76.945	21.834	4.262	1.00	15.17
ATOM	CZ2	TRP	H	36	76.311	19.687	3.123	1.00	13.17
ATOM	CZ3	TRP	H	36	74.666	20.008	1.367	1.00	14.14
ATOM	CH2	TRP	H	36	75.508	19.176	2.130	1.00	13.90
ATOM	C	TRP	H	36	74.587	26.298	0.998	1.00	15.07
ATOM	O	TRP	H	36	74.433	27.393	1.569	1.00	14.43
ATOM	N	ILE	H	37	73.999	25.957	-0.145	1.00	14.15
ATOM	CA	ILE	H	37	73.028	26.769	-0.862	1.00	14.19
ATOM	CB	ILE	H	37	73.644	27.357	-2.191	1.00	13.79
ATOM	CG2	ILE	H	37	72.623	28.239	-2.912	1.00	10.80
ATOM	CG1	ILE	H	37	74.924	28.157	-1.906	1.00	12.98
ATOM	CD1	ILE	H	37	76.391	27.361	-2.001	1.00	9.84
ATOM	C	ILE	H	37	71.857	25.834	-1.255	1.00	14.48
ATOM	O	ILE	H	37	72.059	24.660	-1.573	1.00	14.48
ATOM	N	ARG	H	38	70.632	26.337	-1.187	1.00	15.05
ATOM	CA	ARG	H	38	69.490	25.537	-1.594	1.00	13.99
ATOM	CB	ARG	H	38	68.654	25.107	-0.400	1.00	12.72
ATOM	CG	ARG	H	38	67.837	26.195	0.206	1.00	11.35
ATOM	CD	ARG	H	38	66.955	25.629	1.271	1.00	12.76
ATOM	NE	ARG	H	38	66.226	26.687	1.942	1.00	17.72
ATOM	CZ	ARG	H	38	65.375	26.498	2.942	1.00	16.18
ATOM	NH1	ARG	H	38	65.136	25.280	3.392	1.00	9.66
ATOM	NH2	ARG	H	38	64.786	27.544	3.501	1.00	14.95

TABLE 2-continued

		Atom A.A.			X	Y	Z	Occ	B
		Type							
ATOM	C	ARG	H	38	68.622	26.289	-2.601	1.00	13.81
ATOM	O	ARG	H	38	68.718	27.514	-2.765	1.00	11.23
ATOM	N	GLN	H	39	67.776	25.544	-3.285	1.00	12.87
ATOM	CA	GLN	H	39	66.919	26.147	-4.265	1.00	14.66
ATOM	CB	GLN	H	39	67.527	26.167	-5.612	1.00	16.19
ATOM	CG	GLN	H	39	66.876	26.910	-6.694	1.00	15.68
ATOM	CD	GLN	H	39	67.681	27.024	-7.956	1.00	15.98
ATOM	OE1	GLN	H	39	67.798	28.106	-8.538	1.00	17.80
ATOM	NE2	GLN	H	39	68.259	25.910	-8.390	1.00	16.85
ATOM	C	GLN	H	39	65.600	25.396	-4.367	1.00	15.76
ATOM	O	GLN	H	39	65.556	24.249	-4.835	1.00	14.34
ATOM	N	PRO	H	40	64.512	26.015	-3.868	1.00	17.06
ATOM	CD	PRO	H	40	64.495	27.302	-3.152	1.00	15.97
ATOM	CA	PRO	H	40	63.173	25.436	-3.899	1.00	15.94
ATOM	CB	PRO	H	40	62.335	26.497	-3.198	1.00	16.60
ATOM	CG	PRO	H	40	63.286	27.140	-2.272	1.00	17.11
ATOM	C	PRO	H	40	62.768	25.339	-5.350	1.00	17.70
ATOM	O	PRO	H	40	63.214	26.134	-6.162	1.00	16.65
ATOM	N	PRO	H	41	61.958	24.334	-5.710	1.00	20.76
ATOM	CD	PRO	H	41	61.398	23.245	-4.889	1.00	22.23
ATOM	CA	PRO	H	41	61.336	24.210	-7.108	1.00	20.87
ATOM	CB	PRO	H	41	60.416	23.185	-7.025	1.00	22.27
ATOM	CG	PRO	H	41	60.893	22.279	-5.936	1.00	23.84
ATOM	C	PRO	H	41	61.017	25.555	-7.609	1.00	20.24
ATOM	O	PRO	H	41	60.256	26.225	-6.917	1.00	22.84
ATOM	N	GLY	H	42	61.540	25.993	-8.744	1.00	21.26
ATOM	CA	GLY	H	42	61.119	27.248	-9.331	1.00	20.76
ATOM	C	GLY	H	42	61.459	28.521	-8.583	1.00	21.38
ATOM	O	GLY	H	42	60.877	29.562	-8.877	1.00	23.41
ATOM	N	LYS	H	43	62.367	28.474	-7.614	1.00	21.11
ATOM	CA	LYS	H	43	62.721	29.693	-6.885	1.00	21.46
ATOM	CB	LYS	H	43	62.341	29.597	-5.402	1.00	24.52
ATOM	CG	LYS	H	43	60.863	29.358	-5.133	1.00	26.93
ATOM	CD	LYS	H	43	60.568	29.524	-3.660	1.00	33.74
ATOM	CE	LYS	H	43	59.089	29.328	-3.340	1.00	38.50
ATOM	NZ	LYS	H	43	58.826	29.556	-1.884	1.00	39.74
ATOM	C	LYS	H	43	64.210	29.976	-7.021	1.00	20.27
ATOM	O	LYS	H	43	64.348	29.184	-7.599	1.00	20.32
ATOM	N	ALA	H	44	64.646	31.106	-6.487	1.00	19.41
ATOM	CA	ALA	H	44	66.051	31.491	-6.557	1.00	19.41
ATOM	CB	ALA	H	44	66.189	32.990	-6.372	1.00	19.26
ATOM	C	ALA	H	44	66.925	30.764	-5.538	1.00	19.34
ATOM	O	ALA	H	44	66.435	30.088	-4.620	1.00	19.44
ATOM	N	LEU	H	45	68.232	30.901	-5.717	1.00	17.25
ATOM	CA	LEU	H	45	69.196	30.299	-4.815	1.00	15.89
ATOM	CB	LEU	H	45	70.620	30.447	-5.373	1.00	10.63
ATOM	CD	LEU	H	45	70.953	29.865	-6.735	1.00	12.90
ATOM	CD1	LEU	H	45	72.289	30.431	-7.221	1.00	8.13
ATOM	CD2	LEU	H	45	71.013	28.351	-6.645	1.00	10.96
ATOM	C	LEU	H	45	69.105	31.048	-3.488	1.00	24.70
ATOM	O	LEU	H	45	68.854	32.254	-3.465	1.00	17.03
ATOM	N	GLU	H	46	69.320	30.326	-2.398	1.00	15.19
ATOM	CA	GLU	H	46	69.317	30.877	-1.058	1.00	14.24
ATOM	CB	GLU	H	46	68.054	30.488	-0.307	1.00	13.44
ATOM	CG	GLU	H	46	68.093	30.929	1.136	1.00	14.99
ATOM	CD	GLU	H	46	66.813	30.604	1.879	1.00	20.34
ATOM	OE1	GLU	H	46	66.322	29.460	1.784	1.00	20.65
ATOM	OE2	GLU	H	46	66.295	31.499	2.563	1.00	22.75
ATOM	C	GLU	H	46	70.504	30.332	-0.300	1.00	13.87
ATOM	O	GLU	H	46	70.608	29.121	-0.094	1.00	14.81
ATOM	N	TRP	H	47	71.368	31.228	0.161	1.00	15.80
ATOM	CA	TRP	H	47	72.548	30.846	0.923	1.00	15.32
ATOM	CB	TRP	H	47	73.496	32.034	1.070	1.00	15.93
ATOM	CG	TRP	H	47	74.728	31.714	1.868	1.00	18.77
ATOM	CD2	TRP	H	47	74.966	32.053	3.238	1.00	18.77
ATOM	CE2	TRP	H	47	76.256	31.564	3.575	1.00	19.72
ATOM	CE3	TRP	H	47	74.221	32.729	4.215	1.00	16.45
ATOM	CG1	TRP	H	47	75.848	31.041	1.435	1.00	17.15
ATOM	NE1	TRP	H	47	76.767	30.952	2.459	1.00	19.64
ATOM	CZ2	TRP	H	47	76.814	31.733	4.846	1.00	16.17
ATOM	CZ3	TRP	H	47	74.783	32.895	5.476	1.00	18.48
ATOM	CH2	TRP	H	47	76.067	32.398	5.777	1.00	17.28
ATOM	C	TRP	H	47	72.095	30.349	2.293	1.00	15.44
ATOM	O	TRP	H	47	71.236	30.960	2.922	1.00	14.94
ATOM	N	LEU	H	48	72.674	29.240	2.742	1.00	13.88
ATOM	CA	LEU	H	48	72.311	28.639	4.021	1.00	14.64

TABLE 2-continued

		Atom A.A.			X	Y	Z	Occ	B
		Type							
ATOM	CB	LEU	H	48	72.057	27.151	3.829	1.00	15.18
ATOM	CG	LEU	H	48	70.642	26.595	3.685	1.00	19.59
ATOM	CD1	LEU	H	48	69.668	27.639	3.236	1.00	19.86
ATOM	CD2	LEU	H	48	70.658	25.396	2.779	1.00	14.67
ATOM	C	LEU	H	48	73.348	28.813	5.122	1.00	16.42
ATOM	O	LEU	H	48	73.030	29.297	6.217	1.00	16.87
ATOM	N	ALA	H	49	74.588	28.416	4.834	1.00	17.65
ATOM	CA	ALA	H	49	75.660	28.485	5.819	1.00	15.42
ATOM	CB	ALA	H	49	75.326	27.536	7.008	1.00	10.92
ATOM	C	ALA	H	49	77.000	28.083	5.197	1.00	15.85
ATOM	O	ALA	H	49	77.051	27.654	4.046	1.00	11.51
ATOM	N	ASP	H	50	78.085	28.311	5.941	1.00	17.23
ATOM	CA	ASP	H	50	79.427	27.915	5.526	1.00	19.09
ATOM	CB	ASP	H	50	80.068	28.898	4.515	1.00	21.53
ATOM	CG	ASP	H	50	80.480	30.247	5.125	1.00	28.53
ATOM	OD1	ASP	H	50	80.865	30.328	6.307	1.00	32.68
ATOM	OD2	ASP	H	50	80.448	31.257	4.392	1.00	31.09
ATOM	C	ASP	H	50	80.315	27.663	6.746	1.00	18.22
ATOM	O	ASP	H	50	79.981	28.049	7.867	1.00	17.40
ATOM	N	ILE	H	51	81.426	26.982	6.525	1.00	18.70
ATOM	CA	ILE	H	51	82.3,6	126.68	37.588	1.00	18.57
ATOM	CB	ILE	H	51	82.191	25.214	8.098	1.00	16.66
ATOM	CG2	ILE	H	51	82.568	24.215	6.992	1.00	15.80
ATOM	CG1	ILE	H	51	83.005	24.994	9.387	1.00	14.81
ATOM	CD1	ILE	H	51	82.725	23.688	10.108	1.00	10.85
ATOM	C	ILE	H	51	83.757	26.900	6.994	1.00	20.10
ATOM	O	ILE	H	51	84.028	26.479	5.850	1.00	20.16
ATOM	N	TRP	H	52	84.613	27.592	7.750	1.00	17.80
ATOM	CA	TRP	H	52	85.976	27.885	7.322	1.00	18.52
ATOM	CB	TRP	H	52	86.438	29.230	7.882	1.00	17.60
ATOM	CG	TRP	H	52	85.852	30.427	7.186	1.00	18.48
ATOM	CD2	TRP	H	52	86.315	31.773	7.275	1.00	18.83
ATOM	CE2	TRP	H	52	85.460	32.568	6.470	1.00	17.83
ATOM	CE3	TRP	H	52	87.372	32.393	7.960	1.00	20.10
ATOM	CD1	TRP	H	52	84.765	30.454	6.346	1.00	18.77
ATOM	NE1	TRP	H	52	84.525	31.739	5.915	1.00	19.18
ATOM	CZ2	TRP	H	52	85.628	33.943	6.336	1.00	17.47
ATOM	CZ3	TRP	H	52	87.536	33.759	7.823	1.00	16.79
ATOM	CH2	TRP	H	52	86.668	34.520	7.018	1.00	17.22
ATOM	C	TRP	H	52	86.951	26.806	7.758	1.00	20.38
ATOM	O	TRP	H	52	86.658	26.004	8.640	1.00	18.84
ATOM	N	TRP	H	52A	88.135	26.830	7.159	1.00	23.43
ATOM	CA	TRP	H	52A	89.203	25.877	7.463	1.00	24.45
ATOM	CB	TRP	H	52A	90.459	26.230	6.661	1.00	23.73
ATOM	CG	TRP	H	52A	91.148	27.485	7.136	1.00	23.91
ATOM	CD2	TRP	H	52A	90.769	28.845	6.861	1.00	22.37
ATOM	CE2	TRP	H	52A	91.713	29.677	7.500	1.00	24.65
ATOM	CE3	TRP	H	52A	89.731	29.437	6.132	1.00	21.82
ATOM	CG1	TRP	H	52A	92.266	27.551	7.912	1.00	25.27
ATOM	NE1	TRP	H	52A	92.612	28.863	8.134	1.00	26.22
ATOM	CZ2	TRP	H	52A	91.652	31.068	7.435	1.00	21.13
ATOM	CZ3	TRP	H	52A	89.669	30.822	6.066	1.00	22.40
ATOM	CH2	TRP	H	52A	90.627	31.622	6.716	1.00	24.82
ATOM	C	TRP	H	52A	89.537	25.895	8.952	1.00	25.32
ATOM	O	TRP	H	52A	89.974	24.886	9.509	1.00	27.89
ATOM	N	ASP	H	52B	89.338	27.046	9.584	1.00	24.77
ATOM	CA	ASP	H	52B	89.624	27.204	10.998	1.00	26.84
ATOM	CB	ASP	H	52B	90.186	28.606	11.274	1.00	27.51
ATOM	CG	ASP	H	52B	89.193	29.722	10.979	1.00	31.35
ATOM	OG1	ASP	H	52B	87.991	29.447	10.793	1.00	31.83
ATOM	OG2	ASP	H	52B	89.619	30.898	10.942	1.00	33.88
ATOM	C	ASP	H	52B	88.418	26.911	11.893	1.00	27.40
ATOM	O	ASP	H	52B	88.410	27.245	13.072	1.00	26.88
ATOM	N	ASP	H	52C	87.392	26.313	11.305	1.00	28.03
ATOM	CA	ASP	H	52C	86.163	25.955	11.998	1.00	26.36
ATOM	CB	ASP	H	52C	86.446	25.160	13.274	1.00	28.42
ATOM	CG	ASP	H	52C	85.327	24.180	13.603	1.00	33.76
ATOM	OD1	ASP	H	52C	84.868	24.153	14.764	1.00	36.60
ATOM	OD2	ASP	H	52C	84.902	23.430	12.697	1.00	34.49
ATOM	C	ASP	H	52C	85.184	27.093	12.269	1.00	25.03
ATOM	O	ASP	H	52C	84.178	26.896	12.958	1.00	26.18
ATOM	N	LYS	H	53	85.440	28.274	11.713	1.00	23.11
ATOM	CA	LYS	H	53	84.492	29.376	11.893	1.00	24.05
ATOM	CB	LYS	H	53	85.050	30.712	11.388	1.00	25.09
ATOM	CG	LYS	H	53	84.286	31.929	11.912	1.00	24.49
ATOM	CD	LYS	H	53	84.751	33.225	11.245	1.00	25.32

TABLE 2-continued

		Atom A.A.			X	Y	Z	Occ	B
		Type							
ATOM	CE	LYS	H	53	84.428	33.243	9.741	1.00	27.10
ATOM	NZ	LYS	H	53	82.961	33.405	9.382	1.00	25.06
ATOM	C	LYS	H	53	83.237	29.016	11.078	1.00	24.81
ATOM	O	LYS	H	53	83.328	28.634	9.900	1.00	22.11
ATOM	N	LYS	H	54	82.076	29.153	11.706	1.00	24.62
ATOM	CA	LYS	H	54	80.798	28.831	11.085	1.00	23.21
ATOM	CB	LYS	H	54	80.045	27.879	11.995	1.00	20.83
ATOM	CG	LYS	H	54	80.861	26.659	12.357	1.00	20.72
ATOM	CG	LYS	H	54	80.211	25.853	13.454	1.00	20.64
ATOM	CE	LYS	H	54	81.055	24.631	13.802	1.00	22.89
ATOM	NZ	LYS	H	54	82.409	25.036	14.297	1.00	23.84
ATOM	C	LYS	H	54	79.975	30.090	10.870	1.00	23.07
ATOM	O	LYS	H	54	79.984	30.988	11.704	1.00	24.80
ATOM	N	ASP	H	55	79.286	30.171	9.740	1.00	23.45
ATOM	CA	ASP	H	55	78.452	31.331	9.448	1.00	23.61
ATOM	CB	ASP	H	55	79.083	32.190	8.358	1.00	29.01
ATOM	CG	ASP	H	55	78.710	33.653	8.481	1.00	33.21
ATOM	OD1	ASP	H	55	79.219	34.452	7.674	1.00	36.92
ATOM	OD2	ASP	H	55	77.911	34.015	9.375	1.00	37.49
ATOM	C	ASP	H	55	77.085	30.801	9.028	1.00	22.55
ATOM	O	ASP	H	55	77.000	29.775	8.357	1.00	22.79
ATOM	N	TYR	H	56	76.023	31.495	9.418	1.00	21.97
ATOM	CA	TYR	H	56	74.675	31.022	9.154	1.00	22.29
ATOM	CB	TYR	H	56	74.051	30.491	10.449	1.00	19.74
ATOM	CG	TYR	H	56	74.749	29.308	11.084	1.00	18.86
ATOM	CG1	TYR	H	56	74.608	28.034	10.554	1.00	19.13
ATOM	CE1	TYR	H	56	75.211	26.947	11.141	1.00	19.36
ATOM	CD2	TYR	H	56	75.522	29.462	12.227	1.00	14.87
ATOM	CE2	TYR	H	56	76.127	28.379	12.821	1.00	15.48
ATOM	CZ	TYR	H	56	75.971	27.126	12.281	1.00	17.68
ATOM	OH	TYR	H	56	76.565	26.031	12.868	1.00	20.54
ATOM	C	TYR	H	56	73.736	32.071	8.662	1.00	22.36
ATOM	O	TYR	H	56	73.833	33.228	9.047	1.00	22.95
ATOM	N	ASN	H	57	72.780	31.643	7.849	1.00	24.93
ATOM	CA	ASN	H	57	71.742	32.543	7.357	1.00	27.64
ATOM	CB	ASN	H	57	70.862	31.833	6.315	1.00	28.33
ATOM	CG	ASN	H	57	69.825	32.756	5.693	1.00	29.14
ATOM	OD1	ASN	H	57	68.986	33.312	6.385	1.00	31.07
ATOM	ND2	ASN	H	57	69.874	32.909	4.386	1.00	29.86
ATOM	C	ASN	H	57	70.929	32.879	8.617	1.00	27.04
ATOM	O	ASN	H	57	70.524	31.981	9.357	1.00	23.79
ATOM	N	PRO	H	58	70.762	34.176	8.921	1.00	28.56
ATOM	CD	PRO	H	58	71.297	35.280	8.113	1.00	28.44
ATOM	CA	PRO	H	58	70.025	34.708	10.077	1.00	29.68
ATOM	CB	PRO	H	58	70.043	36.205	9.816	1.00	31.68
ATOM	CG	PRO	H	58	71.336	36.388	9.102	1.00	32.72
ATOM	C	PRO	H	58	68.595	34.207	10.165	1.00	30.03
ATOM	O	PRO	H	58	68.138	33.842	11.241	1.00	32.06
ATOM	N	SER	H	59	67.902	34.203	9.028	1.00	30.81
ATOM	CA	SER	H	59	66.521	33.739	8.924	1.00	33.61
ATOM	CB	SER	H	59	66.045	33.796	7.464	1.00	33.98
ATOM	OG	SER	H	59	66.414	35.012	6.825	1.00	42.18
ATOM	C	SER	H	59	66.398	32.292	9.371	1.00	34.64
ATOM	O	SER	H	59	65.354	31.878	9.882	1.00	37.21
ATOM	N	LEU	H	60	67.461	31.521	9.142	1.00	34.74
ATOM	CA	LEU	H	60	67.485	30.100	9.463	1.00	33.58
ATOM	CB	LEU	H	60	67.896	29.314	8.205	1.00	32.72
ATOM	CG	LEU	H	60	66.922	28.895	7.093	1.00	34.81
ATOM	CD1	LEU	H	60	65.565	29.513	7.313	1.00	36.52
ATOM	CD2	LEU	H	60	67.479	29.259	5.716	1.00	30.66
ATOM	C	LEU	H	60	68.406	29.661	10.606	1.00	34.55
ATOM	O	LEU	H	60	68.276	28.523	11.082	1.00	32.36
ATOM	N	LYS	H	61	69.321	30.539	11.062	1.00	35.17
ATOM	CA	LYS	H	61	70.2	2	30.163	12.092	1.00 35.08
ATOM	CB	LYS	H	61	70.959	31.376	12.750	1.00	36.66
ATOM	CG	LYS	H	61	72.030	30.921	13.748	1.00	42.58
ATOM	CD	LYS	H	61	72.964	32.023	14.233	1.00	47.58
ATOM	CE	LYS	H	61	74.154	31.417	15.007	1.00	48.86
ATOM	NZ	LYS	H	61	75.157	32.426	15.480	1.00	51.14
ATOM	C	LYS	H	61	69.830	29.172	13.163	1.00	34.17
ATOM	O	LYS	H	61	70.520	28.174	13.423	1.00	29.94
ATOM	N	SER	H	62	68.646	29.426	13.726	1.00	30.94
ATOM	CA	SER	H	62	68.051	28.597	14.770	1.00	28.25
ATOM	CB	SER	H	62	66.650	29.117	15.072	1.00	30.62
ATOM	CG	SER	H	62	65.918	29.317	13.866	1.00	33.57

TABLE 2-continued

		Atom A.A.			X	Y	Z	Occ	B
		Type							
ATOM	C	SER	H	62	67.946	27.110	14.440	1.00	28.84
ATOM	O	SER	H	62	68.078	26.252	15.317	1.00	28.71
ATOM	N	ARG	H	63	67.708	26.807	13.171	1.00	26.01
ATOM	CA	ARG	H	63	67.528	25.432	12.743	1.00	23.24
ATOM	CB	ARG	H	63	66.394	25.407	11.739	1.00	24.03
ATOM	CG	ARG	H	63	65.149	26.109	12.252	1.00	27.07
ATOM	CD	ARG	H	63	64.142	26.336	11.146	1.00	30.24
ATOM	NE	ARG	H	63	63.910	25.102	10.417	1.00	29.49
ATOM	CZ	ARG	H	63	63.630	25.049	9.127	1.00	24.96
ATOM	NH1	ARG	H	63	63.535	26.166	8.415	1.00	23.27
ATOM	ND2	ARG	H	63	63.471	23.873	8.556	1.00	24.48
ATOM	C	ARG	H	63	68.741	24.751	12.145	1.00	22.40
ATOM	O	ARG	H	63	68.731	23.546	11.929	1.00	21.50
ATOM	N	LEU	H	64	69.804	25.518	11.941	1.00	22.16
ATOM	CA	LEU	H	64	71.023	25.034	11.296	1.00	21.65
ATOM	CB	LEU	H	64	71.466	26.058	10.243	1.00	19.30
ATOM	CG	LEU	H	64	70.890	26.155	8.832	1.00	20.78
ATOM	CD1	LEU	H	64	69.545	25.524	8.719	1.00	20.71
ATOM	CD2	LEU	H	64	70.879	27.617	8.396	1.00	15.66
ATOM	C	LEU	H	64	72.234	24.732	12.156	1.00	19.31
ATOM	O	LEU	H	64	72.564	25.472	13.070	1.00	20.05
ATOM	N	THR	H	65	72.941	23.676	11.785	1.00	19.59
ATOM	CA	THR	H	65	74.185	23.294	12.442	1.00	20.65
ATOM	CB	THR	H	65	73.998	22.193	13.493	1.00	20.20
ATOM	OG1	THR	H	65	72.990	22.595	14.428	1.00	24.09
ATOM	CG2	THR	H	65	75.315	21.946	14.225	1.00	19.32
ATOM	C	THR	H	65	75.144	22.768	11.378	1.00	19.21
ATOM	O	THR	H	65	74.857	21.778	10.702	1.00	21.02
ATOM	N	ILE	H	66	76.262	23.452	11.204	1.00	19.16
ATOM	CA	ILE	H	66	77.254	23.021	10.240	1.00	17.30
ATOM	CB	ILE	H	66	77.546	24.145	9.217	1.00	16.44
ATOM	CG2	ILE	H	66	78.223	25.316	9.884	1.00	17.96
ATOM	CG1	ILE	H	66	78.367	23.611	8.048	1.00	16.66
ATOM	CD1	ILE	H	66	78.283	24.492	6.803	1.00	16.98
ATOM	C	ILE	H	66	78.509	22.541	10.984	1.00	17.84
ATOM	O	ILE	H	66	78.856	23.062	12.040	1.00	18.17
ATOM	N	SER	H	67	79.131	21.486	10.482	1.00	18.11
ATOM	CA	SER	H	67	80.321	20.948	11.105	1.00	20.14
ATOM	CB	SER	H	67	79.934	19.982	12.222	1.00	19.34
ATOM	OG	SER	H	67	79.148	18.916	11.722	1.00	22.34
ATOM	C	SER	H	67	81.129	20.235	10.042	1.00	21.51
ATOM	O	SER	H	67	80.617	19.939	8.963	1.00	23.77
ATOM	N	LYS	H	68	82.389	19.945	10.326	1.00	22.37
ATOM	CA	LYS	H	68	83.220	19.276	9.337	1.00	24.76
ATOM	CB	LYS	H	68	84.170	20.268	8.653	1.00	24.88
ATOM	CG	LYS	H	68	85.243	20.860	9.600	1.00	26.98
ATOM	CD	LYS	H	68	86.178	21.863	8.913	1.00	24.59
ATOM	CE	LYS	H	68	87.077	22.575	9.923	1.00	25.04
ATOM	NZ	LYS	H	68	87.950	21.660	10.691	1.00	22.91
ATOM	C	LYS	H	68	84.065	18.220	9.995	1.00	2.60
ATOM	O	LYS	H	68	84.222	18.194	11.211	1.00	26.90
ATOM	N	ASP	H	69	84.609	17.350	9.162	1.00	30.57
ATOM	CA	ASP	H	69	85.497	16.301	9.603	1.00	32.63
ATOM	CB	ASP	H	69	84.751	14.987	9.808	1.00	32.99
ATOM	CG	ASP	H	69	85.630	13.919	10.414	1.00	34.81
ATOM	OD1	ASP	H	69	85.157	13.155	11.274	1.00	36.75
ATOM	OD2	ASP	H	69	86.800	13.839	10.027	1.00	31.40
ATOM	C	ASP	H	69	86.530	16.184	8.487	1.00	34.03
ATOM	O	ASP	H	69	86.370	15.392	7.547	1.00	32.76
ATOM	N	THR	H	70	87.571	17.008	8.594	1.00	36.91
ATOM	CA	THR	H	70	88.660	17.047	7.624	1.00	38.63
ATOM	CB	THR	H	70	89.797	17.966	8.100	1.00	37.90
ATOM	OG1	THR	H	70	89.244	19.134	8.721	1.00	40.53
ATOM	CG2	THR	H	70	90.630	18.400	6.924	1.00	41.19
ATOM	C	THR	H	70	89.193	15.640	7.441	1.00	39.84
ATOM	O	THR	H	70	89.470	15.209	6.323	1.00	40.13
ATOM	N	SER	H	71	89.243	14.904	8.546	1.00	40.90
ATOM	CA	SER	H	71	89.711	13.526	8.543	1.00	42.40
ATOM	CB	SER	H	71	89.550	12.917	9.938	1.00	42.28
ATOM	OG	SER	H	71	89.247	13.928	10.895	1.00	46.77
ATOM	C	SER	H	71	88.900	12.714	7.539	1.00	42.54
ATOM	O	SER	H	71	89.441	11.844	6.858	1.00	45.17
ATOM	N	LYS	H	72	87.610	13.028	7.429	1.00	39.45
ATOM	CA	LYS	H	72	86.728	12.317	6.517	1.00	36.17
ATOM	CB	LYS	H	72	85.4.5	411.88	67.253	1.00	35.09
ATOM	C	LYS	H	72	86.394	13.122	5.253	1.00	34.32

TABLE 2-continued

		Atom A.A.			X	Y	Z	Occ	B
		Type							
ATOM	O	LYS	H	72	85.624	12.670	4.404	1.00	36.05
ATOM	N	ASN	H	73	86.985	14.303	5.110	1.00	30.90
ATOM	CA	ASN	H	73	86.725	15.122	3.935	1.00	28.57
ATOM	CB	ASN	H	73	87.339	14.479	2.698	1.00	30.95
ATOM	CG	ASN	H	73	88.753	14.930	2.459	1.00	32.43
ATOM	OD1	ASN	H	73	89.410	15.448	3.356	1.00	33.76
ATOM	ND2	ASN	H	73	89.217	14.781	1.231	1.00	33.57
ATOM	C	ASN	H	73	85.235	15.368	3.706	1.00	27.51
ATOM	O	ASN	H	73	84.723	15.252	2.581	1.00	24.45
ATOM	N	GLN	H	74	84.535	15.700	4.783	1.00	26.55
ATOM	CA	GLN	H	74	83.120	15.977	4.680	1.00	25.83
ATOM	CB	GLN	H	74	82.305	14.693	4.841	1.00	27.06
ATOM	CG	GLN	H	74	82.244	14.191	6.232	1.00	29.34
ATOM	CD	GLN	H	74	81.624	12.830	6.295	1.00	32.28
ATOM	OE1	GLN	H	74	81.764	12.043	5.367	1.00	29.45
ATOM	NE2	GLN	H	74	80.935	12.535	7.398	1.00	32.68
ATOM	C	GLN	H	74	82.649	17.068	5.638	1.00	23.47
ATOM	O	GLN	H	74	83.254	17.328	6.684	1.00	19.87
ATOM	N	VAL	H	75	81.633	17.784	5.185	1.00	20.78
ATOM	CA	VAL	H	75	81.016	18.858	5.934	1.00	18.65
ATOM	CG	VAL	H	75	81.073	20.188	5.119	1.00	19.56
ATOM	CG1	VAL	H	75	80.267	21.297	5.808	1.00	17.72
ATOM	CG2	VAL	H	75	82.528	20.639	4.948	1.00	16.40
ATOM	C	VAL	H	75	79.583	18.378	6.069	1.00	17.42
ATOM	O	VAL	H	75	79.042	17.751	5.185	1.00	18.13
ATOM	N	VAL	H	76	78.982	18.619	7.242	1.00	17.43
ATOM	CA	VAL	H	76	77.615	18.177	7.491	1.00	17.51
ATOM	CB	VAL	H	76	77.579	17.122	8.652	1.00	18.76
ATOM	CG1	VAL	H	76	76.140	16.849	9.115	1.00	16.58
ATOM	CG2	VAL	H	76	78.239	15.822	8.202	1.00	16.10
ATOM	C	VAL	H	76	76.753	19.363	7.872	1.00	16.23
ATOM	O	VAL	H	76	77.217	20.261	8.559	1.00	16.73
ATOM	N	LEU	H	77	75.523	19.387	7.375	1.00	15.92
ATOM	CA	LEU	H	77	74.573	20.441	7.701	1.00	17.74
ATOM	CB	LEU	H	77	74.182	21.259	6.454	1.00	17.08
ATOM	CG	LEU	H	77	73.669	22.718	6.499	1.00	18.21
ATOM	CD1	LEU	H	77	72.305	22.832	5.904	1.00	18.50
ATOM	CD2	LEU	H	77	73.717	23.340	7.886	1.00	20.05
ATOM	C	LEU	H	77	73.347	19.700	8.233	1.00	19.52
ATOM	O	LEU	H	77	72.890	18.745	7.606	1.00	18.14
ATOM	N	LYS	H	78	72.894	20.072	9.432	1.00	19.66
ATOM	CA	LYS	H	78	71.709	19.478	10.039	1.00	21.64
ATOM	CB	LYS	H	78	72.019	18.898	11.420	1.00	24.63
ATOM	CG	LYS	H	78	72.773	17.585	11.372	1.00	29.51
ATOM	CD	LYS	H	78	72.910	17.009	12.771	1.00	35.12
ATOM	CE	LYS	H	78	73.805	15.761	12.808	1.00	38.85
ATOM	NZ	LYS	H	78	73.139	14.504	12.308	1.00	43.57
ATOM	C	LYS	H	78	70.667	20.580	10.147	1.00	18.69
ATOM	O	LYS	H	78	70.941	21.647	10.687	1.00	21.34
ATOM	N	VAL	H	79	69.498	20.338	9.573	1.00	18.22
ATOM	CA	VAL	H	79	68.408	21.305	9.561	1.00	17.88
ATOM	CB	VAL	H	79	67.869	21.543	8.126	1.00	15.85
ATOM	CG1	VAL	H	79	66.903	22.712	8.117	1.00	18.65
ATOM	CG2	VAL	H	79	69.058	21.782	7.149	1.00	13.37
ATOM	C	VAL	H	79	67.288	20.688	10.373	1.00	19.10
ATOM	O	VAL	H	79	66.766	19.628	10.020	1.00	19.43
ATOM	N	THR	H	80	66.910	21.343	11.455	1.00	20.81
ATOM	CA	THR	H	80	65.866	20.808	12.315	1.00	21.37
ATOM	CB	THR	H	80	66.162	21.141	13.782	1.00	17.57
ATOM	OG1	THR	H	80	66.408	22.543	13.898	1.00	20.71
ATOM	CG2	THR	H	80	67.380	20.380	14.248	1.00	21.24
ATOM	C	THR	H	80	64.476	21.295	11.945	1.00	18.46
ATOM	O	THR	H	80	64.323	22.234	11.161	1.00	18.70
ATOM	N	ASN	H	81	63.480	20.594	12.471	1.00	19.47
ATOM	CA	ASN	H	81	62.081	20.917	12.263	1.00	20.71
ATOM	CB	ASN	H	81	61.693	22.053	13.203	1.00	23.15
ATOM	CG	ASN	H	81	60.208	22.296	13.243	1.00	26.34
ATOM	OD1	ASN	H	81	59.409	21.384	13.099	1.00	28.57
ATOM	ND2	ASN	H	81	59.830	23.541	13.429	1.00	28.83
ATOM	C	ASN	H	81	61.728	21.235	10.800	1.00	20.55
ATOM	O	ASN	H	81	61.222	22.316	10.475	1.00	18.95
ATOM	N	MET	H	82	61.995	20.268	9.925	1.00	19.37
ATOM	CA	MET	H	82	61.731	20.396	8.500	1.00	19.90
ATOM	CB	MET	H	82	62.119	19.104	7.775	1.00	20.79
ATOM	CG	MET	H	82	63.643	18.886	7.651	1.00	19.47
ATOM	SD	MET	H	82	64.499	20.227	6.746	1.00	21.79

TABLE 2-continued

		Atom A.A.		X	Y	Z	Occ	B
	Type							
ATOM	CE	MET	H	82	64.228	19.776	5.039	1.00 15.01
ATOM	C	MET	H	82	60.276	20.755	8.216	1.00 22.71
ATOM	O	MET	H	82	59.360	20.168	8.793	1.00 24.24
ATOM	N	ASP	H	83	60.080	21.683	7.284	1.00 22.76
ATOM	CA	ASP	H	83	58.759	22.184	6.888	1.00 23.77
ATOM	CB	ASP	H	83	58.714	23.696	7.144	1.00 25.06
ATOM	CG	ASP	H	83	57.367	24.298	6.842	1.00 28.59
ATOM	OD1	ASP	H	83	56.478	24.190	7.701	1.00 32.41
ATOM	OD2	ASP	H	83	57.178	24.852	5.742	1.00 29.90
ATOM	C	ASP	H	83	58.596	21.944	5.395	1.00 22.22
ATOM	O	ASP	H	83	59.590	21.841	4.699	1.00 23.36
ATOM	N	PRO	H	84	57.350	21.834	4.882	1.00 20.50
ATOM	CD	PRO	H	84	56.066	21.715	5.600	1.00 20.73
ATOM	CA	PRO	H	84	57.143	21.619	3.446	1.00 18.92
ATOM	CB	PRO	H	84	55.641	21.822	3.305	1.00 18.31
ATOM	CG	PRO	H	84	55.129	21.194	4.526	1.00 18.56
ATOM	C	PRO	H	84	57.916	22.652	2.619	1.00 19.61
ATOM	O	PRO	H	84	58.437	22.349	1.553	1.00 20.74
ATOM	N	ALA	H	85	58.004	23.872	3.132	1.00 19.68
ATOM	CA	ALA	H	85	58.720	24.946	2.465	1.00 21.18
ATOM	CB	ALA	H	85	58.457	26.256	3.166	1.00 22.00
ATOM	C	ALA	H	85	60.235	24.709	2.362	1.00 22.08
ATOM	O	ALA	H	85	60.949	25.498	1.735	1.00 24.05
ATOM	N	ASP	H	86	60.740	23.682	3.032	1.00 18.30
ATOM	CA	ASP	H	86	62.152	23.379	2.952	1.00 17.61
ATOM	CB	ASP	H	86	62.664	22.784	4.262	1.00 16.88
ATOM	CG	ASP	H	86	62.547	23.752	5.417	1.00 22.66
ATOM	OD1	ASP	H	86	62.032	23.343	6.483	1.00 19.55
ATOM	OD2	ASP	H	86	62.954	24.932	5.257	1.00 24.22
ATOM	C	ASP	H	86	62.415	22.421	1.791	1.00 17.63
ATOM	O	ASP	H	86	63.568	22.018	1.574	1.00 17.70
ATOM	N	THR	H	87	61.360	22.018	1.074	1.00 15.36
ATOM	CA	THR	H	87	61.526	21.122	-0.066	1.00 14.35
ATOM	CB	THR	H	87	60.183	20.740	-0.680	1.00 13.84
ATOM	OG1	THR	H	87	59.454	19.945	0.257	1.00 15.44
ATOM	CG2	THR	H	87	60.387	19.913	-1.948	1.00 15.26
ATOM	C	THR	H	87	62.370	21.895	-1.069	1.00 15.26
ATOM	O	THR	H	87	62.031	23.023	-1.444	1.00 12.69
ATOM	N	ALA	H	88	63.507	21.317	-1.446	1.00 16.68
ATOM	CA	ALA	H	88	64.422	21.994	-2.352	1.00 16.96
ATOM	CB	ALA	H	88	64.946	23.281	-1.663	1.00 15.82
ATOM	C	ALA	H	88	65.	01	21.115	-2.711 1.00 0
								15.92
ATOM	O	ALA	H	88	65.736	19.998	-2.218	1.00 15.04
ATOM	N	THR	H	89	66.429	21.627	-3.610	1.00 14.79
ATOM	CA	THR	H	89	67.655	20.971	-4.010	1.00 14.63
ATOM	CB	THR	H	89	67.923	21.180	-5.485	1.00 15.26
ATOM	OG1	THR	H	89	66.989	20.403	-6.232	1.00 17.61
ATOM	CG2	THR	H	89	69.360	20.774	-5.854	1.00 13.56
ATOM	C	THR	H	89	68.738	21.675	-3.190	1.00 14.21
ATOM	O	THR	H	89	68.802	22.907	-3.156	1.00 14.78
ATOM	N	TYR	H	90	69.651	20.894	-2.494	1.00 15.66
ATOM	CA	TYR	H	90	70.605	21.418	-1.638	1.00 13.86
ATOM	CB	TYR	H	90	70.527	20.751	-0.254	1.00 12.67
ATOM	CG	TYR	H	90	69.304	21.132	0.547	1.00 11.49
ATOM	CD1	TYR	H	90	68.035	20.632	0.227	1.00 12.32
ATOM	CE1	TYR	H	90	66.907	21.050	0.926	1.00 12.25
ATOM	CD2	TYR	H	90	69.405	22.037	1.585	1.00 8.94
ATOM	CE2	TYR	H	90	68.293	22.458	2.286	1.00 13.05
ATOM	CZ	TYR	H	90	67.053	21.967	1.951	1.00 13.38
ATOM	OH	TYR	H	90	65.981	22.433	2.651	1.00 16.83
ATOM	C	TYR	H	90	71.966	21.156	-2.262	1.00 14.93
ATOM	O	TYR	H	90	72.273	20.023	-2.664	1.00 12.21
ATOM	N	TYR	H	91	72.778	22.211	-2.319	1.00 14.42
ATOM	CA	TYR	H	91	74.122	22.158	-2.893	1.00 13.29
ATOM	CB	TYR	H	91	74.260	23.169	-4.047	1.00 13.73
ATOM	CG	TYR	H	91	73.312	23.032	-5.214	1.00 15.62
ATOM	CD1	TYR	H	91	72.169	23.826	-5.309	1.00 17.17
ATOM	CE1	TYR	H	91	71.343	23.766	-6.438	1.00 17.39
ATOM	CD2	TYR	H	91	73.600	22.168	-6.271	1.00 14.12
ATOM	CE2	TYR	H	91	72.774	22.102	-7.402	1.00 14.64
ATOM	CZ	TYR	H	91	71.662	22.899	-7.471	1.00 17.01
ATOM	OH	TYR	H	91	70.867	22.826	-8.572	1.00 19.82
ATOM	C	TYR	H	91	75.189	22.562	-1.881	1.00 11.93
ATOM	O	TYR	H	91	74.949	23.392	-1.016	1.00 11.94
ATOM	N	CYS	H	92	76.375	21.990	-1.989	1.00 12.26

TABLE 2-continued

		Atom A.A.			X	Y	Z	Occ	B
		Type							
ATOM	CA	CYS	H	92	77.470	22.439	-1.144	1.00	12.39
ATOM	C	CYS	H	92	78.467	22.930	-2.191	1.00	13.50
ATOM	O	CYS	H	92	78.452	22.480	-3.358	1.00	11.63
ATOM	CB	CYS	H	92	78.043	21.338	-0.249	1.00	12.10
ATOM	SG	CYS	H	92	78.729	19.877	-1.079	1.00	15.31
ATOM	N	ALA	H	93	79.242	23.935	-1.826	1.00	14.24
ATOM	CA	ALA	H	93	80.178	24.503	-2.755	1.00	15.22
ATOM	CB	ALA	H	93	79.506	25.690	-3.505	1.00	12.31
ATOM	C	ALA	H	93	81.456	24.952	-2.051	1.00	15.72
ATOM	O	ALA	H	93	81.436	25.311	-0.872	1.00	14.75
ATOM	N	ARG	H	94	82.559	24.936	-2.795	1.00	16.63
ATOM	CA	ARG	H	94	83.849	25.353	-2.268	1.00	15.90
ATOM	CB	ARG	H	94	84.963	24.513	-2.909	1.00	15.45
ATOM	CG	ARG	H	94	86.371	24.681	-2.281	1.00	13.98
ATOM	CD	ARG	H	94	87.148	25.873	-2.794	1.00	13.40
ATOM	NE	ARG	H	94	87.492	25.804	-4.213	1.00	16.03
ATOM	CZ	ARG	H	94	88.506	25.108	-4.717	1.00	18.37
ATOM	NH1	ARG	H	94	89.289	24.390	-3.932	1.00	18.16
ATOM	NH2	ARG	H	94	88.783	25.180	-6.006	1.00	18.51
ATOM	C	ARG	H	94	84.089	26.850	-2.519	1.00	13.99
ATOM	O	ARG	H	94	83.743	27.379	-3.576	1.00	13.67
ATOM	N	SER	H	95	84.679	27.521	-1.536	1.00	16.14
ATOM	CA	SER	H	95	85.011	28.939	-1.639	1.00	15.68
ATOM	CB	SER	H	95	84.065	29.810	-0.780	1.00	15.30
ATOM	OG	SER	H	95	82.715	29.760	-1.213	1.00	13.60
ATOM	C	SER	H	95	86.451	29.119	-1.144	1.00	15.90
ATOM	O	SER	H	95	86.965	28.290	-0.372	1.00	15.38
ATOM	N	MET	H	96	87.095	30.191	-1.599	1.00	17.08
ATOM	CA	MET	H	96	88.465	30.527	-1.201	1.00	19.15
ATOM	CB	MET	H	96	89.439	30.332	-2.370	1.00	19.64
ATOM	CG	MET	H	96	89.701	28.849	-2.678	1.00	25.79
ATOM	SD	MET	H	96	90.549	28.511	-4.238	1.00	29.25
ATOM	CE	MET	H	96	91.543	27.150	-3.780	1.00	30.33
ATOM	C	MET	H	96	88.418	31.977	-0.727	1.00	16.53
ATOM	O	MET	H	96	88.319	32.907	-1.522	1.00	17.07
ATOM	N	ILE	H	97	88.419	32.128	0.593	1.00	16.76
ATOM	CA	ILE	H	97	88.320	33.415	1.268	1.00	14.34
ATOM	CB	ILE	H	97	88.410	33.245	2.802	1.00	13.83
ATOM	CG2	ILE	H	97	88.001	34.513	3.491	1.00	10.54
ATOM	CG1	ILE	H	97	87.524	32.085	3.272	1.00	16.40
ATOM	CD1	ILE	H	97	86.055	32.197	2.875	1.00	16.82
ATOM	C	ILE	H	97	89.381	34.388	0.774	1.00	15.53
ATOM	O	ILE	H	97	90.555	34.047	0.695	1.00	6.36
ATOM	N	THR	H	98	88.917	35.599	0.466	1.00	14.74
ATOM	CA	THR	H	98	89.661	36.739	-0.068	1.00	12.35
ATOM	CB	THR	H	98	90.976	37.091	0.680	1.00	10.22
ATOM	OG1	THR	H	98	92.000	36.156	0.326	1.00	10.30
ATOM	CG2	THR	H	98	90.766	37.122	2.191	1.00	7.62
ATOM	C	THR	H	98	89.923	36.565	-1.556	1.00	13.74
ATOM	O	THR	H	98	90.549	37.415	-2.187	1.00	17.87
ATOM	N	ASN	H	99	89.402	35.481	-2.124	1.00	14.64
ATOM	CA	ASN	H	99	89.551	35.205	-3.541	1.00	15.20
ATOM	CB	ASN	H	99	90.448	33.998	-3.760	1.00	16.40
ATOM	CG	ASN	H	99	91.902	34.344	-3.591	1.00	17.20
ATOM	OD1	ASN	H	99	92.388	35.290	-4.214	1.00	15.38
ATOM	ND2	ASN	H	99	92.594	33.626	-2.720	1.00	15.23
ATOM	C	ASN	H	99	88.213	35.049	-4.259	1.00	17.88
ATOM	O	ASN	H	99	87.855	35.899	-5.083	1.00	18.92
ATOM	N	TRP	H	100	87.441	34.017	-3.928	1.00	17.14
ATOM	CA	TRP	H	100	86.145	33.834	-4.591	1.00	18.19
ATOM	CB	TRP	H	100	86.341	33.387	-6.047	1.00	19.31
ATOM	CG	TRP	H	100	87.406	32.345	-6.185	1.00	19.32
ATOM	CD2	TRP	H	100	88.710	32.538	-6.722	1.00	19.62
ATOM	CE2	TRP	H	100	89.396	31.306	-6.597	1.00	22.56
ATOM	CE3	TRP	H	100	89.373	33.635	-7.294	1.00	17.80
ATOM	CD1	TRP	H	100	87.343	31.044	-5.773	1.00	19.51
ATOM	NE1	TRP	H	100	88.531	30.415	-6.011	1.00	21.48
ATOM	CZ2	TRP	H	100	90.729	31.131	-7.027	1.00	21.08
ATOM	CZ3	TRP	H	100	90.690	33.470	-7.722	1.00	20.58
ATOM	CH2	TRP	H	100	91.356	32.218	-7.583	1.00	23.10
ATOM	C	TRP	H	100	85.183	32.874	-3.908	1.00	16.39
ATOM	O	TRP	H	100	85.584	31.928	-3.245	1.00	15.36
ATOM	N	TYR	H	100A	83.901	33.129	-4.105	1.00	15.37
ATOM	CA	TYR	H	100	82.862	32.289	-3.555	1.00	16.59
ATOM	CB	TYR	H	100	81.656	33.136	-3.135	1.00	16.72
ATOM	CG	TYR	H	100	81.746	33.717	-1.749	1.00	22.50

TABLE 2-continued

		Atom A.A.		X	Y	Z	Occ	B	
	Type								
ATOM	CD1	TYR	H	100	81.600	35.098	-1.553	1.00	23.43
ATOM	CE1	TYR	H	100	81.645	35.637	-0.273	1.00	22.21
ATOM	CD2	TYR	H	100	81.744	32.883	-0.626	1.00	24.26
ATOM	CE2	TYR	H	100	81.793	33.405	0.659	1.00	27.56
ATOM	CZ	TYR	H	100	81.840	34.783	0.829	1.00	29.81
ATOM	OH	TYR	H	100	81.860	35.292	2.103	1.00	34.18
ATOM	C	TYR	H	100	82.385	31.279	-4.587	1.00	14.72
ATOM	O	TYR	H	100	82.272	31.596	-5.772	1.00	14.44
ATOM	N	PHE	H	100B	82.115	30.070	-4.118	1.00	14.18
ATOM	CA	PHE	H	100	81.552	28.985	-4.923	1.00	15.04
ATOM	CB	PHE	H	100	80.018	29.135	-4.968	1.00	11.93
ATOM	CG	PHE	H	100	79.433	29.732	-3.719	1.00	10.44
ATOM	CD1	PHE	H	100	78.547	30.789	-3.798	1.00	12.27
ATOM	CD2	PHE	H	100	79.803	29.258	-2.469	1.00	10.01
ATOM	CE1	PHE	H	100	78.027	31.378	-2.647	1.00	14.34
ATOM	CE2	PHE	H	100	79.304	29.823	-1.308	1.00	10.04
ATOM	CZ	PHE	H	100	78.411	30.889	-1.386	1.00	13.85
ATOM	C	PHE	H	100	82.095	28.814	-6.341	1.00	16.03
ATOM	O	PHE	H	100	81.350	28.924	-7.316	1.00	16.54
ATOM	N	ASP	H	101	83.381	28.510	-6.459	1.00	15.78
ATOM	CA	ASP	H	101	83.966	28.305	-7.776	1.00	17.03
ATOM	CB	ASP	H	101	85.467	28.643	-7.788	1.00	16.29
ATOM	CG	ASP	H	101	86.280	27.761	-6.876	1.00	17.74
ATOM	OD1	ASP	H	101	87.419	27.421	-7.233	1.00	23.19
ATOM	OD2	ASP	H	101	85.815	27.429	-5.782	1.00	18.97
ATOM	C	ASP	H	101	83.710	26.868	-8.224	1.00	17.89
ATOM	O	ASP	H	101	83.770	26.569	-9.414	1.00	18.15
ATOM	N	VAL	H	102	83.420	25.977	-7.277	1.00	16.57
ATOM	CA	VAL	H	102	83.120	24.589	-7.613	1.00	18.26
ATOM	CB	VAL	H	102	84.332	23.662	-7.370	1.00	17.45
ATOM	CG1	VAL	H	102	84.069	22.280	-7.969	1.00	15.35
ATOM	CG2	VAL	H	102	85.804	24.285	-7.957	1.00	16.60
ATOM	C	VAL	H	102	81.940	24.118	-6.753	1.00	18.17
ATOM	O	VAL	H	102	81.984	24.245	-5.532	1.00	19.18
ATOM	N	TRP	H	103	80.908	23.565	-7.392	1.00	17.66
ATOM	CA	TRP	H	103	79.695	23.070	-6.714	1.00	16.97
ATOM	CB	TRP	H	103	78.450	23.733	-7.307	1.00	14.66
ATOM	CG	TRP	H	103	78.402	25.206	-7.217	1.00	13.16
ATOM	CD2	TRP	H	103	77.335	25.990	-6.683	1.00	13.16
ATOM	CE2	TRP	H	103	77.674	27.346	-6.885	1.00	11.97
ATOM	CE3	TRP	H	103	76.116	25.680	-6.053	1.00	14.23
ATOM	CG1	TRP	H	103	79.327	26.091	-7.698	1.00	12.35
ATOM	NE1	TRP	H	103	78.897	27.374	-7.503	1.00	10.43
ATOM	CZ2	TRP	H	103	76.839	28.396	-6.485	1.00	11.68
ATOM	CZ3	TRP	H	103	75.287	26.723	-5.652	1.00	12.59
ATOM	CH2	TRP	H	103	75.652	28.066	-5.870	1.00	12.82
ATOM	C	TRP	H	103	79.470	21.562	-6.876	1.00	18.07
ATOM	O	TRP	H	103	79.944	20.953	-7.839	1.00	19.15
ATOM	N	GLY	H	104	78.716	20.973	-5.950	1.00	16.51
ATOM	CA	GLY	H	104	78.372	19.568	-6.057	1.00	15.81
ATOM	C	GLY	H	104	77.235	19.521	-7.080	1.00	17.22
ATOM	O	GLY	H	104	76.809	20.561	-7.578	1.00	16.55
ATOM	N	ALA	H	105	76.699	18.340	-7.373	1.00	18.21
ATOM	CA	ALA	H	105	75.623	18.238	-8.359	1.00	15.09
ATOM	CB	ALA	H	105	75.555	16.842	-8.906	1.00	17.38
ATOM	C	ALA	H	105	74.283	18.634	-7.752	1.00	15.46
ATOM	O	ALA	H	105	73.356	19.008	-8.470	1.00	15.25
ATOM	N	GLY	H	106	74.202	18.570	-6.425	1.00	13.51
ATOM	CA	GLY	H	106	72.984	18.921	-5.713	1.00	14.41
ATOM	C	GLY	H	106	72.153	17.692	-5.417	1.00	14.89
ATOM	O	GLY	H	106	72.152	16.742	-6.204	1.00	16.09
ATOM	N	THR	H	107	71.498	17.668	-4.261	1.00	15.25
ATOM	CA	THR	H	107	70.647	16.531	-3.907	1.00	12.89
ATOM	CB	THR	H	107	71.260	15.655	-2.764	1.00	12.03
ATOM	OG1	THR	H	107	70.529	14.434	-2.627	1.00	14.85
ATOM	CG2	THR	H	107	71.265	16.380	-1.449	1.00	14.04
ATOM	C	THR	H	107	69.269	17.071	-3.563	1.00	13.69
ATOM	O	THR	H	107	69.136	18.102	-2.898	1.00	12.77
ATOM	N	THR	H	108	68.251	16.402	-4.094	1.00	14.91
ATOM	CA	THR	H	108	66.861	16.767	-3.896	1.00	14.31
ATOM	CB	THR	H	108	65.998	16.259	-5.054	1.00	16.49
ATOM	OG1	THR	H	108	66.604	16.644	-6.288	1.00	23.43
ATOM	CG2	THR	H	108	64.614	16.876	-5.002	1.00	18.43
ATOM	C	THR	H	108	66.287	16.220	-2.598	1.00	13.70
ATOM	O	THR	H	108	66.414	15.027	-2.291	1.00	11.70
ATOM	N	VAL	H	109	65.670	17.119	-1.836	1.00	12.30

TABLE 2-continued

		Atom A.A.			X	Y	Z	Occ	B
		Type							
ATOM	CA	VAL	H	109	65.026	16.784	-0.582	1.00	14.43
ATOM	CB	VAL	H	109	65.729	17.472	0.619	1.00	14.88
ATOM	CG1	VAL	H	109	65.026	17.122	1.920	1.00	13.86
ATOM	CG2	VAL	H	109	67.193	17.060	0.672	1.00	10.78
ATOM	C	VAL	H	109	63.568	17.258	-0.672	1.00	16.33
ATOM	O	VAL	H	109	63.292	18.397	-1.089	1.00	16.26
ATOM	N	THR	H	110	62.645	16.340	-0.382	1.00	16.17
ATOM	CA	THR	H	110	61.216	16.641	-0.371	1.00	14.13
ATOM	CB	THR	H	110	60.426	15.726	-1.325	1.00	13.82
ATOM	OG1	THR	H	110	60.771	16.028	-2.678	1.00	10.99
ATOM	CG2	THR	H	110	58.529	15.931	-1.147	1.00	12.81
ATOM	C	THR	H	110	60.707	16.415	1.050	1.00	13.72
ATOM	O	THR	H	110	61.045	15.409	1.680	1.00	14.07
ATOM	N	VAL	H	111	59.395	17.404	1.585	1.00	14.52
ATOM	CA	VAL	H	111	59.414	17.308	2.913	1.00	22.91
ATOM	CB	VAL	H	111	59.539	18.632	3.659	1.00	13.54
ATOM	CG1	VAL	H	111	59.004	18.481	5.091	1.00	12.26
ATOM	CG2	VAL	H	111	61.003	19.060	3.675	1.00	12.73
ATOM	C	VAL	H	111	57.946	16.927	2.735	1.00	23.85
ATOM	O	VAL	H	111	57.115	17.748	2.328	1.00	12.86
ATOM	N	SER	H	112	57.635	15.664	3.000	1.00	13.52
ATOM	CA	SER	H	112	56.277	15.186	2.825	1.00	14.65
ATOM	CB	SER	H	112	56.067	14.741	1.369	1.00	13.71
ATOM	OG	SER	H	112	54.733	14.274	1.173	1.00	16.01
ATOM	C	SER	H	112	55.895	14.049	3.757	1.00	25.63
ATOM	O	SER	H	112	56.743	13.287	4.216	1.00	16.01
ATOM	N	SER	H	113	54.594	13.929	3.998	1.00	17.91
ATOM	CA	SER	H	113	54.044	12.883	4.851	1.00	19.30
ATOM	CB	SER	H	113	52.757	13.394	5.523	1.00	20.59
ATOM	OG	SER	H	113	52.993	14.594	6.251	1.00	22.75
ATOM	C	SER	H	113	53.763	11.611	4.016	1.00	18.16
ATOM	O	SER	H	113	53.570	10.527	4.555	1.00	19.67
ATOM	N	ALA	H	114	53.747	11.757	2.698	1.00	17.12
ATOM	CA	ALA	H	114	53.492	10.633	1.808	1.00	16.60
ATOM	CB	ALA	H	114	53.203	11.129	0.405	1.00	15.09
ATOM	C	ALA	H	114	54.709	9.708	1.809	1.00	17.50
ATOM	O	ALA	H	114	55.829	10.144	2.067	1.00	27.91
ATOM	N	SER	H	115	54.489	8.442	1.491	1.00	16.28
ATOM	CA	SER	H	115	55.570	7.478	1.489	1.00	19.52
ATOM	CB	SER	H	115	55.079	6.132	2.064	1.00	19.19
ATOM	OG	SER	H	115	54.606	5.275	1.047	1.00	27.19
ATOM	C	SER	H	115	56.242	7.290	0.127	1.00	18.16
ATOM	O	SER	H	115	55.718	7.698	-0.910	1.00	17.69
ATOM	N	THR	H	116	57.435	6.711	0.158	1.00	18.51
ATOM	CA	THR	H	116	58.225	6.436	-1.034	1.00	17.26
ATOM	CB	THR	H	116	59.628	5.914	-0.630	1.00	15.24
ATOM	OG1	THR	H	116	60.286	6.915	0.161	1.00	16.91
ATOM	CG2	THR	H	116	60.471	5.593	-1.848	1.00	10.10
ATOM	C	THR	H	116	57.514	5.381	-1.880	1.00	18.11
ATOM	O	THR	H	116	56.921	4.448	-1.334	1.00	17.85
ATOM	N	LYS	H	117	57.535	5.566	-3.202	1.00	15.14
ATOM	CA	LYS	H	117	56.928	4.625	-4.138	1.00	14.76
ATOM	CB	LYS	H	117	55.487	5.047	-4.448	1.00	11.84
ATOM	CG	LYS	H	117	54.753	4.082	-5.354	1.00	11.64
ATOM	CG	LYS	H	117	53.331	4.533	-5.609	1.00	13.39
ATOM	CE	LYS	H	117	52.618	3.541	-6.493	1.00	14.85
ATOM	NZ	LYS	H	117	52.517	2.187	-5.850	1.00	19.06
ATOM	C	LYS	H	117	57.774	4.596	-5.429	1.00	15.11
ATOM	O	LYS	H	117	58.127	5.650	-5.977	1.00	16.09
ATOM	N	GLY	H	118	58.155	3.400	-5.867	1.00	14.77
ATOM	CA	GLY	H	118	58.963	3.255	-7.067	1.00	13.25
ATOM	C	GLY	H	118	58.079	3.364	-8.279	1.00	13.95
ATOM	O	GLY	H	118	56.894	3.074	-8.202	1.00	16.47
ATOM	N	PRO	H	119	58.625	3.759	-9.426	1.00	15.62
ATOM	CG	PRO	H	119	60.035	4.122	-9.637	1.00	19.10
ATOM	CA	PRO	H	119	57.860	3.915	-10.664	1.00	15.67
ATOM	CB	PRO	H	119	58.772	4.812	-11.495	1.00	15.38
ATOM	CG	PRO	H	119	60.120	4.281	-11.169	1.00	16.10
ATOM	C	PRO	H	119	57.538	2.660	-11.451	1.00	14.47
ATOM	O	PRO	H	119	58.185	1.611	-11.304	1.00	14.94
ATOM	N	SER	H	120	56.558	2.791	-12.328	1.00	13.35
ATOM	CA	SER	H	120	56.178	1.714	-13.232	1.00	15.97
ATOM	CB	SER	H	120	54.668	1.481	-13.221	1.00	18.07
ATOM	OG	SER	H	120	54.260	0.992	-11.952	1.00	22.46
ATOM	C	SER	H	120	56.608	2.310	-14.556	1.00	14.66
ATOM	O	SER	H	120	56.604	3.525	-14.702	1.00	16.58

TABLE 2-continued

		Atom A.A.			X	Y	Z	Occ	B
		Type							
ATOM	N	VAL	H	121	57.044	1.486	-15.497	1.00	14.09
ATOM	CA	VAL	H	121	57.502	2.004	-16.775	1.00	15.16
ATOM	CB	VAL	H	121	59.038	1.826	-16.919	1.00	13.34
ATOM	CD1	VAL	H	121	59.524	2.468	-18.215	1.00	14.30
ATOM	CG2	VAL	H	121	59.755	2.411	-15.710	1.00	11.15
ATOM	C	VAL	H	121	56.753	1.298	-17.902	1.00	16.62
ATOM	O	VAL	H	121	56.621	0.064	-17.905	1.00	18.28
ATOM	N	PHE	H	122	56.211	2.086	-18.821	1.00	15.27
ATOM	CA	PHE	H	122	55.444	1.553	-19.935	1.00	16.26
ATOM	CB	PHE	H	122	53.971	1.986	-19.827	1.00	13.75
ATOM	CG	PHE	H	122	53.328	1.608	-18.525	1.00	17.83
ATOM	CD1	PHE	H	122	53.066	0.272	-18.225	1.00	16.34
ATOM	CD2	PHE	H	122	53.022	2.577	-17.578	1.00	17.41
ATOM	CE1	PHE	H	122	52.520	-0.088	-17.010	1.00	15.75
ATOM	CE2	PHE	H	122	52.472	2.217	-16.349	1.00	17.96
ATOM	CZ	PHE	H	122	52.224	0.883	-16.071	1.00	16.23
ATOM	C	PHE	H	122	56.028	2.100	-21.211	1.00	16.57
ATOM	O	PHE	H	122	56.629	3.222	-21.244	1.00	18.33
ATOM	N	PRO	H	123	55.989	1.309	-22.281	1.00	15.62
ATOM	CD	PRO	H	123	55.570	-0.103	-22.354	1.00	14.76
ATOM	CA	PRO	H	123	56.530	1.768	-23.555	1.00	14.94
ATOM	CB	PRO	H	123	56.649	0.472	-24.337	1.00	17.14
ATOM	CG	PRO	H	123	55.456	-0.323	-23.836	1.00	16.17
ATOM	C	PRO	H	123	55.648	2.735	-24.319	1.00	16.60
ATOM	O	PRO	H	123	54.411	2.680	-24.245	1.00	17.55
ATOM	N	LEU	H	124	56.286	3.650	-25.031	1.00	13.37
ATOM	CA	LEU	H	124	55.561	4.556	-25.890	1.00	14.24
ATOM	CB	LEU	H	124	55.994	6.013	-25.655	1.00	15.79
ATOM	CG	LEU	H	124	55.665	6.606	-24.265	1.00	17.62
ATOM	CD1	LEU	H	124	56.269	7.985	-24.102	1.00	13.09
ATOM	CD2	LEU	H	124	54.153	6.660	-24.041	1.00	18.38
ATOM	C	LEU	H	124	56.077	3.994	-27.221	1.00	16.57
ATOM	O	LEU	H	124	57.307	4.426	-27.742	1.00	15.81
ATOM	N	ALA	H	125	55.420	2.937	-27.697	1.00	16.47
ATOM	CA	ALA	H	125	55.828	2.245	-28.920	1.00	15.66
ATOM	CB	ALA	H	125	54.977	1.002	-29.140	1.00	10.29
ATOM	C	ALA	H	125	55.819	3.109	-30.154	1.00	17.52
ATOM	O	ALA	H	125	54.968	3.984	-30.318	1.00	21.55
ATOM	N	PRO	H	126	56.789	2.892	-31.042	1.00	20.30
ATOM	CD	PRO	H	126	57.897	1.929	-30.946	1.00	20.63
ATOM	CA	PRO	H	126	56.878	3.667	-32.279	1.00	22.95
ATOM	CB	PRO	H	126	58.198	3.188	-32.886	1.00	21.13
ATOM	CG	PRO	H	126	58.302	1.785	-32.395	1.00	22.39
ATOM	C	PRO	H	126	55.700	3.375	-33.193	1.00	27.03
ATOM	O	PRO	H	126	55.427	2.226	-33.504	1.00	27.46
ATOM	N	SER	H	127	54.992	4.430	-33.577	1.00	34.03
ATOM	CA	SER	H	127	53.833	4.346	-34.460	1.00	39.73
ATOM	CB	SER	H	127	53.179	5.724	-34.629	1.00	43.44
ATOM	OG	SER	H	127	52.642	5.910	-35.940	1.00	42.93
ATOM	C	SER	H	127	54.300	3.881	-35.803	1.00	42.00
ATOM	O	SER	H	127	53.500	3.580	-36.684	1.00	43.71
ATOM	N	SER	H	128	55.597	3.962	-36.008	1.00	44.63
ATOM	CA	SER	H	128	56.137	3.532	-37.262	1.00	48.81
ATOM	CB	SER	H	128	57.449	4.268	-37.540	1.00	50.45
ATOM	OG	SER	H	128	57.252	5.678	-37.548	1.00	48.06
ATOM	C	SER	H	128	56.315	2.023	-37.164	1.00	50.25
ATOM	O	SER	H	128	55.845	1.393	-36.207	1.00	49.98
ATOM	N	LYS	H	129	56.944	1.443	-38.175	1.00	49.86
ATOM	CA	LYS	H	129	57.180	0.014	-38.191	1.00	49.05
ATOM	CB	LYS	H	129	55.874	-0.722	-38.414	1.00	49.61
ATOM	C	LYS	H	129	58.151	-0.266	-39.320	1.00	48.36
ATOM	O	LYS	H	129	59.112	-1.022	-39.152	1.00	44.64
ATOM	NZ	LYS	H	129	51.040	-1.190	-37.021	0.00	0.00
ATOM	CE	LYS	H	129	52.290	-0.431	-36.870	0.00	0.00
ATOM	CD	LYS	H	129	53.427	-0.974	-37.734	0.00	0.00
ATOM	CG	LYS	H	129	54.730	-0.196	-37.554	0.00	0.00
ATOM	N	SER	H	130	57.862	0.364	-40.464	1.00	48.61
ATOM	CA	SER	H	130	58.643	0.255	-41.703	1.00	47.96
ATOM	CB	SER	H	130	57.736	0.583	-42.898	1.00	47.61
ATOM	C	SER	H	130	59.875	1.176	-41.704	1.00	48.17
ATOM	O	SER	H	130	60.004	2.065	-40.830	1.00	48.15
ATOM	N	THR	H	131	60.739	0.991	-42.701	0.01	47.53
ATOM	CA	THR	H	131	61.974	1.757	-42.843	0.01	47.59
ATOM	CB	THR	H	131	63.005	0.935	-43.613	0.01	46.60
ATOM	C	THR	H	131	61.827	3.143	-43.476	0.01	47.59
ATOM	O	THR	H	131	62.023	4.157	-42.811	0.01	47.36

TABLE 2-continued

		Atom A.A.		X	Y	Z	Occ	B	
	Type								
ATOM	N	SER	H	132	61.563	3.181	-44.778	0.01	48.07
ATOM	CA	SER	H	132	61.404	4.433	-45.510	0.01	48.10
ATOM	CB	SER	H	132	61.123	4.153	-46.979	0.01	48.72
ATOM	C	SER	H	132	60.313	5.324	-44.927	0.01	47.75
ATOM	O	SER	H	132	59.137	5.192	-45.270	0.01	48.15
ATOM	N	GLY	H	133	60.717	6.221	-44.035	0.01	46.82
ATOM	CA	GLY	H	133	59.778	7.138	-43.419	0.01	45.30
ATOM	C	GLY	H	133	60.485	8.243	-42.661	0.01	43.62
ATOM	O	GLY	H	133	59.855	8.993	-41.914	0.01	44.14
ATOM	N	GLY	H	134	61.792	8.371	-42.878	1.00	42.62
ATOM	CA	GLY	H	134	62.547	9.392	-42.187	1.00	37.35
ATOM	C	GLY	H	134	62.780	9.112	-40.710	1.00	34.73
ATOM	O	GLY	H	134	63.626	8.277	-40.355	1.00	32.41
ATOM	N	THR	H	135	61.982	9.751	-39.859	1.00	33.59
ATOM	CA	THR	H	135	62.140	9.647	-38.406	1.00	32.75
ATOM	CB	THR	H	135	62.648	11.011	-37.859	1.00	34.16
ATOM	OG1	THR	H	135	63.967	11.256	-38.361	1.00	36.29
ATOM	CG2	THR	H	135	62.691	11.031	-36.355	1.00	37.02
ATOM	C	THR	H	135	60.920	9.202	-37.598	1.00	29.09
ATOM	O	THR	H	135	59.800	9.638	-37.832	1.00	31.07
ATOM	N	ALA	H	136	61.164	8.374	-36.597	1.00	25.01
ATOM	CA	ALA	H	136	60.105	7.878	-35.744	1.00	23.72
ATOM	CB	ALA	H	136	60.022	6.363	-35.859	1.00	24.23
ATOM	C	ALA	H	136	60.388	8.260	-34.297	1.00	22.99
ATOM	O	ALA	H	136	61.545	8.331	-33.884	1.00	22.43
ATOM	N	ALA	H	137	59.338	8.518	-33.529	1.00	21.07
ATOM	CA	ALA	H	137	59.520	8.836	-32.125	1.00	19.57
ATOM	CB	ALA	H	137	58.811	10.101	-31.763	1.00	18.29
ATOM	C	ALA	H	137	58.991	7.686	-31.293	1.00	20.25
ATOM	O	ALA	H	137	58.015	7.025	-31.664	1.00	20.92
ATOM	N	LEU	H	138	59.678	7.422	-30.194	1.00	19.10
ATOM	CA	LEU	H	138	59.317	6.375	-29.258	1.00	15.77
ATOM	CB	LEU	H	138	60.036	5.075	-29.618	1.00	16.18
ATOM	CG	LEU	H	138	61.569	5.057	-29.693	1.00	14.59
ATOM	CD1	LEU	H	138	62.140	4.576	-28.386	1.00	16.58
ATOM	CD2	LEU	H	138	61.983	4.113	-30.775	1.00	15.53
ATOM	C	LEU	H	138	59.760	6.897	-27.899	1.00	15.97
ATOM	O	LEU	H	138	60.466	7.904	-27.818	1.00	16.00
ATOM	N	GLY	H	139	59.338	6.252	-26.827	1.00	15.65
ATOM	CA	GLY	H	139	59.737	6.721	-25.523	1.00	14.54
ATOM	C	GLY	H	139	59.295	5.785	-24.437	1.00	15.97
ATOM	O	GLY	H	139	58.892	4.647	-24.709	1.00	16.46
ATOM	N	CYS	H	140	59.326	6.290	-23.209	1.00	15.70
ATOM	CA	CYS	H	140	58.925	5.539	-22.035	1.00	14.57
ATOM	C	CYS	H	140	58.121	6.419	-21.085	1.00	13.88
ATOM	O	CYS	H	140	58.457	7.592	-20.881	1.00	11.51
ATOM	CB	CYS	H	140	60.153	5.011	-21.302	1.00	16.76
ATOM	SO	CYS	H	140	60.792	3.452	-21.985	1.00	16.67
ATOM	N	LEU	H	141	57.003	5.873	-20.604	1.00	14.15
ATOM	CA	LEU	H	141	56.138	6.532	-19.637	1.00	11.75
ATOM	CB	LEU	H	141	54.664	6.189	-19.886	1.00	12.89
ATOM	CG	LEU	H	141	53.621	6.757	-18.916	1.00	11.36
ATOM	CD1	LEU	H	141	53.620	8.316	-18.934	1.00	9.80
ATOM	CD2	LEU	H	141	52.248	6.198	-19.277	1.00	10.76
ATOM	C	LEU	H	141	56.590	5.992	-18.276	1.00	13.36
ATOM	O	LEU	H	141	56.578	4.788	-18.037	1.00	13.78
ATOM	N	VAL	H	142	57.044	6.905	-17.421	1.00	14.52
ATOM	CA	VAL	H	142	57.542	6.601	-16.086	1.00	13.75
ATOM	CB	VAL	H	142	58.923	7.264	-15.872	1.00	12.16
ATOM	CG1	VAL	H	142	59.516	6.856	-14.542	1.00	9.59
ATOM	CG2	VAL	H	142	59.866	6.851	-17.005	1.00	10.00
ATOM	C	VAL	H	142	56.527	7.183	-15.125	1.00	15.66
ATOM	O	VAL	H	142	56.541	8.384	-14.850	1.00	15.64
ATOM	N	LYS	H	143	55.616	6.348	-14.630	1.00	17.91
ATOM	CA	LYS	H	143	54.600	6.875	-13.752	1.00	17.78
ATOM	CB	LYS	H	143	53.271	7.025	-14.502	1.00	22.02
ATOM	CG	LYS	H	143	52.450	5.788	-14.689	1.00	23.22
ATOM	CD	LYS	H	143	51.228	6.108	-15.557	1.00	27.56
ATOM	CE	LYS	H	143	50.239	7.105	-14.929	1.00	28.88
ATOM	NZ	LYS	H	143	49.292	6.527	-13.914	1.00	29.43
ATOM	C	LYS	H	143	54.384	6.264	-12.390	1.00	15.32
ATOM	O	LYS	H	143	54.827	5.144	-12.106	1.00	11.57
ATOM	N	ASP	H	144	53.786	7.102	-11.538	1.00	15.37
ATOM	CA	ASP	H	144	53.392	6.800	-10.166	1.00	15.38
ATOM	CB	ASP	H	144	52.338	5.686	-10.153	1.00	18.41
ATOM	CG	ASP	H	144	51.111	6.029	-10.984	1.00	19.01

TABLE 2-continued

		Atom A.A.			X	Y	Z	Occ	B
		Type							
ATOM	OD1	ASP	H	144	50.851	7.224	-11.190	1.00	18.51
ATOM	OD2	ASP	H	144	50.409	5.101	-11.444	1.00	22.72
ATOM	C	ASP	H	144	54.518	6.499	-9.191	1.00	13.76
ATOM	O	ASP	H	144	54.548	5.453	-8.542	1.00	12.14
ATOM	N	TYR	H	145	55.434	7.451	-9.075	1.00	14.87
ATOM	CA	TYR	H	145	56.557	7.312	-8.164	1.00	11.80
ATOM	CB	TYR	H	145	57.880	7.176	-8.936	1.00	12.15
ATOM	CG	TYR	H	145	58.300	8.405	-9.722	1.00	13.86
ATOM	CD1	TYR	H	145	57.996	8.535	-11.083	1.00	10.29
ATOM	CE1	TYR	H	145	58.360	9.682	-11.778	1.00	10.58
ATOM	CD2	TYR	H	145	58.980	9.452	-9.089	1.00	10.94
ATOM	CE2	TYR	H	145	59.344	10.597	-9.772	1.00	10.46
ATOM	CZ	TYR	H	145	59.036	10.709	-11.104	1.00	10.53
ATOM	OH	TYR	H	145	59.414	11.855	-11.742	1.00	12.24
ATOM	C	TYR	H	145	56.560	8.543	-7.272	1.00	11.16
ATOM	O	TYR	H	145	55.919	9.561	-7.591	1.00	9.37
ATOM	N	PHE	H	146	57.271	8.440	-6.157	1.00	11.54
ATOM	CA	PHE	H	146	57.397	9.518	-5.199	1.00	10.60
ATOM	CB	PHE	H	146	56.155	9.580	-4.292	1.00	12.01
ATOM	CG	PHE	H	146	56.050	10.860	-3.486	1.00	10.87
ATOM	CD1	PHE	H	146	56.420	10.888	-2.145	1.00	9.67
ATOM	CD2	PHE	H	146	55.620	12.047	-4.095	1.00	10.37
ATOM	CE1	PHE	H	146	56.376	12.071	-1.422	1.00	7.13
ATOM	CE2	PHE	H	146	55.569	13.239	-3.387	1.00	11.35
ATOM	CZ	PHE	H	146	55.950	13.259	-2.045	1.00	10.49
ATOM	C	PHE	H	146	58.603	9.165	-4.351	1.00	11.66
ATOM	O	PHE	H	146	58.849	7.993	-4.102	1.00	13.17
ATOM	N	PRO	H	147	59.475	10.144	-4.061	1.00	15.11
ATOM	CD	PRO	H	147	60.393	10.039	-2.903	1.00	11.77
ATOM	CA	PRO	H	147	59.374	11.538	-4.512	1.00	12.86
ATOM	CD	PRO	H	147	59.920	12.318	-3.301	1.00	11.39
ATOM	CG	PRO	H	147	61.014	11.442	-2.810	1.00	13.59
ATOM	C	PRO	H	147	60.293	11.691	-5.721	1.00	11.82
ATOM	O	PRO	H	147	60.710	10.694	-6.331	1.00	10.54
ATOM	N	GLU	H	148	60.563	12.933	-6.100	1.00	13.23
ATOM	CA	GLU	H	148	61.502	13.210	-7.172	1.00	12.55
ATOM	CB	GLU	H	148	61.467	14.700	-7.516	1.00	13.76
ATOM	CG	GLU	H	148	60.350	15.097	-8.443	1.00	16.65
ATOM	CD	GLU	H	148	60.705	14.890	-9.894	1.00	18.85
ATOM	OE1	GLU	H	148	60.868	15.905	-10.600	1.00	20.04
ATOM	OE2	GLU	H	148	60.816	13.720	-10.333	1.00	20.68
ATOM	C	GLU	H	148	62.873	12.884	-6.537	1.00	12.83
ATOM	O	GLU	H	148	63.027	12.967	-5.306	1.00	13.72
ATOM	N	PRO	H	149	63.889	12.558	-7.358	1.00	13.44
ATOM	CD	PRO	H	149	65.297	12.743	-6.955	1.00	9.52
ATOM	CA	PRO	H	149	63.793	12.483	-8.813	1.00	12.75
ATOM	CB	PRO	H	149	64.933	13.390	-9.233	1.00	13.35
ATOM	CG	PRO	H	149	66.009	12.955	-8.279	1.00	11.58
ATOM	C	PRO	H	149	64.003	11.072	-9.379	1.00	11.79
ATOM	O	PRO	H	149	64.357	10.138	-8.672	1.00	13.53
ATOM	N	VAL	H	150	63.802	10.957	-10.677	1.00	11.06
ATOM	CA	VAL	H	150	64.017	9.726	-11.415	1.00	16.43
ATOM	CB	VAL	H	150	62.641	9.208	-12.035	1.00	17.41
ATOM	CG1	VAL	H	150	62.438	9.689	-13.470	1.00	15.21
ATOM	CG2	VAL	H	150	62.540	7.717	-11.953	1.00	19.94
ATOM	C	VAL	H	150	65.002	10.163	-12.527	1.00	16.34
ATOM	O	VAL	H	150	65.097	11.351	-12.825	1.00	16.73
ATOM	N	THR	H	151	65.834	9.262	-13.031	1.00	16.34
ATOM	CA	THR	H	151	66.702	9.616	-14.150	1.00	15.33
ATOM	CB	THR	H	151	68.214	9.492	-13.860	1.00	16.67
ATOM	OG1	THR	H	151	68.521	8.147	-13.507	1.00	19.39
ATOM	CG2	THR	H	151	68.638	10.415	-12.762	1.00	18.99
ATOM	C	THR	H	151	66.364	8.607	-15.232	1.00	15.33
ATOM	O	THR	H	151	65.975	7.474	-14.927	1.00	15.10
ATOM	N	VAL	H	152	66.463	9.024	-16.489	1.00	15.67
ATOM	CA	VAL	H	152	66.186	8.130	-17.593	1.00	15.90
ATOM	CB	VAL	H	152	64.840	8.463	-18.298	1.00	16.43
ATOM	CG1	VAL	H	152	64.559	7.429	-19.389	1.00	17.02
ATOM	CG2	VAL	H	152	63.687	8.514	-17.289	1.00	12.53
ATOM	C	VAL	H	152	67.304	8.188	-18.631	1.00	15.46
ATOM	O	VAL	H	152	67.725	9.273	-19.044	1.00	15.77
ATOM	N	SER	H	153	67.823	7.025	-19.010	1.00	15.40
ATOM	CA	SER	H	153	68.846	6.961	-20.048	1.00	17.96
ATOM	CB	SER	H	153	70.220	6.517	-19.500	1.00	19.47
ATOM	CG	SER	H	153	70.209	5.207	-18.971	1.00	19.50
ATOM	C	SER	H	153	68.321	5.993	-21.100	1.00	17.07

TABLE 2-continued

		Atom A.A.		X	Y	Z	Occ	B
Atom	Type							
ATOM	O	SER	H	153	67.328	5.298	-20.857	1.00 16.03
ATOM	N	TRP	H	154	68.	51	5.983-22.271	1.00 16.08
ATOM	CA	TRP	H	154	68.550	5.122	-23.369	1.00 16.39
ATOM	CB	TRP	H	154	68.061	5.975	-24.556	1.00 15.81
ATOM	CG	TRP	H	154	66.678	6.533	-24.338	1.00 16.04
ATOM	CD2	TRP	H	154	65.446	5.855	-24.584	1.00 15.49
ATOM	CE2	TRP	H	154	64.406	6.704	-24.147	1.00 15.24
ATOM	CE3	TRP	H	154	65.117	4.606	-25.127	1.00 13.01
ATOM	CG1	TRP	H	154	66.343	7.750	-23.788	1.00 16.52
ATOM	NE1	TRP	H	154	64.980	7.852	-23.666	1.00 14.13
ATOM	CZ2	TRP	H	154	63.061	6.338	-24.239	1.00 13.45
ATOM	CZ3	TRP	H	154	63.781	4.250	-25.215	1.00 11.20
ATOM	CH2	TRP	H	154	62.773	5.110	-24.774	1.00 11.53
ATOM	C	TRP	H	154	69.743	4.288	-23.792	1.00 19.86
ATOM	O	TRP	H	154	70.850	4.819	-23.995	1.00 18.11
ATOM	N	ASN	H	155	69.536	2.978	-23.886	1.00 19.14
ATOM	CA	ASN	H	155	70.595	2.051	-24.284	1.00 18.51
ATOM	CB	ASN	H	155	70.884	2.203	-25.773	1.00 16.21
ATOM	CG	ASN	H	155	69.744	1.697	-26.624	1.00 14.90
ATOM	OD1	ASN	H	155	68.890	0.968	-26.132	1.00 15.81
ATOM	ND2	ASN	H	155	69.734	2.045	-27.902	1.00 14.10
ATOM	C	ASN	H	155	71.854	2.231	-23.424	1.00 21.54
ATOM	O	ASN	H	155	72.986	2.289	-23.926	1.00 21.60
ATOM	N	SER	H	156	71.618	2.307	-22.114	1.00 23.82
ATOM	CA	SER	H	156	72.657	2.477	-21.097	1.00 25.32
ATOM	CB	SER	H	156	73.478	1.194	-20.947	1.00 23.36
ATOM	OG	SER	H	156	72.655	0.122	-20.528	1.00 23.97
ATOM	C	SER	H	156	73.569	3.678	-21.339	1.00 26.35
ATOM	O	SER	H	156	74.757	3.628	-21.021	1.00 26.24
ATOM	N	GLY	H	157	73.001	4.756	-21.888	1.00 24.38
ATOM	CA	GLY	H	157	73.763	5.966	-22.160	1.00 21.04
ATOM	C	GLY	H	157	74.256	6.104	-23.590	1.00 23.32
ATOM	O	GLY	H	157	74.639	7.183	-24.016	1.00 23.51
ATOM	N	ALA	H	158	74.194	5.020	-24.352	1.00 23.69
ATOM	CA	ALA	H	158	74.666	5.015	-25.727	1.00 17.48
ATOM	CB	ALA	H	158	74.790	3.588	-26.228	1.00 17.39
ATOM	C	ALA	H	158	73.797	5.822	-26.668	1.00 13.71
ATOM	O	ALA	H	158	74.243	6.195	-27.753	1.00 13.65
ATOM	N	LEU	H	159	72.544	6.058	-26.281	1.00 18.26
ATOM	CA	LEU	H	159	71.636	6.827	-27.127	1.00 19.74
ATOM	CB	LEU	H	159	70.335	6.056	-27.370	1.00 18.94
ATOM	CG	LEU	H	159	69.576	6.197	-28.689	1.00 19.52
ATOM	CD1	LEU	H	159	68.134	5.790	-28.448	1.00 16.51
ATOM	CD2	LEU	H	159	69.649	7.583	-29.248	1.00 23.06
ATOM	C	LEU	H	159	71.322	8.107	-26.384	1.00 18.47
ATOM	O	LEU	H	159	70.659	8.083	-25.357	1.00 18.48
ATOM	N	THR	H	160	71.791	9.229	-26.904	1.00 23.36
ATOM	CA	THR	H	160	71.554	10.499	-26.250	1.00 23.65
ATOM	CB	THR	H	160	72.826	10.963	-25.546	1.00 21.22
ATOM	OG1	THR	H	160	73.915	10.925	-26.475	1.00 22.67
ATOM	CG2	THR	H	160	73.148	10.037	-24.385	1.00 23.98
ATOM	C	THR	H	160	71.050	11.574	-27.202	1.00 23.49
ATOM	O	THR	H	160	70.370	12.512	-26.785	1.00 19.91
ATOM	N	SER	H	161	71.344	11.442	-28.487	1.00 23.44
ATOM	CA	SER	H	161	70.887	12.454	-29.421	1.00 24.43
ATOM	CB	SER	H	161	71.613	12.343	-30.769	1.00 25.80
ATOM	CG	SER	H	161	71.513	11.035	-31.312	1.00 36.45
ATOM	C	SER	H	161	69.385	12.371	-29.615	1.00 23.52
ATOM	O	SER	H	161	68.837	11.284	-29.794	1.00 26.83
ATOM	N	GLY	H	162	68.718	13.515	-29.511	1.00 22.52
ATOM	CA	GLY	H	162	67.287	13.574	-29.719	1.00 19.26
ATOM	C	GLY	H	162	66.453	13.105	-28.558	1.00 18.67
ATOM	O	GLY	H	162	65.263	12.867	-28.727	1.00 19.57
ATOM	N	VAL	H	163	67.069	12.956	-27.392	1.00 18.18
ATOM	CA	VAL	H	163	66.344	12.514	-26.209	1.00 18.28
ATOM	CB	VAL	H	163	67.252	11.766	-25.184	1.00 16.13
ATOM	CG1	VAL	H	163	66.465	11.412	-23.930	1.00 15.25
ATOM	CG2	VAL	H	163	67.799	10.503	-25.794	1.00 16.95
ATOM	C	VAL	H	163	65.763	13.728	-25.521	1.00 18.72
ATOM	O	VAL	H	163	66.399	14.777	-25.452	1.00 21.28
ATOM	N	HIS	H	164	64.541	13.586	-25.031	1.00 17.35
ATOM	CA	HIS	H	164	63.871	14.649	-24.313	1.00 16.94
ATOM	CB	HIS	H	164	62.817	15.341	-25.182	1.00 19.00
ATOM	CG	HIS	H	164	63.372	16.361	-26.128	1.00 18.12
ATOM	CG2	HIS	H	164	63.975	17.549	-25.898	1.00 16.70

TABLE 2-continued

		Atom A.A.		X	Y	Z	Occ	B	
	Type								
ATOM	ND1	HIS	H	164	63.256	16.251	-27.497	1.00	18.61
ATOM	CE1	HIS	H	164	63.753	17.331	-28.068	1.00	14.03
ATOM	NE2	HIS	H	164	64.194	18.133	-27.119	1.00	18.56
ATOM	C	HIS	H	164	63.175	13.985	-23.152	1.00	17.34
ATOM	O	HIS	H	164	62.250	13.191	-23.347	1.00	16.54
ATOM	N	THR	H	165	63.663	14.252	-21.952	1.00	17.07
ATOM	CA	THR	H	165	63.049	13.703	-20.752	1.00	16.08
ATOM	CB	THR	H	165	64.097	13.062	-19.842	1.00	15.02
ATOM	OG1	THR	H	165	64.689	11.978	-20.559	1.00	14.53
ATOM	CG2	THR	H	165	63.475	12.517	-18.570	1.00	13.69
ATOM	C	THR	H	165	62.325	14.853	-20.083	1.00	13.93
ATOM	O	THR	H	165	62.933	15.766	-19.533	1.00	12.69
ATOM	N	PHE	H	166	61.011	14.828	-20.218	1.00	13.31
ATOM	CA	PHE	H	166	60.151	15.860	-19.676	1.00	11.35
ATOM	CB	PHE	H	166	58.715	15.647	-20.176	1.00	11.84
ATOM	CG	PHE	H	166	58.554	15.834	-21.666	1.00	13.49
ATOM	CD1	PHE	H	166	58.575	14.738	-22.528	1.00	16.51
ATOM	CD2	PHE	H	166	58.389	17.106	-22.205	1.00	14.83
ATOM	CH1	PHE	H	166	58.437	14.903	-23.904	1.00	15.29
ATOM	CE2	PHE	H	166	58.251	17.283	-23.576	1.00	14.45
ATOM	CZ	PHE	H	166	58.275	16.181	-24.427	1.00	15.22
ATOM	C	PHE	H	166	60.172	15.945	-18.154	1.00	12.15
ATOM	O	PHE	H	166	60.378	14.945	-17.466	1.00	9.27
ATOM	N	PRO	H	167	60.059	17.175	-17.619	1.00	13.86
ATOM	CD	PRO	H	167	60.046	18.419	-18.415	1.00	15.57
ATOM	CA	PRO	H	167	60.040	17.482	-16.190	1.00	11.73
ATOM	CB	PRO	H	167	59.691	18.962	-16.170	1.00	12.97
ATOM	CG	PRO	H	167	60.362	19.470	-17.371	1.00	17.36
ATOM	C	PRO	H	167	58.873	16.727	-15.611	1.00	12.24
ATOM	O	PRO	H	167	57.799	16.701	-16.234	1.00	13.95
ATOM	N	ALA	H	168	59.057	16.122	-14.439	1.00	12.11
ATOM	CA	ALA	H	168	57.976	15.386	-13.793	1.00	12.13
ATOM	CB	ALA	H	168	58.475	14.688	-12.552	1.00	8.32
ATOM	C	ALA	H	168	56.858	16.345	-13.423	1.00	13.78
ATOM	O	ALA	H	168	57.081	17.544	-13.234	1.00	15.51
ATOM	N	VAL	H	169	55.645	15.831	-13.371	1.00	12.89
ATOM	CA	VAL	H	169	54.506	16.635	-12.988	1.00	15.57
ATOM	CB	VAL	H	169	53.612	16.990	-14.232	1.00	16.84
ATOM	CG1	VAL	H	169	52.333	17.668	-13.794	1.00	19.49
ATOM	CG2	VAL	H	169	54.368	17.932	-15.193	1.00	17.39
ATOM	C	VAL	H	169	53.761	15.763	-11.980	1.00	15.66
ATOM	O	VAL	H	169	53.637	14.553	-12.179	1.00	17.42
ATOM	N	LEU	H	170	53.393	16.347	-10.844	1.00	15.29
ATOM	CA	LEU	H	170	52.668	15.627	-9.804	1.00	15.27
ATOM	CB	LEU	H	170	52.716	16.381	-8.461	1.00	12.42
ATOM	CG	LEU	H	170	52.125	15.662	-7.235	1.00	13.03
ATOM	CD1	LEU	H	170	53.065	14.595	-6.769	1.00	13.43
ATOM	CD2	LEU	H	170	51.929	16.616	-6.109	1.00	18.10
ATOM	C	LEU	H	170	51.220	15.507	-10.249	1.00	18.26
ATOM	O	LEU	H	170	50.696	16.503	-10.610	1.00	18.33
ATOM	N	GLN	H	171	50.721	14.276	-10.277	1.00	19.12
ATOM	CA	GLN	H	171	49.349	13.976	-10.672	1.00	18.69
ATOM	CB	GLN	H	171	49.243	12.496	-11.041	1.00	15.23
ATOM	CG	GLN	H	171	50.154	12.095	-12.186	1.00	18.70
ATOM	CD	GLN	H	171	50.341	10.594	-12.300	1.00	21.99
ATOM	OE1	GLN	H	171	50.953	9.969	-11.436	1.00	22.59
ATOM	NE2	GLN	H	171	49.852	10.011	-13.385	1.00	21.12
ATOM	C	GLN	H	171	48.437	14.260	-9.479	1.00	21.17
ATOM	O	GLN	H	171	48.901	14.416	-8.335	1.00	18.05
ATOM	N	SER	H	172	47.131	14.270	-9.730	1.00	24.36
ATOM	CA	SER	H	172	46.177	14.508	-8.657	1.00	24.61
ATOM	CB	SER	H	172	44.760	14.628	-9.222	1.00	28.12
ATOM	OG	SER	H	172	44.475	13.541	-10.090	1.00	35.60
ATOM	C	SER	H	172	46.275	13.373	-7.629	1.00	23.66
ATOM	O	SER	H	172	45.942	13.572	-6.464	1.00	26.39
ATOM	N	SER	H	173	46.758	12.201	-8.050	1.00	19.22
ATOM	CA	SER	H	173	46.938	11.055	-7.151	1.00	18.61
ATOM	CB	SER	H	173	47.319	9.825	-7.961	1.00	19.87
ATOM	OG	SER	H	173	48.551	10.027	-8.630	1.00	23.71
ATOM	C	SER	H	173	48.027	11.307	-6.101	1.00	17.92
ATOM	O	SER	H	173	48.162	10.562	-5.125	1.00	18.89
ATOM	N	GLY	H	174	48.800	12.367	-6.309	1.00	17.55
ATOM	CA	GLY	H	174	49.869	12.711	-5.389	1.00	16.52
ATOM	C	GLY	H	174	51.158	12.016	-5.774	1.00	15.28
ATOM	O	GLY	H	174	52.121	12.031	-5.011	1.00	15.34
ATOM	N	LEU	H	175	51.189	11.425	-6.966	1.00	12.52

TABLE 2-continued

		Atom A.A.		X	Y	Z	Occ	B	
	Type								
ATOM	CA	LEU	H	175	52.373	10.715	-7.436	1.00	12.10
ATOM	CB	LEU	H	175	52.034	9.252	-7.725	1.00	11.95
ATOM	CG	LEU	H	175	51.598	8.371	-6.561	1.00	13.01
ATOM	CG1	LEU	H	175	51.038	7.035	-7.062	1.00	12.11
ATOM	CD2	LEU	H	175	52.778	8.189	-5.608	1.00	15.83
ATOM	C	LEU	H	175	52.835	11.377	-8.712	1.00	11.41
ATOM	O	LEU	H	175	52.012	11.899	-9.452	1.00	12.88
ATOM	N	TYR	H	176	54.149	11.379	-8.959	1.00	12.75
ATOM	CA	TYR	H	176	54.715	11.984	-10.169	1.00	9.90
ATOM	CB	TYR	H	176	56.186	12.344	-9.977	1.00	6.99
ATOM	CG	TYR	H	176	56.437	13.446	-8.977	1.00	9.80
ATOM	CD1	TYR	H	176	56.298	14.786	-9.332	1.00	9.18
ATOM	CE1	TYR	H	176	56.529	15.796	-8.404	1.00	8.22
ATOM	CD2	TYR	H	176	56.812	13.145	-7.670	1.00	9.26
ATOM	CE2	TYR	H	176	57.039	14.139	-6.746	1.00	10.18
ATOM	CZ	TYR	H	176	56.900	15.461	-7.115	1.00	8.46
ATOM	OH	TYR	H	176	57.141	16.439	-6.181	1.00	9.44
ATOM	C	TYR	H	176	54.617	11.068	-11.365	1.00	9.94
ATOM	O	TYR	H	176	54.491	9.855	-11.230	1.00	13.21
ATOM	N	SER	H	177	54.755	11.661	-12.536	1.00	10.40
ATOM	CA	SER	H	177	54.729	10.927	-13.787	1.00	13.02
ATOM	CB	SER	H	177	53.276	10.688	-14.232	1.00	12.24
ATOM	OG	SER	H	177	53.214	9.929	-15.425	1.00	15.89
ATOM	C	SER	H	177	55.462	11.760	-14.833	1.00	11.43
ATOM	O	SER	H	177	55.457	12.991	-14.759	1.00	13.35
ATOM	N	LEU	H	178	56.133	11.085	-15.761	1.00	10.36
ATOM	CA	LEU	H	178	56.826	11.750	-16.849	1.00	12.46
ATOM	CB	LEU	H	178	58.150	12.364	-16.371	1.00	11.05
ATOM	CG	LEU	H	178	59.297	11.492	-15.880	1.00	7.67
ATOM	CG1	LEU	H	178	60.068	10.867	-17.044	1.00	8.40
ATOM	CD2	LEU	H	178	60.216	12.376	-15.113	1.00	8.48
ATOM	C	LEU	H	178	57.090	10.782	-17.995	1.00	12.58
ATOM	O	LEU	H	178	56.963	9.584	-17.827	1.00	13.76
ATOM	N	SER	H	179	57.403	11.325	-19.167	1.00	14.34
ATOM	CA	SER	H	179	57.763	10.541	-20.351	1.00	14.75
ATOM	CB	SER	H	179	56.769	10.762	-21.504	1.00	14.23
ATOM	OG	SER	H	179	55.540	10.086	-21.291	1.00	15.49
ATOM	C	SER	H	179	59.155	11.009	-20.803	1.00	14.23
ATOM	O	SER	H	179	59.560	12.141	-20.548	1.00	12.08
ATOM	N	SER	H	180	59.888	10.108	-21.437	1.00	14.48
ATOM	CA	SER	H	180	61.219	10.376	-21.985	1.00	13.43
ATOM	CB	SER	H	180	62.301	9.565	-21.280	1.00	12.19
ATOM	OG	SER	H	180	63.564	9.759	-21.901	1.00	14.67
ATOM	C	SER	H	180	61.046	9.835	-23.383	1.00	13.99
ATOM	O	SER	H	180	60.680	8.671	-23.571	1.00	15.36
ATOM	N	VAL	H	181	61.257	10.690	-24.358	1.00	15.02
ATOM	CA	VAL	H	181	61.078	10.307	-25.735	1.00	15.74
ATOM	CB	VAL	H	181	59.957	11.166	-26.398	1.00	15.83
ATOM	CG1	VAL	H	181	58.639	10.960	-25.647	1.00	12.76
ATOM	CG2	VAL	H	181	60.357	12.647	-26.430	1.00	15.72
ATOM	C	VAL	H	181	62.377	10.488	-26.475	1.00	17.47
ATOM	O	VAL	H	181	63.265	11.199	-26.000	1.00	15.89
ATOM	N	VAL	H	182	62.496	9.801	-27.607	1.00	17.14
ATOM	CA	VAL	H	182	63.679	9.890	-28.453	1.00	13.84
ATOM	CB	VAL	H	182	64.781	8.846	-28.048	1.00	16.69
ATOM	CG1	VAL	H	182	64.312	7.417	-28.260	1.00	14.43
ATOM	CG2	VAL	H	182	66.050	9.117	-28.818	1.00	17.22
ATOM	C	VAL	H	182	63.226	9.693	-29.900	1.00	21.36
ATOM	O	VAL	H	182	62.267	8.963	-30.161	1.00	23.83
ATOM	N	THR	H	183	63.805	10.447	-30.823	1.00	13.93
ATOM	CA	THR	H	183	63.450	10.295	-32.227	1.00	21.38
ATOM	CB	THR	H	183	63.218	11.664	-32.950	1.00	21.63
ATOM	OG1	THR	H	183	64.273	12.570	-32.639	1.00	24.70
ATOM	CG2	THR	H	183	61.890	12.294	-32.534	1.00	23.70
ATOM	C	THR	H	183	64.595	9.514	-32.857	1.00	21.52
ATOM	O	THR	H	183	65.764	9.774	-32.565	1.00	23.10
ATOM	N	VAL	H	184	64.259	8.488	-33.628	1.00	23.35
ATOM	CA	VAL	H	184	65.259	7.652	-34.266	1.00	19.98
ATOM	CB	VAL	H	184	65.373	6.269	-33.537	1.00	21.07
ATOM	CG1	VAL	H	184	65.755	6.479	-32.084	1.00	23.71
ATOM	CG2	VAL	H	184	64.059	5.439	-33.668	1.00	17.17
ATOM	C	VAL	H	184	64.959	7.437	-35.756	1.00	22.10
ATOM	O	VAL	H	184	63.900	7.836	-36.253	1.00	21.90
ATOM	N	PRO	H	185	65.898	6.821	-36.495	1.00	22.12
ATOM	CD	PRO	H	185	67.247	6.371	-36.096	1.00	23.90
ATOM	CA	PRO	H	185	65.669	6.580	-37.923	1.00	23.15

TABLE 2-continued

		Atom A.A.			X	Y	Z	Occ	B
		Type							
ATOM	CB	PRO	H	185	66.988	5.933	-38.365	1.00	22.25
ATOM	CG	PRO	H	185	67.988	6.449	-37.377	1.00	21.22
ATOM	C	PRO	H	185	64.522	5.584	-38.097	1.00	23.63
ATOM	O	PRO	H	185	64.509	4.542	-37.439	1.00	24.96
ATOM	N	SER	H	186	63.579	5.864	-38.992	1.00	24.50
ATOM	CA	SER	H	186	62.472	4.932	-39.208	1.00	26.40
ATOM	CB	SER	H	186	61.556	5.427	-40.309	1.00	23.78
ATOM	OG	SER	H	186	60.922	6.625	-39.929	1.00	31.60
ATOM	C	SER	H	186	63.008	3.566	-39.596	1.00	26.90
ATOM	O	SER	H	186	62.520	2.530	-39.132	1.00	28.22
ATOM	N	SER	H	187	64.055	3.578	-40.411	1.00	25.91
ATOM	CA	SER	H	187	64.671	2.352	-40.884	1.00	24.43
ATOM	CB	SER	H	187	65.803	2.698	-41.846	1.00	25.38
ATOM	OG	SER	H	187	66.663	3.674	-41.269	1.00	32.83
ATOM	C	SER	H	187	65.387	1.464	-39.764	1.00	22.75
ATOM	O	SER	H	187	65.330	0.257	-39.942	1.00	23.52
ATOM	N	SER	H	188	65.441	2.048	-38.600	1.00	22.42
ATOM	CA	SER	H	188	65.971	1.274	-37.489	1.00	21.39
ATOM	CB	SER	H	188	66.727	2.186	-36.518	1.00	24.28
ATOM	OG	SER	H	188	65.870	3.153	-35.929	1.00	24.35
ATOM	C	SER	H	188	64.919	0.478	-36.737	1.00	19.89
ATOM	O	SER	H	188	65.252	-0.418	-35.967	1.00	21.67
ATOM	N	LEU	H	189	63.656	0.819	-36.931	1.00	19.37
ATOM	CA	LEU	H	189	62.572	0.120	-36.250	1.00	21.16
ATOM	CB	LEU	H	189	61.215	0.740	-36.620	1.00	22.65
ATOM	CG	LEU	H	189	60.574	1.843	-35.769	1.00	24.15
ATOM	CD1	LEU	H	189	61.486	2.396	-34.677	1.00	21.90
ATOM	CD2	LEU	H	189	60.117	2.929	-36.689	1.00	20.64
ATOM	C	LEU	H	189	62.567	-1.358	-36.594	1.00	20.08
ATOM	O	LEU	H	189	62.342	-1.726	-37.741	1.00	21.74
ATOM	N	GLY	H	190	62.405	-2.204	-35.586	1.00	22.92
ATOM	CA	GLY	H	190	62.376	-3.638	-35.815	1.00	23.25
ATOM	C	GLY	H	190	63.359	-4.270	-35.860	1.00	25.44
ATOM	O	GLY	H	190	63.889	-5.489	-35.736	1.00	24.73
ATOM	N	THR	H	191	64.396	-3.451	-36.039	1.00	27.60
ATOM	CA	THR	H	191	66.159	-3.958	-36.098	1.00	28.13
ATOM	CB	THR	H	191	66.858	-3.649	-37.469	1.00	29.33
ATOM	OG1	THR	H	191	66.835	-2.246	-37.749	1.00	34.09
ATOM	CG2	THR	H	191	66.345	-4.368	-38.597	1.00	32.02
ATOM	C	THR	H	191	67.001	-3.468	-34.931	1.00	27.84
ATOM	O	THR	H	191	67.686	-4.254	-34.293	1.00	29.90
ATOM	N	GLN	H	192	66.937	-2.183	-34.620	1.00	26.52
ATOM	CA	GLN	H	192	67.721	-1.670	-33.505	1.00	26.83
ATOM	CB	GLN	H	192	68.092	-0.204	-33.751	1.00	27.16
ATOM	CG	GLN	H	192	69.541	0.149	-33.391	1.00	36.31
ATOM	CD	GLN	H	192	69.792	0.041	-31.908	1.00	38.23
ATOM	OE1	GLN	H	192	70.777	-0.544	-31.457	1.00	36.83
ATOM	NE2	GLN	H	192	68.870	0.584	-31.132	1.00	44.67
ATOM	C	GLN	H	192	66.946	-1.821	-32.193	1.00	25.50
ATOM	O	GLN	H	192	65.771	-1.483	-32.121	1.00	26.11
ATOM	N	THR	H	193	67.585	-2.373	-31.173	1.00	23.13
ATOM	CA	THR	H	193	66.946	-2.531	-29.876	1.00	23.22
ATOM	CB	THR	H	193	67.600	-3.679	-29.086	1.00	25.71
ATOM	OG1	THR	H	193	67.396	-4.909	-29.794	1.00	27.62
ATOM	CG2	THR	H	193	67.012	-3.794	-27.692	1.00	27.67
ATOM	C	THR	H	193	67.023	-1.216	-29.080	1.00	23.94
ATOM	O	THR	H	193	68.081	-0.588	-28.981	1.00	23.16
ATOM	N	TYR	H	194	65.889	-0.783	-28.545	1.00	21.58
ATOM	CA	TYR	H	194	65.823	0.444	-27.774	1.00	18.67
ATOM	CB	TYR	H	194	64.901	1.445	-28.442	1.00	18.25
ATOM	CG	TYR	H	194	65.447	1.934	-29.754	1.00	18.87
ATOM	CD1	TYR	H	194	66.497	2.842	-29.782	1.00	17.22
ATOM	CE1	TYR	H	194	66.999	3.310	-30.971	1.00	20.86
ATOM	CD2	TYR	H	194	64.908	1.497	-30.969	1.00	19.91
ATOM	CE2	TYR	H	194	65.401	1.963	-32.180	1.00	20.11
ATOM	CZ	TYR	H	194	66.450	2.875	-32.176	1.00	22.81
ATOM	OH	TYR	H	194	66.949	3.387	-33.355	1.00	21.52
ATOM	C	TYR	H	194	65.325	0.114	-26.397	1.00	18.70
ATOM	O	TYR	H	194	64.280	-0.533	-26.231	1.00	18.91
ATOM	N	ILE	H	195	66.100	0.535	-25.407	1.00	15.98
ATOM	CA	ILE	H	195	65.782	0.268	-24.025	1.00	15.14
ATOM	CB	ILE	H	195	66.731	-0.820	-23.489	1.00	14.19
ATOM	CG2	ILE	H	195	66.476	-1.079	-22.032	1.00	14.73
ATOM	CG1	ILE	H	195	66.594	-2.082	-24.339	1.00	17.52
ATOM	CD1	ILE	H	195	67.386	-3.252	-23.844	1.00	21.62
ATOM	C	ILE	H	195	65.932	1.533	-23.183	1.00	16.46

TABLE 2-continued

		Atom A.A.			X	Y	Z	Occ	B
		Type							
ATOM	O	ILE	H	195	66.932	2.239	-23.308	1.00	4.40
ATOM	N	CYS	H	196	64.910	1.866	-22.392	1.00	5.74
ATOM	CA	CYS	H	196	65.020	3.026	-21.504	1.00	5.04
ATOM	C	CYS	H	196	65.414	2.433	-20.151	1.00	5.47
ATOM	O	CYS	H	196	64.961	1.344	-19.799	1.00	7.09
ATOM	CB	CYS	H	196	63.720	3.839	-21.418	1.00	1.99
ATOM	SO	CYS	H	196	62.289	2.978	-20.709	1.00	5.97
ATOM	N	ASN	H	197	66.369	3.080	-19.479	1.00	4.76
ATOM	CA	ASN	H	197	66.881	2.639	-18.185	1.00	5.71
ATOM	CB	ASN	H	197	68.424	2.530	-18.227	1.00	3.36
ATOM	CG	ASN	H	197	68.955	2.061	-19.583	1.00	4.38
ATOM	OD1	ASN	H	197	69.482	2.855	-20.369	1.00	2.39
ATOM	ND2	ASN	H	197	68.618	0.772	-19.864	1.00	4.64
ATOM	C	ASN	H	197	66.436	3.704	-17.173	1.00	7.43
ATOM	O	ASN	H	197	66.676	4.862	-17.212	1.00	7.96
ATOM	N	VAL	H	198	65.532	3.314	-16.294	1.00	5.31
ATOM	CA	VAL	H	198	64.973	4.220	-15.318	1.00	5.22
ATOM	CB	VAL	H	198	63.412	4.109	-15.323	1.00	6.02
ATOM	CG1	VAL	H	198	62.776	5.110	-14.359	1.00	5.86
ATOM	CG2	VAL	H	198	62.866	4.306	-16.761	1.00	2.38
ATOM	C	VAL	H	198	65.520	3.951	-13.934	1.00	5.38
ATOM	O	VAL	H	198	65.449	2.831	-13.425	1.00	8.68
ATOM	N	ASN	H	199	66.057	4.985	-13.305	1.00	5.30
ATOM	CA	ASN	H	199	66.604	4.828	-11.970	1.00	5.88
ATOM	CB	ASN	H	199	68.122	5.034	-12.009	1.00	7.62
ATOM	CG	ASN	H	199	68.789	4.716	-10.708	1.00	9.95
ATOM	OD1	ASN	H	199	69.967	4.990	-10.544	1.00	4.61
ATOM	ND2	ASN	H	199	68.063	4.113	-9.782	1.00	2.49
ATOM	C	ASN	H	199	65.925	5.821	-11.029	1.00	5.25
ATOM	O	ASN	H	199	65.808	7.003	-11.356	1.00	4.39
ATOM	N	HIS	H	200	65.353	5.293	-9.947	1.00	2.48
ATOM	CA	HIS	H	200	64.670	6.081	-8.921	1.00	5.53
ATOM	CB	HIS	H	200	63.185	5.663	-8.790	1.00	4.60
ATOM	CG	HIS	H	200	62.378	6.502	-7.830	1.00	5.76
ATOM	CD2	HIS	H	200	62.211	7.843	-7.734	1.00	4.93
ATOM	ND1	HIS	H	200	61.591	5.954	-6.835	1.00	6.92
ATOM	CE1	HIS	H	200	60.976	6.919	-6.171	1.00	4.09
ATOM	NE2	HIS	H	200	61.339	8.074	-6.696	1.00	3.32
ATOM	C	HIS	H	200	65.447	5.843	-7.624	1.00	4.98
ATOM	O	HIS	H	200	65.119	4.978	-6.805	1.00	3.34
ATOM	N	LYS	H	201	66.526	6.595	-7.479	1.00	5.91
ATOM	CA	LYS	H	201	67.	80	6.488	-6.310	1.00
								18.09	
ATOM	CB	LYS	H	201	68.496	7.515	-6.381	1.00	9.93
ATOM	CG	LYS	H	201	69.484	7.233	-7.489	1.00	8.78
ATOM	CD	LYS	H	201	70.774	8.000	-7.249	1.00	8.66
ATOM	CE	LYS	H	201	71.815	7.701	-8.301	1.00	8.20
ATOM	NZ	LYS	H	201	73.115	8.340	-7.925	1.00	3.65
ATOM	G	LYS	H	201	66.627	6.591	-4.989	1.00	7.71
ATOM	O	LYS	H	201	66.927	5.840	-4.053	1.00	6.20
ATOM	N	PRO	H	202	65.637	7.512	-4.884	1.00	6.23
ATOM	CD	PRO	H	202	65.277	8.587	-5.828	1.00	2.43
ATOM	CA	PRO	H	202	64.862	7.663	-3.644	1.00	4.45
ATOM	CB	PRO	H	202	63.777	8.643	-4.056	1.00	3.02
ATOM	CG	PRO	H	202	64.516	9.552	-4.928	1.00	4.37
ATOM	C	PRO	H	202	64.261	6.357	-3.091	1.00	4.39
ATOM	O	PRO	H	202	64.013	6.259	-1.895	1.00	6.85
ATOM	N	SER	H	203	64.055	5.359	-3.949	1.00	5.31
ATOM	CA	SER	H	203	63.502	4.057	-3.545	1.00	7.23
ATOM	CD	SER	H	203	62.151	3.798	-4.231	1.00	4.94
ATOM	CG	SER	H	203	62.302	3.553	-5.635	1.00	5.74
ATOM	C	SER	H	203	64.444	2.909	-3.920	1.00	8.91
ATOM	O	SER	H	203	64.077	1.735	-3.796	1.00	9.89
ATOM	N	ASN	H	204	65.619	3.247	-4.446	1.00	9.73
ATOM	CA	ASN	H	204	66.589	2.245	-4.867	1.00	1.67
ATOM	CD	ASN	H	204	67.081	1.459	-3.649	1.00	4.42
ATOM	CG	ASN	H	204	68.422	0.782	-3.881	1.00	6.57
ATOM	OD1	ASN	H	204	69.212	1.197	-4.734	1.00	8.87
ATOM	ND2	ASN	H	204	68.693	-0.257	-3.103	1.00	7.26
ATOM	C	ASN	H	204	66.004	1.293	-5.927	1.00	3.47
ATOM	O	ASN	H	204	66.334	0.109	-5.956	1.00	3.25
ATOM	N	THR	H	205	65.129	1.818	-6.784	1.00	3.37
ATOM	CA	THR	H	205	64.492	1.037	-7.845	1.00	4.11
ATOM	CD	THR	H	205	62.955	1.294	-7.917	1.00	5.63
ATOM	OG1	THR	H	205	62.321	0.840	-6.717	1.00	8.17
ATOM	CG2	THR	H	205	62.332	0.567	-9.101	1.00	6.85

TABLE 2-continued

		Atom A.A.			X	Y	Z	Occ	B
		Type							
ATOM	C	THR	H	205	65.063	1.389	-9.210	1.00	24.23
ATOM	O	THR	H	205	65.224	2.566	-9.526	1.00	22.91
ATOM	N	LYS	H	206	65.340	0.362	-10.016	1.00	23.89
ATOM	CA	LYS	H	206	65.866	0.510	-11.374	1.00	24.37
ATOM	CB	LYS	H	206	67.286	-0.037	-11.478	1.00	29.60
ATOM	CG	LYS	H	206	68.294	0.567	-10.528	1.00	33.86
ATOM	CD	LYS	H	206	69.653	-0.045	-10.797	1.00	41.22
ATOM	CE	LYS	H	206	70.686	0.392	-9.786	1.00	45.98
ATOM	NZ	LYS	H	206	71.959	-0.336	-10.034	1.00	50.69
ATOM	C	LYS	H	206	64.988	-0.341	-12.266	1.00	23.86
ATOM	O	LYS	H	206	64.677	-1.478	-11.913	1.00	25.27
ATOM	N	VAL	H	207	64.627	0.175	-13.434	1.00	21.70
ATOM	CA	VAL	H	207	63.771	-0.552	-14.363	1.00	18.59
ATOM	CB	VAL	H	207	62.285	-0.056	-14.268	1.00	18.43
ATOM	CG1	VAL	H	207	61.415	-0.781	-15.279	1.00	17.97
ATOM	CG2	VAL	H	207	61.727	-0.264	-12.878	1.00	16.57
ATOM	C	VAL	H	207	64.241	-0.337	-15.806	1.00	18.98
ATOM	O	VAL	H	207	64.441	0.797	-16.224	1.00	17.46
ATOM	N	ASP	H	208	64.515	-1.412	-16.536	1.00	18.90
ATOM	CA	ASP	H	208	64.879	-1.263	-17.938	1.00	21.28
ATOM	CB	ASP	H	208	66.054	-2.146	-18.334	1.00	24.33
ATOM	CG	ASP	H	208	67.309	-1.813	-17.583	1.00	27.92
ATOM	OD1	ASP	H	208	67.899	-2.730	-16.991	1.00	32.30
ATOM	OD2	ASP	H	208	67.704	-0.637	-17.569	1.00	27.86
ATOM	C	ASP	H	208	63.642	-1.722	-18.671	1.00	20.84
ATOM	O	ASP	H	208	63.037	-2.736	-18.312	1.00	22.22
ATOM	N	LYS	H	209	63.230	-0.960	-19.668	1.00	20.63
ATOM	CA	LYS	H	209	62.047	-1.305	-20.429	1.00	19.95
ATOM	CB	LYS	H	209	60.912	-0.320	-20.125	1.00	20.48
ATOM	CG	LYS	H	209	59.709	-0.423	-21.045	1.00	22.51
ATOM	CD	LYS	H	209	59.031	-1.791	-20.990	1.00	23.59
ATOM	CE	LYS	H	209	58.585	-2.147	-19.585	1.00	24.09
ATOM	NZ	LYS	H	209	57.765	-3.385	-19.580	1.00	23.79
ATOM	C	LYS	H	209	62.371	-1.277	-21.899	1.00	21.05
ATOM	O	LYS	H	209	62.857	-0.263	-22.411	1.00	19.10
ATOM	N	ARG	H	210	62.159	-2.409	-22.565	1.00	22.99
ATOM	CA	ARG	H	210	62.407	-2.490	-23.996	1.00	23.52
ATOM	CB	ARG	H	210	62.569	-3.951	-24.432	1.00	25.36
ATOM	CG	ARG	H	210	63.135	-4.115	-25.838	1.00	34.19
ATOM	CD	ARG	H	210	63.578	-5.558	-26.136	1.00	41.11
ATOM	NE	ARG	H	210	64.549	-6.110	-25.172	1.00	45.70
ATOM	CZ	ARG	H	210	65.558	-6.917	-25.506	1.00	45.18
ATOM	NH1	ARG	H	210	65.738	-7.255	-26.778	1.00	45.60
ATOM	NH2	ARG	H	210	66.357	-7.428	-24.571	1.00	44.97
ATOM	C	ARG	H	210	61.225	-1.822	-24.715	1.00	22.56
ATOM	O	ARG	H	210	60.064	-1.975	-24.314	1.00	21.94
ATOM	N	VAL	H	211	61.523	-1.042	-25.745	1.00	20.28
ATOM	CA	VAL	H	211	60.488	-0.355	-26.506	1.00	19.78
ATOM	CB	VAL	H	211	60.659	1.195	-26.412	1.00	16.83
ATOM	CG1	VAL	H	211	59.537	1.891	-27.110	1.00	11.98
ATOM	CG2	VAL	H	211	60.714	1.628	-24.960	1.00	14.99
ATOM	C	VAL	H	211	60.627	-0.837	-27.943	1.00	20.10
ATOM	O	VAL	H	211	61.671	-0.677	-28.561	1.00	22.07
ATOM	N	GLU	H	212	59.578	-1.449	-28.474	1.00	22.41
ATOM	CA	GLU	H	212	59.615	-1.993	-29.831	1.00	22.33
ATOM	CB	GLU	H	212	59.888	-3.486	-29.741	1.00	24.22
ATOM	CG	GLU	H	212	58.992	-4.175	-28.714	1.00	30.31
ATOM	CD	GLU	H	212	59.156	-5.688	-28.681	1.00	36.52
ATOM	OE1	GLU	H	212	58.119	-6.380	-28.685	1.00	42.79
ATOM	OE2	GLU	H	212	60.302	-6.195	-28.638	1.00	38.30
ATOM	C	GLU	H	212	58.278	-1.780	-30.509	1.00	21.74
ATOM	O	GLU	H	212	57.274	-1.487	-29.844	1.00	23.29
ATOM	N	PRO	H	213	58.239	-1.885	-31.844	1.00	20.03
ATOM	CG	PRO	H	213	59.332	-2.079	-32.808	1.00	19.08
ATOM	CA	PRO	H	213	56.966	-1.695	-32.536	1.00	18.93
ATOM	CB	PRO	H	213	57.345	-1.935	-34.001	1.00	18.96
ATOM	CG	PRO	H	213	58.748	-1.473	-34.068	1.00	17.26
ATOM	C	PRO	H	213	55.994	-2.757	-32.005	1.00	18.93
ATOM	O	PRO	H	213	56.412	-3.857	-31.628	1.00	18.24
ATOM	N	LYS	H	214	54.717	-2.409	-31.924	1.00	19.00
ATOM	CA	LYS	H	214	53.706	-3.332	-31.410	1.00	19.14
ATOM	CB	LYS	H	214	52.483	-2.552	-30.924	1.00	16.91
ATOM	CG	LYS	H	214	51.526	-3.410	-30.161	1.00	17.14
ATOM	CD	LYS	H	214	50.262	-2.680	-29.811	1.00	20.10
ATOM	CE	LYS	H	214	49.434	-3.588	-28.931	1.00	24.84
ATOM	NZ	LYS	H	214	48.149	-2.977	-28.549	1.00	28.31

TABLE 2-continued

		Atom A.A.			X	Y	Z	Occ	B
		Type							
ATOM	C	LYS	H	214	53.222	-4.400	-32.394	1.00	19.27
ATOM	O	LYS	H	214	53.060	-4.132	-33.577	1.00	20.70
ATOM	N	SER	H	215	52.998	-5.614	-31.902	1.00	21.20
ATOM	CA	SER	H	215	52.459	-6.677	-32.744	1.00	21.88
ATOM	CB	SER	H	215	52.848	-8.059	-32.209	1.00	21.65
ATOM	OG	SER	H	215	52.273	-9.089	-33.001	1.00	19.53
ATOM	C	SER	H	215	50.931	-6.494	-32.683	1.00	21.88
ATOM	O	SER	H	215	50.308	-6.622	-31.615	1.00	20.22
ATOM	N	CYS	H	216	50.340	-6.142	-33.813	1.00	21.67
ATOM	CA	CYS	H	216	48.902	-5.919	-33.871	1.00	23.98
ATOM	C	CYS	H	216	48.066	-7.189	-33.695	1.00	27.00
ATOM	O	CYS	H	216	48.470	-8.289	-34.111	1.00	26.45
ATOM	CB	CYS	H	216	48.538	-5.216	-35.174	1.00	18.31
ATOM	SG	CYS	H	216	49.561	-3.741	-35.453	1.00	18.30
ATOM	N	ASP	H	217	46.945	-7.040	-32.990	1.00	31.27
ATOM	CA	ASP	H	217	46.009	-8.136	-32.750	1.00	33.27
ATOM	CB	ASP	H	217	45.320	-7.991	-31.392	1.00	33.17
ATOM	CG	ASP	H	217	44.278	-9.088	-31.123	1.00	36.31
ATOM	OD1	ASP	H	217	43.634	-9.600	-32.069	1.00	32.97
ATOM	OD2	ASP	H	217	44.085	-9.424	-29.935	1.00	37.95
ATOM	C	ASP	H	217	44.977	-8.004	-33.849	1.00	36.08
ATOM	O	ASP	H	217	44.272	-6.989	-33.945	1.00	37.14
ATOM	N	LYS	H	218	44.896	-9.035	-34.679	1.00	36.90
ATOM	CA	LYS	H	218	43.951	-9.047	-35.772	1.00	37.91
ATOM	CB	LYS	H	218	44.203	-7.863	-36.721	1.00	41.24
ATOM	CG	LYS	H	218	45.634	-7.710	-37.172	1.00	41.93
ATOM	CD	LYS	H	218	45.801	-6.602	-38.194	1.00	45.62
ATOM	CE	LYS	H	218	45.758	-5.216	-37.587	1.00	45.59
ATOM	NZ	LYS	H	218	45.929	-4.191	-38.654	1.00	46.72
ATOM	C	LYS	H	218	44.039	-10.359	-36.519	1.00	37.04
ATOM	O	LYS	H	218	44.749	-11.268	-36.108	1.00	33.26
ATOM	N	THR	H	219	43.284	-10.447	-37.604	1.00	38.01
ATOM	CA	THR	H	219	43.248	-11.628	-38.450	1.00	39.39
ATOM	CB	THR	H	219	41.948	-11.656	-39.246	1.00	42.48
ATOM	OG1	THR	H	219	41.822	-10.426	-39.989	1.00	47.38
ATOM	CG2	THR	H	219	40.770	-11.783	-38.286	1.00	39.71
ATOM	C	THR	H	219	44.432	-11.539	-39.390	1.00	38.37
ATOM	O	THR	H	219	44.447	-10.745	-40.343	1.00	36.99
ATOM	N	HIS	H	220	45.435	-12.349	-39.089	1.00	36.18
ATOM	CA	HIS	H	220	46.672	-12.372	-39.862	1.00	34.59
ATOM	CB	HIS	H	220	47.858	-12.471	-38.889	1.00	33.40
ATOM	CG	HIS	H	220	47.890	-11.347	-37.893	1.00	32.87
ATOM	CD2	HIS	H	220	47.558	-11.302	-36.580	1.00	30.42
ATOM	ND1	HIS	H	220	48.780	-10.067	-38.231	1.00	31.96
ATOM	CE1	HIS	H	220	48.196	-9.282	-37.170	1.00	27.03
ATOM	NE2	HIS	H	220	47.759	-10.006	-36.156	1.00	29.87
ATOM	C	HIS	H	220	46.656	-13.500	-40.894	1.00	32.03
ATOM	O	HIS	H	220	46.005	-13.277	-41.939	1.00	33.00
ATOM	OXT	HIS	H	220	47.241	-14.578	-40.662	1.00	26.67

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 11

<210> SEQ ID NO 1

<211> LENGTH: 450

<212> TYPE: PRT

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of artificial sequence: N-terminal variable segment of Synagis heavy chain humanized antibody

<400> SEQUENCE: 1

Gln Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln
1 5 10 15

Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser
20 25 30

-continued

450

<210> SEQ ID NO 2
 <211> LENGTH: 227
 <212> TYPE: PRT
 <213> ORGANISM: Artificial sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of artificial sequence: N-terminal
 fragment of Synagis heavy chain humanized antibody

<400> SEQUENCE: 2

Gln Val Thr Leu Arg Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln
 1 5 10 15
 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser
 20 25 30
 Gly Met Ser Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu
 35 40 45
 Trp Leu Ala Asp Ile Trp Trp Asp Asp Lys Lys Asp Tyr Asn Pro Ser
 50 55 60
 Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val
 65 70 75 80
 Val Leu Lys Val Thr Asn Met Asp Pro Ala Asp Thr Ala Thr Tyr Tyr
 85 90 95
 Cys Ala Arg Ser Met Ile Thr Asn Trp Tyr Phe Asp Val Trp Gly Ala
 100 105 110
 Gly Thr Thr Cys Thr Cys Ser Ser Ala Ser Thr Lys Gly Pro Ser Val
 115 120 125
 Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala
 130 135 140
 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser
 145 150 155 160
 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val
 165 170 175
 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro
 180 185 190
 Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys
 195 200 205
 Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp
 210 215 220
 Lys Thr His
 225

<210> SEQ ID NO 3
 <211> LENGTH: 223
 <212> TYPE: PRT
 <213> ORGANISM: Artificial sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of artificial sequence: C-terminal
 fragment of heavy chain of Synagis humanized antibody

<400> SEQUENCE: 3

Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val
 1 5 10 15
 Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr
 20 25 30
 Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu
 35 40 45
 Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys

-continued

50	55	60
Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser 65 70 75 80		
Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys 85 90 95		
Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile 100 105 110		
Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro 115 120 125		
Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu 130 135 140		
Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn 145 150 155 160		
Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser 165 170 175		
Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg 180 185 190		
Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu 195 200 205		
His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 210 215 220		

<210> SEQ ID NO 4
 <211> LENGTH: 12
 <212> TYPE: PRT
 <213> ORGANISM: Artificial sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of artificial sequence:
 Complementary determining region H1 ("CDRs") of Synagis heavy
 chain humanized antibody

<400> SEQUENCE: 4

Gly Phe Ser Leu Ser Thr Ser Gly Met Ser Val Gly 1 5 10

<210> SEQ ID NO 5
 <211> LENGTH: 16
 <212> TYPE: PRT
 <213> ORGANISM: Artificial sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of artificial sequence:
 Complementary determining region H2 ("CDRs") of Synagis heavy
 chain humanized antibody

<400> SEQUENCE: 5

Asp Ile Trp Trp Asp Asp Lys Lys Asp Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15
--

<210> SEQ ID NO 6
 <211> LENGTH: 10
 <212> TYPE: PRT
 <213> ORGANISM: Artificial sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of artificial sequence:
 Complementary determining region H3 ("CDRs") of Synagis heavy
 chain humanized antibody

<400> SEQUENCE: 6

Ser Met Ile Thr Asn Trp Tyr Phe Asp Val 1 5 10

<210> SEQ ID NO 7

-continued

<211> LENGTH: 213
 <212> TYPE: PRT
 <213> ORGANISM: Artificial sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of artificial sequence: Light chain
 of Synagis humanized antibody

<400> SEQUENCE: 7

Asp Ile Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly
 1 5 10 15
 Asp Arg Val Thr Ile Thr Cys Lys Cys Gln Leu Ser Val Gly Tyr Met
 20 25 30
 His Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr
 35 40 45
 Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
 50 55 60
 Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp
 65 70 75 80
 Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Gly Ser Gly Tyr Pro Phe Thr
 85 90 95
 Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala Pro
 100 105 110
 Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr
 115 120 125
 Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys
 130 135 140
 Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu
 145 150 155 160
 Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser
 165 170 175
 Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala
 180 185 190
 Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe
 195 200 205
 Asn Arg Gly Glu Cys
 210

<210> SEQ ID NO 8
 <211> LENGTH: 10
 <212> TYPE: PRT
 <213> ORGANISM: Artificial sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of artificial sequence:
 Complementary determining region L1 ("CDRs") of Synagis light
 chain humanized antibody

<400> SEQUENCE: 8

Lys Cys Gln Leu Ser Val Gly Tyr Met His
 1 5 10

<210> SEQ ID NO 9
 <211> LENGTH: 7
 <212> TYPE: PRT
 <213> ORGANISM: Artificial sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of artificial sequence:
 Complementary determining region L2 ("CDRs") of Synagis light
 chain humanized antibody

<400> SEQUENCE: 9

Asp Thr Ser Lys Leu Ala Ser

-continued

1 5

<210> SEQ ID NO 10
 <211> LENGTH: 9
 <212> TYPE: PRT
 <213> ORGANISM: Artificial sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of artificial sequence:
 Complementary determining region L3 ("CDRs") of Synagis light
 chain humanized antibody

<400> SEQUENCE: 10

Phe Gln Gly Ser Gly Tyr Pro Phe Thr
 1 5

<210> SEQ ID NO 11
 <211> LENGTH: 209
 <212> TYPE: PRT
 <213> ORGANISM: Artificial sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Description of artificial sequence: Synagis
 humanized antibody light chain fragment

<400> SEQUENCE: 11

Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly Asp Arg Val
 1 5 10 15

Thr Ile Thr Cys Lys Cys Gln Leu Ser Val Gly Tyr Met His Trp Tyr
 20 25 30

Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Thr Ser
 35 40 45

Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly
 50 55 60

Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Asp Asp Phe Ala
 65 70 75 80

Thr Tyr Tyr Cys Phe Gln Gly Ser Gly Tyr Pro Phe Thr Phe Gly Gly
 85 90 95

Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe
 100 105 110

Ile Phe Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val
 115 120 125

Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys
 130 135 140

Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu
 145 150 155 160

Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu
 165 170 175

Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr
 180 185 190

His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu
 195 200 205

Cys

What is claimed is:

1. A method of identifying a Synagis binding compound, comprising the step of using a three-dimensional structural representation of Synagis, Synagis Fab, or a fragment thereof comprising a Synagis antigen binding site, to computationally screen a candidate compound for an ability to bind the Synagis antigen binding site.

60

2. The method of claim 1 further including the steps of: synthesizing the candidate compound; and screening the candidate compound for Synagis binding activity.

65 3. A method of identifying a Synagis binding compound, comprising the steps of (a) using a three-dimensional structural representation of Synagis, Synagis Fab, or a fragment thereof comprising a Synagis antigen binding site, to computationally screen a candidate compound for an ability to

135

bind the Synagis antigen binding site, (b) synthesizing the candidate compound; and (c) screening the candidate compound for Synagis binding activity, wherein the structural information comprises the atomic structure coordinates of residues comprising a Synagis CDR.

4. The method of claim 3 in which the Synagis CDR is L1, L2, L3, H1, H2 or H3.

5. The method of claim 4 in which the structural information comprises the antigen binding site of Synagis.

6. The method of claim 5 in which the structural information comprises the Fv fragment of Synagis.

7. The method of claim 6 in which the structural information comprises the Fab fragment of Synagis.

8. A method of identifying a Synagis binding compound comprising the step of using a three-dimensional structural representation of Synagis, Synagis Fab, or a fragment thereof comprising a Synagis antigen binding site, to computationally design a synthesizable candidate compound that binds Synagis.

9. The method of claim 8 in which the computational design comprises the steps of: identifying chemical entities or fragments capable of associating with the Synagis binding site; and assembling the chemical entities or fragments into a single molecule to provide the structure of the candidate compound.

10. The method of claim 9 further including the steps of: synthesizing the candidate compound; and screening the candidate compound for Synagis binding activity.

136

11. A method of identifying a Synagis binding compound comprising the step of using a three-dimensional structural representation of Synagis, Synagis Fab, or a fragment thereof comprising a Synagis antigen binding site, to computationally design a synthesizable candidate compound that binds Synagis, wherein the structural information comprises the atomic structure coordinates of residues comprising a Synagis CDR.

12. The method of claim 11 in which the Synagis CDR is L1, L2, L3, H1, H2 or H3.

13. The method of claim 11 in which the structural information comprises the antigen binding site of Synagis.

14. The method of claim 11 in which the structural information comprises the Fv fragment of Synagis.

15. The method of claim 12 in which the structural information comprises the Fab fragment of Synagis.

16. The method of claim 11 in which the computational design comprises the steps of: identifying chemical entities or fragments capable of associating with the Synagis binding site; and assembling the chemical entities or fragments into a single molecule to provide the structure of the candidate compound.

17. The method of claim 16 further including the steps of: synthesizing the candidate compound; and screening the candidate compound for Synagis binding activity.

* * * * *